Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2614685,EC(50),"The normotensive group of rabbits had a calculated EC(50) of 12.7 ng/ml, while the hypertensive group had an EC(50) of 6.9 ng/ml, indicating that the hypertensive rabbits were much more sensitive to the propranolol than the normotensive group.",Effect of propranolol on the myocardial contractility of normotensive and spontaneously hypertensive rabbits: relationship of pharmacokinetics and pharmacodynamics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614685/),[ng] / [ml],12.7,1518,DB00571,Propranolol
,2614685,EC(50),"The normotensive group of rabbits had a calculated EC(50) of 12.7 ng/ml, while the hypertensive group had an EC(50) of 6.9 ng/ml, indicating that the hypertensive rabbits were much more sensitive to the propranolol than the normotensive group.",Effect of propranolol on the myocardial contractility of normotensive and spontaneously hypertensive rabbits: relationship of pharmacokinetics and pharmacodynamics. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2614685/),[ng] / [ml],6.9,1519,DB00571,Propranolol
,24783511,m/,"The detection used the transitions of protonated molecules at m/z 234.2-->84.1 for MPH and m/z 260.3-->183.1 for propranolol (IS), separately.",[LC-MS/MS assay of methylphenidate: stability and pharmacokinetics in human]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783511/),,234.2,1575,DB00571,Propranolol
,24783511,m/z,"The detection used the transitions of protonated molecules at m/z 234.2-->84.1 for MPH and m/z 260.3-->183.1 for propranolol (IS), separately.",[LC-MS/MS assay of methylphenidate: stability and pharmacokinetics in human]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783511/),,260.3,1576,DB00571,Propranolol
,24783511,m/z,"The detection used the transitions of protonated molecules at m/z 234.2-->84.1 for MPH and m/z 260.3-->183.1 for propranolol (IS), separately.",[LC-MS/MS assay of methylphenidate: stability and pharmacokinetics in human]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24783511/),,183.1,1577,DB00571,Propranolol
,18379090,lag time,"In addition, a lag time of 4 h was observed in in vivo experiment, which indicated that the DRCOPT can be used in therapeutic regimens with the characteristics of chronotherapy.",A novel time-controlled release system based on drug-resin complexes and elementary osmotic pump. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18379090/),h,4,1977,DB00571,Propranolol
,6639842,oral clearance,"Rifampicin (600 mg/day) caused a large increase in propranolol's oral clearance (35.7 +/- 16.3 vs 96.1 +/- 26.9 ml min-1 kg-1, mean +/- s.d.), but neither the elimination half-life nor extent of plasma binding were affected.",Induction of propranolol metabolism by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639842/),[ml] / [kg·min],35.7,2502,DB00571,Propranolol
,6639842,oral clearance,"Rifampicin (600 mg/day) caused a large increase in propranolol's oral clearance (35.7 +/- 16.3 vs 96.1 +/- 26.9 ml min-1 kg-1, mean +/- s.d.), but neither the elimination half-life nor extent of plasma binding were affected.",Induction of propranolol metabolism by rifampicin. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6639842/),[ml] / [kg·min],96.1,2503,DB00571,Propranolol
,7224706,overall distribution volume,"Extensive tissue uptake of propranolol occurred after intravenous dosing, the overall distribution volume was 11 liters/kg.",Bioavailability of propranolol in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224706/),[l] / [kg],11,3004,DB00571,Propranolol
,7224706,Biological half-life,"Biological half-life was 1.5 hr, but was prolonged after oral and intraportal drug administration.",Bioavailability of propranolol in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224706/),h,1.5,3005,DB00571,Propranolol
,7224706,overall oral bioavailability,"Accordingly, the overall oral bioavailability was 27%.",Bioavailability of propranolol in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7224706/),%,27,3006,DB00571,Propranolol
,7236871,sensitivity,A radioimmunoassay has been developed for propranolol with a sensitivity of 2.37 nmol l-1 in unextracted plasma using a 50 microliter sample.,A propranolol radioimmunoassay and its use in the study of its pharmacokinetics following low doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7236871/),[nM] / [l],2.37,4215,DB00571,Propranolol
,2897462,AUC0-infinity,"Comparison of the pharmacokinetic parameters of propranolol between etintidine and the placebo groups indicates that etintidine significantly increased the AUC0-infinity values (573.5 vs. 146.4 ng.hr/ml, p = 0.0001) and prolonged the elimination half-life (4.61 vs. 2.33 hr) of propranolol.",Etintidine-propranolol interaction study in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),[h·ng] / [ml],573.5,6731,DB00571,Propranolol
,2897462,AUC0-infinity,"Comparison of the pharmacokinetic parameters of propranolol between etintidine and the placebo groups indicates that etintidine significantly increased the AUC0-infinity values (573.5 vs. 146.4 ng.hr/ml, p = 0.0001) and prolonged the elimination half-life (4.61 vs. 2.33 hr) of propranolol.",Etintidine-propranolol interaction study in humans. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),[h·ng] / [ml],146.4,6732,DB00571,Propranolol
,2897462,elimination half-life,"Comparison of the pharmacokinetic parameters of propranolol between etintidine and the placebo groups indicates that etintidine significantly increased the AUC0-infinity values (573.5 vs. 146.4 ng.hr/ml, p = 0.0001) and prolonged the elimination half-life (4.61 vs. 2.33 hr) of propranolol.",Etintidine-propranolol interaction study in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),h,4.61,6733,DB00571,Propranolol
,2897462,elimination half-life,"Comparison of the pharmacokinetic parameters of propranolol between etintidine and the placebo groups indicates that etintidine significantly increased the AUC0-infinity values (573.5 vs. 146.4 ng.hr/ml, p = 0.0001) and prolonged the elimination half-life (4.61 vs. 2.33 hr) of propranolol.",Etintidine-propranolol interaction study in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),h,2.33,6734,DB00571,Propranolol
,2897462,AUC0-24,"Statistical evaluation of the pharmacokinetic parameters of 4-hydroxypropranolol indicates that etintidine also increased the AUC0-24 values (43.8 vs. 16.4 ng.hr/ml, p = 0.0028) and prolonged the elimination half-life (4.87 vs. 1.97 hr) of 4-hydroxypropranolol.",Etintidine-propranolol interaction study in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),[h·ng] / [ml],43.8,6735,DB00571,Propranolol
,2897462,AUC0-24,"Statistical evaluation of the pharmacokinetic parameters of 4-hydroxypropranolol indicates that etintidine also increased the AUC0-24 values (43.8 vs. 16.4 ng.hr/ml, p = 0.0028) and prolonged the elimination half-life (4.87 vs. 1.97 hr) of 4-hydroxypropranolol.",Etintidine-propranolol interaction study in humans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),[h·ng] / [ml],16.4,6736,DB00571,Propranolol
,2897462,elimination half-life,"Statistical evaluation of the pharmacokinetic parameters of 4-hydroxypropranolol indicates that etintidine also increased the AUC0-24 values (43.8 vs. 16.4 ng.hr/ml, p = 0.0028) and prolonged the elimination half-life (4.87 vs. 1.97 hr) of 4-hydroxypropranolol.",Etintidine-propranolol interaction study in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),h,4.87,6737,DB00571,Propranolol
,2897462,elimination half-life,"Statistical evaluation of the pharmacokinetic parameters of 4-hydroxypropranolol indicates that etintidine also increased the AUC0-24 values (43.8 vs. 16.4 ng.hr/ml, p = 0.0028) and prolonged the elimination half-life (4.87 vs. 1.97 hr) of 4-hydroxypropranolol.",Etintidine-propranolol interaction study in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2897462/),h,1.97,6738,DB00571,Propranolol
,7108766,percentages of unbound,"After 3 weeks of phenobarbital therapy, the percentages of unbound propranolol fell from 15.2 +/- 1.2 (mean +/- S.E.) to 2.4 +/- 0.3 (P less than .001).",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),,15.2,6835,DB00571,Propranolol
,7108766,percentages of unbound,"After 3 weeks of phenobarbital therapy, the percentages of unbound propranolol fell from 15.2 +/- 1.2 (mean +/- S.E.) to 2.4 +/- 0.3 (P less than .001).",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),,2.4,6836,DB00571,Propranolol
,7108766,Km,"Using this model, the Km for phenobarbital-stimulated production of the binding protein was 1200 ng/ml, the turnover T1/2 of the protein was 3.4 days and the T1/2 for the lag phase was also 3.4 days.",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),[ng] / [ml],1200,6837,DB00571,Propranolol
,7108766,turnover T1/2,"Using this model, the Km for phenobarbital-stimulated production of the binding protein was 1200 ng/ml, the turnover T1/2 of the protein was 3.4 days and the T1/2 for the lag phase was also 3.4 days.",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),d,3.4,6838,DB00571,Propranolol
,7108766,T1/2,"Using this model, the Km for phenobarbital-stimulated production of the binding protein was 1200 ng/ml, the turnover T1/2 of the protein was 3.4 days and the T1/2 for the lag phase was also 3.4 days.",Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7108766/),d,3.4,6839,DB00571,Propranolol
,522894,maximum concentration,A maximum concentration of 374 +/- 33 ng/ml (N = 10) was reached 5 min after injection.,Propranolol in conscious spontaneously hypertensive rats. Disposition after subcutaneous and intracerebroventricular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/522894/),[ng] / [ml],374,7082,DB00571,Propranolol
,522894,half-life of t 1/2 alpha,After a distribution phase with a half-life of t 1/2 alpha = 17 min propranolol was eliminated with a t 1/2 beta = 59 min.,Propranolol in conscious spontaneously hypertensive rats. Disposition after subcutaneous and intracerebroventricular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/522894/),min,17,7083,DB00571,Propranolol
,522894,t 1/2 beta,After a distribution phase with a half-life of t 1/2 alpha = 17 min propranolol was eliminated with a t 1/2 beta = 59 min.,Propranolol in conscious spontaneously hypertensive rats. Disposition after subcutaneous and intracerebroventricular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/522894/),min,59,7084,DB00571,Propranolol
,522894,concentrations,"Highest concentrations (10.4 +/- 1.5 micrograms/g, N = 5) were found in lungs 30 min after injection.",Propranolol in conscious spontaneously hypertensive rats. Disposition after subcutaneous and intracerebroventricular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/522894/),[μg] / [g],10.4,7085,DB00571,Propranolol
,522894,maximal concentration,"4. Upon i.c.v. injection of propranolol, a maximal concentration of 573 +/- 47 ng/ml (N = 3) was reached in plasma already 2 min after injection.",Propranolol in conscious spontaneously hypertensive rats. Disposition after subcutaneous and intracerebroventricular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/522894/),[ng] / [ml],573,7086,DB00571,Propranolol
,522894,t 1/2 alpha,In this case t 1/2 alpha was 13 min and t 1/2 beta was 80 min.,Propranolol in conscious spontaneously hypertensive rats. Disposition after subcutaneous and intracerebroventricular administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/522894/),min,13,7087,DB00571,Propranolol
,522894,t 1/2 beta,In this case t 1/2 alpha was 13 min and t 1/2 beta was 80 min.,Propranolol in conscious spontaneously hypertensive rats. Disposition after subcutaneous and intracerebroventricular administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/522894/),min,80,7088,DB00571,Propranolol
,16632,half-life,The peak plasma level of penbutolol was reached 1 h after administration and its half-life was 4.5 h.,Comparative beta-adrenoceptor blocking effects and pharmacokinetics of penbutolol and propranolol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16632/),h,4.5,7103,DB00571,Propranolol
<,8794984,bioavailability,"Propranolol, a beta-adrenoceptor blocker, suffers from a high degree of first-pass metabolism resulting in very low bioavailability (< 10%) following administration with conventional oral formulations.",Carboxymethylcellulose-sodium based transdermal drug delivery system for propranolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794984/),%,10,7354,DB00571,Propranolol
,8794984,drug permeation rate,This zero-order permeation profile was characterized by a drug permeation rate of 52.87 +/- 11.63 micrograms cm-2 h-1.,Carboxymethylcellulose-sodium based transdermal drug delivery system for propranolol. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8794984/),[μg] / [(cm)^2·h],52.87,7355,DB00571,Propranolol
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,714,8258,DB00571,Propranolol
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,256,8259,DB00571,Propranolol
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,1534,8260,DB00571,Propranolol
,16949884,Area under the % effect-time curve,"Area under the % effect-time curve (% min) was 714+/-214 in Healthy/Placebo, 256+/-249 in Arthritis/Placebo, 1534+/-367 in Healthy/Statin, and 1713+/-393 in Arthritis/Statin.","Pravastatin reverses the down-regulating effect of inflammation on beta-adrenergic receptors: a disease-drug interaction between inflammation, pravastatin, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16949884/),%·min,1713,8261,DB00571,Propranolol
,29947117,total run-time,The total run-time was 18 min.,Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29947117/),min,18,8853,DB00571,Propranolol
,29947117,extraction efficiencies,"The mean extraction efficiencies of terizidone and IS were 76 and 89%, respectively.",Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29947117/),%,76,8854,DB00571,Propranolol
,29947117,extraction efficiencies,"The mean extraction efficiencies of terizidone and IS were 76 and 89%, respectively.",Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29947117/),%,89,8855,DB00571,Propranolol
,29947117,plasma concentration,The mean plasma concentration of terizidone in patients at all sampling time points was 51.8 ± 28 μg/mL.,Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29947117/),[μg] / [ml],51.8,8856,DB00571,Propranolol
,7379441,intrinsic plasma clearance (Cli),"As oral doses of propranolol were increased from 20 to 320 mg, there was a decrease in intrinsic plasma clearance (Cli) from 425 to 200 1/hr.",Effect of dose and uremia on plasma and urine profiles of propranolol metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379441/),[1] / [h],425,9089,DB00571,Propranolol
,7379441,intrinsic plasma clearance (Cli),"As oral doses of propranolol were increased from 20 to 320 mg, there was a decrease in intrinsic plasma clearance (Cli) from 425 to 200 1/hr.",Effect of dose and uremia on plasma and urine profiles of propranolol metabolites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379441/),[1] / [h],200,9090,DB00571,Propranolol
,7379441,Half-life,Half-life rose from 3 to 5 hr.,Effect of dose and uremia on plasma and urine profiles of propranolol metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379441/),h,3 to 5,9091,DB00571,Propranolol
,7379441,plasma NLA,"Mean plasma NLA was 4.372 ng/ml, and mean plasma NAA level was 238 ng/ml when mean plasma propranolol level was 15 ng/ml.",Effect of dose and uremia on plasma and urine profiles of propranolol metabolites. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379441/),[ng] / [ml],4.372,9092,DB00571,Propranolol
,6631714,area under the serum drug concentration time curve,"In contrast, the area under the serum drug concentration time curve after oral administration was increased from 6.95 to 19.3 micrograms X min/ml, which corresponded to a 2.5-fold increase in the systemic availability of l-propranolol (from 7 to 18%).",Effect of experimental renal failure on the disposition kinetics of l-propranolol in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631714/),[min·μg] / [ml],6.,10427,DB00571,Propranolol
,6631714,area under the serum drug concentration time curve,"In contrast, the area under the serum drug concentration time curve after oral administration was increased from 6.95 to 19.3 micrograms X min/ml, which corresponded to a 2.5-fold increase in the systemic availability of l-propranolol (from 7 to 18%).",Effect of experimental renal failure on the disposition kinetics of l-propranolol in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631714/),[min·μg] / [ml],19,10428,DB00571,Propranolol
,6631714,systemic availability,"In contrast, the area under the serum drug concentration time curve after oral administration was increased from 6.95 to 19.3 micrograms X min/ml, which corresponded to a 2.5-fold increase in the systemic availability of l-propranolol (from 7 to 18%).",Effect of experimental renal failure on the disposition kinetics of l-propranolol in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631714/),%,7,10429,DB00571,Propranolol
,6631714,systemic availability,"In contrast, the area under the serum drug concentration time curve after oral administration was increased from 6.95 to 19.3 micrograms X min/ml, which corresponded to a 2.5-fold increase in the systemic availability of l-propranolol (from 7 to 18%).",Effect of experimental renal failure on the disposition kinetics of l-propranolol in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631714/),%,18,10430,DB00571,Propranolol
,1452619,lower detection limit,The lower detection limit for the assay was found to be 1 ng/ml from 1 ml of plasma.,Assay of timolol in human plasma using gas chromatography with electron-capture detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1452619/),[ng] / [ml],1,10731,DB00571,Propranolol
at least,1452619,recovery,A recovery of at least 80% of timolol was found using the extraction method described.,Assay of timolol in human plasma using gas chromatography with electron-capture detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1452619/),%,80,10732,DB00571,Propranolol
,3392231,elimination half-life,The mean elimination half-life of propranolol was 6.3 hours during all three treatments.,The effect of cimetidine dose timing on oral propranolol kinetics in adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392231/),h,6.3,11709,DB00571,Propranolol
,11748690,flow-rate,The flow-rate was kept at 0.5 mL/min and column effluent was monitored with a fluorescence detector at an excitation wavelength of 230 nm and an emission wavelength of 340 nm.,Determination of propranolol concentration in small volume of rat plasma by HPLC with fluorometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748690/),[ml] / [min],0.5,11846,DB00571,Propranolol
,11748690,Retention times,"Retention times for pronethalol and propranolol were 8.5 min and 10.5 min, respectively.",Determination of propranolol concentration in small volume of rat plasma by HPLC with fluorometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748690/),min,8.5,11847,DB00571,Propranolol
,11748690,Retention times,"Retention times for pronethalol and propranolol were 8.5 min and 10.5 min, respectively.",Determination of propranolol concentration in small volume of rat plasma by HPLC with fluorometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748690/),min,10.5,11848,DB00571,Propranolol
,11748690,detection limit,The detection limit was 1.34 ng/mL.,Determination of propranolol concentration in small volume of rat plasma by HPLC with fluorometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748690/),[ng] / [ml],1.34,11849,DB00571,Propranolol
,2702801,total oral clearance,The total oral clearance of propranolol increased about fourfold in both phenotypes from 219.2 +/- 52.8 to 976.7 L/hr in the EMs and from 75.0 +/- 12.6 to 289.8 +/- 78.2 L/hr in the PMs.,Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702801/),[l] / [h],219.2,12007,DB00571,Propranolol
,2702801,total oral clearance,The total oral clearance of propranolol increased about fourfold in both phenotypes from 219.2 +/- 52.8 to 976.7 L/hr in the EMs and from 75.0 +/- 12.6 to 289.8 +/- 78.2 L/hr in the PMs.,Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702801/),[l] / [h],976.7,12008,DB00571,Propranolol
,2702801,total oral clearance,The total oral clearance of propranolol increased about fourfold in both phenotypes from 219.2 +/- 52.8 to 976.7 L/hr in the EMs and from 75.0 +/- 12.6 to 289.8 +/- 78.2 L/hr in the PMs.,Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702801/),[l] / [h],75.0,12009,DB00571,Propranolol
,2702801,total oral clearance,The total oral clearance of propranolol increased about fourfold in both phenotypes from 219.2 +/- 52.8 to 976.7 L/hr in the EMs and from 75.0 +/- 12.6 to 289.8 +/- 78.2 L/hr in the PMs.,Influence of debrisoquin phenotype on the inducibility of propranolol metabolism. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2702801/),[l] / [h],289.8,12010,DB00571,Propranolol
,2571709,Cls,"An i.v. dose-linearity study indicated dose-independent pharmacokinetics for propranolol at 1-2 mg kg-1, with a mean Cls, Vss, MRTi.v. and t0.5 beta of 0.076 L min-1 kg-1, 4.74 L kg-1, 57.81 min and 47.10 min, respectively.",The effect of Miglycol 812 oil on the oral absorption of propranolol in the rat. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571709/),[l] / [kg·min],0.076,14436,DB00571,Propranolol
,2571709,Vss,"An i.v. dose-linearity study indicated dose-independent pharmacokinetics for propranolol at 1-2 mg kg-1, with a mean Cls, Vss, MRTi.v. and t0.5 beta of 0.076 L min-1 kg-1, 4.74 L kg-1, 57.81 min and 47.10 min, respectively.",The effect of Miglycol 812 oil on the oral absorption of propranolol in the rat. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571709/),min,57.81,14437,DB00571,Propranolol
,2571709,MRTi.v.,"An i.v. dose-linearity study indicated dose-independent pharmacokinetics for propranolol at 1-2 mg kg-1, with a mean Cls, Vss, MRTi.v. and t0.5 beta of 0.076 L min-1 kg-1, 4.74 L kg-1, 57.81 min and 47.10 min, respectively.",The effect of Miglycol 812 oil on the oral absorption of propranolol in the rat. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571709/),min,57.81,14438,DB00571,Propranolol
,2571709,t0.5 beta,"An i.v. dose-linearity study indicated dose-independent pharmacokinetics for propranolol at 1-2 mg kg-1, with a mean Cls, Vss, MRTi.v. and t0.5 beta of 0.076 L min-1 kg-1, 4.74 L kg-1, 57.81 min and 47.10 min, respectively.",The effect of Miglycol 812 oil on the oral absorption of propranolol in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571709/),min,47.10,14439,DB00571,Propranolol
,2571709,mean absorption time (MAT),"After oral administration of propranolol (10 mg kg-1) in aqueous solution, with or without Tween 80 (6%), the mean absorption time (MAT) and terminal half-life were approximately 55 min and 86 min, respectively.",The effect of Miglycol 812 oil on the oral absorption of propranolol in the rat. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571709/),min,55,14440,DB00571,Propranolol
,2571709,terminal half-life,"After oral administration of propranolol (10 mg kg-1) in aqueous solution, with or without Tween 80 (6%), the mean absorption time (MAT) and terminal half-life were approximately 55 min and 86 min, respectively.",The effect of Miglycol 812 oil on the oral absorption of propranolol in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571709/),min,86,14441,DB00571,Propranolol
,2571709,MAT,"The MAT for propranolol administered in a 50% octanoic and lauric acid (1:1 by weight) oil-in-water emulsion, stabilized with 6% Tween 80 (129-90 min), was significantly longer compared with that for a 50% Miglyol 812 oil-in-water emulsion containing the same surfactant (16.55 min).",The effect of Miglycol 812 oil on the oral absorption of propranolol in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571709/),min,129-90,14442,DB00571,Propranolol
,2571709,MAT,"The MAT for propranolol administered in a 50% octanoic and lauric acid (1:1 by weight) oil-in-water emulsion, stabilized with 6% Tween 80 (129-90 min), was significantly longer compared with that for a 50% Miglyol 812 oil-in-water emulsion containing the same surfactant (16.55 min).",The effect of Miglycol 812 oil on the oral absorption of propranolol in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571709/),min,16.55,14443,DB00571,Propranolol
,2571709,terminal half-life,"The terminal half-life of propranolol administered in the fatty acid formulation (128.96 min), unlike that for the Miglyol emulsion (54-37 min), was significantly longer compared with that observed after i.v. administration (t0.5 beta = 47 min).",The effect of Miglycol 812 oil on the oral absorption of propranolol in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571709/),min,128.96,14444,DB00571,Propranolol
,2571709,terminal half-life,"The terminal half-life of propranolol administered in the fatty acid formulation (128.96 min), unlike that for the Miglyol emulsion (54-37 min), was significantly longer compared with that observed after i.v. administration (t0.5 beta = 47 min).",The effect of Miglycol 812 oil on the oral absorption of propranolol in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571709/),min,54-37,14445,DB00571,Propranolol
,2571709,t0.5 beta,"The terminal half-life of propranolol administered in the fatty acid formulation (128.96 min), unlike that for the Miglyol emulsion (54-37 min), was significantly longer compared with that observed after i.v. administration (t0.5 beta = 47 min).",The effect of Miglycol 812 oil on the oral absorption of propranolol in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571709/),min,47,14446,DB00571,Propranolol
,1352223,intrinsic clearance of total drug (CLint),"When vitamin K3 (20 mg/kg) in polyethylene glycol 300 (PEG 300) was coinfused with (+)-propranolol (2 mg/kg) into the pyloric vein (a tributary flowing directly into the hepatic portal vein), a significant decrease in the intrinsic clearance of total drug (CLint) from 94.1 +/- 50.1 to 32.9 +/- 11.5 ml/min/kg was observed (p less than 0.01 vs. vehicle control).",The influence of vitamin K3 treatment on the pharmacokinetics and metabolism of (+)-propranolol in the rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352223/),[ml] / [kg·min],94.1,15194,DB00571,Propranolol
,1352223,intrinsic clearance of total drug (CLint),"When vitamin K3 (20 mg/kg) in polyethylene glycol 300 (PEG 300) was coinfused with (+)-propranolol (2 mg/kg) into the pyloric vein (a tributary flowing directly into the hepatic portal vein), a significant decrease in the intrinsic clearance of total drug (CLint) from 94.1 +/- 50.1 to 32.9 +/- 11.5 ml/min/kg was observed (p less than 0.01 vs. vehicle control).",The influence of vitamin K3 treatment on the pharmacokinetics and metabolism of (+)-propranolol in the rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352223/),[ml] / [kg·min],32.9,15195,DB00571,Propranolol
,1352223,CLint,"Interestingly, the PEG 300 vehicle control group exhibited a significantly (p less than 0.05) higher CLint than that observed in a saline control group (94.1 +/- 50.1 vs. 45.9 +/- 13.7 ml/min/kg).",The influence of vitamin K3 treatment on the pharmacokinetics and metabolism of (+)-propranolol in the rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352223/),[ml] / [kg·min],94.1,15196,DB00571,Propranolol
,1352223,CLint,"Interestingly, the PEG 300 vehicle control group exhibited a significantly (p less than 0.05) higher CLint than that observed in a saline control group (94.1 +/- 50.1 vs. 45.9 +/- 13.7 ml/min/kg).",The influence of vitamin K3 treatment on the pharmacokinetics and metabolism of (+)-propranolol in the rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1352223/),[ml] / [kg·min],45.9,15197,DB00571,Propranolol
,7905493,hepatic venous pressure gradient,"The hepatic venous pressure gradient decreased from 15.7 +/- 5.0 to 12.9 +/- 4.0 mmHg (-17 +/- 13%, P < 0.01).",Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905493/),mmhg,15.7,16025,DB00571,Propranolol
,7905493,hepatic venous pressure gradient,"The hepatic venous pressure gradient decreased from 15.7 +/- 5.0 to 12.9 +/- 4.0 mmHg (-17 +/- 13%, P < 0.01).",Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905493/),mmhg,12.9,16026,DB00571,Propranolol
,7905493,Cmax,Tertatolol was rapidly absorbed with a Cmax of 70 +/- 51 micrograms/l at a peak time of 0.75 +/- 0.26 h.,Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905493/),[μg] / [l],70,16027,DB00571,Propranolol
,7905493,peak time,Tertatolol was rapidly absorbed with a Cmax of 70 +/- 51 micrograms/l at a peak time of 0.75 +/- 0.26 h.,Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905493/),h,0.75,16028,DB00571,Propranolol
,7905493,plasma clearance,"In comparison with healthy volunteers referred to in literature sources, plasma clearance was reduced to 49 +/- 28 ml/min, bioavailability was increased to 72 +/- 20%, and the volume of distribution was increased to 50 +/- 34 l, probably due, in part, to a weaker protein binding -85%--effect.",Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905493/),[ml] / [min],49,16029,DB00571,Propranolol
,7905493,bioavailability,"In comparison with healthy volunteers referred to in literature sources, plasma clearance was reduced to 49 +/- 28 ml/min, bioavailability was increased to 72 +/- 20%, and the volume of distribution was increased to 50 +/- 34 l, probably due, in part, to a weaker protein binding -85%--effect.",Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905493/),%,72,16030,DB00571,Propranolol
,7905493,volume of distribution,"In comparison with healthy volunteers referred to in literature sources, plasma clearance was reduced to 49 +/- 28 ml/min, bioavailability was increased to 72 +/- 20%, and the volume of distribution was increased to 50 +/- 34 l, probably due, in part, to a weaker protein binding -85%--effect.",Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7905493/),l,50,16031,DB00571,Propranolol
,9342502,oral bioavailability,Nefazodone undergoes significant first-pass metabolism resulting in an oral bioavailability of approximately 20%.,Clinical pharmacokinetics of nefazodone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9342502/),%,20,16638,DB00571,Propranolol
,26452534,lag time,"All formulations exhibited good buoyancy properties in vitro reflected by floating lag time of 1-110 sec, total floating time of 9-16 h and prolonged release behaviour (upto 12 h).",Formulation of Gastric Floating System Using Bio-Sourced Terminalia Catappa Gum and in vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26452534/),s,1-110,17529,DB00571,Propranolol
,26452534,total floating time,"All formulations exhibited good buoyancy properties in vitro reflected by floating lag time of 1-110 sec, total floating time of 9-16 h and prolonged release behaviour (upto 12 h).",Formulation of Gastric Floating System Using Bio-Sourced Terminalia Catappa Gum and in vivo Evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26452534/),h,9-16,17530,DB00571,Propranolol
,26452534,bioavailability,Pharmacokinetic studies of the optimised Terminalia catappa formulation and a commercial product (Ciplar LA 80) carried out on healthy human volunteers showed a significant improvement in the bioavailability (132%) of propranolol HCl released from from the experimental Terminalia catappa formulations compared with Ciplar LA 80.,Formulation of Gastric Floating System Using Bio-Sourced Terminalia Catappa Gum and in vivo Evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26452534/),%,132,17531,DB00571,Propranolol
,2407090,apparent volume of distribution,"The drug has a large apparent volume of distribution (approximately 4 liters/kg), exhibits extensive plasma protein binding (approximately 95%) and produces at least 30 metabolites.",Clinical pharmacokinetics of moricizine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),[l] / [kg],4,17631,DB00571,Propranolol
,2407090,plasma protein binding,"The drug has a large apparent volume of distribution (approximately 4 liters/kg), exhibits extensive plasma protein binding (approximately 95%) and produces at least 30 metabolites.",Clinical pharmacokinetics of moricizine. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),%,95,17632,DB00571,Propranolol
,2407090,elimination half-life,"The elimination half-life of moricizine is 2 to 6 hours, but its duration of antiarrhythmic action is much longer suggesting active metabolites.",Clinical pharmacokinetics of moricizine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2407090/),h,2 to 6,17633,DB00571,Propranolol
,3358897,Cmax,2. The peak plasma concentrations (Cmax) and areas under the plasma concentration-time curves (AUC) of verapamil were similar during combined treatment with propranolol (mean +/- s.d.: Cmax = 491 +/- 397 ng ml-1; AUC = 2075 +/- 1524 ng ml-1 h) or atenolol (mean +/- s.d.: Cmax = 372 +/- 320 ng ml-1; AUC = 1985 +/- 1660 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],491,18517,DB00571,Propranolol
,3358897,AUC,2. The peak plasma concentrations (Cmax) and areas under the plasma concentration-time curves (AUC) of verapamil were similar during combined treatment with propranolol (mean +/- s.d.: Cmax = 491 +/- 397 ng ml-1; AUC = 2075 +/- 1524 ng ml-1 h) or atenolol (mean +/- s.d.: Cmax = 372 +/- 320 ng ml-1; AUC = 1985 +/- 1660 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],2075,18518,DB00571,Propranolol
,3358897,Cmax,2. The peak plasma concentrations (Cmax) and areas under the plasma concentration-time curves (AUC) of verapamil were similar during combined treatment with propranolol (mean +/- s.d.: Cmax = 491 +/- 397 ng ml-1; AUC = 2075 +/- 1524 ng ml-1 h) or atenolol (mean +/- s.d.: Cmax = 372 +/- 320 ng ml-1; AUC = 1985 +/- 1660 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],372,18519,DB00571,Propranolol
,3358897,AUC,2. The peak plasma concentrations (Cmax) and areas under the plasma concentration-time curves (AUC) of verapamil were similar during combined treatment with propranolol (mean +/- s.d.: Cmax = 491 +/- 397 ng ml-1; AUC = 2075 +/- 1524 ng ml-1 h) or atenolol (mean +/- s.d.: Cmax = 372 +/- 320 ng ml-1; AUC = 1985 +/- 1660 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],1985,18520,DB00571,Propranolol
,3358897,Cmax,3. No differences in Cmax and AUC were observed during verapamil monotherapy (mean +/- s.d.: Cmax = 287 +/- 105 ng ml-1; AUC = 1375 +/- 455 ng ml-1 h) vs combined treatment with propranolol (mean +/- s.d.: Cmax = 312 +/- 55 ng ml-1; AUC = 1566 +/- 486 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],287,18521,DB00571,Propranolol
,3358897,AUC,3. No differences in Cmax and AUC were observed during verapamil monotherapy (mean +/- s.d.: Cmax = 287 +/- 105 ng ml-1; AUC = 1375 +/- 455 ng ml-1 h) vs combined treatment with propranolol (mean +/- s.d.: Cmax = 312 +/- 55 ng ml-1; AUC = 1566 +/- 486 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],1375,18522,DB00571,Propranolol
,3358897,Cmax,3. No differences in Cmax and AUC were observed during verapamil monotherapy (mean +/- s.d.: Cmax = 287 +/- 105 ng ml-1; AUC = 1375 +/- 455 ng ml-1 h) vs combined treatment with propranolol (mean +/- s.d.: Cmax = 312 +/- 55 ng ml-1; AUC = 1566 +/- 486 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],312,18523,DB00571,Propranolol
,3358897,AUC,3. No differences in Cmax and AUC were observed during verapamil monotherapy (mean +/- s.d.: Cmax = 287 +/- 105 ng ml-1; AUC = 1375 +/- 455 ng ml-1 h) vs combined treatment with propranolol (mean +/- s.d.: Cmax = 312 +/- 55 ng ml-1; AUC = 1566 +/- 486 ng ml-1 h).,The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],1566,18524,DB00571,Propranolol
,3358897,Cmax,"4. Treatment with verapamil increased the Cmax (mean +/- s.d.: 227 +/- 117 vs 116 +/- 62 ng ml-1, P less than 0.05) and AUC (1389 +/- 617 vs 837 +/- 316 ng ml-1 h, P = 0.0625) of propranolol in all subjects.",The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],227,18525,DB00571,Propranolol
,3358897,Cmax,"4. Treatment with verapamil increased the Cmax (mean +/- s.d.: 227 +/- 117 vs 116 +/- 62 ng ml-1, P less than 0.05) and AUC (1389 +/- 617 vs 837 +/- 316 ng ml-1 h, P = 0.0625) of propranolol in all subjects.",The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[ng] / [ml],116,18526,DB00571,Propranolol
,3358897,AUC,"4. Treatment with verapamil increased the Cmax (mean +/- s.d.: 227 +/- 117 vs 116 +/- 62 ng ml-1, P less than 0.05) and AUC (1389 +/- 617 vs 837 +/- 316 ng ml-1 h, P = 0.0625) of propranolol in all subjects.",The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],1389,18527,DB00571,Propranolol
,3358897,AUC,"4. Treatment with verapamil increased the Cmax (mean +/- s.d.: 227 +/- 117 vs 116 +/- 62 ng ml-1, P less than 0.05) and AUC (1389 +/- 617 vs 837 +/- 316 ng ml-1 h, P = 0.0625) of propranolol in all subjects.",The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358897/),[h·ng] / [ml],837,18528,DB00571,Propranolol
,3689632,elimination half-life,3 After the single intravenous dose the elimination half-life tended to be prolonged in the cirrhotic group (median 7.15 h) compared with controls (median 2.92 h) (P = 0.055).,A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689632/),h,7.15,18673,DB00571,Propranolol
,3689632,elimination half-life,3 After the single intravenous dose the elimination half-life tended to be prolonged in the cirrhotic group (median 7.15 h) compared with controls (median 2.92 h) (P = 0.055).,A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3689632/),h,2.92,18674,DB00571,Propranolol
,18651608,total chromatographic runtime,"The total chromatographic runtime was 3.0 min with retention time for 6-MNA and IS at 1.97 and 1.26 min, respectively.","High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651608/),min,3.0,18842,DB00571,Propranolol
,18651608,retention time,"The total chromatographic runtime was 3.0 min with retention time for 6-MNA and IS at 1.97 and 1.26 min, respectively.","High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651608/),min,1.97,18843,DB00571,Propranolol
,18651608,retention time,"The total chromatographic runtime was 3.0 min with retention time for 6-MNA and IS at 1.97 and 1.26 min, respectively.","High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651608/),min,1.26,18844,DB00571,Propranolol
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,15.8,21283,DB00571,Propranolol
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,21.8,21284,DB00571,Propranolol
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30.5,21285,DB00571,Propranolol
,6116195,half-life,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30-35,21286,DB00571,Propranolol
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,15.8,21287,DB00571,Propranolol
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,21.8,21288,DB00571,Propranolol
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30.5,21289,DB00571,Propranolol
,6116195,time required for 50% recovery of beta,"After oral administration, the pharmacological half-life (time required for 50% recovery of beta-blocking action) was 15.8 +/- 4.5 h for propranolol (3 mg/kg), 21.8 +/- 6.4 h for D-32 (0.5 mg/kg), 30.5 +/- 3.1 h for atenolol (6 mg/kg) and 30-35 h for pindolol (0.2 mg/kg).","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,30-35,21290,DB00571,Propranolol
,6116195,half-life,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,4.4,21291,DB00571,Propranolol
,6116195,half-life,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,5.9,21292,DB00571,Propranolol
,6116195,serum half-like,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,1.4,21293,DB00571,Propranolol
,6116195,serum half-like,"The pharmacological half-life after i.v. administration was 4.4 +/- 0.7 h for propranolol (300 microgram/kg) and 5.9 +/- 0.4 h for D-32 (150 microgram/kg), whereas the serum half-like (time required for 50% decrease in serum concentration) of propranolol was 1.4 h and that of D-32 was 1.3 h.","Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6116195/),h,1.3,21294,DB00571,Propranolol
,3429696,Cmax,"The Cmax following administration of LA 60 mg was 9.5 and 11.4 ng/mL on days 1 and 4, respectively, compared with 18.8 and 20.0 ng/mL with 20 mg tid (P less than .0001).",Pharmacokinetics and pharmacodynamics of long-acting propranolol 60-mg capsules: a comparative evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429696/),[ng] / [ml],9.5,23079,DB00571,Propranolol
,3429696,Cmax,"The Cmax following administration of LA 60 mg was 9.5 and 11.4 ng/mL on days 1 and 4, respectively, compared with 18.8 and 20.0 ng/mL with 20 mg tid (P less than .0001).",Pharmacokinetics and pharmacodynamics of long-acting propranolol 60-mg capsules: a comparative evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429696/),[ng] / [ml],11.4,23080,DB00571,Propranolol
,3429696,Cmax,"The Cmax following administration of LA 60 mg was 9.5 and 11.4 ng/mL on days 1 and 4, respectively, compared with 18.8 and 20.0 ng/mL with 20 mg tid (P less than .0001).",Pharmacokinetics and pharmacodynamics of long-acting propranolol 60-mg capsules: a comparative evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429696/),[ng] / [ml],18.8,23081,DB00571,Propranolol
,3429696,Cmax,"The Cmax following administration of LA 60 mg was 9.5 and 11.4 ng/mL on days 1 and 4, respectively, compared with 18.8 and 20.0 ng/mL with 20 mg tid (P less than .0001).",Pharmacokinetics and pharmacodynamics of long-acting propranolol 60-mg capsules: a comparative evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429696/),[ng] / [ml],20.0,23082,DB00571,Propranolol
,11377051,Extraction recovery,"Extraction recovery was 92.12% and 89.58% for V and N, respectively.",A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),%,92.12,23174,DB00571,Propranolol
,11377051,Extraction recovery,"Extraction recovery was 92.12% and 89.58% for V and N, respectively.",A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),%,89.58,23175,DB00571,Propranolol
,11377051,recovery,Its recovery was 82.50% on the average.,A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),%,82.50,23176,DB00571,Propranolol
,11377051,Limit of detection,"Limit of detection was 0.924 ng/ml and limit of determination was 3,080 ng/ml for V, what corresponds concentration in plasma 1.232 ng/ml.",A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),[ng] / [ml],0.924,23177,DB00571,Propranolol
,11377051,V,"Limit of detection was 0.924 ng/ml and limit of determination was 3,080 ng/ml for V, what corresponds concentration in plasma 1.232 ng/ml.",A validated method for the determination of verapamil and norverapamil in human plasma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),[ng] / [ml],"3,080",23178,DB00571,Propranolol
,11377051,V,"Limit of detection was 0.924 ng/ml and limit of determination was 3,080 ng/ml for V, what corresponds concentration in plasma 1.232 ng/ml.",A validated method for the determination of verapamil and norverapamil in human plasma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),[ng] / [ml],1.232,23179,DB00571,Propranolol
,11377051,limit of detection,"For N limit of detection was 0.030 ng/ml and limit of determination was 1.001 ng/ml what corresponds 0,4 ng/ml in plasma.",A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),[ng] / [ml],0.030,23180,DB00571,Propranolol
,11377051,limit of determination,"For N limit of detection was 0.030 ng/ml and limit of determination was 1.001 ng/ml what corresponds 0,4 ng/ml in plasma.",A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),[ng] / [ml],1.001,23181,DB00571,Propranolol
,11377051,limit of determination,"For N limit of detection was 0.030 ng/ml and limit of determination was 1.001 ng/ml what corresponds 0,4 ng/ml in plasma.",A validated method for the determination of verapamil and norverapamil in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11377051/),[ng] / [ml],"0,4",23182,DB00571,Propranolol
,1564097,detection limit,The method had good accuracy and precision and the detection limit (0.3 ng/ml with a signal-to-noise ratio of 3:1) allowed the assessment of vincamine concentrations in plasma in pharmacokinetic studies on healthy human volunteers.,Determination of vincamine in human plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564097/),[ng] / [ml],0.3,23196,DB00571,Propranolol
,1564097,signal-to-noise ratio,The method had good accuracy and precision and the detection limit (0.3 ng/ml with a signal-to-noise ratio of 3:1) allowed the assessment of vincamine concentrations in plasma in pharmacokinetic studies on healthy human volunteers.,Determination of vincamine in human plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564097/),,3:1,23197,DB00571,Propranolol
,2398465,bioavailability,"Using a four-way crossover study, the bioavailability of propranolol following oral administration was determined to be 12.3 +/- 5.9%, indicating that propranolol is subject to extensive hepatic first-pass metabolism in rabbits.",Bioavailability of propranolol following oral and transdermal administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2398465/),%,12.3,24021,DB00571,Propranolol
,2398465,bioavailability,"Transdermal delivery of propranolol, via an adhesive delivery device, resulted in a bioavailability of 74.8 +/- 10.1%, indicating that the transdermal delivery of propranolol can significantly increase systemic bioavailability over oral administration.",Bioavailability of propranolol following oral and transdermal administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2398465/),%,74.8,24022,DB00571,Propranolol
,2454364,elimination half-life,The elimination half-life after single oral doses varies from 6-7 h.,A new molecule with vasodilating and beta-adrenoceptor blocking properties. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454364/),h,6-7,24549,DB00571,Propranolol
,2454364,renal clearance,The renal clearance of 4 ml/min is negligible in comparison with the total body clearance of 590 ml/min.,A new molecule with vasodilating and beta-adrenoceptor blocking properties. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454364/),[ml] / [min],4,24550,DB00571,Propranolol
,2454364,total body clearance,The renal clearance of 4 ml/min is negligible in comparison with the total body clearance of 590 ml/min.,A new molecule with vasodilating and beta-adrenoceptor blocking properties. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454364/),[ml] / [min],590,24551,DB00571,Propranolol
,2454364,absolute bioavailability,"Therefore, the absolute bioavailability of 24% indicates some degree of first-pass extraction.",A new molecule with vasodilating and beta-adrenoceptor blocking properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454364/),%,24,24552,DB00571,Propranolol
,2454364,distribution volume,"The highly lipophilic drug is extensively distributed to the tissues, as shown by the distribution volume of 132 l.",A new molecule with vasodilating and beta-adrenoceptor blocking properties. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454364/),l,132,24553,DB00571,Propranolol
,2454364,responder rate,"In a 1-year open clinical trial with hypertensives WHO I and II, the responder rate was about 85% with carvedilol as monotherapy.",A new molecule with vasodilating and beta-adrenoceptor blocking properties. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454364/),%,85,24554,DB00571,Propranolol
,1149212,half-life,Propranolol disappeared from plasma with a half-life of 4.7 hours and its removal appeared to follow dose independent kinetics with no evidence of saturation of hepatic metabolism.,Studies of the absorption and removal of propranolol in hypertensive patients during therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1149212/),h,4.7,25022,DB00571,Propranolol
,3800032,peak venous plasma concentrations,"All subjects experienced mild CNS toxicity, consisting of tinnitus, facial tingling, or subtle visual disturbances, associated with peak venous plasma concentrations of 0.81 to 2.7 micrograms/ml.",Propranolol reduces bupivacaine clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),[μg] / [ml],0.81 to 2.7,25303,DB00571,Propranolol
,3800032,clearance,"Mean bupivacaine clearance was 0.33 +/- 0.12 l/min for the control session and 0.21 +/- 0.12 l/min during propranolol use, a significant 35% reduction (P less than 0.01).",Propranolol reduces bupivacaine clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),[l] / [min],0.33,25304,DB00571,Propranolol
,3800032,clearance,"Mean bupivacaine clearance was 0.33 +/- 0.12 l/min for the control session and 0.21 +/- 0.12 l/min during propranolol use, a significant 35% reduction (P less than 0.01).",Propranolol reduces bupivacaine clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),[l] / [min],0.21,25305,DB00571,Propranolol
,3800032,terminal elimination rate constant (beta),"The terminal elimination rate constant (beta) was 0.27 +/- 0.16 h-1 for the control session and 0.14 +/- 0.069 h-1 with propranolol (P less than 0.05); terminal elimination half-lives were 2.6 and 4.9 h, respectively.",Propranolol reduces bupivacaine clearance. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),1/[h],0.27,25306,DB00571,Propranolol
,3800032,terminal elimination rate constant (beta),"The terminal elimination rate constant (beta) was 0.27 +/- 0.16 h-1 for the control session and 0.14 +/- 0.069 h-1 with propranolol (P less than 0.05); terminal elimination half-lives were 2.6 and 4.9 h, respectively.",Propranolol reduces bupivacaine clearance. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),1/[h],0.14,25307,DB00571,Propranolol
,3800032,terminal elimination half-lives,"The terminal elimination rate constant (beta) was 0.27 +/- 0.16 h-1 for the control session and 0.14 +/- 0.069 h-1 with propranolol (P less than 0.05); terminal elimination half-lives were 2.6 and 4.9 h, respectively.",Propranolol reduces bupivacaine clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),h,2.6,25308,DB00571,Propranolol
,3800032,terminal elimination half-lives,"The terminal elimination rate constant (beta) was 0.27 +/- 0.16 h-1 for the control session and 0.14 +/- 0.069 h-1 with propranolol (P less than 0.05); terminal elimination half-lives were 2.6 and 4.9 h, respectively.",Propranolol reduces bupivacaine clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),h,4.9,25309,DB00571,Propranolol
>,20515530,Recovery,"Recovery of talinolol at concentrations of 1, 25, and 250 ng/mL was >78%.",Quantitation of talinolol in rat plasma by LC-MS-MS. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515530/),%,78,25497,DB00571,Propranolol
,15708686,mobile phase flow rate,"Analysis of verapamil and internal standard, propranolol was performed with direct injection of 10 microl of rat plasma to the system and were eluted at 22 and 12 min, respectively, at a mobile phase flow rate of 0.5 (mobile phase A) and 0.15 ml/min (mobile phase B).",Direct determination of verapamil in rat plasma by coupled column microbore-HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15708686/),[ml] / [min],0.5,26025,DB00571,Propranolol
,15708686,mobile phase flow rate,"Analysis of verapamil and internal standard, propranolol was performed with direct injection of 10 microl of rat plasma to the system and were eluted at 22 and 12 min, respectively, at a mobile phase flow rate of 0.5 (mobile phase A) and 0.15 ml/min (mobile phase B).",Direct determination of verapamil in rat plasma by coupled column microbore-HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15708686/),[ml] / [min],0.15,26026,DB00571,Propranolol
,15708686,total run time,The peaks of verapamil and internal standard were good shapes and well separated from any interfering endogenous peaks during a total run time of 25 min.,Direct determination of verapamil in rat plasma by coupled column microbore-HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15708686/),min,25,26027,DB00571,Propranolol
,15708686,LOD,"The LOD and LOQ were 0.01 and 0.025 microg/ml, respectively, for verapamil using 10 microl of rat plasma.",Direct determination of verapamil in rat plasma by coupled column microbore-HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15708686/),[μg] / [ml],0.01,26028,DB00571,Propranolol
,15708686,LOQ,"The LOD and LOQ were 0.01 and 0.025 microg/ml, respectively, for verapamil using 10 microl of rat plasma.",Direct determination of verapamil in rat plasma by coupled column microbore-HPLC method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15708686/),[μg] / [ml],0.025,26029,DB00571,Propranolol
,17200973,total analytical run time,"The total analytical run time was relatively short (5 min), and the limit of assay quantification was 2 ng/mL using 0.1 mL of human plasma.",Determination of roxatidine in human plasma by liquid chromatography/electrospray mass spectrometry and application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17200973/),min,5,26383,DB00571,Propranolol
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),min,30,27657,DB00571,Propranolol
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,15,27658,DB00571,Propranolol
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,2,27659,DB00571,Propranolol
,8198018,half-life,"Fluvastatin is rapidly absorbed from the gastrointestinal tract; has a 30-minute half-life, the shortest of any currently available HMG-CoA reductase inhibitor (lovastatin, 15 hours; pravastatin, 2 hours; simvastatin, 15.6 hours); is highly selective for the liver, undergoing extensive first-pass metabolism; has no active circulating metabolites; and does not penetrate the blood-brain barrier, unlike lovastatin and simvastatin.",Clinical implications of the biopharmaceutical properties of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198018/),h,15.6,27660,DB00571,Propranolol
,33789781,AUC levels,"The AUC levels for propranolol on days 2 and 4 were 493 ± 44 h × ng/mL and 334 ± 54 h × ng/mL, respectively), whereas in noninfected rats that received only propranolol, levels were 38 ± 11 h × ng/mL and 76 ± 16.",Alpha-1 Acid Glycoprotein as a Biomarker for Subclinical Illness and Altered Drug Binding in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33789781/),[h·ng] / [ml],493,27676,DB00571,Propranolol
,33789781,AUC levels,"The AUC levels for propranolol on days 2 and 4 were 493 ± 44 h × ng/mL and 334 ± 54 h × ng/mL, respectively), whereas in noninfected rats that received only propranolol, levels were 38 ± 11 h × ng/mL and 76 ± 16.",Alpha-1 Acid Glycoprotein as a Biomarker for Subclinical Illness and Altered Drug Binding in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33789781/),[h·ng] / [ml],334,27677,DB00571,Propranolol
,33789781,AUC levels,"The AUC levels for propranolol on days 2 and 4 were 493 ± 44 h × ng/mL and 334 ± 54 h × ng/mL, respectively), whereas in noninfected rats that received only propranolol, levels were 38 ± 11 h × ng/mL and 76 ± 16.",Alpha-1 Acid Glycoprotein as a Biomarker for Subclinical Illness and Altered Drug Binding in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33789781/),[h·ng] / [ml],38,27678,DB00571,Propranolol
,33789781,AUC levels,"The AUC levels for propranolol on days 2 and 4 were 493 ± 44 h × ng/mL and 334 ± 54 h × ng/mL, respectively), whereas in noninfected rats that received only propranolol, levels were 38 ± 11 h × ng/mL and 76 ± 16.",Alpha-1 Acid Glycoprotein as a Biomarker for Subclinical Illness and Altered Drug Binding in Rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33789781/),,76,27679,DB00571,Propranolol
less,15686983,run time,Abouthiouzine and the internal standard were monitored using UV detection at 240 nm; the run time was less than 5 min.,Liquid chromatographic assay of abouthiouzine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686983/),min,5,28166,DB00571,Propranolol
,15686983,detection limit,The detection limit of abouthiouzine is 0.5 microg/ml.,Liquid chromatographic assay of abouthiouzine in plasma and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15686983/),[μg] / [ml],0.5,28167,DB00571,Propranolol
,7803571,tR,"The retention times of propranolol and I.S. enantiomer derivatives are short (tR = 5.5-6.2 min and 8.8-10.1 min, respectively).",Microassay of propranolol enantiomers and conjugates in human plasma and urine by high-performance liquid chromatography after chiral derivatization for pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7803571/),min,5.5-6.2,28769,DB00571,Propranolol
,7803571,tR,"The retention times of propranolol and I.S. enantiomer derivatives are short (tR = 5.5-6.2 min and 8.8-10.1 min, respectively).",Microassay of propranolol enantiomers and conjugates in human plasma and urine by high-performance liquid chromatography after chiral derivatization for pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7803571/),min,8.8-10.1,28770,DB00571,Propranolol
,7803571,Sensitivity,Sensitivity is about 1 ng ml-1 per enantiomer.,Microassay of propranolol enantiomers and conjugates in human plasma and urine by high-performance liquid chromatography after chiral derivatization for pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7803571/),[ng] / [ml],1,28771,DB00571,Propranolol
,18937306,total chromatographic run time,The total chromatographic run time of 4 min for each sample made it possible to analyze more than 250 human plasma samples per day.,"Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18937306/),min,4,28782,DB00571,Propranolol
,7308238,initial elimination half-lives,"The initial elimination half-lives for Pranolium in the dog and primate were between 0.6 to 3.1 hours after i.v. dosage, but could not be determined after oral dosage.","Disposition of pranolium chloride in dogs, baboons and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308238/),h,0.6 to 3.1,29821,DB00571,Propranolol
,427002,Plasma half time,Plasma half time was 2.9 +/- 0.3 (s.e. mean) h for both routes; peak drug levels occurred 1--2 h after ingestion and bioavailability was 53%.,Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427002/),h,2.9,30762,DB00571,Propranolol
,427002,bioavailability,Plasma half time was 2.9 +/- 0.3 (s.e. mean) h for both routes; peak drug levels occurred 1--2 h after ingestion and bioavailability was 53%.,Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427002/),%,53,30763,DB00571,Propranolol
,427002,Plasma protein binding,Plasma protein binding was 38% and was independent of plasma concentration; the drug was not concentrated in the red cell.,Pindolol pharmacokinetics in relation to time course of inhibition of exercise tachycardia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/427002/),%,38,30764,DB00571,Propranolol
,3592861,peak concentrations (Cmax,"Concomitant administration of H caused a significant (p less than 0.05) increase in P peak concentrations (Cmax, 34 +/- 5: 73 +/- 10 ng/ml) and the area under plasma concentration time curve (AUC, 142 +/- 18: 254 +/- 56 ng/ml X hr) of P with significant (p less than 0.05) 24% reduction of the apparent oral clearance.",Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592861/),[ng] / [ml],34,32740,DB00571,Propranolol
,3592861,peak concentrations (Cmax,"Concomitant administration of H caused a significant (p less than 0.05) increase in P peak concentrations (Cmax, 34 +/- 5: 73 +/- 10 ng/ml) and the area under plasma concentration time curve (AUC, 142 +/- 18: 254 +/- 56 ng/ml X hr) of P with significant (p less than 0.05) 24% reduction of the apparent oral clearance.",Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592861/),[ng] / [ml],73,32741,DB00571,Propranolol
,3592861,area under plasma concentration time curve (AUC,"Concomitant administration of H caused a significant (p less than 0.05) increase in P peak concentrations (Cmax, 34 +/- 5: 73 +/- 10 ng/ml) and the area under plasma concentration time curve (AUC, 142 +/- 18: 254 +/- 56 ng/ml X hr) of P with significant (p less than 0.05) 24% reduction of the apparent oral clearance.",Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592861/),[ng] / [h·ml],142,32742,DB00571,Propranolol
,3592861,area under plasma concentration time curve (AUC,"Concomitant administration of H caused a significant (p less than 0.05) increase in P peak concentrations (Cmax, 34 +/- 5: 73 +/- 10 ng/ml) and the area under plasma concentration time curve (AUC, 142 +/- 18: 254 +/- 56 ng/ml X hr) of P with significant (p less than 0.05) 24% reduction of the apparent oral clearance.",Influence of hydralazine on the pharmacokinetics of orally administered d-propranolol and lidocaine in conscious dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3592861/),[ng] / [h·ml],254,32743,DB00571,Propranolol
,973955,half-life,The half-life of atenolol in blood was calculated to ablut 9 hours.,"Human pharmacokinetic and pharmacodynamic studies on the atenolo (ICI 66,082), a new cardioselective beta-adrenoceptor blocking drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/973955/),h,9,33107,DB00571,Propranolol
>,24947446,CL,"2. The clearance (CL) values of high CL compounds (CL > 50 mL/min/kg, namely propranolol, diazepam, phenytoin, ethinylestradiol, lorcaserin and fenfluramine) decreased significantly (1.5- to 6-fold) in DIO and AM rats as compared to lean rats, while there was no clear trend for change in CL for the low-to-moderate CL compounds (CL < 50 mL/min/kg, namely atenolol, chlorzoxazone, vancomycin and sibutramine).","Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24947446/),[ml] / [kg·min],50,34154,DB00571,Propranolol
<,24947446,CL,"2. The clearance (CL) values of high CL compounds (CL > 50 mL/min/kg, namely propranolol, diazepam, phenytoin, ethinylestradiol, lorcaserin and fenfluramine) decreased significantly (1.5- to 6-fold) in DIO and AM rats as compared to lean rats, while there was no clear trend for change in CL for the low-to-moderate CL compounds (CL < 50 mL/min/kg, namely atenolol, chlorzoxazone, vancomycin and sibutramine).","Role of hepatic blood flow and metabolism in the pharmacokinetics of ten drugs in lean, aged and obese rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24947446/),[ml] / [kg·min],50,34155,DB00571,Propranolol
,16015049,trough reductions,"Mean trough reductions were -8.0/-6.7 mm Hg and -7.6/-5.8 mm Hg, respectively.",Comparison of a chronotherapeutically administered beta blocker vs. a traditionally administered beta blocker in patients with hypertension. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16015049/),hg·mm,-8.0,34790,DB00571,Propranolol
,16015049,trough reductions,"Mean trough reductions were -8.0/-6.7 mm Hg and -7.6/-5.8 mm Hg, respectively.",Comparison of a chronotherapeutically administered beta blocker vs. a traditionally administered beta blocker in patients with hypertension. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16015049/),hg·mm,-,34791,DB00571,Propranolol
,16015049,trough reductions,"Mean trough reductions were -8.0/-6.7 mm Hg and -7.6/-5.8 mm Hg, respectively.",Comparison of a chronotherapeutically administered beta blocker vs. a traditionally administered beta blocker in patients with hypertension. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16015049/),hg·mm,7.6,34792,DB00571,Propranolol
,3718810,V,After intravenous administration there was no difference in plasma clearance but the volume of distribution was greater (V = 339 l vs 198 l) and the half-life was longer (t1/2 = 5.0 h vs 3.0 h) in the obese group.,A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718810/),l,339,34802,DB00571,Propranolol
,3718810,V,After intravenous administration there was no difference in plasma clearance but the volume of distribution was greater (V = 339 l vs 198 l) and the half-life was longer (t1/2 = 5.0 h vs 3.0 h) in the obese group.,A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718810/),l,198,34803,DB00571,Propranolol
,3718810,t1/2,After intravenous administration there was no difference in plasma clearance but the volume of distribution was greater (V = 339 l vs 198 l) and the half-life was longer (t1/2 = 5.0 h vs 3.0 h) in the obese group.,A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718810/),h,5.0,34804,DB00571,Propranolol
,3718810,t1/2,After intravenous administration there was no difference in plasma clearance but the volume of distribution was greater (V = 339 l vs 198 l) and the half-life was longer (t1/2 = 5.0 h vs 3.0 h) in the obese group.,A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718810/),h,3.0,34805,DB00571,Propranolol
,3718810,systemic availability,A trend towards higher systemic availability in the obese group (35% vs 27%) was not statistically significant.,A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718810/),%,35,34806,DB00571,Propranolol
,3718810,systemic availability,A trend towards higher systemic availability in the obese group (35% vs 27%) was not statistically significant.,A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718810/),%,27,34807,DB00571,Propranolol
,10201688,CO,The CO of individual pigs varied from 1.33 to 6.44 l/min.,Recirculatory and compartmental pharmacokinetic modeling of alfentanil in pigs: the influence of cardiac output. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10201688/),[l] / [min],1.33 to 6.44,35223,DB00571,Propranolol
,8489559,relative bioavailability,"The relative bioavailability of propranolol (CAS 525-66-6) from three SR suppositories containing stearic acid, 7.5 and 10% and bees wax, 5%, was 86.4, 87.8, and 83.6% respectively.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),%,7.5,37713,DB00571,Propranolol
,8489559,relative bioavailability,"The relative bioavailability of propranolol (CAS 525-66-6) from three SR suppositories containing stearic acid, 7.5 and 10% and bees wax, 5%, was 86.4, 87.8, and 83.6% respectively.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),%,10,37714,DB00571,Propranolol
,8489559,relative bioavailability,"The relative bioavailability of propranolol (CAS 525-66-6) from three SR suppositories containing stearic acid, 7.5 and 10% and bees wax, 5%, was 86.4, 87.8, and 83.6% respectively.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),%,5,37715,DB00571,Propranolol
,8489559,relative bioavailability,"The relative bioavailability of propranolol (CAS 525-66-6) from three SR suppositories containing stearic acid, 7.5 and 10% and bees wax, 5%, was 86.4, 87.8, and 83.6% respectively.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),%,86.4,37716,DB00571,Propranolol
,8489559,relative bioavailability,"The relative bioavailability of propranolol (CAS 525-66-6) from three SR suppositories containing stearic acid, 7.5 and 10% and bees wax, 5%, was 86.4, 87.8, and 83.6% respectively.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),%,87.8,37717,DB00571,Propranolol
,8489559,relative bioavailability,"The relative bioavailability of propranolol (CAS 525-66-6) from three SR suppositories containing stearic acid, 7.5 and 10% and bees wax, 5%, was 86.4, 87.8, and 83.6% respectively.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),%,83.6,37718,DB00571,Propranolol
,8489559,minimum concentration,"A minimum concentration of 40-60 ng/ml drug in plasma was maintained during 1-10 h, and there has been a minimum of about 40-50% of beta-blockade during 1-9 h post administration.",In vitro and in vivo studies on slow release propranolol hydrochloride suppositories. Pharmacokinetic and pharmacodynamic evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8489559/),[ng] / [ml],40-60,37719,DB00571,Propranolol
,10124,plasma half-life,The mean (+/-SD) plasma half-life for oral doses is 1.94 +/- 0.37 and for intravenous doses is 2.31 +/- 0.64 hr.,Pharmacokinetics of oxprenolol in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10124/),h,1.94,38269,DB00571,Propranolol
,10124,plasma half-life,The mean (+/-SD) plasma half-life for oral doses is 1.94 +/- 0.37 and for intravenous doses is 2.31 +/- 0.64 hr.,Pharmacokinetics of oxprenolol in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10124/),h,2.31,38270,DB00571,Propranolol
,10124,bioavailabilty,Comparison of oral and intravenous data reveals the variation in bioavailabilty of orally administered oxprenolol to range from 19% to 74%.,Pharmacokinetics of oxprenolol in normal subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10124/),%,19,38271,DB00571,Propranolol
,10124,bioavailabilty,Comparison of oral and intravenous data reveals the variation in bioavailabilty of orally administered oxprenolol to range from 19% to 74%.,Pharmacokinetics of oxprenolol in normal subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10124/),%,74,38272,DB00571,Propranolol
,8111301,rate of drug administration to the systemic,The rate of drug administration to the systemic bed was 0.08 mg/h per cm propercuten.,[The pharmacokinetics of propranolol when used with the propercuten transdermal therapeutic system (experimental data)]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8111301/),[mg] / [cm·h],0.08,38988,DB00571,Propranolol
,8111301,elimination time,"The constant injection rate was maintained during 5 days, but when propercuten was withdrawn the elimination time of propranolol was 24 hours.",[The pharmacokinetics of propranolol when used with the propercuten transdermal therapeutic system (experimental data)]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8111301/),h,24,38989,DB00571,Propranolol
,3373560,excretions,"About 98% of the ivg applied dose was absorbed after 6 h in gravid rats, and the combined 6-h excretions of radioactivity in the urine (ivg = 24.6%; po = 22.9%) and feces (ivg = 16.8%; po = 14.6%) were equivalent in both groups.",Transplacental and mammary passage of radioactivity in rats treated vaginally and orally with [14C]propranolol. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3373560/),%,24.6,41390,DB00571,Propranolol
,3373560,excretions,"About 98% of the ivg applied dose was absorbed after 6 h in gravid rats, and the combined 6-h excretions of radioactivity in the urine (ivg = 24.6%; po = 22.9%) and feces (ivg = 16.8%; po = 14.6%) were equivalent in both groups.",Transplacental and mammary passage of radioactivity in rats treated vaginally and orally with [14C]propranolol. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3373560/),%,22.9,41391,DB00571,Propranolol
,3373560,excretions,"About 98% of the ivg applied dose was absorbed after 6 h in gravid rats, and the combined 6-h excretions of radioactivity in the urine (ivg = 24.6%; po = 22.9%) and feces (ivg = 16.8%; po = 14.6%) were equivalent in both groups.",Transplacental and mammary passage of radioactivity in rats treated vaginally and orally with [14C]propranolol. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3373560/),%,16.8,41392,DB00571,Propranolol
,3373560,excretions,"About 98% of the ivg applied dose was absorbed after 6 h in gravid rats, and the combined 6-h excretions of radioactivity in the urine (ivg = 24.6%; po = 22.9%) and feces (ivg = 16.8%; po = 14.6%) were equivalent in both groups.",Transplacental and mammary passage of radioactivity in rats treated vaginally and orally with [14C]propranolol. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3373560/),%,14.6,41393,DB00571,Propranolol
,6362951,systemic bioavailability,The high hepatic extraction results in low systemic bioavailability (20%) after oral drug administration.,Clinical pharmacokinetics of verapamil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6362951/),%,20,41666,DB00571,Propranolol
,33917412,flow rate,"The polar organic mobile phase composed of acetonitrile/methanol/trifluoroacetic acid/triethylamine (98:2:0.05: 0.025, v/v/v/v) and a flow rate of 0.5 mL/min was applied.",Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33917412/),[ml] / [min],0.5,42615,DB00571,Propranolol
,33917412,recoveries,The intra- and inter-day precisions were not more than 11.6% and the recoveries of S-(-)- and R-(+)-VER at all quality control levels ranged from 92.3% to 98.2%.,Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33917412/),%,92.3,42616,DB00571,Propranolol
,33917412,recoveries,The intra- and inter-day precisions were not more than 11.6% and the recoveries of S-(-)- and R-(+)-VER at all quality control levels ranged from 92.3% to 98.2%.,Development and Validation of a Chiral Liquid Chromatographic Assay for Enantiomeric Separation and Quantification of Verapamil in Rat Plasma: Stereoselective Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33917412/),%,98.2,42617,DB00571,Propranolol
,6151871,brain:plasma uptake ratio,"Propranolol, by far the most lipophilic beta-blocker in vitro, had the highest in vivo metabolic clearance and volume of distribution (Vd), the most rapid entry into CSF, and the highest brain:plasma uptake ratio (38.0).","Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151871/),,38.0,44818,DB00571,Propranolol
,6151871,brain:plasma ratio,"Sotalol, the most hydrophilic drug in vitro, had the lowest in vivo clearance and Vd, the slowest CSF entry, and the lowest brain:plasma ratio (0.52).","Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151871/),,0.52,44819,DB00571,Propranolol
,6151871,brain:plasma uptake ratio,"Acebutolol had slightly greater in vitro lipophilicity than sotalol, intermediate values of in vivo plasma kinetics and CSF entry rate, and a slightly greater brain:plasma uptake ratio (0.71).","Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. ",Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6151871/),,0.71,44820,DB00571,Propranolol
,25882014,maximum concentration,"What is more, the plasma pharmacokinetic showed the maximum concentration in plasma was 0.41 μg/mL and 1.17 μg/mL after topical and oral administration respectively.",Propranolol hydrochloride-loaded liposomal gel for transdermal delivery: Characterization and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25882014/),[μg] / [ml],0.41,44923,DB00571,Propranolol
,25882014,maximum concentration,"What is more, the plasma pharmacokinetic showed the maximum concentration in plasma was 0.41 μg/mL and 1.17 μg/mL after topical and oral administration respectively.",Propranolol hydrochloride-loaded liposomal gel for transdermal delivery: Characterization and in vivo evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25882014/),[μg] / [ml],1.17,44924,DB00571,Propranolol
,12554132,flow-rate,"Chromatography was performed on an ODS MS column with a mobile phase consisting of acetonitrile (containing 0.1% trifluoroacetic acid, v/v)-0.1% trifluoroacetic acid (55:45, v/v) at a flow-rate of 0.3 ml/min.",Determination of the active metabolite of sibutramine by liquid chromatography-electrospray ionization tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12554132/),[ml] / [min],0.3,45326,DB00571,Propranolol
,2901480,recirculation rate,Lung isolated from 7-week-old rats was perfused with pH 7.4 Krebs-Ringer bicarbonate buffer solution (35 mL) containing 1 to 100 micrograms mL-1 of propranolol and 3% BSA at the recirculation rate of 8 mL min-1.,Propranolol uptake with high capacity by rat perfused lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901480/),[ml] / [min],8,45362,DB00571,Propranolol
,2901480,pulmonary perfusion clearance,Pharmacokinetic analysis for the perfusate propranolol concentration-time curves when loaded at 1 to 10 micrograms mL-1 yielded almost comparable values for the pulmonary perfusion clearance (0.387 +/- 0.092 to 0.486 +/- 0.095 mL min-1 g-1).,Propranolol uptake with high capacity by rat perfused lung. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901480/),[ml] / [g·min],0.387,45363,DB00571,Propranolol
,2901480,pulmonary perfusion clearance,Pharmacokinetic analysis for the perfusate propranolol concentration-time curves when loaded at 1 to 10 micrograms mL-1 yielded almost comparable values for the pulmonary perfusion clearance (0.387 +/- 0.092 to 0.486 +/- 0.095 mL min-1 g-1).,Propranolol uptake with high capacity by rat perfused lung. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2901480/),[ml] / [g·min],0.486,45364,DB00571,Propranolol
,1017154,peak blood,"However, peak blood and plasma concentrations of propranolol in the chronic renal failure group were 2- to 3-fold higher (161 +/- 41 ng/ml) than those observed in the dialysis patients (47 +/- 9 ng/ml) and in the healthy volunteers (26 +/- 1 ng/ml).",Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1017154/),[ng] / [ml],161,47005,DB00571,Propranolol
,1017154,peak blood,"However, peak blood and plasma concentrations of propranolol in the chronic renal failure group were 2- to 3-fold higher (161 +/- 41 ng/ml) than those observed in the dialysis patients (47 +/- 9 ng/ml) and in the healthy volunteers (26 +/- 1 ng/ml).",Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1017154/),[ng] / [ml],47,47006,DB00571,Propranolol
,1017154,plasma concentrations,"However, peak blood and plasma concentrations of propranolol in the chronic renal failure group were 2- to 3-fold higher (161 +/- 41 ng/ml) than those observed in the dialysis patients (47 +/- 9 ng/ml) and in the healthy volunteers (26 +/- 1 ng/ml).",Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1017154/),[ng] / [ml],26,47007,DB00571,Propranolol
,7650226,Cmax S/R ratios,"Specifically, for phase B, which had the highest Cmax concentrations, the Cmax S/R ratio was significantly lower than the other oral dosage groups A and C (Cmax S/R ratios: 1.44 versus 1.54 and 1.54, respectively; P < .05).",The effect of dosage release formulations on the pharmacokinetics of propranolol stereoisomers in humans. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650226/),,1.44,47410,DB00571,Propranolol
,7650226,Cmax S/R ratios,"Specifically, for phase B, which had the highest Cmax concentrations, the Cmax S/R ratio was significantly lower than the other oral dosage groups A and C (Cmax S/R ratios: 1.44 versus 1.54 and 1.54, respectively; P < .05).",The effect of dosage release formulations on the pharmacokinetics of propranolol stereoisomers in humans. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650226/),,1.54,47411,DB00571,Propranolol
,1501071,bioavailability,"The bioavailability of aspirin following nasal administration was 100%, whereas the oral bioavailability was only 58.8% at the dose studied.",Absorption of acetylsalicylic acid from the rat nasal cavity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501071/),%,100,47766,DB00571,Propranolol
,1501071,oral bioavailability,"The bioavailability of aspirin following nasal administration was 100%, whereas the oral bioavailability was only 58.8% at the dose studied.",Absorption of acetylsalicylic acid from the rat nasal cavity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501071/),%,58.8,47767,DB00571,Propranolol
,6111331,maximum effect,The maximum effect (34.4 +/- 2.2%) occurred after 40 mg.,"Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),%,34.4,49948,DB00571,Propranolol
,6111331,plasma elimination half-lives,"The plasma elimination half-lives after 10, 20 and 40 mg were 11.4 +/- 2.5, 15.9 +/- 4.9 and 15.1 +/- 3.1 h.","Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),h,11.4,49949,DB00571,Propranolol
,6111331,plasma elimination half-lives,"The plasma elimination half-lives after 10, 20 and 40 mg were 11.4 +/- 2.5, 15.9 +/- 4.9 and 15.1 +/- 3.1 h.","Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),h,15.9,49950,DB00571,Propranolol
,6111331,plasma elimination half-lives,"The plasma elimination half-lives after 10, 20 and 40 mg were 11.4 +/- 2.5, 15.9 +/- 4.9 and 15.1 +/- 3.1 h.","Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),h,15.1,49951,DB00571,Propranolol
,6111331,half-life,The half-life for betaxolol was 24.5 h which was longer than that for any of the other drugs.,"Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6111331/),h,24.5,49952,DB00571,Propranolol
,11085362,fraction absorbed,"The fraction absorbed of PPL was approximately 70% after oral administration, and the bioavailability varied among individual horses from 1 to 79% depending on the first pass metabolism.",Pharmacokinetics of propranolol and its metabolites in horses after intravenous or oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085362/),%,70,50258,DB00571,Propranolol
,11085362,bioavailability,"The fraction absorbed of PPL was approximately 70% after oral administration, and the bioavailability varied among individual horses from 1 to 79% depending on the first pass metabolism.",Pharmacokinetics of propranolol and its metabolites in horses after intravenous or oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085362/),%,1,50259,DB00571,Propranolol
,11085362,bioavailability,"The fraction absorbed of PPL was approximately 70% after oral administration, and the bioavailability varied among individual horses from 1 to 79% depending on the first pass metabolism.",Pharmacokinetics of propranolol and its metabolites in horses after intravenous or oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085362/),%,79,50260,DB00571,Propranolol
,11085362,T 1/2,T 1/2 of PPL in horses was approximately 2 h.,Pharmacokinetics of propranolol and its metabolites in horses after intravenous or oral administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11085362/),h,2,50261,DB00571,Propranolol
,6716273,Cpmax,"Coadministration of oral hydralazine and propranolol in conscious dogs caused an increase in peak plasma concentration ( Cpmax ) and area under the oral plasma concentration-time curve (AUC) of propranolol ( Cpmax = 19.2 +/- 5.8 ng/ml, control; Cpmax = 91.5 +/- 12.8 ng/ml, posthydralazine : AUC = 65.7 +/- 14.6 ng X hr/ml, control; AUC = 152.4 +/- 23.9 ng X hr/ml, posthydralazine : mean +/- S.E.M., n = 5; P less than .01 and P less than .01), without change either in the peak plasma level, time to peak or plasma AUC of [14C] propranolol and metabolites (P greater than .70, P greater than .90 and P greater than .60, respectively) or in urinary recovery (urinary recovery = 39.7 +/- 4.3% dose, control; urinary recovery = 41.8 +/- 6.2% dose, posthydralazine ).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),[ng] / [ml],19.2,51119,DB00571,Propranolol
,6716273,Cpmax,"Coadministration of oral hydralazine and propranolol in conscious dogs caused an increase in peak plasma concentration ( Cpmax ) and area under the oral plasma concentration-time curve (AUC) of propranolol ( Cpmax = 19.2 +/- 5.8 ng/ml, control; Cpmax = 91.5 +/- 12.8 ng/ml, posthydralazine : AUC = 65.7 +/- 14.6 ng X hr/ml, control; AUC = 152.4 +/- 23.9 ng X hr/ml, posthydralazine : mean +/- S.E.M., n = 5; P less than .01 and P less than .01), without change either in the peak plasma level, time to peak or plasma AUC of [14C] propranolol and metabolites (P greater than .70, P greater than .90 and P greater than .60, respectively) or in urinary recovery (urinary recovery = 39.7 +/- 4.3% dose, control; urinary recovery = 41.8 +/- 6.2% dose, posthydralazine ).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),[ng] / [ml],91.5,51120,DB00571,Propranolol
,6716273,AUC,"Coadministration of oral hydralazine and propranolol in conscious dogs caused an increase in peak plasma concentration ( Cpmax ) and area under the oral plasma concentration-time curve (AUC) of propranolol ( Cpmax = 19.2 +/- 5.8 ng/ml, control; Cpmax = 91.5 +/- 12.8 ng/ml, posthydralazine : AUC = 65.7 +/- 14.6 ng X hr/ml, control; AUC = 152.4 +/- 23.9 ng X hr/ml, posthydralazine : mean +/- S.E.M., n = 5; P less than .01 and P less than .01), without change either in the peak plasma level, time to peak or plasma AUC of [14C] propranolol and metabolites (P greater than .70, P greater than .90 and P greater than .60, respectively) or in urinary recovery (urinary recovery = 39.7 +/- 4.3% dose, control; urinary recovery = 41.8 +/- 6.2% dose, posthydralazine ).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),[h·ng] / [ml],65.7,51121,DB00571,Propranolol
,6716273,AUC,"Coadministration of oral hydralazine and propranolol in conscious dogs caused an increase in peak plasma concentration ( Cpmax ) and area under the oral plasma concentration-time curve (AUC) of propranolol ( Cpmax = 19.2 +/- 5.8 ng/ml, control; Cpmax = 91.5 +/- 12.8 ng/ml, posthydralazine : AUC = 65.7 +/- 14.6 ng X hr/ml, control; AUC = 152.4 +/- 23.9 ng X hr/ml, posthydralazine : mean +/- S.E.M., n = 5; P less than .01 and P less than .01), without change either in the peak plasma level, time to peak or plasma AUC of [14C] propranolol and metabolites (P greater than .70, P greater than .90 and P greater than .60, respectively) or in urinary recovery (urinary recovery = 39.7 +/- 4.3% dose, control; urinary recovery = 41.8 +/- 6.2% dose, posthydralazine ).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),[h·ng] / [ml],152.4,51122,DB00571,Propranolol
,6716273,Oral bioavailability,"Oral bioavailability increased from 7.3 +/- 2.1 to 23.6 +/- 5.1% (mean +/- S.E.M., n = 5, P less than .025), hepatic extraction showed correspondingly inverse changes and estimated hepatic blood flow increased from 34.9 +/- 3.8 to 63.3 +/- 10.8 ml/min/kg (P less than .025).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),%,7.3,51123,DB00571,Propranolol
,6716273,Oral bioavailability,"Oral bioavailability increased from 7.3 +/- 2.1 to 23.6 +/- 5.1% (mean +/- S.E.M., n = 5, P less than .025), hepatic extraction showed correspondingly inverse changes and estimated hepatic blood flow increased from 34.9 +/- 3.8 to 63.3 +/- 10.8 ml/min/kg (P less than .025).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),%,23.6,51124,DB00571,Propranolol
,6716273,hepatic blood flow,"Oral bioavailability increased from 7.3 +/- 2.1 to 23.6 +/- 5.1% (mean +/- S.E.M., n = 5, P less than .025), hepatic extraction showed correspondingly inverse changes and estimated hepatic blood flow increased from 34.9 +/- 3.8 to 63.3 +/- 10.8 ml/min/kg (P less than .025).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),[ml] / [kg·min],34.9,51125,DB00571,Propranolol
,6716273,hepatic blood flow,"Oral bioavailability increased from 7.3 +/- 2.1 to 23.6 +/- 5.1% (mean +/- S.E.M., n = 5, P less than .025), hepatic extraction showed correspondingly inverse changes and estimated hepatic blood flow increased from 34.9 +/- 3.8 to 63.3 +/- 10.8 ml/min/kg (P less than .025).","Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow. ",QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6716273/),[ml] / [kg·min],63.3,51126,DB00571,Propranolol
,2550636,maximum serum concentration (Cmax),"The maximum serum concentration (Cmax) of lisinopril and time to reach maximum concentration (Tmax) were 64 +/- 16 ng/ml and 7.5 +/- 1.5 h, respectively.","Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[ng] / [ml],64,52064,DB00571,Propranolol
,2550636,time to reach maximum concentration (Tmax),"The maximum serum concentration (Cmax) of lisinopril and time to reach maximum concentration (Tmax) were 64 +/- 16 ng/ml and 7.5 +/- 1.5 h, respectively.","Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),h,7.5,52065,DB00571,Propranolol
,2550636,area under the serum curve (AUC),The area under the serum curve (AUC) was 916 +/- 239 h.,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),h,916,52066,DB00571,Propranolol
,2550636,Cmax,The Cmax of enalaprilat (89 +/- 34 ng/ml) was greater than that of lisinopril whilst Tmax was shorter (4.3 +/- 1.7 h) and AUC smaller (718 +/- 17 h.ng/ml) (P less than 0.01).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[ng] / [ml],89,52067,DB00571,Propranolol
,2550636,Tmax,The Cmax of enalaprilat (89 +/- 34 ng/ml) was greater than that of lisinopril whilst Tmax was shorter (4.3 +/- 1.7 h) and AUC smaller (718 +/- 17 h.ng/ml) (P less than 0.01).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),h,4.3,52068,DB00571,Propranolol
,2550636,AUC,The Cmax of enalaprilat (89 +/- 34 ng/ml) was greater than that of lisinopril whilst Tmax was shorter (4.3 +/- 1.7 h) and AUC smaller (718 +/- 17 h.ng/ml) (P less than 0.01).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[h·ng] / [ml],718,52069,DB00571,Propranolol
,2550636,Renal clearance of drug,Renal clearance of drug 48 h post-dosing showed that enalaprilat (164 +/- 38 ml/min) was cleared from plasma significantly more rapidly than lisinopril (82 +/- 16 ml/min) (P less than 0.001).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[ml] / [min],164,52070,DB00571,Propranolol
,2550636,Renal clearance of drug,Renal clearance of drug 48 h post-dosing showed that enalaprilat (164 +/- 38 ml/min) was cleared from plasma significantly more rapidly than lisinopril (82 +/- 16 ml/min) (P less than 0.001).,"Comparative pharmacokinetics and pharmacodynamics of lisinopril and enalapril, alone and in combination with propranolol. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550636/),[ml] / [min],82,52071,DB00571,Propranolol
,2885168,half-life,"Since esmolol is rapidly metabolised by blood-borne esterases, it has a very short half-life (about 9 mins) and a short duration of action.","Esmolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2885168/),min,9,53140,DB00571,Propranolol
,8786248,hepatic blood flow,Adjusted mean estimated hepatic blood flow after exercise corrected for body weight for the young subjects who did not exercise (15.6 mL/min/Kg) and those who did (18.2 mL/min/Kg) groups were of borderline significance.,The lack of effect of aerobic exercise training on propranolol pharmacokinetics in young and elderly adults. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786248/),[ml] / [kg·min],15.6,54346,DB00571,Propranolol
,8786248,hepatic blood flow,Adjusted mean estimated hepatic blood flow after exercise corrected for body weight for the young subjects who did not exercise (15.6 mL/min/Kg) and those who did (18.2 mL/min/Kg) groups were of borderline significance.,The lack of effect of aerobic exercise training on propranolol pharmacokinetics in young and elderly adults. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786248/),[ml] / [kg·min],18.2,54347,DB00571,Propranolol
,3252038,M/P,"Observed M/P values fell from 2.13 +/- 0.42 to 1.23 +/- 0.34) AAG administration, closely approximated M/P observed in vivo.",Effect of altered serum protein binding on propranolol distribution into milk in the lactating rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252038/),,2.13,54631,DB00571,Propranolol
,3252038,M/P,"Observed M/P values fell from 2.13 +/- 0.42 to 1.23 +/- 0.34) AAG administration, closely approximated M/P observed in vivo.",Effect of altered serum protein binding on propranolol distribution into milk in the lactating rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3252038/),,1.23,54632,DB00571,Propranolol
,15355124,oral clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],22-36,55128,DB00571,Propranolol
,15355124,renal clearance,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),[ml] / [min],10-20,55129,DB00571,Propranolol
,15355124,half-life,"The pharmacokinetics of topiramate are characterised by linear pharmacokinetics over the dose range 100-800 mg, low oral clearance (22-36 mL/min), which, in monotherapy, is predominantly through renal excretion (renal clearance 10-20 mL/min), and a long half-life (19-25 hours), which is reduced when coadministered with inducing AEDs such as phenytoin, phenobarbital and carbamazepine.",Pharmacokinetic interactions of topiramate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),h,19-25,55130,DB00571,Propranolol
,15355124,absolute bioavailability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55131,DB00571,Propranolol
,15355124,oral availability,"The absolute bioavailability, or oral availability, of topiramate is 81-95% and is not affected by food.",Pharmacokinetic interactions of topiramate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355124/),%,81-95,55132,DB00571,Propranolol
,7851052,Bioavailability,"Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism.",Sumatriptan clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7851052/),%,96,55552,DB00571,Propranolol
,7851052,Bioavailability,"Bioavailability is high (96%) following subcutaneous injection, but low (14%) following oral administration because of first-pass metabolism.",Sumatriptan clinical pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7851052/),%,14,55553,DB00571,Propranolol
,7851052,elimination half-life,"Total plasma clearance is rapid, with an elimination half-life of around 2 hours.",Sumatriptan clinical pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7851052/),h,2,55554,DB00571,Propranolol
,455886,areas under the plasma concentration--time curves (AUCs),"The areas under the plasma concentration--time curves (AUCs) of propranolol glucuronide (PG), 41 +/- 15 ng .",Presystemic and systemic glucuronidation of propranolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455886/),ng,41,55738,DB00571,Propranolol
,455886,AUCs,"After oral doses of 20 and 80 mg, the AUCs of PG were 302 +/- 105 and 1,398 +/- 409 ng . hr/ml; these were 7 times the AUCs of propranolol, 44 +/- 15 and 220 +/- 38 ng . hr/ml.",Presystemic and systemic glucuronidation of propranolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455886/),[h·ng] / [ml],302,55739,DB00571,Propranolol
,455886,AUCs,"After oral doses of 20 and 80 mg, the AUCs of PG were 302 +/- 105 and 1,398 +/- 409 ng . hr/ml; these were 7 times the AUCs of propranolol, 44 +/- 15 and 220 +/- 38 ng . hr/ml.",Presystemic and systemic glucuronidation of propranolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455886/),[h·ng] / [ml],"1,398",55740,DB00571,Propranolol
,455886,AUCs,"After oral doses of 20 and 80 mg, the AUCs of PG were 302 +/- 105 and 1,398 +/- 409 ng . hr/ml; these were 7 times the AUCs of propranolol, 44 +/- 15 and 220 +/- 38 ng . hr/ml.",Presystemic and systemic glucuronidation of propranolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455886/),[h·ng] / [ml],44,55741,DB00571,Propranolol
,455886,AUCs,"After oral doses of 20 and 80 mg, the AUCs of PG were 302 +/- 105 and 1,398 +/- 409 ng . hr/ml; these were 7 times the AUCs of propranolol, 44 +/- 15 and 220 +/- 38 ng . hr/ml.",Presystemic and systemic glucuronidation of propranolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455886/),[h·ng] / [ml],220,55742,DB00571,Propranolol
,455886,time lapse to peak concentration,"The time lapse to peak concentration, 1.5 to 3.0 hr, and the plasma half-life, 3.2 to 3.7 hr, were the same for PG and propranolol.",Presystemic and systemic glucuronidation of propranolol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455886/),h,1.5 to 3.0,55743,DB00571,Propranolol
,455886,plasma half-life,"The time lapse to peak concentration, 1.5 to 3.0 hr, and the plasma half-life, 3.2 to 3.7 hr, were the same for PG and propranolol.",Presystemic and systemic glucuronidation of propranolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/455886/),h,3.2 to 3.7,55744,DB00571,Propranolol
,15793873,k,"The mean values of k were 0.19+/-0.04 h(-1) and 0.28+/-0.06 h(-1), of t(1/2) 3.56+/-0.73 h and 2.45+/-0.50 h, of T(max) 2.21+/-0.45 and 1.75+/-0.33 h, and of Xu(0-24) 5.65+/-0.98 and 2.95+/-0.62 micromoL for S-(-)- and R-(+)-propranolol glucuronide, respectively.",Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793873/),1/[h],0.19,56341,DB00571,Propranolol
,15793873,k,"The mean values of k were 0.19+/-0.04 h(-1) and 0.28+/-0.06 h(-1), of t(1/2) 3.56+/-0.73 h and 2.45+/-0.50 h, of T(max) 2.21+/-0.45 and 1.75+/-0.33 h, and of Xu(0-24) 5.65+/-0.98 and 2.95+/-0.62 micromoL for S-(-)- and R-(+)-propranolol glucuronide, respectively.",Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793873/),1/[h],0.28,56342,DB00571,Propranolol
,15793873,t(1/2),"The mean values of k were 0.19+/-0.04 h(-1) and 0.28+/-0.06 h(-1), of t(1/2) 3.56+/-0.73 h and 2.45+/-0.50 h, of T(max) 2.21+/-0.45 and 1.75+/-0.33 h, and of Xu(0-24) 5.65+/-0.98 and 2.95+/-0.62 micromoL for S-(-)- and R-(+)-propranolol glucuronide, respectively.",Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793873/),h,3.56,56343,DB00571,Propranolol
,15793873,t(1/2),"The mean values of k were 0.19+/-0.04 h(-1) and 0.28+/-0.06 h(-1), of t(1/2) 3.56+/-0.73 h and 2.45+/-0.50 h, of T(max) 2.21+/-0.45 and 1.75+/-0.33 h, and of Xu(0-24) 5.65+/-0.98 and 2.95+/-0.62 micromoL for S-(-)- and R-(+)-propranolol glucuronide, respectively.",Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793873/),h,2.45,56344,DB00571,Propranolol
,15793873,T(max),"The mean values of k were 0.19+/-0.04 h(-1) and 0.28+/-0.06 h(-1), of t(1/2) 3.56+/-0.73 h and 2.45+/-0.50 h, of T(max) 2.21+/-0.45 and 1.75+/-0.33 h, and of Xu(0-24) 5.65+/-0.98 and 2.95+/-0.62 micromoL for S-(-)- and R-(+)-propranolol glucuronide, respectively.",Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793873/),h,2.21,56345,DB00571,Propranolol
,15793873,T(max),"The mean values of k were 0.19+/-0.04 h(-1) and 0.28+/-0.06 h(-1), of t(1/2) 3.56+/-0.73 h and 2.45+/-0.50 h, of T(max) 2.21+/-0.45 and 1.75+/-0.33 h, and of Xu(0-24) 5.65+/-0.98 and 2.95+/-0.62 micromoL for S-(-)- and R-(+)-propranolol glucuronide, respectively.",Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793873/),h,1.75,56346,DB00571,Propranolol
,15793873,Xu(0-24),"The mean values of k were 0.19+/-0.04 h(-1) and 0.28+/-0.06 h(-1), of t(1/2) 3.56+/-0.73 h and 2.45+/-0.50 h, of T(max) 2.21+/-0.45 and 1.75+/-0.33 h, and of Xu(0-24) 5.65+/-0.98 and 2.95+/-0.62 micromoL for S-(-)- and R-(+)-propranolol glucuronide, respectively.",Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793873/),μM,5.65,56347,DB00571,Propranolol
,15793873,Xu(0-24),"The mean values of k were 0.19+/-0.04 h(-1) and 0.28+/-0.06 h(-1), of t(1/2) 3.56+/-0.73 h and 2.45+/-0.50 h, of T(max) 2.21+/-0.45 and 1.75+/-0.33 h, and of Xu(0-24) 5.65+/-0.98 and 2.95+/-0.62 micromoL for S-(-)- and R-(+)-propranolol glucuronide, respectively.",Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793873/),μM,2.95,56348,DB00571,Propranolol
,15793873,cumulative excretion percentages,"The cumulative excretion percentages in urine of doses were 14.7+/-2.46% and 7.68+/-1.60% for S-(-)- and R-(+)-propranolol glucuronide, respectively.",Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793873/),%,14.7,56349,DB00571,Propranolol
,15793873,cumulative excretion percentages,"The cumulative excretion percentages in urine of doses were 14.7+/-2.46% and 7.68+/-1.60% for S-(-)- and R-(+)-propranolol glucuronide, respectively.",Stereoselective urinary excretion of S-(-)- and R-(+)-propranolol glucuronide following oral administration of RS-propranolol in Chinese Han subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15793873/),%,7.68,56350,DB00571,Propranolol
,4205524,total hepatic blood flow,Phenobarbital significantly increased total hepatic blood flow from 179+/-15 to 239+/-27 ml/min.,Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4205524/),[ml] / [min],179,56651,DB00571,Propranolol
,4205524,total hepatic blood flow,Phenobarbital significantly increased total hepatic blood flow from 179+/-15 to 239+/-27 ml/min.,Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4205524/),[ml] / [min],239,56652,DB00571,Propranolol
,6512676,availability,The mean availability of propranolol after oral administration increased from 0.120 in control to 0.215 in ARF (p less than 0.005).,Increased availability of propranolol in rats with uranyl nitrate-induced acute renal failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512676/),,0.120,57292,DB00571,Propranolol
,6512676,availability,The mean availability of propranolol after oral administration increased from 0.120 in control to 0.215 in ARF (p less than 0.005).,Increased availability of propranolol in rats with uranyl nitrate-induced acute renal failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512676/),,0.215,57293,DB00571,Propranolol
,6512676,intrinsic clearance,"On the other hand, hepatic clearance of propranolol determined by liver perfusion studies showed a significant reduction in ARF and the calculated intrinsic clearance of unbound propranolol at a dose of 6.25 mg was 26.8 +/- 2.3 ml/min in control and 16.0 +/- 2.3 ml/min in ARF (p less than 0.01).",Increased availability of propranolol in rats with uranyl nitrate-induced acute renal failure. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512676/),[ml] / [min],26.8,57294,DB00571,Propranolol
,6512676,intrinsic clearance,"On the other hand, hepatic clearance of propranolol determined by liver perfusion studies showed a significant reduction in ARF and the calculated intrinsic clearance of unbound propranolol at a dose of 6.25 mg was 26.8 +/- 2.3 ml/min in control and 16.0 +/- 2.3 ml/min in ARF (p less than 0.01).",Increased availability of propranolol in rats with uranyl nitrate-induced acute renal failure. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512676/),[ml] / [min],16.0,57295,DB00571,Propranolol
,7215417,peaks plasma concentration (Cmax),Individual variation was observed in bioavailability; the peaks plasma concentration (Cmax) of 50 to 103 ng/ml being achieved at different times(0.5--3h).,Pharmacokinetics of oral timolol studied by mass fragmentography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215417/),[ng] / [ml],50 to 103,57352,DB00571,Propranolol
,7215417,residual level,The residual level after 12 h differed greatly between the subjects (0.8 to 7.2 ng/ml).,Pharmacokinetics of oral timolol studied by mass fragmentography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215417/),[ng] / [ml],0.8 to 7.2,57353,DB00571,Propranolol
,7215417,half-life of the terminal elimination phase,The mean half-life of the terminal elimination phase was 2.62 +/- 0.17 h.,Pharmacokinetics of oral timolol studied by mass fragmentography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215417/),h,2.62,57354,DB00571,Propranolol
,7215417,renal to body clearance ratio,"Extra-renal elimination (metabolic and biliary) represented the main route of elimination, with a renal to body clearance ratio of 0.123.",Pharmacokinetics of oral timolol studied by mass fragmentography. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7215417/),,0.123,57355,DB00571,Propranolol
,27557455,m/z,The acquisition was set up in the multiple reaction monitoring mode with the transitions m/z 360.3 → 138.0 for N-butylscopolamine and m/z 260.2 → 116.1 for IS.,A fast and sensitive UHPLC-MS/MS method for the determination of N-butylscopolamine in human plasma: application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557455/),,360.3,57809,DB00571,Propranolol
,27557455,m/z,The acquisition was set up in the multiple reaction monitoring mode with the transitions m/z 360.3 → 138.0 for N-butylscopolamine and m/z 260.2 → 116.1 for IS.,A fast and sensitive UHPLC-MS/MS method for the determination of N-butylscopolamine in human plasma: application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557455/),,138.0,57810,DB00571,Propranolol
,27557455,m/z,The acquisition was set up in the multiple reaction monitoring mode with the transitions m/z 360.3 → 138.0 for N-butylscopolamine and m/z 260.2 → 116.1 for IS.,A fast and sensitive UHPLC-MS/MS method for the determination of N-butylscopolamine in human plasma: application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557455/),,260.2,57811,DB00571,Propranolol
,27557455,m/z,The acquisition was set up in the multiple reaction monitoring mode with the transitions m/z 360.3 → 138.0 for N-butylscopolamine and m/z 260.2 → 116.1 for IS.,A fast and sensitive UHPLC-MS/MS method for the determination of N-butylscopolamine in human plasma: application in a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27557455/),,116.1,57812,DB00571,Propranolol
,8866453,terminal elimination half-life (t1/2),"The terminal elimination half-life (t1/2) for 4'-OHP was 69.4 min, the apparent volume of distribution (Vd) was 3.39 L/kg and the total clearance (Clt) was 53.6 mL/min.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),min,69.4,59495,DB00571,Propranolol
,8866453,apparent volume of distribution (Vd),"The terminal elimination half-life (t1/2) for 4'-OHP was 69.4 min, the apparent volume of distribution (Vd) was 3.39 L/kg and the total clearance (Clt) was 53.6 mL/min.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[l] / [kg],3.39,59496,DB00571,Propranolol
,8866453,total clearance (Clt),"The terminal elimination half-life (t1/2) for 4'-OHP was 69.4 min, the apparent volume of distribution (Vd) was 3.39 L/kg and the total clearance (Clt) was 53.6 mL/min.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ml] / [min],53.6,59497,DB00571,Propranolol
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],30,59498,DB00571,Propranolol
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],60,59499,DB00571,Propranolol
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],120,59500,DB00571,Propranolol
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],240,59501,DB00571,Propranolol
,8866453,steady-state plasma concentrations,"These data were subsequently used to calculate the loading and maintenance doses of 4'-OHP required to produce targeted steady-state plasma concentrations for 4'-OHP of 30, 60, 120, 240 and 480 ng/mL.","Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866453/),[ng] / [ml],480,59502,DB00571,Propranolol
,7082779,bioavailability,"Experiments have been carried out in dogs and man to determine the effect of hydrochlorothiazide (HCT) on the pharmacokinetics of propranolol and to evaluate the bioavailability of two dosage forms containing both propranolol and HCT (40/25 and 80/25 mg, respectively).",Biopharmaceutical characteristics of a new propranolol/hydrochlorothiazide tablet combination. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082779/),mg,40,59942,DB00571,Propranolol
,7082779,bioavailability,"Experiments have been carried out in dogs and man to determine the effect of hydrochlorothiazide (HCT) on the pharmacokinetics of propranolol and to evaluate the bioavailability of two dosage forms containing both propranolol and HCT (40/25 and 80/25 mg, respectively).",Biopharmaceutical characteristics of a new propranolol/hydrochlorothiazide tablet combination. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7082779/),mg,80,59943,DB00571,Propranolol
,3508566,clearance,"The oral administration of hydralazine hydrochloride, 7.5 mg/kg, 15 min prior to antipyrine administration reduced antipyrine clearance from 9.66 +/- 1.18 to 8.19 +/- 0.76 ml/min/kg (P less than 0.05).",Effect of hydralazine on the elimination of antipyrine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508566/),[ml] / [kg·min],9.66,61364,DB00571,Propranolol
,3508566,clearance,"The oral administration of hydralazine hydrochloride, 7.5 mg/kg, 15 min prior to antipyrine administration reduced antipyrine clearance from 9.66 +/- 1.18 to 8.19 +/- 0.76 ml/min/kg (P less than 0.05).",Effect of hydralazine on the elimination of antipyrine in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3508566/),[ml] / [kg·min],8.19,61365,DB00571,Propranolol
,7589027,maximum concentration (Cmax,"The sauna significantly increased the maximum concentration (Cmax 41 vs. 28 ng.ml-1) of propranolol and the mean plasma propranolol concentration 60 and 90 min, and 2 and 3 h after drug administration.",Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589027/),[ng] / [ml],41,63008,DB00571,Propranolol
,7589027,maximum concentration (Cmax,"The sauna significantly increased the maximum concentration (Cmax 41 vs. 28 ng.ml-1) of propranolol and the mean plasma propranolol concentration 60 and 90 min, and 2 and 3 h after drug administration.",Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589027/),[ng] / [ml],28,63009,DB00571,Propranolol
,7589027,AUC0-5h,It also significantly increased the AUC0-5h (119 vs 71 micrograms.,Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589027/),μg,119,63010,DB00571,Propranolol
,7589027,AUC0-5h,It also significantly increased the AUC0-5h (119 vs 71 micrograms.,Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589027/),μg,71,63011,DB00571,Propranolol
,1540484,peak plasma concentrations,The mean peak plasma concentrations of both (+)- and (-)-propranolol were significantly higher (P less than 0.05) in the elderly (105.7 +/- 19.7 and 165.0 +/- 29.7 nmol l-1) compared with the young subjects (68.6 +/- 10.1 and 115.7 +/- 18.1 nmol l-1).,Lack of effect of ageing on the stereochemical disposition of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540484/),[nM] / [l],105.7,63693,DB00571,Propranolol
,1540484,peak plasma concentrations,The mean peak plasma concentrations of both (+)- and (-)-propranolol were significantly higher (P less than 0.05) in the elderly (105.7 +/- 19.7 and 165.0 +/- 29.7 nmol l-1) compared with the young subjects (68.6 +/- 10.1 and 115.7 +/- 18.1 nmol l-1).,Lack of effect of ageing on the stereochemical disposition of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540484/),[nM] / [l],165.0,63694,DB00571,Propranolol
,1540484,peak plasma concentrations,The mean peak plasma concentrations of both (+)- and (-)-propranolol were significantly higher (P less than 0.05) in the elderly (105.7 +/- 19.7 and 165.0 +/- 29.7 nmol l-1) compared with the young subjects (68.6 +/- 10.1 and 115.7 +/- 18.1 nmol l-1).,Lack of effect of ageing on the stereochemical disposition of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540484/),[nM] / [l],68.6,63695,DB00571,Propranolol
,1540484,peak plasma concentrations,The mean peak plasma concentrations of both (+)- and (-)-propranolol were significantly higher (P less than 0.05) in the elderly (105.7 +/- 19.7 and 165.0 +/- 29.7 nmol l-1) compared with the young subjects (68.6 +/- 10.1 and 115.7 +/- 18.1 nmol l-1).,Lack of effect of ageing on the stereochemical disposition of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540484/),[nM] / [l],115.7,63696,DB00571,Propranolol
,1540484,oral clearances,The oral clearances of both (+)- and (-)-propranolol were significantly higher (P less than 0.05) in the young (6933 +/- 598 and 4554 +/- 372 ml min-1) than in the elderly (4548 +/- 712 and 2941 +/- 473 ml min-1).,Lack of effect of ageing on the stereochemical disposition of propranolol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540484/),[ml] / [min],6933,63697,DB00571,Propranolol
,1540484,oral clearances,The oral clearances of both (+)- and (-)-propranolol were significantly higher (P less than 0.05) in the young (6933 +/- 598 and 4554 +/- 372 ml min-1) than in the elderly (4548 +/- 712 and 2941 +/- 473 ml min-1).,Lack of effect of ageing on the stereochemical disposition of propranolol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540484/),[ml] / [min],4554,63698,DB00571,Propranolol
,1540484,oral clearances,The oral clearances of both (+)- and (-)-propranolol were significantly higher (P less than 0.05) in the young (6933 +/- 598 and 4554 +/- 372 ml min-1) than in the elderly (4548 +/- 712 and 2941 +/- 473 ml min-1).,Lack of effect of ageing on the stereochemical disposition of propranolol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540484/),[ml] / [min],4548,63699,DB00571,Propranolol
,1540484,oral clearances,The oral clearances of both (+)- and (-)-propranolol were significantly higher (P less than 0.05) in the young (6933 +/- 598 and 4554 +/- 372 ml min-1) than in the elderly (4548 +/- 712 and 2941 +/- 473 ml min-1).,Lack of effect of ageing on the stereochemical disposition of propranolol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540484/),[ml] / [min],2941,63700,DB00571,Propranolol
,15351061,flow rate,The mobile phase was sodium phosphate buffer (pH 2.5) containing 1 ml/l triethylamine and methanol at flow rate of 2.8 ml/min.,Simple and rapid HPLC method for determination of amlodipine in human serum with fluorescence detection and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15351061/),[ml] / [min],2.8,63960,DB00571,Propranolol
,7212504,oral clearance,"After treatment of thyrotoxicosis there was a fall (P less than 0.05) in the oral clearance of both total (4.2 +/- 0.6 to 2.7 +/- 0.4 L/min, mean +/- SEM) and free (30.5 +/- 4.7 to 25.5 +/- 4.1 L/min) propranolol although the half-life of propranolol did not change significantly.",Increased clearance of propranolol in thyrotoxicosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212504/),[l] / [min],4.2,64580,DB00571,Propranolol
,7212504,oral clearance,"After treatment of thyrotoxicosis there was a fall (P less than 0.05) in the oral clearance of both total (4.2 +/- 0.6 to 2.7 +/- 0.4 L/min, mean +/- SEM) and free (30.5 +/- 4.7 to 25.5 +/- 4.1 L/min) propranolol although the half-life of propranolol did not change significantly.",Increased clearance of propranolol in thyrotoxicosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212504/),[l] / [min],2.7,64581,DB00571,Propranolol
,7212504,oral clearance,"After treatment of thyrotoxicosis there was a fall (P less than 0.05) in the oral clearance of both total (4.2 +/- 0.6 to 2.7 +/- 0.4 L/min, mean +/- SEM) and free (30.5 +/- 4.7 to 25.5 +/- 4.1 L/min) propranolol although the half-life of propranolol did not change significantly.",Increased clearance of propranolol in thyrotoxicosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212504/),[l] / [min],30.5,64582,DB00571,Propranolol
,7212504,oral clearance,"After treatment of thyrotoxicosis there was a fall (P less than 0.05) in the oral clearance of both total (4.2 +/- 0.6 to 2.7 +/- 0.4 L/min, mean +/- SEM) and free (30.5 +/- 4.7 to 25.5 +/- 4.1 L/min) propranolol although the half-life of propranolol did not change significantly.",Increased clearance of propranolol in thyrotoxicosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212504/),[l] / [min],25.5,64583,DB00571,Propranolol
,7212504,free fraction,The free fraction of propranolol was higher (p less than 0.05) in the thyrotoxic (14.2% +/- 1.3%) than in the euthyroid (11.4% +/- 0.8%) state.,Increased clearance of propranolol in thyrotoxicosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212504/),%,14.2,64584,DB00571,Propranolol
,7212504,free fraction,The free fraction of propranolol was higher (p less than 0.05) in the thyrotoxic (14.2% +/- 1.3%) than in the euthyroid (11.4% +/- 0.8%) state.,Increased clearance of propranolol in thyrotoxicosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7212504/),%,11.4,64585,DB00571,Propranolol
,6631718,bioavailability,The bioavailability of (-)-propranolol (5.7 +/- 1.6%; mean +/- S.E.) was considerably lower (P less than .01) than that of (+)-propranolol (16.1 +/- 5.9%) after single doses.,Stereoselective increase in propranolol bioavailability during chronic dosing in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631718/),%,5.7,64945,DB00571,Propranolol
,6631718,bioavailability,The bioavailability of (-)-propranolol (5.7 +/- 1.6%; mean +/- S.E.) was considerably lower (P less than .01) than that of (+)-propranolol (16.1 +/- 5.9%) after single doses.,Stereoselective increase in propranolol bioavailability during chronic dosing in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631718/),%,16.1,64946,DB00571,Propranolol
,6631718,bioavailability,"Chronic pretreatment led to a 167% increase in the bioavailability of (-)-propranolol to 15.2 +/- 3.7% (P less than .01), with only a 47% increase in (+)-propranolol to 23.7 +/- 4.5% (N.S.).",Stereoselective increase in propranolol bioavailability during chronic dosing in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631718/),%,15.2,64947,DB00571,Propranolol
,6631718,bioavailability,"Chronic pretreatment led to a 167% increase in the bioavailability of (-)-propranolol to 15.2 +/- 3.7% (P less than .01), with only a 47% increase in (+)-propranolol to 23.7 +/- 4.5% (N.S.).",Stereoselective increase in propranolol bioavailability during chronic dosing in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631718/),%,23.7,64948,DB00571,Propranolol
,7056277,Peak plasma levels,"Peak plasma levels occurred after 2-3h and averaged 15, 27 and 45 microgram/l in the three dose groups.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),[μg] / [l],15,65023,DB00571,Propranolol
,7056277,Peak plasma levels,"Peak plasma levels occurred after 2-3h and averaged 15, 27 and 45 microgram/l in the three dose groups.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),[μg] / [l],27,65024,DB00571,Propranolol
,7056277,Peak plasma levels,"Peak plasma levels occurred after 2-3h and averaged 15, 27 and 45 microgram/l in the three dose groups.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),[μg] / [l],45,65025,DB00571,Propranolol
,7056277,Areas under the plasma concentration - time curves (AUC0 leads to 12),"Areas under the plasma concentration - time curves (AUC0 leads to 12), which were 75, 147 and 250 microgram 1(-1)h respectively, and cumulative urinary recovery (20%) were independent of the dose administered and the type of formulation.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),μg,75,65026,DB00571,Propranolol
,7056277,Areas under the plasma concentration - time curves (AUC0 leads to 12),"Areas under the plasma concentration - time curves (AUC0 leads to 12), which were 75, 147 and 250 microgram 1(-1)h respectively, and cumulative urinary recovery (20%) were independent of the dose administered and the type of formulation.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),μg,147,65027,DB00571,Propranolol
,7056277,Areas under the plasma concentration - time curves (AUC0 leads to 12),"Areas under the plasma concentration - time curves (AUC0 leads to 12), which were 75, 147 and 250 microgram 1(-1)h respectively, and cumulative urinary recovery (20%) were independent of the dose administered and the type of formulation.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),μg,250,65028,DB00571,Propranolol
,7056277,cumulative urinary recovery,"Areas under the plasma concentration - time curves (AUC0 leads to 12), which were 75, 147 and 250 microgram 1(-1)h respectively, and cumulative urinary recovery (20%) were independent of the dose administered and the type of formulation.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),%,20,65029,DB00571,Propranolol
,7056277,plasma clearance,"The plasma clearance was calculated to be 505 ml/min, renal clearance 108 ml/min and nonrenal clearance 396 ml/min.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),[ml] / [min],505,65030,DB00571,Propranolol
,7056277,renal clearance,"The plasma clearance was calculated to be 505 ml/min, renal clearance 108 ml/min and nonrenal clearance 396 ml/min.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),[ml] / [min],108,65031,DB00571,Propranolol
,7056277,nonrenal clearance,"The plasma clearance was calculated to be 505 ml/min, renal clearance 108 ml/min and nonrenal clearance 396 ml/min.",Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7056277/),[ml] / [min],396,65032,DB00571,Propranolol
,2882883,peak serum bromazepam concentrations,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ng] / [ml],132,67537,DB00571,Propranolol
,2882883,peak serum bromazepam concentrations,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ng] / [ml],82,67538,DB00571,Propranolol
,2882883,volume of distribution,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[l] / [kg],0.88,67539,DB00571,Propranolol
,2882883,volume of distribution,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[l] / [kg],1.44,67540,DB00571,Propranolol
,2882883,oral clearance,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ml] / [kg·min],0.41,67541,DB00571,Propranolol
,2882883,oral clearance,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ml] / [kg·min],0.76,67542,DB00571,Propranolol
,2882883,serum free fraction,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),,34,67543,DB00571,Propranolol
,2882883,serum free fraction,"Compared with young subjects, the elderly had significantly higher peak serum bromazepam concentrations (132 vs. 82 ng/ml), smaller volume of distribution (0.88 vs. 1.44 L/kg), lower oral clearance (0.41 vs. 0.76 ml/min/kg), and increased serum free fraction (34.8% vs. 28.8% unbound).","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),,28.8,67544,DB00571,Propranolol
,2882883,clearance,Coadministration of cimetidine (1.2 gm daily) significantly reduced bromazepam clearance (0.41 vs. 0.82 ml/min/kg) and prolonged elimination half-life (29 vs. 23 hours).,"Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ml] / [kg·min],0.41,67545,DB00571,Propranolol
,2882883,clearance,Coadministration of cimetidine (1.2 gm daily) significantly reduced bromazepam clearance (0.41 vs. 0.82 ml/min/kg) and prolonged elimination half-life (29 vs. 23 hours).,"Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ml] / [kg·min],0.82,67546,DB00571,Propranolol
,2882883,elimination half-life,Coadministration of cimetidine (1.2 gm daily) significantly reduced bromazepam clearance (0.41 vs. 0.82 ml/min/kg) and prolonged elimination half-life (29 vs. 23 hours).,"Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),h,29,67547,DB00571,Propranolol
,2882883,elimination half-life,Coadministration of cimetidine (1.2 gm daily) significantly reduced bromazepam clearance (0.41 vs. 0.82 ml/min/kg) and prolonged elimination half-life (29 vs. 23 hours).,"Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),h,23,67548,DB00571,Propranolol
,2882883,half-life,"Propranolol (160 mg daily) significantly prolonged bromazepam half-life (28 vs. 23 hours), but the reduction in clearance associated with propranolol (0.65 vs. 0.82 ml/min/kg) did not reach significance.","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),h,28,67549,DB00571,Propranolol
,2882883,half-life,"Propranolol (160 mg daily) significantly prolonged bromazepam half-life (28 vs. 23 hours), but the reduction in clearance associated with propranolol (0.65 vs. 0.82 ml/min/kg) did not reach significance.","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),h,23,67550,DB00571,Propranolol
,2882883,clearance,"Propranolol (160 mg daily) significantly prolonged bromazepam half-life (28 vs. 23 hours), but the reduction in clearance associated with propranolol (0.65 vs. 0.82 ml/min/kg) did not reach significance.","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ml] / [kg·min],0.65,67551,DB00571,Propranolol
,2882883,clearance,"Propranolol (160 mg daily) significantly prolonged bromazepam half-life (28 vs. 23 hours), but the reduction in clearance associated with propranolol (0.65 vs. 0.82 ml/min/kg) did not reach significance.","Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),[ml] / [kg·min],0.82,67552,DB00571,Propranolol
,2882883,half-life,Bromazepam has the pharmacokinetic characteristics of benzodiazepines with half-life values between 20 and 30 hours.,"Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882883/),h,20 and 30,67553,DB00571,Propranolol
,8513649,peak plasma concentration,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[μg] / [l],12 to 22,68577,DB00571,Propranolol
,8513649,volume of distribution,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[l] / [kg],0.8 to 1.3,68578,DB00571,Propranolol
,8513649,elimination half-life,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),h,9 to 16,68579,DB00571,Propranolol
,8513649,clearance,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[ml] / [kg·min],0.7 to 1.5,68580,DB00571,Propranolol
,8513649,Absolute bioavailability,Absolute bioavailability of oral alprazolam averages 80 to 100%.,Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),%,80 to 100,68581,DB00571,Propranolol
,8513649,steady-state plasma alpra,"Although a therapeutic concentration range is not clearly established, some studies indicate that optimal reduction of anxiety associated with panic disorder occurs at steady-state plasma alprazolam concentrations of 20 to 40 micrograms/L.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[μg] / [l],20 to 40,68582,DB00571,Propranolol
,3429695,AUC,"When compared with controls, obese subjects showed a significant increase (P less than .01) in AUC (161.0 +/- 67.0 vs 109.6 +/- 23.1 hr.micrograms/L), and significant decreases (P less than .01) in Vss (208.9 +/- 71.9 vs 318.6 +/- 91.8 L), V beta (234.3 +/- 70.4 vs 340.7 +/- 89.1 L), and total clearance (57.5 +/- 18.3 vs 75.9 +/- 15.4 L/hr).",Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429695/),[h·μg] / [l],161.0,68703,DB00571,Propranolol
,3429695,AUC,"When compared with controls, obese subjects showed a significant increase (P less than .01) in AUC (161.0 +/- 67.0 vs 109.6 +/- 23.1 hr.micrograms/L), and significant decreases (P less than .01) in Vss (208.9 +/- 71.9 vs 318.6 +/- 91.8 L), V beta (234.3 +/- 70.4 vs 340.7 +/- 89.1 L), and total clearance (57.5 +/- 18.3 vs 75.9 +/- 15.4 L/hr).",Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429695/),[h·μg] / [l],109.6,68704,DB00571,Propranolol
,3429695,Vss,"When compared with controls, obese subjects showed a significant increase (P less than .01) in AUC (161.0 +/- 67.0 vs 109.6 +/- 23.1 hr.micrograms/L), and significant decreases (P less than .01) in Vss (208.9 +/- 71.9 vs 318.6 +/- 91.8 L), V beta (234.3 +/- 70.4 vs 340.7 +/- 89.1 L), and total clearance (57.5 +/- 18.3 vs 75.9 +/- 15.4 L/hr).",Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429695/),l,208.9,68705,DB00571,Propranolol
,3429695,Vss,"When compared with controls, obese subjects showed a significant increase (P less than .01) in AUC (161.0 +/- 67.0 vs 109.6 +/- 23.1 hr.micrograms/L), and significant decreases (P less than .01) in Vss (208.9 +/- 71.9 vs 318.6 +/- 91.8 L), V beta (234.3 +/- 70.4 vs 340.7 +/- 89.1 L), and total clearance (57.5 +/- 18.3 vs 75.9 +/- 15.4 L/hr).",Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429695/),l,318.6,68706,DB00571,Propranolol
,3429695,V beta,"When compared with controls, obese subjects showed a significant increase (P less than .01) in AUC (161.0 +/- 67.0 vs 109.6 +/- 23.1 hr.micrograms/L), and significant decreases (P less than .01) in Vss (208.9 +/- 71.9 vs 318.6 +/- 91.8 L), V beta (234.3 +/- 70.4 vs 340.7 +/- 89.1 L), and total clearance (57.5 +/- 18.3 vs 75.9 +/- 15.4 L/hr).",Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429695/),l,234.3,68707,DB00571,Propranolol
,3429695,V beta,"When compared with controls, obese subjects showed a significant increase (P less than .01) in AUC (161.0 +/- 67.0 vs 109.6 +/- 23.1 hr.micrograms/L), and significant decreases (P less than .01) in Vss (208.9 +/- 71.9 vs 318.6 +/- 91.8 L), V beta (234.3 +/- 70.4 vs 340.7 +/- 89.1 L), and total clearance (57.5 +/- 18.3 vs 75.9 +/- 15.4 L/hr).",Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429695/),l,340.7,68708,DB00571,Propranolol
,3429695,total clearance,"When compared with controls, obese subjects showed a significant increase (P less than .01) in AUC (161.0 +/- 67.0 vs 109.6 +/- 23.1 hr.micrograms/L), and significant decreases (P less than .01) in Vss (208.9 +/- 71.9 vs 318.6 +/- 91.8 L), V beta (234.3 +/- 70.4 vs 340.7 +/- 89.1 L), and total clearance (57.5 +/- 18.3 vs 75.9 +/- 15.4 L/hr).",Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429695/),[l] / [h],57.5,68709,DB00571,Propranolol
,3429695,total clearance,"When compared with controls, obese subjects showed a significant increase (P less than .01) in AUC (161.0 +/- 67.0 vs 109.6 +/- 23.1 hr.micrograms/L), and significant decreases (P less than .01) in Vss (208.9 +/- 71.9 vs 318.6 +/- 91.8 L), V beta (234.3 +/- 70.4 vs 340.7 +/- 89.1 L), and total clearance (57.5 +/- 18.3 vs 75.9 +/- 15.4 L/hr).",Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429695/),[l] / [h],75.9,68710,DB00571,Propranolol
,3429695,Elimination half-life,Elimination half-life was similar for the two populations (3.5 +/- 0.9 hr in obese subjects vs 3.1 +/- 0.9 hr in controls).,Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429695/),h,3.5,68711,DB00571,Propranolol
,3429695,Elimination half-life,Elimination half-life was similar for the two populations (3.5 +/- 0.9 hr in obese subjects vs 3.1 +/- 0.9 hr in controls).,Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3429695/),h,3.1,68712,DB00571,Propranolol
,3997299,clearance,"Following propranolol pretreatment of 40 mg at 8-hourly intervals given for three days, isoniazid clearance (13.0 l/hour +/- s.e.m. 2.6 l/hour) was significantly lower (p less than 0.01) than that obtained during the control study (16.4 l/hour +/- s.e.m. 3.0 l/hour).",Impairment of isoniazid clearance by propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997299/),[l] / [h],13.0,70840,DB00571,Propranolol
,3997299,clearance,"Following propranolol pretreatment of 40 mg at 8-hourly intervals given for three days, isoniazid clearance (13.0 l/hour +/- s.e.m. 2.6 l/hour) was significantly lower (p less than 0.01) than that obtained during the control study (16.4 l/hour +/- s.e.m. 3.0 l/hour).",Impairment of isoniazid clearance by propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3997299/),[l] / [h],16.4,70841,DB00571,Propranolol
,6378211,peak plasma level (Cmax),"After a single oral dose with LA in 10 subjects, the blood level slowly increased to reach the peak plasma level (Cmax) of 11.56 +/- 2.15 ng/ml (mean +/- SE) at 5 h which was lower than that of CV (42.93 +/- 19.26 ng/ml).",Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378211/),[ng] / [ml],11.56,70884,DB00571,Propranolol
,6378211,peak plasma level,"However, the peak plasma level was almost constant for another 5 h with LA (11.03 +/- 2.38 ng/ml at 10 h).",Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378211/),[ng] / [ml],11.03,70885,DB00571,Propranolol
,6378211,elimination half-life,"The elimination half-life with LA was significantly longer than with CV (6.5 +/- 1.0, 3.9 +/- 0.5 h, respectively).",Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378211/),h,6.5,70886,DB00571,Propranolol
,6378211,elimination half-life,"The elimination half-life with LA was significantly longer than with CV (6.5 +/- 1.0, 3.9 +/- 0.5 h, respectively).",Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378211/),h,3.9,70887,DB00571,Propranolol
,6378211,plasma level,"The plasma level at 24 h did not differ between LA and CV (3.34 +/- 0.92, 5.47 +/- 1.38 ng/ml, respectively).",Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378211/),[ng] / [ml],3.34,70888,DB00571,Propranolol
,6378211,plasma level,"The plasma level at 24 h did not differ between LA and CV (3.34 +/- 0.92, 5.47 +/- 1.38 ng/ml, respectively).",Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378211/),[ng] / [ml],5.47,70889,DB00571,Propranolol
,6378211,plasma level,"On Day 8 the plasma level after 24 h of LA turned-out to be higher than that of CV (4.4 +/- 2.2, 3.5 +/- 1.5 ng/ml).",Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378211/),,4,70890,DB00571,Propranolol
,6378211,plasma level,"On Day 8 the plasma level after 24 h of LA turned-out to be higher than that of CV (4.4 +/- 2.2, 3.5 +/- 1.5 ng/ml).",Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6378211/),,3.,70891,DB00571,Propranolol
,28761821,oral plasma clearance (CL/F),The mean value for oral plasma clearance (CL/F) was 126.59 ml/hr.,Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28761821/),[ml] / [h],126.59,73457,DB00571,Propranolol
,28761821,apparent volume of distribution (V/F),"The corresponding values for apparent volume of distribution (V/F), t1/2 beta, maximum blood concentration (C max), and time to reach the maximum blood concentration (T max) were 334.12 Lit, 1.98 hr, 40.25 ng/ml, and 1.68 hr, respectively.",Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28761821/),lit,334.12,73458,DB00571,Propranolol
,28761821,t1/2 beta,"The corresponding values for apparent volume of distribution (V/F), t1/2 beta, maximum blood concentration (C max), and time to reach the maximum blood concentration (T max) were 334.12 Lit, 1.98 hr, 40.25 ng/ml, and 1.68 hr, respectively.",Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28761821/),h,1.98,73459,DB00571,Propranolol
,28761821,t1/2 beta,"The corresponding values for apparent volume of distribution (V/F), t1/2 beta, maximum blood concentration (C max), and time to reach the maximum blood concentration (T max) were 334.12 Lit, 1.98 hr, 40.25 ng/ml, and 1.68 hr, respectively.",Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28761821/),[ng] / [ml],40.25,73460,DB00571,Propranolol
,28761821,maximum blood concentration (C max),"The corresponding values for apparent volume of distribution (V/F), t1/2 beta, maximum blood concentration (C max), and time to reach the maximum blood concentration (T max) were 334.12 Lit, 1.98 hr, 40.25 ng/ml, and 1.68 hr, respectively.",Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28761821/),h,1.98,73461,DB00571,Propranolol
,28761821,maximum blood concentration (C max),"The corresponding values for apparent volume of distribution (V/F), t1/2 beta, maximum blood concentration (C max), and time to reach the maximum blood concentration (T max) were 334.12 Lit, 1.98 hr, 40.25 ng/ml, and 1.68 hr, respectively.",Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28761821/),[ng] / [ml],40.25,73462,DB00571,Propranolol
,28761821,time to reach the maximum blood concentration (T max),"The corresponding values for apparent volume of distribution (V/F), t1/2 beta, maximum blood concentration (C max), and time to reach the maximum blood concentration (T max) were 334.12 Lit, 1.98 hr, 40.25 ng/ml, and 1.68 hr, respectively.",Pharmacokinetic Parameters and Over-Responsiveness of Iranian Population to Propranolol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28761821/),h,1.68,73463,DB00571,Propranolol
,6156360,metabolic clearance rate,"After the addition of minoxidil to the antihypertensive regimen of 7 hypertensive patients, the aldosterone metabolic clearance rate increased from 1,110 +/- 91 to 1,570 +/- 180 liters/day (p less than 0.01), an overall increase of 41%.",Increased aldosterone metabolic clearance in hypertensive patients treated with minoxidil: an effect of greater hepatic perfusion. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6156360/),[l] / [d],"1,110",74784,DB00571,Propranolol
,6156360,metabolic clearance rate,"After the addition of minoxidil to the antihypertensive regimen of 7 hypertensive patients, the aldosterone metabolic clearance rate increased from 1,110 +/- 91 to 1,570 +/- 180 liters/day (p less than 0.01), an overall increase of 41%.",Increased aldosterone metabolic clearance in hypertensive patients treated with minoxidil: an effect of greater hepatic perfusion. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6156360/),[l] / [d],"1,570",74785,DB00571,Propranolol
,15618680,plasma total clearance (CL(tot)),"At 2 mg/kg, the plasma total clearance (CL(tot)) of AP was high (279+/-80 mL/h), and its volume of distribution (Vd(ss)) was large (245+/-99 mL).",Nonlinear pharmacokinetics of aprindine in guinea pigs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618680/),[ml] / [h],279,75391,DB00571,Propranolol
,15618680,volume of distribution (Vd(ss)),"At 2 mg/kg, the plasma total clearance (CL(tot)) of AP was high (279+/-80 mL/h), and its volume of distribution (Vd(ss)) was large (245+/-99 mL).",Nonlinear pharmacokinetics of aprindine in guinea pigs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15618680/),ml,245,75392,DB00571,Propranolol
,2155929,maximal dosage,"After an initial placebo phase, 40 mg d-propranolol was administered orally every 6 h with dosage increased every 2 d until arrhythmia suppression (greater than or equal to 80% VED reduction), intolerable side effects, or a maximal dosage (1,280 mg/d) was reached.",Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2155929/),[mg] / [d],"1,280",75715,DB00571,Propranolol
,10411576,half-life of disappearance,The half-life of disappearance of up-regulated beta-adrenoceptors was estimated to be 2.0 days (1.0-3.9 days).,Mechanism-based modeling of rebound tachycardia after chronic l-propranolol infusion in spontaneous hypertensive rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10411576/),d,2.0,75723,DB00571,Propranolol
,3443142,Areas under the propranolol concentration/time curves,"Areas under the propranolol concentration/time curves were not significantly increased by omeprazole treatment: off treatment mean 787.6, on treatment 802.5 ng-1.ml.h.",Propranolol steady-state pharmacokinetics are unaltered by omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443142/),[h·ml] / [ng],787.6,76702,DB00571,Propranolol
,3443142,Areas under the propranolol concentration/time curves,"Areas under the propranolol concentration/time curves were not significantly increased by omeprazole treatment: off treatment mean 787.6, on treatment 802.5 ng-1.ml.h.",Propranolol steady-state pharmacokinetics are unaltered by omeprazole. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443142/),[h·ml] / [ng],802.5,76703,DB00571,Propranolol
,6631719,systemic availability,"Also, the systemic availability of orally administered propranolol (6 mg/kg) increased from 4.1 to 7.8% from the 1st to the 2nd study day, indicating a decrease in the presystemic clearance of the drug.",Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631719/),,4,77644,DB00571,Propranolol
,6631719,systemic availability,"Also, the systemic availability of orally administered propranolol (6 mg/kg) increased from 4.1 to 7.8% from the 1st to the 2nd study day, indicating a decrease in the presystemic clearance of the drug.",Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6631719/),,7.8,77645,DB00571,Propranolol
,6705442,peak concentrations,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),[ng] / [ml],25,80541,DB00571,Propranolol
,6705442,peak concentrations,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),[ng] / [ml],61,80542,DB00571,Propranolol
,6705442,peak concentrations,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),[ng] / [ml],85,80543,DB00571,Propranolol
,6705442,time to peak concentrations,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),h,2.2,80544,DB00571,Propranolol
,6705442,time to peak concentrations,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),h,0.7,80545,DB00571,Propranolol
,6705442,time to peak concentrations,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),h,0.8,80546,DB00571,Propranolol
,6705442,area under the propranolol concentration: time curves,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),[h·ng] / [ml],153,80547,DB00571,Propranolol
,6705442,area under the propranolol concentration: time curves,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),[h·ng] / [ml],246,80548,DB00571,Propranolol
,6705442,area under the propranolol concentration: time curves,"Hydralazine increased propranolol peak concentrations from 25 +/- 7 ng/ml to 61 +/- 10 and 85 +/- 11 ng/ml, reduced time to peak concentrations from 2.2 +/- 0.2 hr to 0.7 +/- 0.1 and 0.8 +/- 0.1 hr, and increased area under the propranolol concentration: time curves from 153 +/- 38 ng X ml-1 X hr to 246 +/- 64 and 324 ng X ml-1 X hr (in all cases P less than 0.05).",Mechanism by which hydralazine increases propranolol bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705442/),[h·ng] / [ml],324,80549,DB00571,Propranolol
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],378,80807,DB00571,Propranolol
,6096071,renal clearance,A significant pharmacokinetic interaction has also been demonstrated between ranitidine and procainamide: the AUC of procainamide increased and the renal clearance fell significantly from a mean of 378 to 309 ml/min with ranitidine co-administration.,Interactions and non-interactions with ranitidine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],309,80808,DB00571,Propranolol
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],66.7,80809,DB00571,Propranolol
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],48,80810,DB00571,Propranolol
,6096071,clearance,"In a clinical study, warfarin clearance was significantly reduced from 66.7 to 48.7 ml/min by ranitidine, and by cimetidine to 42.9 ml/min.",Interactions and non-interactions with ranitidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6096071/),[ml] / [min],42.9,80811,DB00571,Propranolol
,1587062,AUC,"Area under the serum concentration-time curve (AUC) for both propranolol enantiomers was lower in black subjects than in white subjects (e.g., l-propranolol AUC: 292 +/- 100 versus 394 +/- 121 ng.hr/ml, p less than 0.05) and apparent oral clearance was higher in black subjects than in white subjects (e.g., l-propranolol apparent oral clearance: 27.6 +/- 8.2 versus 20.6 +/- 7.0 ml/min/kg, p less than 0.05).",Racial differences in propranolol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587062/),[h·ng] / [ml],292,82690,DB00571,Propranolol
,1587062,AUC,"Area under the serum concentration-time curve (AUC) for both propranolol enantiomers was lower in black subjects than in white subjects (e.g., l-propranolol AUC: 292 +/- 100 versus 394 +/- 121 ng.hr/ml, p less than 0.05) and apparent oral clearance was higher in black subjects than in white subjects (e.g., l-propranolol apparent oral clearance: 27.6 +/- 8.2 versus 20.6 +/- 7.0 ml/min/kg, p less than 0.05).",Racial differences in propranolol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587062/),[h·ng] / [ml],394,82691,DB00571,Propranolol
,1587062,apparent oral clearance,"Area under the serum concentration-time curve (AUC) for both propranolol enantiomers was lower in black subjects than in white subjects (e.g., l-propranolol AUC: 292 +/- 100 versus 394 +/- 121 ng.hr/ml, p less than 0.05) and apparent oral clearance was higher in black subjects than in white subjects (e.g., l-propranolol apparent oral clearance: 27.6 +/- 8.2 versus 20.6 +/- 7.0 ml/min/kg, p less than 0.05).",Racial differences in propranolol pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587062/),[ml] / [kg·min],27.6,82692,DB00571,Propranolol
,1587062,apparent oral clearance,"Area under the serum concentration-time curve (AUC) for both propranolol enantiomers was lower in black subjects than in white subjects (e.g., l-propranolol AUC: 292 +/- 100 versus 394 +/- 121 ng.hr/ml, p less than 0.05) and apparent oral clearance was higher in black subjects than in white subjects (e.g., l-propranolol apparent oral clearance: 27.6 +/- 8.2 versus 20.6 +/- 7.0 ml/min/kg, p less than 0.05).",Racial differences in propranolol pharmacokinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587062/),[ml] / [kg·min],20.6,82693,DB00571,Propranolol
,117534,plasma clearance,"Pharmacokinetic parameters for propranolol in the cat are as follows: plasma clearance, 31.3 ml/(kg x min); volume of distribution, 1.57 L/kg; elimination half-life, 35 min.",Pharmacokinetics of propranolol in the cat and comparisons with humans and three other species. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/117534/),[ml] / [kg·min],31.3,85197,DB00571,Propranolol
,117534,volume of distribution,"Pharmacokinetic parameters for propranolol in the cat are as follows: plasma clearance, 31.3 ml/(kg x min); volume of distribution, 1.57 L/kg; elimination half-life, 35 min.",Pharmacokinetics of propranolol in the cat and comparisons with humans and three other species. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/117534/),[l] / [kg],1.57,85198,DB00571,Propranolol
,117534,elimination half-life,"Pharmacokinetic parameters for propranolol in the cat are as follows: plasma clearance, 31.3 ml/(kg x min); volume of distribution, 1.57 L/kg; elimination half-life, 35 min.",Pharmacokinetics of propranolol in the cat and comparisons with humans and three other species. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/117534/),min,35,85199,DB00571,Propranolol
,2888791,clearance,"Pretreatment with four days of terbutaline (5 mg q8h) and propranolol (60 mg q8h) significantly decreased mean theophylline clearance (60.1 +/- 12.9 vs 40.6 +/- 9.9 mL/min/1.73m2; P less than .01) increased half-life (8.37 +/- 1.77 vs 12.32 +/- 2.70 hours; P less than .05), and increased postinfusion theophylline concentration (13.5 +/- 2.7 vs 18.95 +/- 2.5 micrograms/mL; P less than .001).",The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],60.1,88065,DB00571,Propranolol
,2888791,clearance,"Pretreatment with four days of terbutaline (5 mg q8h) and propranolol (60 mg q8h) significantly decreased mean theophylline clearance (60.1 +/- 12.9 vs 40.6 +/- 9.9 mL/min/1.73m2; P less than .01) increased half-life (8.37 +/- 1.77 vs 12.32 +/- 2.70 hours; P less than .05), and increased postinfusion theophylline concentration (13.5 +/- 2.7 vs 18.95 +/- 2.5 micrograms/mL; P less than .001).",The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],40.6,88066,DB00571,Propranolol
,2888791,half-life,"Pretreatment with four days of terbutaline (5 mg q8h) and propranolol (60 mg q8h) significantly decreased mean theophylline clearance (60.1 +/- 12.9 vs 40.6 +/- 9.9 mL/min/1.73m2; P less than .01) increased half-life (8.37 +/- 1.77 vs 12.32 +/- 2.70 hours; P less than .05), and increased postinfusion theophylline concentration (13.5 +/- 2.7 vs 18.95 +/- 2.5 micrograms/mL; P less than .001).",The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),h,8.37,88067,DB00571,Propranolol
,2888791,half-life,"Pretreatment with four days of terbutaline (5 mg q8h) and propranolol (60 mg q8h) significantly decreased mean theophylline clearance (60.1 +/- 12.9 vs 40.6 +/- 9.9 mL/min/1.73m2; P less than .01) increased half-life (8.37 +/- 1.77 vs 12.32 +/- 2.70 hours; P less than .05), and increased postinfusion theophylline concentration (13.5 +/- 2.7 vs 18.95 +/- 2.5 micrograms/mL; P less than .001).",The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),h,12.32,88068,DB00571,Propranolol
,2888791,clearance,In five subjects theophylline clearance increased after terbutaline pretreatment (64.6 +/- 13.0 vs 75.0 +/- 13.9 mL/min/1.73m2).,The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],64.6,88069,DB00571,Propranolol
,2888791,clearance,In five subjects theophylline clearance increased after terbutaline pretreatment (64.6 +/- 13.0 vs 75.0 +/- 13.9 mL/min/1.73m2).,The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],75.0,88070,DB00571,Propranolol
,2888791,clearance,Comparison between the propranolol and terbutaline study and the propranolol alone study indicated no mean change in clearance in these five subjects (41.8 +/- 12.7 vs 36.1 +/- 5.1 mL/min/1.73m2).,The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],41.8,88071,DB00571,Propranolol
,2888791,clearance,Comparison between the propranolol and terbutaline study and the propranolol alone study indicated no mean change in clearance in these five subjects (41.8 +/- 12.7 vs 36.1 +/- 5.1 mL/min/1.73m2).,The effects of a beta-2 selective adrenergic agonist and a beta-nonselective antagonist on theophylline clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2888791/),[ml] / [1.73m2·min],36.1,88072,DB00571,Propranolol
,3605749,arterial propranolol concentration,"However, there was a rapid increase in arterial propranolol concentration from 88 +/- 10 ng/ml (mean +/- SEM) prior to halothane to 116 +/- 12 ng/ml (P less than 0.05) and 130 +/- 7 ng/ml (P less than 0.05) 60 and 120 min, respectively, after starting halothane anesthesia (2.0 MAC 1.74%).",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),[ng] / [ml],88,88198,DB00571,Propranolol
,3605749,arterial propranolol concentration,"However, there was a rapid increase in arterial propranolol concentration from 88 +/- 10 ng/ml (mean +/- SEM) prior to halothane to 116 +/- 12 ng/ml (P less than 0.05) and 130 +/- 7 ng/ml (P less than 0.05) 60 and 120 min, respectively, after starting halothane anesthesia (2.0 MAC 1.74%).",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),[ng] / [ml],116,88199,DB00571,Propranolol
,3605749,arterial propranolol concentration,"However, there was a rapid increase in arterial propranolol concentration from 88 +/- 10 ng/ml (mean +/- SEM) prior to halothane to 116 +/- 12 ng/ml (P less than 0.05) and 130 +/- 7 ng/ml (P less than 0.05) 60 and 120 min, respectively, after starting halothane anesthesia (2.0 MAC 1.74%).",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),[ng] / [ml],130,88200,DB00571,Propranolol
,3605749,arterial to venous (A/V) concentration ratio,"The increase in venous propranolol concentration lagged substantially behind that of the arterial concentration, so that, 60 min after starting halothane, the arterial to venous (A/V) concentration ratio increased from 1.13 +/- 0.05 to a maximum of 1.48 +/- 0.08.",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),,1.13,88201,DB00571,Propranolol
,3605749,arterial to venous (A/V) concentration ratio,"The increase in venous propranolol concentration lagged substantially behind that of the arterial concentration, so that, 60 min after starting halothane, the arterial to venous (A/V) concentration ratio increased from 1.13 +/- 0.05 to a maximum of 1.48 +/- 0.08.",Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3605749/),,1.48,88202,DB00571,Propranolol
,2859199,Tmax,"The effects of bucindolol developed as early as 30 min after administration and lasted up to 24 h, whereas its Tmax and T 1/2 were 1.6 and 3.6 h respectively.",Comparative beta-adrenoceptor blocking effect and pharmacokinetics of bucindolol and propranolol in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859199/),h,1.6,89883,DB00571,Propranolol
,2859199,T 1/2,"The effects of bucindolol developed as early as 30 min after administration and lasted up to 24 h, whereas its Tmax and T 1/2 were 1.6 and 3.6 h respectively.",Comparative beta-adrenoceptor blocking effect and pharmacokinetics of bucindolol and propranolol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2859199/),h,3.6,89884,DB00571,Propranolol
,10342912,AUC,"For example, the AUC of cyclosporine increased significantly (33.1 versus 24.7 microg h/ml) at cyclosporine oral dose of 10 mg/kg, however, the value decreased significantly (167 versus 235 microg h/ml) at cyclosporine oral dose of 100 mg/kg.",Effects of propranolol on the pharmacokinetics of cyclosporine after intravenous and oral administration to control rats and rats with uranyl nitrate-induced acute renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10342912/),[h·μg] / [ml],33.1,89959,DB00571,Propranolol
,10342912,AUC,"For example, the AUC of cyclosporine increased significantly (33.1 versus 24.7 microg h/ml) at cyclosporine oral dose of 10 mg/kg, however, the value decreased significantly (167 versus 235 microg h/ml) at cyclosporine oral dose of 100 mg/kg.",Effects of propranolol on the pharmacokinetics of cyclosporine after intravenous and oral administration to control rats and rats with uranyl nitrate-induced acute renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10342912/),[h·μg] / [ml],24.7,89960,DB00571,Propranolol
,10342912,AUC,"For example, the AUC of cyclosporine increased significantly (33.1 versus 24.7 microg h/ml) at cyclosporine oral dose of 10 mg/kg, however, the value decreased significantly (167 versus 235 microg h/ml) at cyclosporine oral dose of 100 mg/kg.",Effects of propranolol on the pharmacokinetics of cyclosporine after intravenous and oral administration to control rats and rats with uranyl nitrate-induced acute renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10342912/),[h·μg] / [ml],167,89961,DB00571,Propranolol
,10342912,AUC,"For example, the AUC of cyclosporine increased significantly (33.1 versus 24.7 microg h/ml) at cyclosporine oral dose of 10 mg/kg, however, the value decreased significantly (167 versus 235 microg h/ml) at cyclosporine oral dose of 100 mg/kg.",Effects of propranolol on the pharmacokinetics of cyclosporine after intravenous and oral administration to control rats and rats with uranyl nitrate-induced acute renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10342912/),[h·μg] / [ml],235,89962,DB00571,Propranolol
,1287187,AUC ratio,The AUC ratio between the S(-)- and R(+)-isomer posed at 0.89 which was statistically not different from that obtained after administration of PL alone.,Enantioselective oral bioavailability of 0-isovaleryl propranolol as a potential prodrug of propranolol. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1287187/),,0.89,90279,DB00571,Propranolol
,2905248,tmax,"A powder capsule formulation of the drug showed rapid absorption (tmax = 1 hour) and linear pharmacokinetics across the dose range 25 to 100mg, but produced some gastrointestinal intolerance.",Pharmacokinetics of roxatidine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905248/),h,1,91442,DB00571,Propranolol
,2905248,tmax,"However, a granulated capsule formulation showed a much slower release (tmax = 3 hours) and was well tolerated.",Pharmacokinetics of roxatidine in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905248/),h,3,91443,DB00571,Propranolol
,2905248,plasma terminal half-life,The plasma terminal half-life of the granulated capsule averaged 6 hours and between 55 and 60% of the dose was recovered in the urine as roxatidine.,Pharmacokinetics of roxatidine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2905248/),h,6,91444,DB00571,Propranolol
,3668812,unbound oral clearance (CLoral),"With regular propranolol, the mean unbound oral clearance (CLoral) decreased 29%, from 503 +/- 281 after a single dose to 359 +/- 143 mL/min/kg at steady state (p less than 0.05).",Nonlinear pharmacokinetics of unbound propranolol after oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668812/),[ml] / [kg·min],503,91859,DB00571,Propranolol
,3668812,unbound oral clearance (CLoral),"With regular propranolol, the mean unbound oral clearance (CLoral) decreased 29%, from 503 +/- 281 after a single dose to 359 +/- 143 mL/min/kg at steady state (p less than 0.05).",Nonlinear pharmacokinetics of unbound propranolol after oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668812/),[ml] / [kg·min],359,91860,DB00571,Propranolol
,3668812,CLoral,"Similarly, CLoral decreased 33% with sustained-release propranolol from 1077 +/- 514 to 721 +/- 385 mL/min/kg (NS).",Nonlinear pharmacokinetics of unbound propranolol after oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668812/),[ml] / [kg·min],1077,91861,DB00571,Propranolol
,3668812,CLoral,"Similarly, CLoral decreased 33% with sustained-release propranolol from 1077 +/- 514 to 721 +/- 385 mL/min/kg (NS).",Nonlinear pharmacokinetics of unbound propranolol after oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668812/),[ml] / [kg·min],721,91862,DB00571,Propranolol
,3668812,accumulation ratios,"The corresponding accumulation ratios for regular and sustained-release propranolol were 1.39 +/- 0.49 and 1.61 +/- 0.81, respectively (NS).",Nonlinear pharmacokinetics of unbound propranolol after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668812/),,1.39,91863,DB00571,Propranolol
,3668812,accumulation ratios,"The corresponding accumulation ratios for regular and sustained-release propranolol were 1.39 +/- 0.49 and 1.61 +/- 0.81, respectively (NS).",Nonlinear pharmacokinetics of unbound propranolol after oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668812/),,1.61,91864,DB00571,Propranolol
,3668812,bioavailability,"Therefore, the mean bioavailability of sustained-release relative to that of regular propranolol was 0.52 +/- 0.23 and 0.54 +/- 0.17 for single doses and at steady-state, respectively.",Nonlinear pharmacokinetics of unbound propranolol after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668812/),,0.52,91865,DB00571,Propranolol
,3668812,bioavailability,"Therefore, the mean bioavailability of sustained-release relative to that of regular propranolol was 0.52 +/- 0.23 and 0.54 +/- 0.17 for single doses and at steady-state, respectively.",Nonlinear pharmacokinetics of unbound propranolol after oral administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668812/),,0.54,91866,DB00571,Propranolol
,3668812,percent unbound,The percent unbound of propranolol ranged from 6.8 to 14.0 with an average of 10.1.,Nonlinear pharmacokinetics of unbound propranolol after oral administration. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3668812/),,10.1,91867,DB00571,Propranolol
,461970,area under the plasma concentration - time curve (AUC),The area under the plasma concentration - time curve (AUC) for (-)-propranolol was only 54 +/- 10 per cent (mean +/- SD; n = 10) of the AUC for (+)-propranolol.,Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/461970/),%,54,93241,DB00571,Propranolol
,461970,time to peak plasma concentration,The time to peak plasma concentration (3.9-4.3 hr) and the half-life (1.6-1.9 hr) were identical for both isomers of propranolol as well as of POG.,Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/461970/),h,3.9-4.3,93242,DB00571,Propranolol
,461970,half-life,The time to peak plasma concentration (3.9-4.3 hr) and the half-life (1.6-1.9 hr) were identical for both isomers of propranolol as well as of POG.,Stereoselective oral bioavailability of (+/-)-propranolol in the dog. A GC-MS study using a stable isotope technique. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/461970/),h,1.6-1.9,93243,DB00571,Propranolol
,3515929,systemic availability,The mean systemic availability is approximately 4 percent.,Metabolism and disposition of buspirone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),%,4,93421,DB00571,Propranolol
,3515929,Half-life,Half-life values observed in healthy volunteers ranged from two to 33 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,two to 33,93422,DB00571,Propranolol
,3515929,half-life,Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,2,93423,DB00571,Propranolol
,3515929,half-life,Mean half-life values observed in healthy volunteers in the 14 studies conducted to date ranged from 2 +/- 1 to 11 +/- 3 hours.,Metabolism and disposition of buspirone. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3515929/),h,11,93424,DB00571,Propranolol
,3224162,oral clearances,"Mean oral clearances of propranolol, assuming complete absorption, (range: 42.1-54.5 ml min-1 kg-1) were similar (p greater than 0.05) in each racial group.",Steady state relative bioavailability and pharmacokinetics of oral propranolol in black and white North Americans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3224162/),[ml] / [kg·min],42.1-54.5,95574,DB00571,Propranolol
>,28680445,ion transitions,MS-MS ion transitions used were 427.602>371.000 for lenvatinib and 260.064>116.005 for IS.,Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28680445/),,427.602,96494,DB00571,Propranolol
>,28680445,ion transitions,MS-MS ion transitions used were 427.602>371.000 for lenvatinib and 260.064>116.005 for IS.,Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28680445/),,371.000,96495,DB00571,Propranolol
>,28680445,ion transitions,MS-MS ion transitions used were 427.602>371.000 for lenvatinib and 260.064>116.005 for IS.,Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28680445/),,260.064,96496,DB00571,Propranolol
>,28680445,ion transitions,MS-MS ion transitions used were 427.602>371.000 for lenvatinib and 260.064>116.005 for IS.,Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28680445/),,116.005,96497,DB00571,Propranolol
,28680445,recoveries,"Intra- and interday accuracy ranged within 95.8-108.3% with mean recoveries of 66.8% for lenvatinib, and precision was <6.7% at all quality control concentration levels.",Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28680445/),%,66.8,96498,DB00571,Propranolol
,28680445,extraction efficiency,Matrix effect analysis showed extraction efficiency of 15.7% for lenvatinib.,Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28680445/),%,15.7,96499,DB00571,Propranolol
,3768243,total oral clearance,"The total oral clearance of propranolol in these subjects varied about three-fold, from 27.5 to 71.4 ml min-1 kg-1.",Partial metabolic clearances as determinants of the oral bioavailability of propranolol. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768243/),[ml] / [kg·min],27.5 to 71.4,96548,DB00571,Propranolol
,3768243,clearance through glucuronidation,"The clearance through glucuronidation was very similar in all subjects, ranging from 6.8 to 9.9 ml min-1 kg-1.",Partial metabolic clearances as determinants of the oral bioavailability of propranolol. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768243/),[ml] / [kg·min],6.8 to 9.9,96549,DB00571,Propranolol
,3768243,clearance through side-chain oxidation,"The clearance through side-chain oxidation varied 2.4-fold, from 10.9 to 25.8 ml min-1 kg-1.",Partial metabolic clearances as determinants of the oral bioavailability of propranolol. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768243/),[ml] / [kg·min],10.9 to 25.8,96550,DB00571,Propranolol
,3768243,clearance through,"The clearance through ring oxidation varied as much as 5.6-fold, from 7.5 to 41.8 ml min-1 kg-1.",Partial metabolic clearances as determinants of the oral bioavailability of propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3768243/),[ml] / [kg·min],7.5 to 41.8,96551,DB00571,Propranolol
,1640364,free fraction,"With 40 g/L of albumin and 2 g/L of AAG in the perfusate, the free fraction of propranolol decreased to 0.031, but extraction remained high (E = 0.960).",Propranolol disposition in the rat: variation in hepatic extraction with unbound drug fraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1640364/),,0.031,97618,DB00571,Propranolol
,9431839,t1/2,Propranolol increased mean zolmitriptan Cmax and AUC by 56% and 37% respectively; mean t1/2 was prolonged from 3.1 to 4.0 h.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),h,3.1,97619,DB00571,Propranolol
,9431839,t1/2,Propranolol increased mean zolmitriptan Cmax and AUC by 56% and 37% respectively; mean t1/2 was prolonged from 3.1 to 4.0 h.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),h,4.0,97620,DB00571,Propranolol
,9431839,AUC ratio (AUCm/AUCp),Mean Cmax and AUC of the pharmacologically active N-desmethyl metabolite were reduced by 24% and 11% respectively and the metabolite:parent AUC ratio (AUCm/AUCp) fell from 0.46 to 0.26.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),,0.46,97621,DB00571,Propranolol
,9431839,AUC ratio (AUCm/AUCp),Mean Cmax and AUC of the pharmacologically active N-desmethyl metabolite were reduced by 24% and 11% respectively and the metabolite:parent AUC ratio (AUCm/AUCp) fell from 0.46 to 0.26.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),,0.26,97622,DB00571,Propranolol
,9431839,AUCm/AUCp,Mean Cmax and AUC for the inactive indole acetic acid metabolite were both reduced by 13% and AUCm/AUCp from 1.04 to 0.59.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),,1.04,97623,DB00571,Propranolol
,9431839,AUCm/AUCp,Mean Cmax and AUC for the inactive indole acetic acid metabolite were both reduced by 13% and AUCm/AUCp from 1.04 to 0.59.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),,0.59,97624,DB00571,Propranolol
,9431839,peak rises,A small pressor effect of short duration was observed following zolmitriptan with mean peak rises of 13 and 11 mmHg in systolic and diastolic pressures respectively; propranolol had no effect on the pressor response.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),mmhg,13,97625,DB00571,Propranolol
,9431839,peak rises,A small pressor effect of short duration was observed following zolmitriptan with mean peak rises of 13 and 11 mmHg in systolic and diastolic pressures respectively; propranolol had no effect on the pressor response.,The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9431839/),mmhg,11,97626,DB00571,Propranolol
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],16.1,99215,DB00571,Propranolol
,2038745,systemic clearance (Cls),"The mean systemic clearance (Cls) for AC in the adults and pups was 16.1 and 13.7 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],13.7,99216,DB00571,Propranolol
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,25.5,99217,DB00571,Propranolol
,2038745,half-lives,"The mean half-lives of AC (t1/2) were 25.5 and 33.3 min in the adult and pup groups, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,33.3,99218,DB00571,Propranolol
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,97.5,99219,DB00571,Propranolol
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,95.1,99220,DB00571,Propranolol
,2038745,t1/2,"In a younger group of pups (18-21 days old) it declined with a longer t1/2 (97.5, 95.1, and 347.6 min in the adults, older pups, and younger pups, respectively).","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,347.6,99221,DB00571,Propranolol
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],5.34,99222,DB00571,Propranolol
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],6.30,99223,DB00571,Propranolol
,2038745,Cls,"The mean AN Cls in the adults, the older pups, and the younger pups was 5.34, 6.30, and 1.91 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.91,99224,DB00571,Propranolol
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,633,99225,DB00571,Propranolol
,2038745,t1/2,The time course of SA was prolonged in the suckling pups (t1/2 of 633 min in the pups vs 78.7 min in the adult).,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),min,78.7,99226,DB00571,Propranolol
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],1.05,99227,DB00571,Propranolol
,2038745,Cls,"The mean Cls values in the adults and the pups were 1.05 and 0.27 ml/min/kg, respectively.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.27,99228,DB00571,Propranolol
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],11.2,99229,DB00571,Propranolol
,2038745,systemic clearance of unbound drug (Clu),The mean systemic clearance of unbound drug (Clu) for SA was 11.2 ml/min/kg in the adults and 0.92 ml/min/kg in the pups.,"Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),[ml] / [kg·min],0.92,99230,DB00571,Propranolol
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,9.7,99231,DB00571,Propranolol
,2038745,free fraction,"The serum protein binding of AC and AN was limited, whereas the mean free fraction for SA was 9.7% in adult serum and 32.5% in pup serum.","Pharmacokinetics of acetaminophen, antipyrine, and salicylic acid in the lactating and nursing rabbit, with model predictions of milk to serum concentration ratios and neonatal dose. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2038745/),%,32.5,99232,DB00571,Propranolol
,3720177,AUC ratio,The mean AUC ratio of conjugated/unchanged propranolol was 13:1 in the fasting state but only about 6:1 in the nonfasting state (P less than 0.001).,Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720177/),,13:1,100581,DB00571,Propranolol
,3720177,AUC ratio,The mean AUC ratio of conjugated/unchanged propranolol was 13:1 in the fasting state but only about 6:1 in the nonfasting state (P less than 0.001).,Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3720177/),,6:1,100582,DB00571,Propranolol
,19489169,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),min,30,100644,DB00571,Propranolol
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,40,100645,DB00571,Propranolol
,19489169,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19489169/),%,60,100646,DB00571,Propranolol
,1673410,half-life,"The half-life of R-propranolol was increased and its apparent oral clearance decreased significantly in DA rats relative to the SD strain [85 +/- 41 min (DA) vs. 26 +/- 10 min (SD) and 0.020 +/- 0.014 liter/min/kg (DA) vs. 0.31 +/- 0.14 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),min,85,100829,DB00571,Propranolol
,1673410,apparent oral clearance,"The half-life of R-propranolol was increased and its apparent oral clearance decreased significantly in DA rats relative to the SD strain [85 +/- 41 min (DA) vs. 26 +/- 10 min (SD) and 0.020 +/- 0.014 liter/min/kg (DA) vs. 0.31 +/- 0.14 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),[l] / [kg·min],0.020,100830,DB00571,Propranolol
,1673410,apparent oral clearance,"The half-life of R-propranolol was increased and its apparent oral clearance decreased significantly in DA rats relative to the SD strain [85 +/- 41 min (DA) vs. 26 +/- 10 min (SD) and 0.020 +/- 0.014 liter/min/kg (DA) vs. 0.31 +/- 0.14 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),[l] / [kg·min],0.31,100831,DB00571,Propranolol
,1673410,half-life,"Strain differences in S-propranolol half-life and apparent oral clearance also were observed, but were not as marked [97 +/- 36 min (DA) vs. 52 +/- 35 min (SD) and 0.20 +/- 0.13 liter/min/kg (DA) vs. 0.70 +/- 0.68 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),min,97,100832,DB00571,Propranolol
,1673410,half-life,"Strain differences in S-propranolol half-life and apparent oral clearance also were observed, but were not as marked [97 +/- 36 min (DA) vs. 52 +/- 35 min (SD) and 0.20 +/- 0.13 liter/min/kg (DA) vs. 0.70 +/- 0.68 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),min,52,100833,DB00571,Propranolol
,1673410,apparent oral clearance,"Strain differences in S-propranolol half-life and apparent oral clearance also were observed, but were not as marked [97 +/- 36 min (DA) vs. 52 +/- 35 min (SD) and 0.20 +/- 0.13 liter/min/kg (DA) vs. 0.70 +/- 0.68 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),[l] / [kg·min],0.20,100834,DB00571,Propranolol
,1673410,apparent oral clearance,"Strain differences in S-propranolol half-life and apparent oral clearance also were observed, but were not as marked [97 +/- 36 min (DA) vs. 52 +/- 35 min (SD) and 0.20 +/- 0.13 liter/min/kg (DA) vs. 0.70 +/- 0.68 liter/min/kg (SD)], respectively.",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),[l] / [kg·min],0.70,100835,DB00571,Propranolol
,1673410,oral clearance ratio,"Due to a more pronounced effect of rat strain on the disposition of R-propranolol, the stereoselective S-/R- oral clearance ratio for propranolol was also strain-dependent [10 +/- 3 (DA) vs. 2.1 +/- 0.9 (SD)].",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),,10,100836,DB00571,Propranolol
,1673410,oral clearance ratio,"Due to a more pronounced effect of rat strain on the disposition of R-propranolol, the stereoselective S-/R- oral clearance ratio for propranolol was also strain-dependent [10 +/- 3 (DA) vs. 2.1 +/- 0.9 (SD)].",Stereoselective differences in propranolol disposition in female Sprague-Dawley and Dark Agouti rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1673410/),,2.1,100837,DB00571,Propranolol
,10801242,cardiac output,Propranolol reduced cardiac output from 10.6 to 4.1 L/min.,Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801242/),[l] / [min],10.6,101363,DB00571,Propranolol
,10801242,cardiac output,Propranolol reduced cardiac output from 10.6 to 4.1 L/min.,Indocyanine green kinetics characterize blood volume and flow distribution and their alteration by propranolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10801242/),[l] / [min],4,101364,DB00571,Propranolol
,2723110,F,"According to the literature, the bioavailability of a single 80 mg oral dose of propranolol (F = 0.22) increases after multiple doses Fss = 0.36).",Saturable first-pass kinetics of propranolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723110/),,0.22,102164,DB00571,Propranolol
,2723110,Fss,"According to the literature, the bioavailability of a single 80 mg oral dose of propranolol (F = 0.22) increases after multiple doses Fss = 0.36).",Saturable first-pass kinetics of propranolol. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723110/),,0.36,102165,DB00571,Propranolol
,2723110,maximal metabolic rate (Vm,"Based on the first pass equations for single dosage and multiple dosing, the maximal metabolic rate (Vm = 0.043 mg l-1 h-1) corresponding to 310 mg per day and the Michaelis constant (Km = 0.10 mg/l) were calculated for propranolol.",Saturable first-pass kinetics of propranolol. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723110/),[mg] / [h·l],0.043,102166,DB00571,Propranolol
,2723110,Michaelis constant (Km,"Based on the first pass equations for single dosage and multiple dosing, the maximal metabolic rate (Vm = 0.043 mg l-1 h-1) corresponding to 310 mg per day and the Michaelis constant (Km = 0.10 mg/l) were calculated for propranolol.",Saturable first-pass kinetics of propranolol. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2723110/),[mg] / [l],0.10,102167,DB00571,Propranolol
,7736686,terminal phase elimination half-life,"Sustained release dosage forms are available, which may be beneficial due to the short terminal phase elimination half-life of conventional immediate release flurbiprofen (3 to 6 hours).",Clinical pharmacokinetics of flurbiprofen and its enantiomers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736686/),h,3 to 6,102250,DB00571,Propranolol
,12852442,absorption half-life,"The absorption half-life of the investigated drugs ranged from 2 to 59 min, and the extent of absorption from 21 to 94% in 2 h in the isolated perfused rat lung model.",Drug absorption from the isolated perfused rat lung--correlations with drug physicochemical properties and epithelial permeability. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12852442/),min,2 to 59,102577,DB00571,Propranolol
,3725870,relative bioavailability F,In comparison with preparation B the relative bioavailability F was 104% for preparation A.,[Comparative pharmacokinetic studies on the relative biologic availability of two propranolol preparations in patients with steady state essential hypertension]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3725870/),%,104,103450,DB00571,Propranolol
,3725870,steady-state plasma concentrations,The steady-state plasma concentrations of propranolol were within the therapeutic range of 50-100 ng/ml.,[Comparative pharmacokinetic studies on the relative biologic availability of two propranolol preparations in patients with steady state essential hypertension]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3725870/),[ng] / [ml],50-100,103451,DB00571,Propranolol
,3725870,rate of elimination constants,"The rate of elimination constants of 0,065 to 0,073 h-1 after preparation A and B explain the long duration of the therapeutic efficacy during chronic treatment.",[Comparative pharmacokinetic studies on the relative biologic availability of two propranolol preparations in patients with steady state essential hypertension]. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3725870/),1/[h],"0,065 to 0,073",103452,DB00571,Propranolol
,8456080,AUC R:S ratio,"The AUC R:S ratio was, therefore, significantly altered (AA, 14 +/- 3.0; control, 4.3 +/- 1.2).",Selective effect of adjuvant arthritis on the disposition of propranolol enantiomers in rats detected using a stereospecific HPLC assay. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8456080/),,14,103960,DB00571,Propranolol
,8456080,AUC R:S ratio,"The AUC R:S ratio was, therefore, significantly altered (AA, 14 +/- 3.0; control, 4.3 +/- 1.2).",Selective effect of adjuvant arthritis on the disposition of propranolol enantiomers in rats detected using a stereospecific HPLC assay. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8456080/),,4.3,103961,DB00571,Propranolol
,3427136,elimination half-life,In 7 pregnant hypertensive patients the elimination half-life of propranolol was enhanced to 6.1 +/- 1.2 h in comparison to 4.4 +/- 0.4 in 9 nonpregnant females.,The influence of phenobarbital on the pharmacokinetics of propranolol in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427136/),h,6.1,104682,DB00571,Propranolol
,3427136,elimination half-life,In 7 pregnant hypertensive patients the elimination half-life of propranolol was enhanced to 6.1 +/- 1.2 h in comparison to 4.4 +/- 0.4 in 9 nonpregnant females.,The influence of phenobarbital on the pharmacokinetics of propranolol in pregnancy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427136/),h,4.4,104683,DB00571,Propranolol
,3427136,half-life,"In 8 out of 11 pregnant hypertensive patients in the 29th week of gestation treated with 90 mg phenobarbital daily for at least 7 days before starting propranolol therapy, the half-life of propranolol was 3.1 +/- 0.4 h only.",The influence of phenobarbital on the pharmacokinetics of propranolol in pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3427136/),h,3.1,104684,DB00571,Propranolol
,23205867,maximal,"Pharmacokinetic parameters evaluated at the steady state in newborns treated with 0.5 mg/kg/6 h showed values of maximal (71.7 ± 29.8 ng/mL), minimal (42.2 ± 20.8 ng/mL) and average concentration (60.8 ± 25.0 ng/mL), time of maximal concentration (2.6 ± 0.9 h) and area under the time-concentration curve (364.7 ± 150.2 ng/mL/h) similar to those observed in adults.",Propranolol concentrations after oral administration in term and preterm neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23205867/),[ng] / [ml],71.7,104779,DB00571,Propranolol
,23205867,maximal,"Pharmacokinetic parameters evaluated at the steady state in newborns treated with 0.5 mg/kg/6 h showed values of maximal (71.7 ± 29.8 ng/mL), minimal (42.2 ± 20.8 ng/mL) and average concentration (60.8 ± 25.0 ng/mL), time of maximal concentration (2.6 ± 0.9 h) and area under the time-concentration curve (364.7 ± 150.2 ng/mL/h) similar to those observed in adults.",Propranolol concentrations after oral administration in term and preterm neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23205867/),[ng] / [ml],42.2,104780,DB00571,Propranolol
,23205867,minimal,"Pharmacokinetic parameters evaluated at the steady state in newborns treated with 0.5 mg/kg/6 h showed values of maximal (71.7 ± 29.8 ng/mL), minimal (42.2 ± 20.8 ng/mL) and average concentration (60.8 ± 25.0 ng/mL), time of maximal concentration (2.6 ± 0.9 h) and area under the time-concentration curve (364.7 ± 150.2 ng/mL/h) similar to those observed in adults.",Propranolol concentrations after oral administration in term and preterm neonates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23205867/),[ng] / [ml],42.2,104781,DB00571,Propranolol
,23205867,concentration,"Pharmacokinetic parameters evaluated at the steady state in newborns treated with 0.5 mg/kg/6 h showed values of maximal (71.7 ± 29.8 ng/mL), minimal (42.2 ± 20.8 ng/mL) and average concentration (60.8 ± 25.0 ng/mL), time of maximal concentration (2.6 ± 0.9 h) and area under the time-concentration curve (364.7 ± 150.2 ng/mL/h) similar to those observed in adults.",Propranolol concentrations after oral administration in term and preterm neonates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23205867/),[ng] / [ml],60.8,104782,DB00571,Propranolol
,23205867,time of maximal concentration,"Pharmacokinetic parameters evaluated at the steady state in newborns treated with 0.5 mg/kg/6 h showed values of maximal (71.7 ± 29.8 ng/mL), minimal (42.2 ± 20.8 ng/mL) and average concentration (60.8 ± 25.0 ng/mL), time of maximal concentration (2.6 ± 0.9 h) and area under the time-concentration curve (364.7 ± 150.2 ng/mL/h) similar to those observed in adults.",Propranolol concentrations after oral administration in term and preterm neonates. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23205867/),h,2.6,104783,DB00571,Propranolol
,23205867,area under the time-concentration curve,"Pharmacokinetic parameters evaluated at the steady state in newborns treated with 0.5 mg/kg/6 h showed values of maximal (71.7 ± 29.8 ng/mL), minimal (42.2 ± 20.8 ng/mL) and average concentration (60.8 ± 25.0 ng/mL), time of maximal concentration (2.6 ± 0.9 h) and area under the time-concentration curve (364.7 ± 150.2 ng/mL/h) similar to those observed in adults.",Propranolol concentrations after oral administration in term and preterm neonates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23205867/),[ng] / [h·ml],364.7,104784,DB00571,Propranolol
,23205867,elimination half-life,"In both dosing groups, elimination half-life was significantly longer (14.9 ± 4.3 and 15.9 ± 6.1 h), and apparent total body clearance (27.2 ± 13.9 and 31.3 ± 13.3 mL/kg/min) lower than those reported in adults, suggesting a slower metabolism in newborns.",Propranolol concentrations after oral administration in term and preterm neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23205867/),h,14.9,104785,DB00571,Propranolol
,23205867,elimination half-life,"In both dosing groups, elimination half-life was significantly longer (14.9 ± 4.3 and 15.9 ± 6.1 h), and apparent total body clearance (27.2 ± 13.9 and 31.3 ± 13.3 mL/kg/min) lower than those reported in adults, suggesting a slower metabolism in newborns.",Propranolol concentrations after oral administration in term and preterm neonates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23205867/),h,15.9,104786,DB00571,Propranolol
,23205867,apparent total body clearance,"In both dosing groups, elimination half-life was significantly longer (14.9 ± 4.3 and 15.9 ± 6.1 h), and apparent total body clearance (27.2 ± 13.9 and 31.3 ± 13.3 mL/kg/min) lower than those reported in adults, suggesting a slower metabolism in newborns.",Propranolol concentrations after oral administration in term and preterm neonates. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23205867/),[ml] / [kg·min],27.2,104787,DB00571,Propranolol
,23205867,apparent total body clearance,"In both dosing groups, elimination half-life was significantly longer (14.9 ± 4.3 and 15.9 ± 6.1 h), and apparent total body clearance (27.2 ± 13.9 and 31.3 ± 13.3 mL/kg/min) lower than those reported in adults, suggesting a slower metabolism in newborns.",Propranolol concentrations after oral administration in term and preterm neonates. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23205867/),[ml] / [kg·min],31.3,104788,DB00571,Propranolol
,520399,time to reach peak concentration,"Food intake significantly shortened the time to reach peak concentration (2.7 h vs 1.5 h), but caused a significant reduction in AUC values, the mean decrease being 20%.",Food-induced reduction in bioavailability of atenolol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/520399/),h,2.7,106126,DB00571,Propranolol
,520399,time to reach peak concentration,"Food intake significantly shortened the time to reach peak concentration (2.7 h vs 1.5 h), but caused a significant reduction in AUC values, the mean decrease being 20%.",Food-induced reduction in bioavailability of atenolol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/520399/),h,1.5,106127,DB00571,Propranolol
,18329563,Peak serum concentrations,"Peak serum concentrations of mepivacaine, C(max) (1.214 +/- 0.746 microg/mL(-1)), were significantly increased by propranolol (2.249 +/- 1.559 microg/mL(-1), P < .05).",Effect of propranolol on mepivacaine serum concentrations in dental practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18329563/),[μg] / [ml],1.214,107406,DB00571,Propranolol
,18329563,Peak serum concentrations,"Peak serum concentrations of mepivacaine, C(max) (1.214 +/- 0.746 microg/mL(-1)), were significantly increased by propranolol (2.249 +/- 1.559 microg/mL(-1), P < .05).",Effect of propranolol on mepivacaine serum concentrations in dental practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18329563/),[μg] / [ml],2.249,107407,DB00571,Propranolol
,18329563,C(max),"Peak serum concentrations of mepivacaine, C(max) (1.214 +/- 0.746 microg/mL(-1)), were significantly increased by propranolol (2.249 +/- 1.559 microg/mL(-1), P < .05).",Effect of propranolol on mepivacaine serum concentrations in dental practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18329563/),[μg] / [ml],1.214,107408,DB00571,Propranolol
,18329563,C(max),"Peak serum concentrations of mepivacaine, C(max) (1.214 +/- 0.746 microg/mL(-1)), were significantly increased by propranolol (2.249 +/- 1.559 microg/mL(-1), P < .05).",Effect of propranolol on mepivacaine serum concentrations in dental practice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18329563/),[μg] / [ml],2.249,107409,DB00571,Propranolol
,6146357,Terminal half-lives,"Terminal half-lives of 26.8 +/- 9.1 h and 51.3 +/- 7.5 h were found for exaprolol and propranolol, respectively.","Biliary excretion and enterohepatic circulation of two beta-adrenergic blocking drugs, exaprolol and propranolol, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146357/),h,26.8,107620,DB00571,Propranolol
,6146357,Terminal half-lives,"Terminal half-lives of 26.8 +/- 9.1 h and 51.3 +/- 7.5 h were found for exaprolol and propranolol, respectively.","Biliary excretion and enterohepatic circulation of two beta-adrenergic blocking drugs, exaprolol and propranolol, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146357/),h,51.3,107621,DB00571,Propranolol
,6146357,recovery of 3H radioactivity,"The recovery of 3H radioactivity in feces following i.v. administration of the drugs (34.2 +/- 0.8 per cent and 12.0 +/- 1.3 per cent 3H of exaprolol and propranolol, respectively) is of biliary origin, as 30.7 +/- 3.5 per cent and 13.4 +/- 3.6 per cent 3H of exaprolol and propranolol, respectively, was excreted in the bile after i.v. administration.","Biliary excretion and enterohepatic circulation of two beta-adrenergic blocking drugs, exaprolol and propranolol, in rats. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146357/),%,34.2,107622,DB00571,Propranolol
,6146357,recovery of 3H radioactivity,"The recovery of 3H radioactivity in feces following i.v. administration of the drugs (34.2 +/- 0.8 per cent and 12.0 +/- 1.3 per cent 3H of exaprolol and propranolol, respectively) is of biliary origin, as 30.7 +/- 3.5 per cent and 13.4 +/- 3.6 per cent 3H of exaprolol and propranolol, respectively, was excreted in the bile after i.v. administration.","Biliary excretion and enterohepatic circulation of two beta-adrenergic blocking drugs, exaprolol and propranolol, in rats. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146357/),%,12.0,107623,DB00571,Propranolol
,6146357,recovery of 3H radioactivity,"The recovery of 3H radioactivity in feces following i.v. administration of the drugs (34.2 +/- 0.8 per cent and 12.0 +/- 1.3 per cent 3H of exaprolol and propranolol, respectively) is of biliary origin, as 30.7 +/- 3.5 per cent and 13.4 +/- 3.6 per cent 3H of exaprolol and propranolol, respectively, was excreted in the bile after i.v. administration.","Biliary excretion and enterohepatic circulation of two beta-adrenergic blocking drugs, exaprolol and propranolol, in rats. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146357/),%,30.7,107624,DB00571,Propranolol
,6146357,recovery of 3H radioactivity,"The recovery of 3H radioactivity in feces following i.v. administration of the drugs (34.2 +/- 0.8 per cent and 12.0 +/- 1.3 per cent 3H of exaprolol and propranolol, respectively) is of biliary origin, as 30.7 +/- 3.5 per cent and 13.4 +/- 3.6 per cent 3H of exaprolol and propranolol, respectively, was excreted in the bile after i.v. administration.","Biliary excretion and enterohepatic circulation of two beta-adrenergic blocking drugs, exaprolol and propranolol, in rats. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6146357/),%,13.4,107625,DB00571,Propranolol
,8792428,fG,"Values for fG, fH and fL were the following: 0.21 +/- 0.07, 0.61 +/- 0.13, and 0.82 +/- 0.09, respectively.","In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792428/),,0.21,107638,DB00571,Propranolol
,8792428,fH,"Values for fG, fH and fL were the following: 0.21 +/- 0.07, 0.61 +/- 0.13, and 0.82 +/- 0.09, respectively.","In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792428/),,0.61,107639,DB00571,Propranolol
,8792428,fL,"Values for fG, fH and fL were the following: 0.21 +/- 0.07, 0.61 +/- 0.13, and 0.82 +/- 0.09, respectively.","In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792428/),,0.82,107640,DB00571,Propranolol
,8792428,apparent permeability coefficient,"The apparent permeability coefficient of propofol across Caco-2 cell monolayers was 24.2 +/- 0.3 x 10(-6) cm.sec-1, which is similar to the apparent permeability coefficient obtained for propranolol (30.7 +/- 1.7 x 10(-6) cm.sec-1), a compound known to easily cross the intestinal epithelial membranes.","In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792428/),[cm] / [s],24.2,107641,DB00571,Propranolol
,8792428,apparent permeability coefficient,"The apparent permeability coefficient of propofol across Caco-2 cell monolayers was 24.2 +/- 0.3 x 10(-6) cm.sec-1, which is similar to the apparent permeability coefficient obtained for propranolol (30.7 +/- 1.7 x 10(-6) cm.sec-1), a compound known to easily cross the intestinal epithelial membranes.","In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792428/),[cm] / [s],30.7,107642,DB00571,Propranolol
,2774225,intrinsic clearance,"Spinal anesthesia had no significant effect on either the intrinsic clearance of propranolol (2.01 +/- 0.75 L/min before and 1.9 +/- 0.7 L/min during spinal anesthesia), or on mean hepatic plasma flow (2.01 +/- 0.5 L/min before and 1.93 +/- 0.5 L/min during spinal anesthesia).",Lack of effect of spinal anesthesia on drug metabolism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774225/),[l] / [min],2.01,108752,DB00571,Propranolol
,2774225,intrinsic clearance,"Spinal anesthesia had no significant effect on either the intrinsic clearance of propranolol (2.01 +/- 0.75 L/min before and 1.9 +/- 0.7 L/min during spinal anesthesia), or on mean hepatic plasma flow (2.01 +/- 0.5 L/min before and 1.93 +/- 0.5 L/min during spinal anesthesia).",Lack of effect of spinal anesthesia on drug metabolism. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774225/),[l] / [min],1.9,108753,DB00571,Propranolol
,2774225,hepatic plasma flow,"Spinal anesthesia had no significant effect on either the intrinsic clearance of propranolol (2.01 +/- 0.75 L/min before and 1.9 +/- 0.7 L/min during spinal anesthesia), or on mean hepatic plasma flow (2.01 +/- 0.5 L/min before and 1.93 +/- 0.5 L/min during spinal anesthesia).",Lack of effect of spinal anesthesia on drug metabolism. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774225/),[l] / [min],2.01,108754,DB00571,Propranolol
,2774225,hepatic plasma flow,"Spinal anesthesia had no significant effect on either the intrinsic clearance of propranolol (2.01 +/- 0.75 L/min before and 1.9 +/- 0.7 L/min during spinal anesthesia), or on mean hepatic plasma flow (2.01 +/- 0.5 L/min before and 1.93 +/- 0.5 L/min during spinal anesthesia).",Lack of effect of spinal anesthesia on drug metabolism. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774225/),[l] / [min],1.93,108755,DB00571,Propranolol
,2774225,systemic clearance,"The systemic clearance and elimination half-life of propranolol were also unchanged by spinal anesthesia (0.9 +/- 0.23 L/min on the first day, 0.7 +/- 0.1 L/min during spinal anesthesia; and 101 +/- 21 min on the first day, 115 +/- 16 min during spinal anesthesia, respectively).",Lack of effect of spinal anesthesia on drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774225/),[l] / [min],0.9,108756,DB00571,Propranolol
,2774225,systemic clearance,"The systemic clearance and elimination half-life of propranolol were also unchanged by spinal anesthesia (0.9 +/- 0.23 L/min on the first day, 0.7 +/- 0.1 L/min during spinal anesthesia; and 101 +/- 21 min on the first day, 115 +/- 16 min during spinal anesthesia, respectively).",Lack of effect of spinal anesthesia on drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774225/),[l] / [min],0.7,108757,DB00571,Propranolol
,2774225,systemic clearance,"The systemic clearance and elimination half-life of propranolol were also unchanged by spinal anesthesia (0.9 +/- 0.23 L/min on the first day, 0.7 +/- 0.1 L/min during spinal anesthesia; and 101 +/- 21 min on the first day, 115 +/- 16 min during spinal anesthesia, respectively).",Lack of effect of spinal anesthesia on drug metabolism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774225/),min,101,108758,DB00571,Propranolol
,2774225,elimination half-life,"The systemic clearance and elimination half-life of propranolol were also unchanged by spinal anesthesia (0.9 +/- 0.23 L/min on the first day, 0.7 +/- 0.1 L/min during spinal anesthesia; and 101 +/- 21 min on the first day, 115 +/- 16 min during spinal anesthesia, respectively).",Lack of effect of spinal anesthesia on drug metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774225/),[l] / [min],0.7,108759,DB00571,Propranolol
,2774225,elimination half-life,"The systemic clearance and elimination half-life of propranolol were also unchanged by spinal anesthesia (0.9 +/- 0.23 L/min on the first day, 0.7 +/- 0.1 L/min during spinal anesthesia; and 101 +/- 21 min on the first day, 115 +/- 16 min during spinal anesthesia, respectively).",Lack of effect of spinal anesthesia on drug metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774225/),min,101,108760,DB00571,Propranolol
,2774225,elimination half-life,"The systemic clearance and elimination half-life of propranolol were also unchanged by spinal anesthesia (0.9 +/- 0.23 L/min on the first day, 0.7 +/- 0.1 L/min during spinal anesthesia; and 101 +/- 21 min on the first day, 115 +/- 16 min during spinal anesthesia, respectively).",Lack of effect of spinal anesthesia on drug metabolism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2774225/),min,115,108761,DB00571,Propranolol
,8201781,maximum HR,That in the maximum HR was 16.9 +/- 5.2 (10.9 +/- 3.1%) in group H and 24.4 +/- 2.4 bpm (21.9 +/- 2.1%) in group C.,Pharmacokinetics of propranolol used for suppressing tachycardia in hyperthyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201781/),,16.9,111244,DB00571,Propranolol
,8201781,maximum HR,That in the maximum HR was 16.9 +/- 5.2 (10.9 +/- 3.1%) in group H and 24.4 +/- 2.4 bpm (21.9 +/- 2.1%) in group C.,Pharmacokinetics of propranolol used for suppressing tachycardia in hyperthyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201781/),bpm,24.4,111245,DB00571,Propranolol
,8201781,peak concentration,The peak concentration of propranolol in plasma was 10.8 +/- 2.4 ng/ml in group H and 55.3 +/- 14.3 ng/ml in group C (p < 0.01).,Pharmacokinetics of propranolol used for suppressing tachycardia in hyperthyroidism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201781/),[ng] / [ml],10.8,111246,DB00571,Propranolol
,8201781,peak concentration,The peak concentration of propranolol in plasma was 10.8 +/- 2.4 ng/ml in group H and 55.3 +/- 14.3 ng/ml in group C (p < 0.01).,Pharmacokinetics of propranolol used for suppressing tachycardia in hyperthyroidism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201781/),[ng] / [ml],55.3,111247,DB00571,Propranolol
,28502673,bioavailability,"Propranolol (PROP) undergoes extensive first-pass metabolism by the liver resulting in a relatively low bioavailability (13-23%); thus, multiple oral doses are required to achieve therapeutic effect.",Glucosamine modulates propranolol pharmacokinetics via intestinal permeability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28502673/),%,13-23,111481,DB00571,Propranolol
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,326,111720,DB00571,Propranolol
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,147,111721,DB00571,Propranolol
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,342,111722,DB00571,Propranolol
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,223,111723,DB00571,Propranolol
,19269904,m/,"Quantification was through positive-ion mode and selected reaction monitoring at m/z 326-->147 for tolterodine, 342-->223 for the 5-hydroxymethyl metabolite and 260-->183 for the internal standard propranolol, respectively.",Determination of tolterodine and its 5-hydroxymethyl metabolite in human plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19269904/),,260,111724,DB00571,Propranolol
,2183495,terminal half-life,The mean terminal half-life of penbutolol is 17.6 to 26.5 hours.,Penbutolol: a new beta-adrenergic blocking agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2183495/),h,17.6 to 26.5,112565,DB00571,Propranolol
,15359582,systemic clearance,"Testosterone BA was less than 10% by ID, IC, and IPV routes, due to high hepatic extraction, consistent with its high systemic clearance (63 ml x min(-1) x kg(-1)) and short terminal plasma half-life (23 min).",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),[ml] / [kg·min],63,112742,DB00571,Propranolol
,15359582,terminal plasma half-life,"Testosterone BA was less than 10% by ID, IC, and IPV routes, due to high hepatic extraction, consistent with its high systemic clearance (63 ml x min(-1) x kg(-1)) and short terminal plasma half-life (23 min).",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),min,23,112743,DB00571,Propranolol
,15359582,BA,"The IPV BA of amoxicillin was 95%+/-6% indicating the absence of hepatic extraction in the rat, but with an ID BA of approximately 39% suggesting incomplete GI absorption to be the main barrier to bioavailability.",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),%,95,112744,DB00571,Propranolol
,15359582,BA,"The IPV BA of amoxicillin was 95%+/-6% indicating the absence of hepatic extraction in the rat, but with an ID BA of approximately 39% suggesting incomplete GI absorption to be the main barrier to bioavailability.",Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),%,39,112745,DB00571,Propranolol
,15359582,BA,Low oral BA of propranolol was due in part to first-pass hepatic extraction (IPV BA of 36%).,Evaluating barriers to bioavailability in vivo: validation of a technique for separately assessing gastrointestinal absorption and hepatic extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15359582/),%,36,112746,DB00571,Propranolol
,15917952,biological half-life,"There was an increase of biological half-life from 4.5 (95% CI = 3.9-6.9) to 10.6 h (95% CI = 8.2-14.7; P < 0.01) and an increase in volume of distribution from 4.9 (95% CI = 3.2-14.3) to 8.3 l/kg (95% CI = 6.5-32.1; P < 0.05), while total clearance remained unchanged 9.2 (95% CI = 7.7-24.6) vs 10.7 ml min(-1) kg(-1) (95% CI = 7.7-26.6; NS) after surgery.",Cardiopulmonary bypass alters the pharmacokinetics of propranolol in patients undergoing cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917952/),h,4.5,113456,DB00571,Propranolol
,15917952,biological half-life,"There was an increase of biological half-life from 4.5 (95% CI = 3.9-6.9) to 10.6 h (95% CI = 8.2-14.7; P < 0.01) and an increase in volume of distribution from 4.9 (95% CI = 3.2-14.3) to 8.3 l/kg (95% CI = 6.5-32.1; P < 0.05), while total clearance remained unchanged 9.2 (95% CI = 7.7-24.6) vs 10.7 ml min(-1) kg(-1) (95% CI = 7.7-26.6; NS) after surgery.",Cardiopulmonary bypass alters the pharmacokinetics of propranolol in patients undergoing cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917952/),h,10.6,113457,DB00571,Propranolol
,15917952,volume of distribution,"There was an increase of biological half-life from 4.5 (95% CI = 3.9-6.9) to 10.6 h (95% CI = 8.2-14.7; P < 0.01) and an increase in volume of distribution from 4.9 (95% CI = 3.2-14.3) to 8.3 l/kg (95% CI = 6.5-32.1; P < 0.05), while total clearance remained unchanged 9.2 (95% CI = 7.7-24.6) vs 10.7 ml min(-1) kg(-1) (95% CI = 7.7-26.6; NS) after surgery.",Cardiopulmonary bypass alters the pharmacokinetics of propranolol in patients undergoing cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917952/),[l] / [kg],4.9,113458,DB00571,Propranolol
,15917952,volume of distribution,"There was an increase of biological half-life from 4.5 (95% CI = 3.9-6.9) to 10.6 h (95% CI = 8.2-14.7; P < 0.01) and an increase in volume of distribution from 4.9 (95% CI = 3.2-14.3) to 8.3 l/kg (95% CI = 6.5-32.1; P < 0.05), while total clearance remained unchanged 9.2 (95% CI = 7.7-24.6) vs 10.7 ml min(-1) kg(-1) (95% CI = 7.7-26.6; NS) after surgery.",Cardiopulmonary bypass alters the pharmacokinetics of propranolol in patients undergoing cardiac surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917952/),[l] / [kg],8.3,113459,DB00571,Propranolol
,15917952,total clearance,"There was an increase of biological half-life from 4.5 (95% CI = 3.9-6.9) to 10.6 h (95% CI = 8.2-14.7; P < 0.01) and an increase in volume of distribution from 4.9 (95% CI = 3.2-14.3) to 8.3 l/kg (95% CI = 6.5-32.1; P < 0.05), while total clearance remained unchanged 9.2 (95% CI = 7.7-24.6) vs 10.7 ml min(-1) kg(-1) (95% CI = 7.7-26.6; NS) after surgery.",Cardiopulmonary bypass alters the pharmacokinetics of propranolol in patients undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917952/),[ml] / [kg·min],9.2,113460,DB00571,Propranolol
,15917952,total clearance,"There was an increase of biological half-life from 4.5 (95% CI = 3.9-6.9) to 10.6 h (95% CI = 8.2-14.7; P < 0.01) and an increase in volume of distribution from 4.9 (95% CI = 3.2-14.3) to 8.3 l/kg (95% CI = 6.5-32.1; P < 0.05), while total clearance remained unchanged 9.2 (95% CI = 7.7-24.6) vs 10.7 ml min(-1) kg(-1) (95% CI = 7.7-26.6; NS) after surgery.",Cardiopulmonary bypass alters the pharmacokinetics of propranolol in patients undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917952/),[ml] / [kg·min],10.7,113461,DB00571,Propranolol
,7104460,relative extent of availability,"Based on plasma levels of propranolol for the 24 h following administration of 2 x 40 mg oral propranolol hydrochloride tablets, the relative extent of availability was shown to be 100.8 per cent for the test tablet formulation; no significant differences were detected between formulations with respect to any of the pharmacokinetic parameters examined.",The relative bioavailability of a commercial propranolol hydrochloride tablet in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104460/),%,100.8,113897,DB00571,Propranolol
,9547698,times to peak concentration,The mean +/- S.D. times to peak concentration of propranolol in aqueous humor were 86.6 +/- 47.6 min in the dog and 54.1 +/- 20.4 min in the rabbit.,Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547698/),min,86.6,114326,DB00571,Propranolol
,9547698,times to peak concentration,The mean +/- S.D. times to peak concentration of propranolol in aqueous humor were 86.6 +/- 47.6 min in the dog and 54.1 +/- 20.4 min in the rabbit.,Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547698/),min,54.1,114327,DB00571,Propranolol
,9547698,terminal rate constant,The terminal rate constant was 0.0189 +/- 0.00429 min-1 in the dog vs. 0.00983 +/- 0.00546 min-1 in the rabbit.,Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547698/),1/[min],0.0189,114328,DB00571,Propranolol
,9547698,terminal rate constant,The terminal rate constant was 0.0189 +/- 0.00429 min-1 in the dog vs. 0.00983 +/- 0.00546 min-1 in the rabbit.,Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547698/),1/[min],0.00983,114329,DB00571,Propranolol
,9547698,Intraocular tissue availability,Intraocular tissue availability of propranolol differed markedly between the dog (n = 3) and rabbit (n = 3) (approximately 0.056 in the dog vs. approximately 0.55 in the rabbit).,Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547698/),,0.056,114330,DB00571,Propranolol
,9547698,Intraocular tissue availability,Intraocular tissue availability of propranolol differed markedly between the dog (n = 3) and rabbit (n = 3) (approximately 0.056 in the dog vs. approximately 0.55 in the rabbit).,Evaluation of microdialysis sampling of aqueous humor for in vivo models of ocular absorption and disposition. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9547698/),,0.55,114331,DB00571,Propranolol
,3693583,elimination half-life,"In both studies, the area under the plasma propranolol concentration-time curve and the peak concentration were significantly less (P less than .0001) after the administration of long-acting propranolol compared with conventional propranolol on both day 1 and day 7; in addition, the elimination half-life was longer after administration of the long-acting preparation (9 hr) compared with that following the conventional dosage form (4 hr).",Comparative pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3693583/),h,9,116826,DB00571,Propranolol
,3693583,elimination half-life,"In both studies, the area under the plasma propranolol concentration-time curve and the peak concentration were significantly less (P less than .0001) after the administration of long-acting propranolol compared with conventional propranolol on both day 1 and day 7; in addition, the elimination half-life was longer after administration of the long-acting preparation (9 hr) compared with that following the conventional dosage form (4 hr).",Comparative pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3693583/),h,4,116827,DB00571,Propranolol
,2389694,"area under the heart rate response, time curve","The area under the heart rate response, time curve after nadolol withdrawal was significantly less than that after propranolol withdrawal (20.3 beats/min.",Comparison of hypersensitivity to adrenergic stimulation after abrupt withdrawal of propranolol and nadolol: influence of half-life differences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2389694/),[beats] / [min],20.3,117231,DB00571,Propranolol
,2776391,oral clearance,"The oral clearance of propranolol was significantly higher (63%, p less than 0.02) in the men (65.7 +/- 7.7 ml/min/kg; mean +/- SE) than in the women (40.2 +/- 6.2 ml/min/kg).",Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2776391/),[ml] / [kg·min],65.7,119081,DB00571,Propranolol
,2776391,oral clearance,"The oral clearance of propranolol was significantly higher (63%, p less than 0.02) in the men (65.7 +/- 7.7 ml/min/kg; mean +/- SE) than in the women (40.2 +/- 6.2 ml/min/kg).",Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2776391/),[ml] / [kg·min],40.2,119082,DB00571,Propranolol
,10571601,area under the curve (AUC),"The area under the curve (AUC) during the study period was significantly different for the two isomers (S-propranolol 1217.0 +/- 118.5 nmol.h/L; R-propranolol 728.8 +/- 103.8 nmol.h/L, P < 0.0001).",Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10571601/),[h·nM] / [l],1217.0,119092,DB00571,Propranolol
,10571601,area under the curve (AUC),"The area under the curve (AUC) during the study period was significantly different for the two isomers (S-propranolol 1217.0 +/- 118.5 nmol.h/L; R-propranolol 728.8 +/- 103.8 nmol.h/L, P < 0.0001).",Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10571601/),[h·nM] / [l],728.8,119093,DB00571,Propranolol
,7077541,systemic bioavailability,"Before surgery, systemic bioavailability of the oral dose was 8 +/- 8% (mean +/- S.D.), whereas after transposition the bioavailability was 102 +/- 9%.",Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7077541/),%,8,119267,DB00571,Propranolol
,7077541,bioavailability,"Before surgery, systemic bioavailability of the oral dose was 8 +/- 8% (mean +/- S.D.), whereas after transposition the bioavailability was 102 +/- 9%.",Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7077541/),%,102,119268,DB00571,Propranolol
,7077541,systemic plasma clearance,The systemic plasma clearance increased from 766 +/- 192 to 976 +/- 280 ml/min.,Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7077541/),[ml] / [min],766,119269,DB00571,Propranolol
,7077541,systemic plasma clearance,The systemic plasma clearance increased from 766 +/- 192 to 976 +/- 280 ml/min.,Lack of gastrointestinal metabolism of propranolol in dogs after portacaval transposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7077541/),[ml] / [min],976,119270,DB00571,Propranolol
,15333515,systemic clearance,The systemic clearance of propranolol (approximately 1.53 l/h/kg) suggested that the hepatic blood flow in CHPs is comparable to that in humans.,The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15333515/),[l] / [h·kg],1.53,119920,DB00571,Propranolol
,3254980,systemic bioavailabilities,"The systemic bioavailabilities of propranolol after the intra-small-intestinal loop and the intra-cheek-pouch administrations were 8.4% and 88.5%, respectively.",Application of propranolol to the keratinized oral mucosa: avoidance of first-pass elimination and the use of 1-dodecylazacycloheptan-2-one (Azone) as an absorption enhancer of bioadhesive film-dosage form. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3254980/),%,8.4,120590,DB00571,Propranolol
,3254980,systemic bioavailabilities,"The systemic bioavailabilities of propranolol after the intra-small-intestinal loop and the intra-cheek-pouch administrations were 8.4% and 88.5%, respectively.",Application of propranolol to the keratinized oral mucosa: avoidance of first-pass elimination and the use of 1-dodecylazacycloheptan-2-one (Azone) as an absorption enhancer of bioadhesive film-dosage form. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3254980/),%,88.5,120591,DB00571,Propranolol
,3254980,bioavailability,The bioavailability of propranolol was improved further (to 97.1%) by a 1-h pretreatment of the cheek pouch with 5% 1-dodecylazacycloheptan-2-one (Azone)-emulsion.,Application of propranolol to the keratinized oral mucosa: avoidance of first-pass elimination and the use of 1-dodecylazacycloheptan-2-one (Azone) as an absorption enhancer of bioadhesive film-dosage form. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3254980/),%,97.1,120592,DB00571,Propranolol
,1712269,terminal half-life,"In clinical pharmacology studies, cilazapril, after its bioactivation to cilazaprilat, was characterised as a potent, reversible angiotensin converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours, which is consistent with saturable binding to ACE.",Clinical pharmacology of cilazapril. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712269/),h,30 to 50,120675,DB00571,Propranolol
,2569324,duration of,"The duration of effective beta-adrenoceptor blockade was significantly longer in the chronic phase and seemed to be longer with LA than with C propranolol although this was not significant (72 +/- 31 vs 48 +/- 18 h, respectively).",Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569324/),h,72,121539,DB00571,Propranolol
,2569324,duration of,"The duration of effective beta-adrenoceptor blockade was significantly longer in the chronic phase and seemed to be longer with LA than with C propranolol although this was not significant (72 +/- 31 vs 48 +/- 18 h, respectively).",Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2569324/),h,48,121540,DB00571,Propranolol
,21586316,AUC(0 → ∞),"The values of AUC(0 → ∞), clearance (Cl(0 → ∞)), volume of distribution (Vd), and elimination half-life (t(1/2β)) of Tet were 59861.149 ± 26962.196 μg/L⁎min, 0.503 ± 0.173 L/min/kg, 179 ± 76.185 L/kg, and 283.808 ± 162.937 min for intravenous injection of 5mg/kg, or 18986.217 ± 7462.308 μg/L⁎min, 0.805 ± 0.267 L/min/kg, 110.284 ± 94.176 L/kg, and 732.919 ± 847.32 min for gavage administration of 10mg/kg , respectively.",The pharmacokinetical study of plant alkaloid tetrandrine with a simple HPLC method in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21586316/),[μg] / [l⁎min],59861.149,121580,DB00571,Propranolol
,21586316,clearance (Cl(0 → ∞)),"The values of AUC(0 → ∞), clearance (Cl(0 → ∞)), volume of distribution (Vd), and elimination half-life (t(1/2β)) of Tet were 59861.149 ± 26962.196 μg/L⁎min, 0.503 ± 0.173 L/min/kg, 179 ± 76.185 L/kg, and 283.808 ± 162.937 min for intravenous injection of 5mg/kg, or 18986.217 ± 7462.308 μg/L⁎min, 0.805 ± 0.267 L/min/kg, 110.284 ± 94.176 L/kg, and 732.919 ± 847.32 min for gavage administration of 10mg/kg , respectively.",The pharmacokinetical study of plant alkaloid tetrandrine with a simple HPLC method in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21586316/),[l] / [kg·min],0.503,121581,DB00571,Propranolol
,21586316,clearance (Cl(0 → ∞)),"The values of AUC(0 → ∞), clearance (Cl(0 → ∞)), volume of distribution (Vd), and elimination half-life (t(1/2β)) of Tet were 59861.149 ± 26962.196 μg/L⁎min, 0.503 ± 0.173 L/min/kg, 179 ± 76.185 L/kg, and 283.808 ± 162.937 min for intravenous injection of 5mg/kg, or 18986.217 ± 7462.308 μg/L⁎min, 0.805 ± 0.267 L/min/kg, 110.284 ± 94.176 L/kg, and 732.919 ± 847.32 min for gavage administration of 10mg/kg , respectively.",The pharmacokinetical study of plant alkaloid tetrandrine with a simple HPLC method in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21586316/),[l] / [kg],179,121582,DB00571,Propranolol
,21586316,volume of distribution (Vd),"The values of AUC(0 → ∞), clearance (Cl(0 → ∞)), volume of distribution (Vd), and elimination half-life (t(1/2β)) of Tet were 59861.149 ± 26962.196 μg/L⁎min, 0.503 ± 0.173 L/min/kg, 179 ± 76.185 L/kg, and 283.808 ± 162.937 min for intravenous injection of 5mg/kg, or 18986.217 ± 7462.308 μg/L⁎min, 0.805 ± 0.267 L/min/kg, 110.284 ± 94.176 L/kg, and 732.919 ± 847.32 min for gavage administration of 10mg/kg , respectively.",The pharmacokinetical study of plant alkaloid tetrandrine with a simple HPLC method in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21586316/),[l] / [kg·min],0.503,121583,DB00571,Propranolol
,21586316,volume of distribution (Vd),"The values of AUC(0 → ∞), clearance (Cl(0 → ∞)), volume of distribution (Vd), and elimination half-life (t(1/2β)) of Tet were 59861.149 ± 26962.196 μg/L⁎min, 0.503 ± 0.173 L/min/kg, 179 ± 76.185 L/kg, and 283.808 ± 162.937 min for intravenous injection of 5mg/kg, or 18986.217 ± 7462.308 μg/L⁎min, 0.805 ± 0.267 L/min/kg, 110.284 ± 94.176 L/kg, and 732.919 ± 847.32 min for gavage administration of 10mg/kg , respectively.",The pharmacokinetical study of plant alkaloid tetrandrine with a simple HPLC method in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21586316/),[l] / [kg],179,121584,DB00571,Propranolol
,21586316,elimination half-life (t(1/2β)),"The values of AUC(0 → ∞), clearance (Cl(0 → ∞)), volume of distribution (Vd), and elimination half-life (t(1/2β)) of Tet were 59861.149 ± 26962.196 μg/L⁎min, 0.503 ± 0.173 L/min/kg, 179 ± 76.185 L/kg, and 283.808 ± 162.937 min for intravenous injection of 5mg/kg, or 18986.217 ± 7462.308 μg/L⁎min, 0.805 ± 0.267 L/min/kg, 110.284 ± 94.176 L/kg, and 732.919 ± 847.32 min for gavage administration of 10mg/kg , respectively.",The pharmacokinetical study of plant alkaloid tetrandrine with a simple HPLC method in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21586316/),min,283.808,121585,DB00571,Propranolol
,21586316,elimination half-life (t(1/2β)),"The values of AUC(0 → ∞), clearance (Cl(0 → ∞)), volume of distribution (Vd), and elimination half-life (t(1/2β)) of Tet were 59861.149 ± 26962.196 μg/L⁎min, 0.503 ± 0.173 L/min/kg, 179 ± 76.185 L/kg, and 283.808 ± 162.937 min for intravenous injection of 5mg/kg, or 18986.217 ± 7462.308 μg/L⁎min, 0.805 ± 0.267 L/min/kg, 110.284 ± 94.176 L/kg, and 732.919 ± 847.32 min for gavage administration of 10mg/kg , respectively.",The pharmacokinetical study of plant alkaloid tetrandrine with a simple HPLC method in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21586316/),[l] / [kg],110.284,121586,DB00571,Propranolol
,12353056,absolute bioavailability,Almotriptan is well absorbed orally; its absolute bioavailability in humans is 70%.,"Almotriptan, a new anti-migraine agent: a review. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12353056/),%,70,123996,DB00571,Propranolol
,12353056,elimination half-life,Its peak plasma levels are reached at 1 to 3 h after its administration; its elimination half-life is 3 to 4 h.,"Almotriptan, a new anti-migraine agent: a review. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12353056/),h,3 to 4,123997,DB00571,Propranolol
,7085853,Fractional extraction,Fractional extraction (arterial - venous + arterial X 100) of epinephrine across the forearm was 26 +/- 8% in the basal state and increased to 33 +/- 6% and further to 51 +/- 4% during the epinephrine infusions.,Release and clearance rates of epinephrine in man: importance of arterial measurements. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),%,26,124601,DB00571,Propranolol
,7085853,Fractional extraction,Fractional extraction (arterial - venous + arterial X 100) of epinephrine across the forearm was 26 +/- 8% in the basal state and increased to 33 +/- 6% and further to 51 +/- 4% during the epinephrine infusions.,Release and clearance rates of epinephrine in man: importance of arterial measurements. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),%,33,124602,DB00571,Propranolol
,7085853,Fractional extraction,Fractional extraction (arterial - venous + arterial X 100) of epinephrine across the forearm was 26 +/- 8% in the basal state and increased to 33 +/- 6% and further to 51 +/- 4% during the epinephrine infusions.,Release and clearance rates of epinephrine in man: importance of arterial measurements. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),%,51,124603,DB00571,Propranolol
,7085853,Whole body clearance,"Whole body clearance of epinephrine, calculated from arterial measurements, was 33 +/- 3 ml/kg . min during the 0.1 microgram/min infusion and 35 +/- 3 ml/kg . min during the 2 micrograms/min epinephrine infusion, values 50% lower than the clearance rates calculated from venous measurements.",Release and clearance rates of epinephrine in man: importance of arterial measurements. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),[ml] / [kg·min],33,124604,DB00571,Propranolol
,7085853,Whole body clearance,"Whole body clearance of epinephrine, calculated from arterial measurements, was 33 +/- 3 ml/kg . min during the 0.1 microgram/min infusion and 35 +/- 3 ml/kg . min during the 2 micrograms/min epinephrine infusion, values 50% lower than the clearance rates calculated from venous measurements.",Release and clearance rates of epinephrine in man: importance of arterial measurements. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),[ml] / [kg·min],35,124605,DB00571,Propranolol
,7085853,whole body clearance,"Propranolol infusion resulted in a fall in whole body clearance to 20 +/- 2 ml/kg . min (P less than 0.001), suggesting that epinephrine clearance is partly dependent on a beta-adrenergic mechanism.",Release and clearance rates of epinephrine in man: importance of arterial measurements. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),[ml] / [kg·min],20,124606,DB00571,Propranolol
,7085853,Basal endogenous release rate (clearance X,"Basal endogenous release rate (clearance X basal epinephrine level) was estimated to be approximately 0.18 microgram/min, a value much less than that reported in studies using venous measurements.",Release and clearance rates of epinephrine in man: importance of arterial measurements. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),[μg] / [min],0.18,124607,DB00571,Propranolol
,7391969,myocardial-to-plasma concentration ratios,The myocardial-to-plasma concentration ratios ranged from 6.2 to 20.3 and were constant with time for each dog.,A model to describe myocardial drug disposition in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7391969/),,6.2 to 20.3,125238,DB00571,Propranolol
,7400970,distribution half-life,"The disposition of the drug can be adequately described by a two-compartment open model with a distribution half-life of 4.8 min, a terminal blood half-life of 63 min and an apparent volume of distribution beta of 8.5 liters/kg.",Kinetics of distribution of di-propranolol in various organs and discrete brain areas of the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7400970/),min,4.8,125267,DB00571,Propranolol
,7400970,terminal blood half-life,"The disposition of the drug can be adequately described by a two-compartment open model with a distribution half-life of 4.8 min, a terminal blood half-life of 63 min and an apparent volume of distribution beta of 8.5 liters/kg.",Kinetics of distribution of di-propranolol in various organs and discrete brain areas of the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7400970/),min,63,125268,DB00571,Propranolol
,7400970,apparent volume of distribution beta,"The disposition of the drug can be adequately described by a two-compartment open model with a distribution half-life of 4.8 min, a terminal blood half-life of 63 min and an apparent volume of distribution beta of 8.5 liters/kg.",Kinetics of distribution of di-propranolol in various organs and discrete brain areas of the rat. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7400970/),[l] / [kg],8.5,125269,DB00571,Propranolol
,2910639,R/S ratios,"The R/S ratios for the clearance to 4-OH-P were similar between EM and PMD (2.5 +/- 0.5 vs 2.5 +/- 0.4, respectively), implying that the different enzymes involved in ring hydroxylation (i.e., the debrisoquin isozyme and other hydroxylases) have similar stereoselective preferences.",Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2910639/),,2.5,125387,DB00571,Propranolol
,2910639,R/S ratios,"The R/S ratios for the clearance to 4-OH-P were similar between EM and PMD (2.5 +/- 0.5 vs 2.5 +/- 0.4, respectively), implying that the different enzymes involved in ring hydroxylation (i.e., the debrisoquin isozyme and other hydroxylases) have similar stereoselective preferences.",Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2910639/),,2.5,125388,DB00571,Propranolol
,28930,Plasma concentrations,Plasma concentrations at the 320-mg daily dose ranged from 20 to 112 ng/ml.,O-methylated catechol-like metabolites of propranolol in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28930/),[ng] / [ml],20 to 112,125521,DB00571,Propranolol
,1783646,maximum concentration,"After a second dose, maximum concentration was reached after 80 +/- 10 min and 98 +/- 12 min, in plasma, and the concentrations in the interstitial water were 594 +/- 138 and 27 +/- 7 nM, respectively.",Measurements by microdialysis of free tissue concentrations of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783646/),nM,594,125607,DB00571,Propranolol
,1783646,maximum concentration,"After a second dose, maximum concentration was reached after 80 +/- 10 min and 98 +/- 12 min, in plasma, and the concentrations in the interstitial water were 594 +/- 138 and 27 +/- 7 nM, respectively.",Measurements by microdialysis of free tissue concentrations of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783646/),nM,27,125608,DB00571,Propranolol
,1783646,maximum concentrations,"The maximum concentrations of propranolol were 97 +/- 29 and 6 +/- 2 nM in plasma and in interstitial water, respectively.",Measurements by microdialysis of free tissue concentrations of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783646/),nM,97,125609,DB00571,Propranolol
,1783646,maximum concentrations,"The maximum concentrations of propranolol were 97 +/- 29 and 6 +/- 2 nM in plasma and in interstitial water, respectively.",Measurements by microdialysis of free tissue concentrations of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783646/),nM,6,125610,DB00571,Propranolol
,2573492,oral clearance,"The greatest effect was on the oral clearance, which was substantially lower for MTP (1.6 vs. 5.5 liters/min) with an associated higher bioavailability (23.1 vs. 10.9%).",Pharmacokinetics and metabolism of a 4'-methylthio derivative of propranolol in the dog. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573492/),[l] / [min],1.6,129336,DB00571,Propranolol
,2573492,oral clearance,"The greatest effect was on the oral clearance, which was substantially lower for MTP (1.6 vs. 5.5 liters/min) with an associated higher bioavailability (23.1 vs. 10.9%).",Pharmacokinetics and metabolism of a 4'-methylthio derivative of propranolol in the dog. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573492/),[l] / [min],5.5,129337,DB00571,Propranolol
,2573492,bioavailability,"The greatest effect was on the oral clearance, which was substantially lower for MTP (1.6 vs. 5.5 liters/min) with an associated higher bioavailability (23.1 vs. 10.9%).",Pharmacokinetics and metabolism of a 4'-methylthio derivative of propranolol in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573492/),%,23.1,129338,DB00571,Propranolol
,2573492,bioavailability,"The greatest effect was on the oral clearance, which was substantially lower for MTP (1.6 vs. 5.5 liters/min) with an associated higher bioavailability (23.1 vs. 10.9%).",Pharmacokinetics and metabolism of a 4'-methylthio derivative of propranolol in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2573492/),%,10.9,129339,DB00571,Propranolol
,1997061,volume of distribution (Vss),Propofol produced marked changes in drug distribution; volume of distribution (Vss) of propranolol increased 54% from 82.5 (SEM 7.3) litre awake to 127.3 (27) litre during propofol anaesthesia (P less than 0.05).,Effect of i.v. anaesthesia with propofol on drug distribution and metabolism in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1997061/),awake·l,82.5,130808,DB00571,Propranolol
,1997061,volume of distribution (Vss),Propofol produced marked changes in drug distribution; volume of distribution (Vss) of propranolol increased 54% from 82.5 (SEM 7.3) litre awake to 127.3 (27) litre during propofol anaesthesia (P less than 0.05).,Effect of i.v. anaesthesia with propofol on drug distribution and metabolism in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1997061/),l,127.3,130809,DB00571,Propranolol
,1997061,free fraction,This change was accompanied by an increase (P less than 0.05) in the free fraction of propranolol from 8.5 (0.7) % in awake to 14.0 (0.7) % in propofol-anaesthetized dogs.,Effect of i.v. anaesthesia with propofol on drug distribution and metabolism in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1997061/),%,8.5,130810,DB00571,Propranolol
,1997061,free fraction,This change was accompanied by an increase (P less than 0.05) in the free fraction of propranolol from 8.5 (0.7) % in awake to 14.0 (0.7) % in propofol-anaesthetized dogs.,Effect of i.v. anaesthesia with propofol on drug distribution and metabolism in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1997061/),,14.0,130811,DB00571,Propranolol
,13958,t1/2 of distribution,The t1/2 of distribution ranges between 5 to 30 minutes.,Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13958/),min,5 to 30,131024,DB00571,Propranolol
,13958,elimination half-life,The beta-blockers are relatively rapidly eliminated from the body and most of them have an elimination half-life between 2 to 4 hours.,Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/13958/),h,2 to 4,131025,DB00571,Propranolol
,32043,potency ratios,"The mean potency ratios of timolol to propranolol as an antagonist of chronotropic effects on exercise tachycardia were 11 to 17 and 3.6 to 5.5 in dose- and concentration-effect relationships, respectively.",Comparison of disposition and effect of timolol and propranolol on exercise tachycardia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043/),,11 to 17,132123,DB00571,Propranolol
,32043,potency ratios,"The mean potency ratios of timolol to propranolol as an antagonist of chronotropic effects on exercise tachycardia were 11 to 17 and 3.6 to 5.5 in dose- and concentration-effect relationships, respectively.",Comparison of disposition and effect of timolol and propranolol on exercise tachycardia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32043/),,3.6 to 5.5,132124,DB00571,Propranolol
,6734027,systemic clearance (Cls),"Plasma concentrations of (+)- and (-)-propranolol as measured by gas chromatography-mass spectrometry demonstrated enantiomeric differences in systemic clearance (Cls) [(+)-propranolol, 1.21 +/- 0.15 l/min; (-)-propranolol, 1.03 +/- 0.12 l/min; P less than 0.01] and apparent volume of distribution (Vd) [(+)-propranolol, 4.82 +/- 0.34 l/kg; (-)-propranolol, 4.08 +/- 0.33 l/kg; P less than 0.001], but no difference in distribution or elimination t1/2s (t1/2 beta 3.5 hr).",Stereoselective clearance and distribution of intravenous propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734027/),[l] / [min],1.21,134675,DB00571,Propranolol
,6734027,systemic clearance (Cls),"Plasma concentrations of (+)- and (-)-propranolol as measured by gas chromatography-mass spectrometry demonstrated enantiomeric differences in systemic clearance (Cls) [(+)-propranolol, 1.21 +/- 0.15 l/min; (-)-propranolol, 1.03 +/- 0.12 l/min; P less than 0.01] and apparent volume of distribution (Vd) [(+)-propranolol, 4.82 +/- 0.34 l/kg; (-)-propranolol, 4.08 +/- 0.33 l/kg; P less than 0.001], but no difference in distribution or elimination t1/2s (t1/2 beta 3.5 hr).",Stereoselective clearance and distribution of intravenous propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734027/),[l] / [min],1.03,134676,DB00571,Propranolol
,6734027,apparent volume of distribution (Vd),"Plasma concentrations of (+)- and (-)-propranolol as measured by gas chromatography-mass spectrometry demonstrated enantiomeric differences in systemic clearance (Cls) [(+)-propranolol, 1.21 +/- 0.15 l/min; (-)-propranolol, 1.03 +/- 0.12 l/min; P less than 0.01] and apparent volume of distribution (Vd) [(+)-propranolol, 4.82 +/- 0.34 l/kg; (-)-propranolol, 4.08 +/- 0.33 l/kg; P less than 0.001], but no difference in distribution or elimination t1/2s (t1/2 beta 3.5 hr).",Stereoselective clearance and distribution of intravenous propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734027/),[l] / [kg],4.82,134677,DB00571,Propranolol
,6734027,apparent volume of distribution (Vd),"Plasma concentrations of (+)- and (-)-propranolol as measured by gas chromatography-mass spectrometry demonstrated enantiomeric differences in systemic clearance (Cls) [(+)-propranolol, 1.21 +/- 0.15 l/min; (-)-propranolol, 1.03 +/- 0.12 l/min; P less than 0.01] and apparent volume of distribution (Vd) [(+)-propranolol, 4.82 +/- 0.34 l/kg; (-)-propranolol, 4.08 +/- 0.33 l/kg; P less than 0.001], but no difference in distribution or elimination t1/2s (t1/2 beta 3.5 hr).",Stereoselective clearance and distribution of intravenous propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734027/),[l] / [kg],4.08,134678,DB00571,Propranolol
,6734027,t1/2 beta,"Plasma concentrations of (+)- and (-)-propranolol as measured by gas chromatography-mass spectrometry demonstrated enantiomeric differences in systemic clearance (Cls) [(+)-propranolol, 1.21 +/- 0.15 l/min; (-)-propranolol, 1.03 +/- 0.12 l/min; P less than 0.01] and apparent volume of distribution (Vd) [(+)-propranolol, 4.82 +/- 0.34 l/kg; (-)-propranolol, 4.08 +/- 0.33 l/kg; P less than 0.001], but no difference in distribution or elimination t1/2s (t1/2 beta 3.5 hr).",Stereoselective clearance and distribution of intravenous propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734027/),h,3.5,134679,DB00571,Propranolol
,6734027,apparent Vd,"The higher apparent Vd of (+)-propranolol is mainly related to its lower plasma binding [(+)-propranolol, 20.3 +/- 0.8% unbound; (-)-propranolol, 17.6 +/- 0.7% unbound; P less than 0.001].",Stereoselective clearance and distribution of intravenous propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734027/),%,20.3,134680,DB00571,Propranolol
,6734027,apparent Vd,"The higher apparent Vd of (+)-propranolol is mainly related to its lower plasma binding [(+)-propranolol, 20.3 +/- 0.8% unbound; (-)-propranolol, 17.6 +/- 0.7% unbound; P less than 0.001].",Stereoselective clearance and distribution of intravenous propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734027/),%,17.6,134681,DB00571,Propranolol
,2753957,Terminal half-lives,"Terminal half-lives of R(+)- and S(-)-propranolol were 19.23 and 51.95 min, respectively, in one rat, and 14.50 and 52.07 min, respectively, in the other.",Quantification of propranolol enantiomers in small blood samples from rats by reversed-phase high-performance liquid chromatography after chiral derivatization. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753957/),min,19.23,134862,DB00571,Propranolol
,2753957,Terminal half-lives,"Terminal half-lives of R(+)- and S(-)-propranolol were 19.23 and 51.95 min, respectively, in one rat, and 14.50 and 52.07 min, respectively, in the other.",Quantification of propranolol enantiomers in small blood samples from rats by reversed-phase high-performance liquid chromatography after chiral derivatization. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753957/),min,51.95,134863,DB00571,Propranolol
,2753957,Terminal half-lives,"Terminal half-lives of R(+)- and S(-)-propranolol were 19.23 and 51.95 min, respectively, in one rat, and 14.50 and 52.07 min, respectively, in the other.",Quantification of propranolol enantiomers in small blood samples from rats by reversed-phase high-performance liquid chromatography after chiral derivatization. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753957/),min,14.50,134864,DB00571,Propranolol
,2753957,Terminal half-lives,"Terminal half-lives of R(+)- and S(-)-propranolol were 19.23 and 51.95 min, respectively, in one rat, and 14.50 and 52.07 min, respectively, in the other.",Quantification of propranolol enantiomers in small blood samples from rats by reversed-phase high-performance liquid chromatography after chiral derivatization. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753957/),min,52.07,134865,DB00571,Propranolol
,6786672,bioavailability,"The mean increase in bioavailability was 136.5 +/- 57.6%, and the results were consistent in each subject.",Influence of cimetidine on pharmacokinetics of propranolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786672/),%,136.5,135115,DB00571,Propranolol
,7589058,maximum concentration,"Compared to controls, vitamin C decreased the maximum concentration of propranolol from 463 to 334 nmol.l-1, and the area under the propranolol concentration-time curve (from 0 to 24 hours) from 3.13 to 1.96 mumol.l-1.h.",Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),[nM] / [l],463,135269,DB00571,Propranolol
,7589058,maximum concentration,"Compared to controls, vitamin C decreased the maximum concentration of propranolol from 463 to 334 nmol.l-1, and the area under the propranolol concentration-time curve (from 0 to 24 hours) from 3.13 to 1.96 mumol.l-1.h.",Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),[nM] / [l],33,135270,DB00571,Propranolol
,7589058,area under the propranolol concentration-time curve (from 0 to 24 hours),"Compared to controls, vitamin C decreased the maximum concentration of propranolol from 463 to 334 nmol.l-1, and the area under the propranolol concentration-time curve (from 0 to 24 hours) from 3.13 to 1.96 mumol.l-1.h.",Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),[h·μM] / [l],3.13,135271,DB00571,Propranolol
,7589058,area under the propranolol concentration-time curve (from 0 to 24 hours),"Compared to controls, vitamin C decreased the maximum concentration of propranolol from 463 to 334 nmol.l-1, and the area under the propranolol concentration-time curve (from 0 to 24 hours) from 3.13 to 1.96 mumol.l-1.h.",Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),[h·μM] / [l],1.96,135272,DB00571,Propranolol
,7589058,time to reach maximum propranolol concentration,The time to reach maximum propranolol concentration was increased from 1.9 to 2.7.,Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),,1.9,135273,DB00571,Propranolol
,7589058,time to reach maximum propranolol concentration,The time to reach maximum propranolol concentration was increased from 1.9 to 2.7.,Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),,2.7,135274,DB00571,Propranolol
,7589058,total amount of drug recovered,The total amount of drug recovered in urine has also significantly diminished (from 12.6 to 4.29 mg).,Influence of vitamin C on the absorption and first pass metabolism of propranolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589058/),mg,12.6,135275,DB00571,Propranolol
,3171976,steady-state maternal total drug concentration,"Propranolol was administered to the mother (bolus dose, 1.5 mg/kg followed by an infusion of 1.2 mg/kg/hr over 3 hr) to achieve an average steady-state maternal total drug concentration of 600 ng/ml.",Effects of gestational age on the disposition of propranolol in pregnant sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171976/),[ng] / [ml],600,137120,DB00571,Propranolol
,3171976,Total steady-state maternal plasma propranolol concentration,"Total steady-state maternal plasma propranolol concentration was 666 +/- 266 ng/ml, reflecting a 4-fold variation in maternal drug clearance and a 14-fold variation in binding.",Effects of gestational age on the disposition of propranolol in pregnant sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171976/),[ng] / [ml],666,137121,DB00571,Propranolol
,6834851,total body clearance,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg·mn],"0,178",137594,DB00571,Propranolol
,6834851,total body clearance,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg·mn],"0,115",137595,DB00571,Propranolol
,6834851,volume of distribution,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg],"9,32",137596,DB00571,Propranolol
,6834851,volume of distribution,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg],"6,02",137597,DB00571,Propranolol
,6834851,half-life,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),mn,"40,25",137598,DB00571,Propranolol
,6834851,half-life,"For propranolol the total body clearance (0,178 +/- 0,064 and 0,115 +/- 0,048 l.kg-1.mn-1; p less than 0,05) and the volume of distribution (9,32 +/- 3,10 and 6,02 +/- 0,96 l.kg-1; p less than 0,01) were significantly diminished; half-life (40,25 +/- 19,45 and 45,62 +/- 32,20 mn) remained inchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),mn,"45,62",137599,DB00571,Propranolol
,6834851,total body clearance,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg·mn],"3,28",137600,DB00571,Propranolol
,6834851,total body clearance,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg·mn],"1,43",137601,DB00571,Propranolol
,6834851,half-life,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),mn,"136,4",137602,DB00571,Propranolol
,6834851,half-life,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),mn,"324,9",137603,DB00571,Propranolol
,6834851,volume of distribution,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg],"0,62",137604,DB00571,Propranolol
,6834851,volume of distribution,"For phenytoin, total body clearance (3,28 +/- 0,94 and 1,43 +/- 0,50 l.kg-1.mn-1; p less than 0,001) was significantly diminished; half-life (136,4 +/- 29,4 and 324,9 +/- 131,6 mn; p less than 0,001) significantly increased; volume of distribution (0,62 +/- 0,13 and 0,62 +/- 0,10 l.kg-1) remained unchanged.","[Pharmacokinetics of propranolol, phenytoin and lidocaine in hypercholesterolemic rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6834851/),[l] / [kg],"0,62",137605,DB00571,Propranolol
,1768562,Blood clearance (CLb),"4. Blood clearance (CLb) of ICG (15.9 +/- 2.2 ml min-1 kg-1; mean +/- s.d.), calculated as infusion rate/blood dye concentration over three time periods (30-50, 80-100 and 130-150 min) during the 150 min infusion, was not different from that obtained with three 1-min infusions (0.5 mg kg-1) administered at corresponding times of the day (CLb = 14.0 +/- 2.2 ml min-1 kg-1, P = 0.06).",Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768562/),[ml] / [kg·min],15.9,137987,DB00571,Propranolol
,1768562,CLb,"4. Blood clearance (CLb) of ICG (15.9 +/- 2.2 ml min-1 kg-1; mean +/- s.d.), calculated as infusion rate/blood dye concentration over three time periods (30-50, 80-100 and 130-150 min) during the 150 min infusion, was not different from that obtained with three 1-min infusions (0.5 mg kg-1) administered at corresponding times of the day (CLb = 14.0 +/- 2.2 ml min-1 kg-1, P = 0.06).",Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1768562/),[ml] / [kg·min],14.0,137988,DB00571,Propranolol
,32679526,flow-rate,"Chromatographic separation was achieved on reverse phase Acquity UPLC BEH C18 column (50 mm × 2.1 mm, i.d., 1.7 μm) with an isocratic mobile phase composed of solvent A (0.1% formic acid in acetonitrile) and B (0.1% formic acid in water) (80:20, v/v) at a flow-rate of 0.4 mL/min.",Development and validation of a high throughput bioanalytical UPLC-MS/MS method for simultaneous determination of tamoxifen and sulphoraphane in rat plasma: Application to an oral pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32679526/),[ml] / [min],0.4,138422,DB00571,Propranolol
,32679526,m/z,"The transitions were m/z = 372.0 [M+H]+ → 71.92 for tamoxifen, m/z = 177.9 [M+H]+ → 113.9 for sulphoraphane and m/z = 260.3 [M+H]+ → 116.1 for propranolol.",Development and validation of a high throughput bioanalytical UPLC-MS/MS method for simultaneous determination of tamoxifen and sulphoraphane in rat plasma: Application to an oral pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32679526/),M+h,372.0,138423,DB00571,Propranolol
,32679526,m/z,"The transitions were m/z = 372.0 [M+H]+ → 71.92 for tamoxifen, m/z = 177.9 [M+H]+ → 113.9 for sulphoraphane and m/z = 260.3 [M+H]+ → 116.1 for propranolol.",Development and validation of a high throughput bioanalytical UPLC-MS/MS method for simultaneous determination of tamoxifen and sulphoraphane in rat plasma: Application to an oral pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32679526/),M+h,71.92,138424,DB00571,Propranolol
,32679526,m/z,"The transitions were m/z = 372.0 [M+H]+ → 71.92 for tamoxifen, m/z = 177.9 [M+H]+ → 113.9 for sulphoraphane and m/z = 260.3 [M+H]+ → 116.1 for propranolol.",Development and validation of a high throughput bioanalytical UPLC-MS/MS method for simultaneous determination of tamoxifen and sulphoraphane in rat plasma: Application to an oral pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32679526/),M+h,177.9,138425,DB00571,Propranolol
,32679526,m/z,"The transitions were m/z = 372.0 [M+H]+ → 71.92 for tamoxifen, m/z = 177.9 [M+H]+ → 113.9 for sulphoraphane and m/z = 260.3 [M+H]+ → 116.1 for propranolol.",Development and validation of a high throughput bioanalytical UPLC-MS/MS method for simultaneous determination of tamoxifen and sulphoraphane in rat plasma: Application to an oral pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32679526/),M+h,113.9,138426,DB00571,Propranolol
,32679526,m/z,"The transitions were m/z = 372.0 [M+H]+ → 71.92 for tamoxifen, m/z = 177.9 [M+H]+ → 113.9 for sulphoraphane and m/z = 260.3 [M+H]+ → 116.1 for propranolol.",Development and validation of a high throughput bioanalytical UPLC-MS/MS method for simultaneous determination of tamoxifen and sulphoraphane in rat plasma: Application to an oral pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32679526/),M,260.3,138427,DB00571,Propranolol
,32679526,m/z,"The transitions were m/z = 372.0 [M+H]+ → 71.92 for tamoxifen, m/z = 177.9 [M+H]+ → 113.9 for sulphoraphane and m/z = 260.3 [M+H]+ → 116.1 for propranolol.",Development and validation of a high throughput bioanalytical UPLC-MS/MS method for simultaneous determination of tamoxifen and sulphoraphane in rat plasma: Application to an oral pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32679526/),,116.1,138428,DB00571,Propranolol
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,33.1,139253,DB00571,Propranolol
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,31.7,139254,DB00571,Propranolol
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,89.0,139255,DB00571,Propranolol
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,86.6,139256,DB00571,Propranolol
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,99.2,139257,DB00571,Propranolol
,34275331,protein binding,"Respectively, average protein binding across three concentrations by RED and SPME was 33.1 and 31.7% for metoprolol, 89.0 and 86.6% for propranolol and 99.2 and 99.0% for diclofenac.","Solid-phase microextraction for assessment of plasma protein binding, a complement to rapid equilibrium dialysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34275331/),%,99.0,139258,DB00571,Propranolol
,9698776,peak plasma concentration (CMAX),"The pharmacokinetic parameters obtained after sublingual or peroral drug administration were: peak plasma concentration (CMAX): 147 +/- 72 vs 41 +/- 12 ng/ml, P < 0.05; time to reach CMAX (TMAX): 34 +/- 18 vs 52 +/- 11 min, P < 0.05; biological half-life (t1/2b): 0.91 +/- 0.54 vs 2.41 +/- 1.16 h, P < 0.05; area under the curve (AUCT): 245 +/- 134 vs 79 +/- 54 ng h-1 ml-1, P < 0.05; total body clearance (CLT/F): 44 +/- 23 vs 26 +/- 12 ml min-1 kg-1, P = NS.",Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698776/),[ng] / [ml],147,140769,DB00571,Propranolol
,9698776,peak plasma concentration (CMAX),"The pharmacokinetic parameters obtained after sublingual or peroral drug administration were: peak plasma concentration (CMAX): 147 +/- 72 vs 41 +/- 12 ng/ml, P < 0.05; time to reach CMAX (TMAX): 34 +/- 18 vs 52 +/- 11 min, P < 0.05; biological half-life (t1/2b): 0.91 +/- 0.54 vs 2.41 +/- 1.16 h, P < 0.05; area under the curve (AUCT): 245 +/- 134 vs 79 +/- 54 ng h-1 ml-1, P < 0.05; total body clearance (CLT/F): 44 +/- 23 vs 26 +/- 12 ml min-1 kg-1, P = NS.",Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698776/),[ng] / [ml],41,140770,DB00571,Propranolol
,9698776,time to reach CMAX (TMAX),"The pharmacokinetic parameters obtained after sublingual or peroral drug administration were: peak plasma concentration (CMAX): 147 +/- 72 vs 41 +/- 12 ng/ml, P < 0.05; time to reach CMAX (TMAX): 34 +/- 18 vs 52 +/- 11 min, P < 0.05; biological half-life (t1/2b): 0.91 +/- 0.54 vs 2.41 +/- 1.16 h, P < 0.05; area under the curve (AUCT): 245 +/- 134 vs 79 +/- 54 ng h-1 ml-1, P < 0.05; total body clearance (CLT/F): 44 +/- 23 vs 26 +/- 12 ml min-1 kg-1, P = NS.",Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698776/),min,34,140771,DB00571,Propranolol
,9698776,time to reach CMAX (TMAX),"The pharmacokinetic parameters obtained after sublingual or peroral drug administration were: peak plasma concentration (CMAX): 147 +/- 72 vs 41 +/- 12 ng/ml, P < 0.05; time to reach CMAX (TMAX): 34 +/- 18 vs 52 +/- 11 min, P < 0.05; biological half-life (t1/2b): 0.91 +/- 0.54 vs 2.41 +/- 1.16 h, P < 0.05; area under the curve (AUCT): 245 +/- 134 vs 79 +/- 54 ng h-1 ml-1, P < 0.05; total body clearance (CLT/F): 44 +/- 23 vs 26 +/- 12 ml min-1 kg-1, P = NS.",Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698776/),min,52,140772,DB00571,Propranolol
,9698776,biological half-life (t1/2b),"The pharmacokinetic parameters obtained after sublingual or peroral drug administration were: peak plasma concentration (CMAX): 147 +/- 72 vs 41 +/- 12 ng/ml, P < 0.05; time to reach CMAX (TMAX): 34 +/- 18 vs 52 +/- 11 min, P < 0.05; biological half-life (t1/2b): 0.91 +/- 0.54 vs 2.41 +/- 1.16 h, P < 0.05; area under the curve (AUCT): 245 +/- 134 vs 79 +/- 54 ng h-1 ml-1, P < 0.05; total body clearance (CLT/F): 44 +/- 23 vs 26 +/- 12 ml min-1 kg-1, P = NS.",Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698776/),h,0.91,140773,DB00571,Propranolol
,9698776,biological half-life (t1/2b),"The pharmacokinetic parameters obtained after sublingual or peroral drug administration were: peak plasma concentration (CMAX): 147 +/- 72 vs 41 +/- 12 ng/ml, P < 0.05; time to reach CMAX (TMAX): 34 +/- 18 vs 52 +/- 11 min, P < 0.05; biological half-life (t1/2b): 0.91 +/- 0.54 vs 2.41 +/- 1.16 h, P < 0.05; area under the curve (AUCT): 245 +/- 134 vs 79 +/- 54 ng h-1 ml-1, P < 0.05; total body clearance (CLT/F): 44 +/- 23 vs 26 +/- 12 ml min-1 kg-1, P = NS.",Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698776/),h,2.41,140774,DB00571,Propranolol
,9698776,area under the curve (AUCT),"The pharmacokinetic parameters obtained after sublingual or peroral drug administration were: peak plasma concentration (CMAX): 147 +/- 72 vs 41 +/- 12 ng/ml, P < 0.05; time to reach CMAX (TMAX): 34 +/- 18 vs 52 +/- 11 min, P < 0.05; biological half-life (t1/2b): 0.91 +/- 0.54 vs 2.41 +/- 1.16 h, P < 0.05; area under the curve (AUCT): 245 +/- 134 vs 79 +/- 54 ng h-1 ml-1, P < 0.05; total body clearance (CLT/F): 44 +/- 23 vs 26 +/- 12 ml min-1 kg-1, P = NS.",Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698776/),[ng] / [h·ml],245,140775,DB00571,Propranolol
,9698776,area under the curve (AUCT),"The pharmacokinetic parameters obtained after sublingual or peroral drug administration were: peak plasma concentration (CMAX): 147 +/- 72 vs 41 +/- 12 ng/ml, P < 0.05; time to reach CMAX (TMAX): 34 +/- 18 vs 52 +/- 11 min, P < 0.05; biological half-life (t1/2b): 0.91 +/- 0.54 vs 2.41 +/- 1.16 h, P < 0.05; area under the curve (AUCT): 245 +/- 134 vs 79 +/- 54 ng h-1 ml-1, P < 0.05; total body clearance (CLT/F): 44 +/- 23 vs 26 +/- 12 ml min-1 kg-1, P = NS.",Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698776/),[ng] / [h·ml],79,140776,DB00571,Propranolol
,9698776,total body clearance (CLT/F),"The pharmacokinetic parameters obtained after sublingual or peroral drug administration were: peak plasma concentration (CMAX): 147 +/- 72 vs 41 +/- 12 ng/ml, P < 0.05; time to reach CMAX (TMAX): 34 +/- 18 vs 52 +/- 11 min, P < 0.05; biological half-life (t1/2b): 0.91 +/- 0.54 vs 2.41 +/- 1.16 h, P < 0.05; area under the curve (AUCT): 245 +/- 134 vs 79 +/- 54 ng h-1 ml-1, P < 0.05; total body clearance (CLT/F): 44 +/- 23 vs 26 +/- 12 ml min-1 kg-1, P = NS.",Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698776/),[ml] / [kg·min],44,140777,DB00571,Propranolol
,9698776,total body clearance (CLT/F),"The pharmacokinetic parameters obtained after sublingual or peroral drug administration were: peak plasma concentration (CMAX): 147 +/- 72 vs 41 +/- 12 ng/ml, P < 0.05; time to reach CMAX (TMAX): 34 +/- 18 vs 52 +/- 11 min, P < 0.05; biological half-life (t1/2b): 0.91 +/- 0.54 vs 2.41 +/- 1.16 h, P < 0.05; area under the curve (AUCT): 245 +/- 134 vs 79 +/- 54 ng h-1 ml-1, P < 0.05; total body clearance (CLT/F): 44 +/- 23 vs 26 +/- 12 ml min-1 kg-1, P = NS.",Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9698776/),[ml] / [kg·min],26,140778,DB00571,Propranolol
,16256710,Permeability (P(eff),"Permeability (P(eff) x 10(4) cm/s) of celiprolol increased significantly from 1.9-2.1 for the lower concentrations to 3.2 for the highest concentration, while the variability decreased.",In vivo non-linear intestinal permeability of celiprolol and propranolol in conscious dogs: evidence for intestinal secretion. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16256710/),,1,141656,DB00571,Propranolol
,16256710,Permeability (P(eff),"Permeability (P(eff) x 10(4) cm/s) of celiprolol increased significantly from 1.9-2.1 for the lower concentrations to 3.2 for the highest concentration, while the variability decreased.",In vivo non-linear intestinal permeability of celiprolol and propranolol in conscious dogs: evidence for intestinal secretion. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16256710/),,3.2,141657,DB00571,Propranolol
,3171877,bioavailability,The bioavailability of PL in the 5% PL Carbopol ointment with AZ was 13%.,The percutaneous absorption of propranolol and prediction of the plasma concentration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3171877/),%,13,141938,DB00571,Propranolol
,9493498,AUC,"3. There was no significant difference in dose-corrected area under the outflow curve (AUC) for [14C]-sucrose, antipyrine or [14C]-taurocholate between the first and second doses whereas the mean propranolol AUC for the second dose was only 0.577+/-0.439 that for the first dose (P<0.05).",A priming dose of propranolol reduces the availability of a subsequent dose in the isolated perfused rat liver preparation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9493498/),that,0.577,142044,DB00571,Propranolol
,7736918,AUC0-8,"In AA, the AUC0-8 of R- and S-PR were not significantly different in MILDKT rats (R, 15.8 +/- 9.5; S, 1.72 +/- 9.1 mg.hr/liter) as compared with MILDcontrol rats (R, 16.2 +/- 12; S, 1.76 +/- 1.2 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],15.8,142779,DB00571,Propranolol
,7736918,AUC0-8,"In AA, the AUC0-8 of R- and S-PR were not significantly different in MILDKT rats (R, 15.8 +/- 9.5; S, 1.72 +/- 9.1 mg.hr/liter) as compared with MILDcontrol rats (R, 16.2 +/- 12; S, 1.76 +/- 1.2 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],1.72,142780,DB00571,Propranolol
,7736918,AUC0-8,"In AA, the AUC0-8 of R- and S-PR were not significantly different in MILDKT rats (R, 15.8 +/- 9.5; S, 1.72 +/- 9.1 mg.hr/liter) as compared with MILDcontrol rats (R, 16.2 +/- 12; S, 1.76 +/- 1.2 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],16.2,142781,DB00571,Propranolol
,7736918,AUC0-8,"In AA, the AUC0-8 of R- and S-PR were not significantly different in MILDKT rats (R, 15.8 +/- 9.5; S, 1.72 +/- 9.1 mg.hr/liter) as compared with MILDcontrol rats (R, 16.2 +/- 12; S, 1.76 +/- 1.2 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],1.76,142782,DB00571,Propranolol
,7736918,AUC0-8,"On the other hand, the AUC0-8 of both enantiomers were significantly lower in SEVEREKT (R, 39.2 +/- 13.2; S, 2.92 +/- 1.2 mg.hr/liter) as compared with SEVEREcontrol (R, 79.9 +/- 17; S, 6.88 +/- 2.1 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],39.2,142783,DB00571,Propranolol
,7736918,AUC0-8,"On the other hand, the AUC0-8 of both enantiomers were significantly lower in SEVEREKT (R, 39.2 +/- 13.2; S, 2.92 +/- 1.2 mg.hr/liter) as compared with SEVEREcontrol (R, 79.9 +/- 17; S, 6.88 +/- 2.1 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],2.92,142784,DB00571,Propranolol
,7736918,AUC0-8,"On the other hand, the AUC0-8 of both enantiomers were significantly lower in SEVEREKT (R, 39.2 +/- 13.2; S, 2.92 +/- 1.2 mg.hr/liter) as compared with SEVEREcontrol (R, 79.9 +/- 17; S, 6.88 +/- 2.1 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],79.9,142785,DB00571,Propranolol
,7736918,AUC0-8,"On the other hand, the AUC0-8 of both enantiomers were significantly lower in SEVEREKT (R, 39.2 +/- 13.2; S, 2.92 +/- 1.2 mg.hr/liter) as compared with SEVEREcontrol (R, 79.9 +/- 17; S, 6.88 +/- 2.1 mg.hr/liter).",Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7736918/),[h·mg] / [l],6.88,142786,DB00571,Propranolol
,6370541,bioavailability,The bioavailability varies from 10% to over 80% in different subjects.,Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,10,143406,DB00571,Propranolol
over,6370541,bioavailability,The bioavailability varies from 10% to over 80% in different subjects.,Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,80,143407,DB00571,Propranolol
,6370541,bioavailability,"Average bioavailability has been reported to correlate with age, with values of approximately 30% in the 30- to 40-year age group and approximately 65% at 80 years.",Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,30,143408,DB00571,Propranolol
,6370541,bioavailability,"Average bioavailability has been reported to correlate with age, with values of approximately 30% in the 30- to 40-year age group and approximately 65% at 80 years.",Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,65,143409,DB00571,Propranolol
,6370541,apparent volume of distribution at equilibrium,"The apparent volume of distribution at equilibrium varies from approximately 200 to over 800L, suggesting that concentration of labetalol occurs in extravascular sites.",Clinical pharmacokinetics of labetalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),l,200 to over 800,143410,DB00571,Propranolol
,6370541,half-life,The half-life of labetalol in plasma is 3 to 3.5 hours.,Clinical pharmacokinetics of labetalol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),h,3 to 3.5,143411,DB00571,Propranolol
,1970766,clearance,"The clearance of HOP, 66 +/- 6 ml/min/kg (mean +/- SE), was considerably higher than that of propranolol previously determined, suggesting extrahepatic as well as hepatic clearance of HOP.",Pharmacokinetics and metabolism of the pharmacologically active 4'-hydroxylated metabolite of propranolol in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970766/),[ml] / [kg·min],66,144563,DB00571,Propranolol
,1970766,plasma half-life,"The plasma half-life of HOP, 77 +/- 6 min, was shorter than that of propranolol.",Pharmacokinetics and metabolism of the pharmacologically active 4'-hydroxylated metabolite of propranolol in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970766/),min,77,144564,DB00571,Propranolol
,1970766,volume of distribution,"Although HOP is considerably less lipophilic than propranolol, its volume of distribution, 6.4 +/- 0.8 liter/kg, surprisingly, was larger.",Pharmacokinetics and metabolism of the pharmacologically active 4'-hydroxylated metabolite of propranolol in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1970766/),[l] / [kg],6.4,144565,DB00571,Propranolol
,7248480,half-lives,The half-lives were between 5 and 8 h.,Bioavailability of propranolol and bendrofluazide formulations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248480/),h,5 and 8,144578,DB00571,Propranolol
,1856255,detection limit,The detection limit for propranolol in serum is 2.5 ng/ml.,A sensitive high-performance liquid chromatographic analysis of propranolol in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1856255/),[ng] / [ml],2.5,145174,DB00571,Propranolol
,1856255,relative,The relative and absolute recoveries varied from 93.8 to 102.3%.,A sensitive high-performance liquid chromatographic analysis of propranolol in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1856255/),%,93.8 to 102.3,145175,DB00571,Propranolol
,1856255,absolute recoveries,The relative and absolute recoveries varied from 93.8 to 102.3%.,A sensitive high-performance liquid chromatographic analysis of propranolol in serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1856255/),%,93.8 to 102.3,145176,DB00571,Propranolol
,6710558,retention time,The retention time for metoclopramide was 4.7 min.,"High-pressure liquid chromatographic method for determination of metoclopramide in serum, urine, and saliva, with a pharmacokinetic study in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710558/),min,4.7,146706,DB00571,Propranolol
,6710558,Recovery,Recovery was in the range of 93-110% for serum and 94-103% for urine.,"High-pressure liquid chromatographic method for determination of metoclopramide in serum, urine, and saliva, with a pharmacokinetic study in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710558/),%,93-110,146707,DB00571,Propranolol
,6710558,Recovery,Recovery was in the range of 93-110% for serum and 94-103% for urine.,"High-pressure liquid chromatographic method for determination of metoclopramide in serum, urine, and saliva, with a pharmacokinetic study in patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6710558/),%,94-103,146708,DB00571,Propranolol
,3663453,Cmax,"In patients with hepatosplenic schistosomiasis, propranolol blood concentrations were greater (P less than 0.05) at all time intervals, Cmax 63.5 (29-143) ng ml-1 (median and range) than controls Cmax 23 (12-37) ng ml-1.",Propranolol disposition in patients with hepatosplenic schistosomiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663453/),[ng] / [ml],63.5,147374,DB00571,Propranolol
,3663453,Cmax,"In patients with hepatosplenic schistosomiasis, propranolol blood concentrations were greater (P less than 0.05) at all time intervals, Cmax 63.5 (29-143) ng ml-1 (median and range) than controls Cmax 23 (12-37) ng ml-1.",Propranolol disposition in patients with hepatosplenic schistosomiasis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663453/),[ng] / [ml],23,147375,DB00571,Propranolol
,3663453,AUC0-12,"Median AUC0-12 was also greater (P less than 0.05) (533 and 218 ng ml-1 h respectively), tmax were not significantly different.",Propranolol disposition in patients with hepatosplenic schistosomiasis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663453/),[h·ng] / [ml],533,147376,DB00571,Propranolol
,3663453,AUC0-12,"Median AUC0-12 was also greater (P less than 0.05) (533 and 218 ng ml-1 h respectively), tmax were not significantly different.",Propranolol disposition in patients with hepatosplenic schistosomiasis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663453/),[h·ng] / [ml],218,147377,DB00571,Propranolol
,3663453,heart rate,"In patients and controls prior to treatment, standing heart rate (77.5 (60-110), 72 (68-74) beats min-1) systolic (120 (105-150), 110 (100-120) mm Hg) and diastolic blood pressure (75 (60-90), 70 (60-80) mm Hg) were not significantly different.",Propranolol disposition in patients with hepatosplenic schistosomiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663453/),[beats] / [min],77.5,147378,DB00571,Propranolol
,3663453,heart rate,"In patients and controls prior to treatment, standing heart rate (77.5 (60-110), 72 (68-74) beats min-1) systolic (120 (105-150), 110 (100-120) mm Hg) and diastolic blood pressure (75 (60-90), 70 (60-80) mm Hg) were not significantly different.",Propranolol disposition in patients with hepatosplenic schistosomiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3663453/),[beats] / [min],72,147379,DB00571,Propranolol
,8785381,AUC,"There was a strong trend to a greater propranolol AUC in the teasing protocol (139 +/- 54 mg mL-1 h-1 fasting, 178 +/- 105 mg mL-1 h-1 teasing; p = 0.1), and time of peak concentration (tmax) was significantly prolonged (80 +/- 22 min and 120 +/- 32 min, respectively; p < 0.03).",Effects of sensory (teasing) exposure to food on oral propranolol bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785381/),[mg] / [h·ml],139,149325,DB00571,Propranolol
,8785381,AUC,"There was a strong trend to a greater propranolol AUC in the teasing protocol (139 +/- 54 mg mL-1 h-1 fasting, 178 +/- 105 mg mL-1 h-1 teasing; p = 0.1), and time of peak concentration (tmax) was significantly prolonged (80 +/- 22 min and 120 +/- 32 min, respectively; p < 0.03).",Effects of sensory (teasing) exposure to food on oral propranolol bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785381/),[mg] / [h·ml],178,149326,DB00571,Propranolol
,8785381,time of peak concentration (tmax),"There was a strong trend to a greater propranolol AUC in the teasing protocol (139 +/- 54 mg mL-1 h-1 fasting, 178 +/- 105 mg mL-1 h-1 teasing; p = 0.1), and time of peak concentration (tmax) was significantly prolonged (80 +/- 22 min and 120 +/- 32 min, respectively; p < 0.03).",Effects of sensory (teasing) exposure to food on oral propranolol bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785381/),min,80,149327,DB00571,Propranolol
,8785381,time of peak concentration (tmax),"There was a strong trend to a greater propranolol AUC in the teasing protocol (139 +/- 54 mg mL-1 h-1 fasting, 178 +/- 105 mg mL-1 h-1 teasing; p = 0.1), and time of peak concentration (tmax) was significantly prolonged (80 +/- 22 min and 120 +/- 32 min, respectively; p < 0.03).",Effects of sensory (teasing) exposure to food on oral propranolol bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785381/),min,120,149328,DB00571,Propranolol
,7795782,retention times,"The retention times of I.S. and propranolol enantiomers are about 12-13 min and 16-18 min, respectively.",High-performance liquid chromatographic determination of (S)- and (R)-propranolol in human plasma and urine with a chiral beta-cyclodextrin bonded phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795782/),min,12-13,150916,DB00571,Propranolol
,7795782,retention times,"The retention times of I.S. and propranolol enantiomers are about 12-13 min and 16-18 min, respectively.",High-performance liquid chromatographic determination of (S)- and (R)-propranolol in human plasma and urine with a chiral beta-cyclodextrin bonded phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795782/),min,16-18,150917,DB00571,Propranolol
,7795782,Peak resolutions,Peak resolutions are 1.4 for I.S. and 2.2 for propranolol.,High-performance liquid chromatographic determination of (S)- and (R)-propranolol in human plasma and urine with a chiral beta-cyclodextrin bonded phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795782/),,1.4,150918,DB00571,Propranolol
,7795782,Peak resolutions,Peak resolutions are 1.4 for I.S. and 2.2 for propranolol.,High-performance liquid chromatographic determination of (S)- and (R)-propranolol in human plasma and urine with a chiral beta-cyclodextrin bonded phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795782/),,2.2,150919,DB00571,Propranolol
,7795782,Sensitivity,Sensitivity is approximately 1.5 ng/ml per propranolol enantiomer.,High-performance liquid chromatographic determination of (S)- and (R)-propranolol in human plasma and urine with a chiral beta-cyclodextrin bonded phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795782/),[ng] / [ml],1.5,150920,DB00571,Propranolol
,3912184,half-life,"In addition, exercise-induced tachycardia was significantly reduced by bornaprolol up to 48 hours after drug intake (pharmacodynamic half-life approximately 63-86 h) and there was a correlation between this reduction and the log plasma bornaprolol concentration over the 48-h period.",Beta-adrenoceptor blocking effects and plasma levels of bornaprolol and propranolol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3912184/),h,63-86,153042,DB00571,Propranolol
,7248483,fraction of,"The means of the fraction of the administered oral dose reaching the systemic circulations intact drug were calculated to be 0.58 and 0.60 for normal volunteers and uremic patients, respectively.",Estimation of the systemic bioavailability of timolol in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248483/),,0,153986,DB00571,Propranolol
,7248483,fraction of,"The means of the fraction of the administered oral dose reaching the systemic circulations intact drug were calculated to be 0.58 and 0.60 for normal volunteers and uremic patients, respectively.",Estimation of the systemic bioavailability of timolol in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7248483/),,0.60,153987,DB00571,Propranolol
,3691620,accumulation ratios (AUC steady-state 0-24 h/AUC single dose 0-infinity),"These changes were reflected in mean accumulation ratios (AUC steady-state 0-24 h/AUC single dose 0-infinity) of 1.49 and 1.68 for R and SR, respectively.",Propranolol pharmacokinetics and pharmacodynamics after single doses and at steady-state. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691620/),,1.49,153990,DB00571,Propranolol
,3691620,accumulation ratios (AUC steady-state 0-24 h/AUC single dose 0-infinity),"These changes were reflected in mean accumulation ratios (AUC steady-state 0-24 h/AUC single dose 0-infinity) of 1.49 and 1.68 for R and SR, respectively.",Propranolol pharmacokinetics and pharmacodynamics after single doses and at steady-state. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3691620/),,1.68,153991,DB00571,Propranolol
,7438675,elimination half-life (t 1/2),"Change in thyroid status from hyperthyroid to euthyroid produced no change in the elimination half-life (t 1/2) of oral propranolol (3.2 +/- 0.5 to 4.1 +/- 0.7 hr), the oral clearance (38.4 +/- 7.3 to 27.4 +/- 2.4 ml/min/kg), the elimination t 1/2 of intravenous propranolol (2.5 +/- 0.3 to 3.5 +/- 0.7 hr), and the apparent volume of distribution (4.8 +/- 0.4 to 3.8 +/- 0.5 l/kg).",Effects of thyroid dysfunction on propranolol kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438675/),h,3.2,155504,DB00571,Propranolol
,7438675,elimination half-life (t 1/2),"Change in thyroid status from hyperthyroid to euthyroid produced no change in the elimination half-life (t 1/2) of oral propranolol (3.2 +/- 0.5 to 4.1 +/- 0.7 hr), the oral clearance (38.4 +/- 7.3 to 27.4 +/- 2.4 ml/min/kg), the elimination t 1/2 of intravenous propranolol (2.5 +/- 0.3 to 3.5 +/- 0.7 hr), and the apparent volume of distribution (4.8 +/- 0.4 to 3.8 +/- 0.5 l/kg).",Effects of thyroid dysfunction on propranolol kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438675/),h,4.1,155505,DB00571,Propranolol
,7438675,oral clearance,"Change in thyroid status from hyperthyroid to euthyroid produced no change in the elimination half-life (t 1/2) of oral propranolol (3.2 +/- 0.5 to 4.1 +/- 0.7 hr), the oral clearance (38.4 +/- 7.3 to 27.4 +/- 2.4 ml/min/kg), the elimination t 1/2 of intravenous propranolol (2.5 +/- 0.3 to 3.5 +/- 0.7 hr), and the apparent volume of distribution (4.8 +/- 0.4 to 3.8 +/- 0.5 l/kg).",Effects of thyroid dysfunction on propranolol kinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438675/),[ml] / [kg·min],38.4,155506,DB00571,Propranolol
,7438675,oral clearance,"Change in thyroid status from hyperthyroid to euthyroid produced no change in the elimination half-life (t 1/2) of oral propranolol (3.2 +/- 0.5 to 4.1 +/- 0.7 hr), the oral clearance (38.4 +/- 7.3 to 27.4 +/- 2.4 ml/min/kg), the elimination t 1/2 of intravenous propranolol (2.5 +/- 0.3 to 3.5 +/- 0.7 hr), and the apparent volume of distribution (4.8 +/- 0.4 to 3.8 +/- 0.5 l/kg).",Effects of thyroid dysfunction on propranolol kinetics. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438675/),[ml] / [kg·min],27.4,155507,DB00571,Propranolol
,7438675,elimination t 1/2,"Change in thyroid status from hyperthyroid to euthyroid produced no change in the elimination half-life (t 1/2) of oral propranolol (3.2 +/- 0.5 to 4.1 +/- 0.7 hr), the oral clearance (38.4 +/- 7.3 to 27.4 +/- 2.4 ml/min/kg), the elimination t 1/2 of intravenous propranolol (2.5 +/- 0.3 to 3.5 +/- 0.7 hr), and the apparent volume of distribution (4.8 +/- 0.4 to 3.8 +/- 0.5 l/kg).",Effects of thyroid dysfunction on propranolol kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438675/),h,2.5,155508,DB00571,Propranolol
,7438675,elimination t 1/2,"Change in thyroid status from hyperthyroid to euthyroid produced no change in the elimination half-life (t 1/2) of oral propranolol (3.2 +/- 0.5 to 4.1 +/- 0.7 hr), the oral clearance (38.4 +/- 7.3 to 27.4 +/- 2.4 ml/min/kg), the elimination t 1/2 of intravenous propranolol (2.5 +/- 0.3 to 3.5 +/- 0.7 hr), and the apparent volume of distribution (4.8 +/- 0.4 to 3.8 +/- 0.5 l/kg).",Effects of thyroid dysfunction on propranolol kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438675/),h,3.5,155509,DB00571,Propranolol
,7438675,apparent volume of distribution,"Change in thyroid status from hyperthyroid to euthyroid produced no change in the elimination half-life (t 1/2) of oral propranolol (3.2 +/- 0.5 to 4.1 +/- 0.7 hr), the oral clearance (38.4 +/- 7.3 to 27.4 +/- 2.4 ml/min/kg), the elimination t 1/2 of intravenous propranolol (2.5 +/- 0.3 to 3.5 +/- 0.7 hr), and the apparent volume of distribution (4.8 +/- 0.4 to 3.8 +/- 0.5 l/kg).",Effects of thyroid dysfunction on propranolol kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438675/),[l] / [kg],4.8,155510,DB00571,Propranolol
,7438675,apparent volume of distribution,"Change in thyroid status from hyperthyroid to euthyroid produced no change in the elimination half-life (t 1/2) of oral propranolol (3.2 +/- 0.5 to 4.1 +/- 0.7 hr), the oral clearance (38.4 +/- 7.3 to 27.4 +/- 2.4 ml/min/kg), the elimination t 1/2 of intravenous propranolol (2.5 +/- 0.3 to 3.5 +/- 0.7 hr), and the apparent volume of distribution (4.8 +/- 0.4 to 3.8 +/- 0.5 l/kg).",Effects of thyroid dysfunction on propranolol kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438675/),[l] / [kg],3.8,155511,DB00571,Propranolol
,7438675,systemic clearance,"The systemic clearance of propranolol, however, was greater when the patients were hyperthyroid (20.8 +/- 2.5 ml/min/kg) than when they had become euthyroid (11.7 +/- 1.7 ml/min/kg).",Effects of thyroid dysfunction on propranolol kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438675/),[ml] / [kg·min],20.8,155512,DB00571,Propranolol
,7438675,systemic clearance,"The systemic clearance of propranolol, however, was greater when the patients were hyperthyroid (20.8 +/- 2.5 ml/min/kg) than when they had become euthyroid (11.7 +/- 1.7 ml/min/kg).",Effects of thyroid dysfunction on propranolol kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438675/),[ml] / [kg·min],11.7,155513,DB00571,Propranolol
,7438675,elimination t 1/2,The elimination t 1/2 after oral propranolol was longer in the hypothyroid (3.7 +/- 0.5 hr) than in the euthyroid state (2.0 +/- 0.1 hr).,Effects of thyroid dysfunction on propranolol kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438675/),h,3.7,155514,DB00571,Propranolol
,7438675,elimination t 1/2,The elimination t 1/2 after oral propranolol was longer in the hypothyroid (3.7 +/- 0.5 hr) than in the euthyroid state (2.0 +/- 0.1 hr).,Effects of thyroid dysfunction on propranolol kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438675/),h,2.0,155515,DB00571,Propranolol
,8877025,Apparent oral clearances,Serum concentrations of R- and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3. Apparent oral clearances of R- and S-propranolol were higher (P < 0.05) in blacks than whites (R-propranolol: 5036 +/- 4175 ml min-1 vs 2854 +/- 879 ml min-1; S-propranolol 3255 +/- 1723 ml min-1 vs 2125 +/- 510 ml min-1; blacks vs whites).,Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],5036,156158,DB00571,Propranolol
,8877025,Apparent oral clearances,Serum concentrations of R- and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3. Apparent oral clearances of R- and S-propranolol were higher (P < 0.05) in blacks than whites (R-propranolol: 5036 +/- 4175 ml min-1 vs 2854 +/- 879 ml min-1; S-propranolol 3255 +/- 1723 ml min-1 vs 2125 +/- 510 ml min-1; blacks vs whites).,Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],2854,156159,DB00571,Propranolol
,8877025,Apparent oral clearances,Serum concentrations of R- and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3. Apparent oral clearances of R- and S-propranolol were higher (P < 0.05) in blacks than whites (R-propranolol: 5036 +/- 4175 ml min-1 vs 2854 +/- 879 ml min-1; S-propranolol 3255 +/- 1723 ml min-1 vs 2125 +/- 510 ml min-1; blacks vs whites).,Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],3255,156160,DB00571,Propranolol
,8877025,Apparent oral clearances,Serum concentrations of R- and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3. Apparent oral clearances of R- and S-propranolol were higher (P < 0.05) in blacks than whites (R-propranolol: 5036 +/- 4175 ml min-1 vs 2854 +/- 879 ml min-1; S-propranolol 3255 +/- 1723 ml min-1 vs 2125 +/- 510 ml min-1; blacks vs whites).,Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],2125,156161,DB00571,Propranolol
,8877025,clearances,"4. R- and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069 +/- 316 ml min-1 vs 841 +/- 161 ml min-1; S-propranolol 947 +/- 271 ml min-1 vs 771 +/- 142 ml min-1; blacks vs whites, P < 0.05).",Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],1069,156162,DB00571,Propranolol
,8877025,clearances,"4. R- and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069 +/- 316 ml min-1 vs 841 +/- 161 ml min-1; S-propranolol 947 +/- 271 ml min-1 vs 771 +/- 142 ml min-1; blacks vs whites, P < 0.05).",Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],841,156163,DB00571,Propranolol
,8877025,clearances,"4. R- and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069 +/- 316 ml min-1 vs 841 +/- 161 ml min-1; S-propranolol 947 +/- 271 ml min-1 vs 771 +/- 142 ml min-1; blacks vs whites, P < 0.05).",Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],947,156164,DB00571,Propranolol
,8877025,clearances,"4. R- and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069 +/- 316 ml min-1 vs 841 +/- 161 ml min-1; S-propranolol 947 +/- 271 ml min-1 vs 771 +/- 142 ml min-1; blacks vs whites, P < 0.05).",Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8877025/),[ml] / [min],771,156165,DB00571,Propranolol
,3757404,Systemic clearance,"Systemic clearance of propranolol increased 38%, from 1005 +/- 57 to 1384 +/- 115 ml/min (mean +/- SE; P less than 0.05) as a result of the meal, with no change in t1/2 or apparent volume of distribution.",Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757404/),[ml] / [min],1005,156314,DB00571,Propranolol
,3757404,Systemic clearance,"Systemic clearance of propranolol increased 38%, from 1005 +/- 57 to 1384 +/- 115 ml/min (mean +/- SE; P less than 0.05) as a result of the meal, with no change in t1/2 or apparent volume of distribution.",Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757404/),[ml] / [min],1384,156315,DB00571,Propranolol
,3757404,oral clearance,"A 12% decrease in oral clearance occurred with the meal but was not statistically significant (3717 +/- 185 ml/min, fasting; 3245 +/- 498 after meal), whereas bioavailability increased 67% (27.2% +/- 1.7% fasting; 45.5% +/- 4.3% after meal; P less than 0.01).",Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757404/),[ml] / [min],3717,156316,DB00571,Propranolol
,3757404,oral clearance,"A 12% decrease in oral clearance occurred with the meal but was not statistically significant (3717 +/- 185 ml/min, fasting; 3245 +/- 498 after meal), whereas bioavailability increased 67% (27.2% +/- 1.7% fasting; 45.5% +/- 4.3% after meal; P less than 0.01).",Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757404/),,3245,156317,DB00571,Propranolol
,3757404,bioavailability,"A 12% decrease in oral clearance occurred with the meal but was not statistically significant (3717 +/- 185 ml/min, fasting; 3245 +/- 498 after meal), whereas bioavailability increased 67% (27.2% +/- 1.7% fasting; 45.5% +/- 4.3% after meal; P less than 0.01).",Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757404/),%,27.2,156318,DB00571,Propranolol
,3757404,bioavailability,"A 12% decrease in oral clearance occurred with the meal but was not statistically significant (3717 +/- 185 ml/min, fasting; 3245 +/- 498 after meal), whereas bioavailability increased 67% (27.2% +/- 1.7% fasting; 45.5% +/- 4.3% after meal; P less than 0.01).",Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757404/),%,45.5,156319,DB00571,Propranolol
,3757404,hepatic blood flow,"Estimated hepatic blood flow, as measured by indocyanine green clearance, rose 34% 60 minutes after the meal (1719 +/- 155 ml/min fasting; 2304 +/- 218 ml/min after meal; P less than 0.02).",Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757404/),[ml] / [min],1719,156320,DB00571,Propranolol
,3757404,hepatic blood flow,"Estimated hepatic blood flow, as measured by indocyanine green clearance, rose 34% 60 minutes after the meal (1719 +/- 155 ml/min fasting; 2304 +/- 218 ml/min after meal; P less than 0.02).",Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3757404/),[ml] / [min],2304,156321,DB00571,Propranolol
,2357863,area under the plasma concentration-time curve,The coadministration of quinidine resulted in a doubling of the area under the plasma concentration-time curve of (+/-)-propranolol (530 +/- 99 versus 1051 +/- 138 ng.hr/ml; p less than 0.05) and a reduction in the clearance of (+/-)-propranolol from 3087 +/- 648 to 1378 +/- 173 ml/min (p less than 0.05).,Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[h·ng] / [ml],530,157270,DB00571,Propranolol
,2357863,area under the plasma concentration-time curve,The coadministration of quinidine resulted in a doubling of the area under the plasma concentration-time curve of (+/-)-propranolol (530 +/- 99 versus 1051 +/- 138 ng.hr/ml; p less than 0.05) and a reduction in the clearance of (+/-)-propranolol from 3087 +/- 648 to 1378 +/- 173 ml/min (p less than 0.05).,Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[h·ng] / [ml],1051,157271,DB00571,Propranolol
,2357863,clearance,The coadministration of quinidine resulted in a doubling of the area under the plasma concentration-time curve of (+/-)-propranolol (530 +/- 99 versus 1051 +/- 138 ng.hr/ml; p less than 0.05) and a reduction in the clearance of (+/-)-propranolol from 3087 +/- 648 to 1378 +/- 173 ml/min (p less than 0.05).,Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[ml] / [min],3087,157272,DB00571,Propranolol
,2357863,clearance,The coadministration of quinidine resulted in a doubling of the area under the plasma concentration-time curve of (+/-)-propranolol (530 +/- 99 versus 1051 +/- 138 ng.hr/ml; p less than 0.05) and a reduction in the clearance of (+/-)-propranolol from 3087 +/- 648 to 1378 +/- 173 ml/min (p less than 0.05).,Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[ml] / [min],1378,157273,DB00571,Propranolol
,2357863,partial metabolic clearance,"The metabolism of propranolol by the 4-hydroxylation pathway was almost abolished by quinidine, resulting in a fall in the partial metabolic clearance by this pathway from 678 +/- 246 to 56 +/- 11 ml/min (p less than 0.05).",Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[ml] / [min],678,157274,DB00571,Propranolol
,2357863,partial metabolic clearance,"The metabolism of propranolol by the 4-hydroxylation pathway was almost abolished by quinidine, resulting in a fall in the partial metabolic clearance by this pathway from 678 +/- 246 to 56 +/- 11 ml/min (p less than 0.05).",Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357863/),[ml] / [min],56,157275,DB00571,Propranolol
,3935852,elimination half-life,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),h,1.35,158315,DB00571,Propranolol
,3935852,elimination half-life,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),h,1.10,158316,DB00571,Propranolol
,3935852,elimination half-life,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),h,1.09,158317,DB00571,Propranolol
,3935852,total area under the curve,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[ng] / [h·ml],42,158318,DB00571,Propranolol
,3935852,total area under the curve,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[ng] / [h·ml],38,158319,DB00571,Propranolol
,3935852,oral clearance,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[l] / [min],6.6,158320,DB00571,Propranolol
,3935852,oral clearance,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[l] / [min],7.2,158321,DB00571,Propranolol
,3935852,oral clearance,"The mean values during control, propranolol, and metoprolol trials of DNG elimination half-life were: 1.35, 1.10, and 1.09 h; total area under the curve: 42, 38, and 42 ng/ml X h; oral clearance: 6.6, 7.2, and 6.4 liters/min.","Kinetics of 1,2-dinitroglycerin following sustained release nitroglycerin: influence of propranolol and metoprolol. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3935852/),[l] / [min],6.4,158322,DB00571,Propranolol
,7554699,area under plasma concentration curve,"The area under plasma concentration curve values (mean +/- SEM), were 322.0 +/- 40.8, 481.6 +/- 77.5, and 766.1 +/- 92.8 nmol.hr/L, respectively, for C/C188, C/T188, and T/T188 subjects (p < 0.05).",Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554699/),[h·nM] / [l],322.0,158558,DB00571,Propranolol
,7554699,area under plasma concentration curve,"The area under plasma concentration curve values (mean +/- SEM), were 322.0 +/- 40.8, 481.6 +/- 77.5, and 766.1 +/- 92.8 nmol.hr/L, respectively, for C/C188, C/T188, and T/T188 subjects (p < 0.05).",Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554699/),[h·nM] / [l],481.6,158559,DB00571,Propranolol
,7554699,area under plasma concentration curve,"The area under plasma concentration curve values (mean +/- SEM), were 322.0 +/- 40.8, 481.6 +/- 77.5, and 766.1 +/- 92.8 nmol.hr/L, respectively, for C/C188, C/T188, and T/T188 subjects (p < 0.05).",Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7554699/),[h·nM] / [l],766.1,158560,DB00571,Propranolol
,9099387,area under the curve,"The change in thyroid status from euthyroid to hyperthyroid caused a significant (P < 0.05), but small reduction in propranolol area under the curve (19,932 +/- 7,900 min.micrograms/L vs 15,911 +/- 1,400 min.micrograms/L) after i.v. administration.",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[min·μg] / [l],"19,932",158740,DB00571,Propranolol
,9099387,area under the curve,"The change in thyroid status from euthyroid to hyperthyroid caused a significant (P < 0.05), but small reduction in propranolol area under the curve (19,932 +/- 7,900 min.micrograms/L vs 15,911 +/- 1,400 min.micrograms/L) after i.v. administration.",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[min·μg] / [l],"15,911",158741,DB00571,Propranolol
,9099387,area under the curve,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[min·μg] / [l],"105,430",158742,DB00571,Propranolol
,9099387,area under the curve,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[min·μg] / [l],"226,811",158743,DB00571,Propranolol
,9099387,peak serum propranolol concentration,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[μg] / [l],651,158744,DB00571,Propranolol
,9099387,peak serum propranolol concentration,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[μg] / [l],1191,158745,DB00571,Propranolol
,9099387,fractional absorption,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),%,57,158746,DB00571,Propranolol
,9099387,fractional absorption,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),%,137,158747,DB00571,Propranolol
,9099387,total body clearance,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[ml] / [kg·min],58,158748,DB00571,Propranolol
,9099387,total body clearance,"In contrast, after oral administration during the hyperthyroid state, a twofold increase (P < 0.05) in propranolol area under the curve (105,430 +/- 57,600 min.micrograms/L vs 226,811 +/- 112,000 min.micrograms/L) and peak serum propranolol concentration (651 +/- 247 micrograms/L vs 1191 +/- 590 micrograms/L) were attributed to significant (P < 0.05) increase in propranolol bioavailability caused by increased fractional absorption (57 +/- 28% vs 137 +/- 73%) and decreased total body clearance (58 +/- 27 ml/min/kg vs 30 +/- 19 ml/min/kg).",Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),[ml] / [kg·min],30,158749,DB00571,Propranolol
,9099387,arrival time,Mean arrival time after oral dosing was significantly lengthened by hyperthyroidism (100 +/- 38 minutes vs 157 +/- 71 minutes).,Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),min,100,158750,DB00571,Propranolol
,9099387,arrival time,Mean arrival time after oral dosing was significantly lengthened by hyperthyroidism (100 +/- 38 minutes vs 157 +/- 71 minutes).,Pharmacokinetics of propranolol in healthy cats during euthyroid and hyperthyroid states. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9099387/),min,157,158751,DB00571,Propranolol
,2575621,detection limits,The detection limits of 1.5 ng/ml enantiomer in plasma and 2.5 ng/ml enantiomer in urine at signal-to-noise ratios higher than 3 permit the performance of pharmacokinetic studies after therapeutic doses.,Simultaneous determination of (R)- and (S)-celiprolol in human plasma and urine: high-performance liquid chromatographic assay on a chiral stationary phase with fluorimetric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575621/),[ng] / [ml],1.5,159995,DB00571,Propranolol
,2575621,detection limits,The detection limits of 1.5 ng/ml enantiomer in plasma and 2.5 ng/ml enantiomer in urine at signal-to-noise ratios higher than 3 permit the performance of pharmacokinetic studies after therapeutic doses.,Simultaneous determination of (R)- and (S)-celiprolol in human plasma and urine: high-performance liquid chromatographic assay on a chiral stationary phase with fluorimetric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575621/),[ng] / [ml],2.5,159996,DB00571,Propranolol
higher,2575621,signal-to-noise ratios,The detection limits of 1.5 ng/ml enantiomer in plasma and 2.5 ng/ml enantiomer in urine at signal-to-noise ratios higher than 3 permit the performance of pharmacokinetic studies after therapeutic doses.,Simultaneous determination of (R)- and (S)-celiprolol in human plasma and urine: high-performance liquid chromatographic assay on a chiral stationary phase with fluorimetric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2575621/),,3,159997,DB00571,Propranolol
,3046813,AUC phase 2/AUC phase 1,"However, AUC oral for propranolol was not affected (mean +/- 1 SD; AUC phase 2/AUC phase 1+= 0.98 +/- 0.28) by these changes in QH, which are comparable to those encountered after food consumption.",Influence of posture on hepatic perfusion and the presystemic biotransformation of propranolol: simulation of the food effect. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3046813/),,0.98,160780,DB00571,Propranolol
,8362221,peak concentration,"Ulcer patients showed a significant decrease in mean peak concentration of propranolol (90 +/- 12 ng/ml versus 151 +/- 23 ng/ml) (p < 0.025), in the absorption constant (1.43 +/- 0.21 h-1 versus 0.96 +/- 0.12 h-1) (p < 0.05), and in the area under concentration-time curve (802 +/- 129 ng/ml.h versus 492 +/- 73 ng/ml.h) (p < 0.05).",Propranolol absorption in peptic ulcer disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8362221/),[ng] / [ml],90,161455,DB00571,Propranolol
,8362221,peak concentration,"Ulcer patients showed a significant decrease in mean peak concentration of propranolol (90 +/- 12 ng/ml versus 151 +/- 23 ng/ml) (p < 0.025), in the absorption constant (1.43 +/- 0.21 h-1 versus 0.96 +/- 0.12 h-1) (p < 0.05), and in the area under concentration-time curve (802 +/- 129 ng/ml.h versus 492 +/- 73 ng/ml.h) (p < 0.05).",Propranolol absorption in peptic ulcer disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8362221/),[ng] / [ml],151,161456,DB00571,Propranolol
,8362221,absorption constant,"Ulcer patients showed a significant decrease in mean peak concentration of propranolol (90 +/- 12 ng/ml versus 151 +/- 23 ng/ml) (p < 0.025), in the absorption constant (1.43 +/- 0.21 h-1 versus 0.96 +/- 0.12 h-1) (p < 0.05), and in the area under concentration-time curve (802 +/- 129 ng/ml.h versus 492 +/- 73 ng/ml.h) (p < 0.05).",Propranolol absorption in peptic ulcer disease. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8362221/),1/[h],1.43,161457,DB00571,Propranolol
,8362221,absorption constant,"Ulcer patients showed a significant decrease in mean peak concentration of propranolol (90 +/- 12 ng/ml versus 151 +/- 23 ng/ml) (p < 0.025), in the absorption constant (1.43 +/- 0.21 h-1 versus 0.96 +/- 0.12 h-1) (p < 0.05), and in the area under concentration-time curve (802 +/- 129 ng/ml.h versus 492 +/- 73 ng/ml.h) (p < 0.05).",Propranolol absorption in peptic ulcer disease. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8362221/),1/[h],0.96,161458,DB00571,Propranolol
,8362221,area under concentration-time curve,"Ulcer patients showed a significant decrease in mean peak concentration of propranolol (90 +/- 12 ng/ml versus 151 +/- 23 ng/ml) (p < 0.025), in the absorption constant (1.43 +/- 0.21 h-1 versus 0.96 +/- 0.12 h-1) (p < 0.05), and in the area under concentration-time curve (802 +/- 129 ng/ml.h versus 492 +/- 73 ng/ml.h) (p < 0.05).",Propranolol absorption in peptic ulcer disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8362221/),[ng] / [h·ml],802,161459,DB00571,Propranolol
,8362221,area under concentration-time curve,"Ulcer patients showed a significant decrease in mean peak concentration of propranolol (90 +/- 12 ng/ml versus 151 +/- 23 ng/ml) (p < 0.025), in the absorption constant (1.43 +/- 0.21 h-1 versus 0.96 +/- 0.12 h-1) (p < 0.05), and in the area under concentration-time curve (802 +/- 129 ng/ml.h versus 492 +/- 73 ng/ml.h) (p < 0.05).",Propranolol absorption in peptic ulcer disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8362221/),[ng] / [h·ml],492,161460,DB00571,Propranolol
,2690330,volume of distribution,The volume of distribution is 0.3 litres/kg corresponding to the volume of extracellular water.,Omeprazole: pharmacokinetics and metabolism in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),[l] / [kg],0.3,161885,DB00571,Propranolol
less,2690330,half-life,"The half-life is less than 1 hour, and omeprazole is almost entirely cleared from plasma within 3-4 hours.",Omeprazole: pharmacokinetics and metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),h,1,161886,DB00571,Propranolol
,2690330,Bioavailability,Bioavailability after a single dose is 35% and increases during repeated once-daily dosing to 60%.,Omeprazole: pharmacokinetics and metabolism in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),%,35,161887,DB00571,Propranolol
,2690330,Bioavailability,Bioavailability after a single dose is 35% and increases during repeated once-daily dosing to 60%.,Omeprazole: pharmacokinetics and metabolism in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2690330/),%,60,161888,DB00571,Propranolol
,7140133,bioavailability (F,Timolol had greater bioavailability (F = 0.61 +/- 0.06(SEM) and 0.32 +/- 0.04) and lower systemic clearance (463 +/- 74 ml kg-1 hr-1 and 1040 +/- 120 ml kg-1 hr-1) than propranolol.,"Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140133/),,0.61,162767,DB00571,Propranolol
,7140133,bioavailability (F,Timolol had greater bioavailability (F = 0.61 +/- 0.06(SEM) and 0.32 +/- 0.04) and lower systemic clearance (463 +/- 74 ml kg-1 hr-1 and 1040 +/- 120 ml kg-1 hr-1) than propranolol.,"Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140133/),,0.32,162768,DB00571,Propranolol
,7140133,systemic clearance,Timolol had greater bioavailability (F = 0.61 +/- 0.06(SEM) and 0.32 +/- 0.04) and lower systemic clearance (463 +/- 74 ml kg-1 hr-1 and 1040 +/- 120 ml kg-1 hr-1) than propranolol.,"Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140133/),[ml] / [h·kg],463,162769,DB00571,Propranolol
,7140133,systemic clearance,Timolol had greater bioavailability (F = 0.61 +/- 0.06(SEM) and 0.32 +/- 0.04) and lower systemic clearance (463 +/- 74 ml kg-1 hr-1 and 1040 +/- 120 ml kg-1 hr-1) than propranolol.,"Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140133/),[ml] / [h·kg],1040,162770,DB00571,Propranolol
,7140133,Half-lifes,Half-lifes were of the same order (2.7 and 2.9 hr).,"Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140133/),h,2.7,162771,DB00571,Propranolol
,7140133,Half-lifes,Half-lifes were of the same order (2.7 and 2.9 hr).,"Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7140133/),h,2.9,162772,DB00571,Propranolol
,2539818,unbound [3H,"AAG-treated rats had greater [3H]propranolol binding in serum (93.0 +/- 3.2 vs 76.7 +/- 3.0%, P less than 0.01) and a lower calculated unbound [3H]propranolol concentration in serum (2.7 +/- 1.3 vs 7.4 +/- 3.1 X 10(6) dpm/ml, P less than 0.001) than albumin-treated rats.",Effects of alpha-1-acid glycoprotein administration on propranolol binding and beta blockade in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2539818/),[dpm] / [ml],2.7,162881,DB00571,Propranolol
,2539818,unbound [3H,"AAG-treated rats had greater [3H]propranolol binding in serum (93.0 +/- 3.2 vs 76.7 +/- 3.0%, P less than 0.01) and a lower calculated unbound [3H]propranolol concentration in serum (2.7 +/- 1.3 vs 7.4 +/- 3.1 X 10(6) dpm/ml, P less than 0.001) than albumin-treated rats.",Effects of alpha-1-acid glycoprotein administration on propranolol binding and beta blockade in rats. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2539818/),[dpm] / [ml],7.4,162882,DB00571,Propranolol
,9004455,IC50,"3. Of the metabolites examined, racemic 4'-hydroxypropranolol (4-OHP) inhibited the formation of 4-OHP, 5'-hydroxypropranolol (5-OHP) and desisopropylpropranolol (DIP) from (S)-propranolol and (R)-propranolol in microsomal studies (IC50 20 microM).",(S)-4'-hydroxypropranolol causes product inhibition and dose-dependent bioavailability of propranolol enantiomers in the isolated perfused rat liver and in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004455/),μM,20,163076,DB00571,Propranolol
,9004455,IC50,"Tissue levels of (S)-4-OHP in recirculating experiments (28.0 microM) at the highest dose (239 nmol/ min) of (S)-propranolol were greater than its IC50 of 20 microM, suggesting that 4-OHP is the inhibiting metabolite in the intact liver.",(S)-4'-hydroxypropranolol causes product inhibition and dose-dependent bioavailability of propranolol enantiomers in the isolated perfused rat liver and in rat liver microsomes. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9004455/),μM,20,163077,DB00571,Propranolol
,3677541,alpha-phase half-life,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),min,3.1,163609,DB00571,Propranolol
,3677541,beta-phase half-life,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),min,106.6,163610,DB00571,Propranolol
,3677541,gamma-phase half-life,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),h,12.4,163611,DB00571,Propranolol
,3677541,volume of central compartment,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),[l] / [kg],0.114,163612,DB00571,Propranolol
,3677541,steady-state volume of distribution,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),[l] / [kg],0.67,163613,DB00571,Propranolol
,3677541,total clearance,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),[ml] / [kg·min],3.6,163614,DB00571,Propranolol
,3677541,renal clearance,"Mean postinfusion kinetic data were: alpha-phase half-life = 3.1 minutes, beta-phase half-life = 106.6 minutes, and gamma-phase half-life = 12.4 hours; volume of central compartment = 0.114 L/kg; steady-state volume of distribution = 0.67 L/kg; total clearance = 3.6 ml/min/kg; and renal clearance = 0.56 ml/min/kg.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),[ml] / [kg·min],0.56,163615,DB00571,Propranolol
,3677541,Absolute bioavailability,Absolute bioavailability was approximately 70% and peak plasma drug concentration occurred 2.3 hours after oral administration.,"Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),%,70,163616,DB00571,Propranolol
,3677541,Cumulative fraction excreted unchanged,"Cumulative fraction excreted unchanged in urine was approximately 15% and 9% of the dose after intravenous and oral administration, respectively.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),%,15,163617,DB00571,Propranolol
,3677541,Cumulative fraction excreted unchanged,"Cumulative fraction excreted unchanged in urine was approximately 15% and 9% of the dose after intravenous and oral administration, respectively.","Disposition kinetics and dynamics of nicainoprol, a new antiarrhythmic agent, in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677541/),%,9,163618,DB00571,Propranolol
,20598332,half-life,"The effective plasma drug concentrations were achieved in 30 minutes, and the half-life was 4 hours.",Propranolol decreases cardiac work in a dose-dependent manner in severely burned children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20598332/),h,4,163810,DB00571,Propranolol
,20020526,concentrations,"AGP concentrations at 2 and 7 days postsurgery were 708 +/- 274 and 176 +/- 111 microg/mL (mean +/- SE), respectively.","Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo)). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020526/),[μg] / [ml],708,167748,DB00571,Propranolol
,20020526,concentrations,"AGP concentrations at 2 and 7 days postsurgery were 708 +/- 274 and 176 +/- 111 microg/mL (mean +/- SE), respectively.","Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo)). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020526/),[μg] / [ml],176,167749,DB00571,Propranolol
,20020526,K(B,"Individual values of AGP concentrations ranged between 110 and 1150 microg/mL, and were associated with K(B,vivo) values of S(-)-propranolol from 7.0 to 30 nM.","Effect of altered AGP plasma binding on heart rate changes by S(-)-propranolol in rats using mechanism-based estimations of in vivo receptor affinity (K(B,vivo)). ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20020526/),nM,7.0 to 30,167750,DB00571,Propranolol
,7696378,clearance,"Following administration of the first single dose of 40 mg of the racemate, the mean (SD) clearance of the (R)- and (S)-isomers was 110 (84) and 61 (37) ml min-1 kg-1, respectively; at steady state these values were 89 (55) and 57 (37) ml min-1 kg-1, respectively.",Direct enantioselective determination of (R)- and (S)-propranolol in human plasma. Application to pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7696378/),[ml] / [kg·min],110,167888,DB00571,Propranolol
,7696378,clearance,"Following administration of the first single dose of 40 mg of the racemate, the mean (SD) clearance of the (R)- and (S)-isomers was 110 (84) and 61 (37) ml min-1 kg-1, respectively; at steady state these values were 89 (55) and 57 (37) ml min-1 kg-1, respectively.",Direct enantioselective determination of (R)- and (S)-propranolol in human plasma. Application to pharmacokinetic studies. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7696378/),[ml] / [kg·min],61,167889,DB00571,Propranolol
,7696378,steady state,"Following administration of the first single dose of 40 mg of the racemate, the mean (SD) clearance of the (R)- and (S)-isomers was 110 (84) and 61 (37) ml min-1 kg-1, respectively; at steady state these values were 89 (55) and 57 (37) ml min-1 kg-1, respectively.",Direct enantioselective determination of (R)- and (S)-propranolol in human plasma. Application to pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7696378/),[ml] / [kg·min],89,167890,DB00571,Propranolol
,7696378,steady state,"Following administration of the first single dose of 40 mg of the racemate, the mean (SD) clearance of the (R)- and (S)-isomers was 110 (84) and 61 (37) ml min-1 kg-1, respectively; at steady state these values were 89 (55) and 57 (37) ml min-1 kg-1, respectively.",Direct enantioselective determination of (R)- and (S)-propranolol in human plasma. Application to pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7696378/),[ml] / [kg·min],57,167891,DB00571,Propranolol
,6733003,elimination half-life,"In the rabbit study, elimination half-life was shorter in the propranolol treated animals (8.20 +/- 0.44 h) than in controls (10.89 +/- 0.62 h).",Interaction between warfarin and propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6733003/),h,8.20,168710,DB00571,Propranolol
,6733003,elimination half-life,"In the rabbit study, elimination half-life was shorter in the propranolol treated animals (8.20 +/- 0.44 h) than in controls (10.89 +/- 0.62 h).",Interaction between warfarin and propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6733003/),h,10.89,168711,DB00571,Propranolol
,6733003,volume of distribution,This was due to a fall in its volume of distribution from 1.13 +/- 0.10 1 kg-1 in controls to 0.81 +/- 0.08 1 kg-1 in the propranolol treated group.,Interaction between warfarin and propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6733003/),[1] / [kg],1.13,168712,DB00571,Propranolol
,6733003,volume of distribution,This was due to a fall in its volume of distribution from 1.13 +/- 0.10 1 kg-1 in controls to 0.81 +/- 0.08 1 kg-1 in the propranolol treated group.,Interaction between warfarin and propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6733003/),[1] / [kg],0.81,168713,DB00571,Propranolol
,6848749,bioavailability,Phenobarbital decreased the bioavailability of propranolol from 7.7 to 3.5%.,"Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848749/),%,7.7,170232,DB00571,Propranolol
,6848749,bioavailability,Phenobarbital decreased the bioavailability of propranolol from 7.7 to 3.5%.,"Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6848749/),%,3.5,170233,DB00571,Propranolol
,1976782,total body clearance,"In obese subjects, the pharmacokinetic data calculated for sotalol were comparable with those measured in controls (total body clearance = 9.4 +/- 2.9 L h-1; volume of distribution during the terminal phase = 79.8 +/- 19.8 L or 0.9 +/- 0.2 L kg-1; terminal half-life = 6.2 +/- 1.6 h).",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),[l] / [h],9.4,170971,DB00571,Propranolol
,1976782,volume of distribution during the terminal phase,"In obese subjects, the pharmacokinetic data calculated for sotalol were comparable with those measured in controls (total body clearance = 9.4 +/- 2.9 L h-1; volume of distribution during the terminal phase = 79.8 +/- 19.8 L or 0.9 +/- 0.2 L kg-1; terminal half-life = 6.2 +/- 1.6 h).",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),l,79.8,170972,DB00571,Propranolol
,1976782,volume of distribution during the terminal phase,"In obese subjects, the pharmacokinetic data calculated for sotalol were comparable with those measured in controls (total body clearance = 9.4 +/- 2.9 L h-1; volume of distribution during the terminal phase = 79.8 +/- 19.8 L or 0.9 +/- 0.2 L kg-1; terminal half-life = 6.2 +/- 1.6 h).",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),[l] / [kg],0.9,170973,DB00571,Propranolol
,1976782,terminal half-life,"In obese subjects, the pharmacokinetic data calculated for sotalol were comparable with those measured in controls (total body clearance = 9.4 +/- 2.9 L h-1; volume of distribution during the terminal phase = 79.8 +/- 19.8 L or 0.9 +/- 0.2 L kg-1; terminal half-life = 6.2 +/- 1.6 h).",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),h,6.2,170974,DB00571,Propranolol
,1976782,total clearance,"For propranolol, total clearance (44.3 +/- 15.9 L h-1) and volume of distribution (230.5 +/- 48.2 L or 2.7 +/- 0.7 L kg-1) were significantly less than control values.",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),[l] / [h],44.3,170975,DB00571,Propranolol
,1976782,volume of distribution,"For propranolol, total clearance (44.3 +/- 15.9 L h-1) and volume of distribution (230.5 +/- 48.2 L or 2.7 +/- 0.7 L kg-1) were significantly less than control values.",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),l,230.5,170976,DB00571,Propranolol
,1976782,volume of distribution,"For propranolol, total clearance (44.3 +/- 15.9 L h-1) and volume of distribution (230.5 +/- 48.2 L or 2.7 +/- 0.7 L kg-1) were significantly less than control values.",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),[l] / [kg],2.7,170977,DB00571,Propranolol
,1976782,terminal half-life,"The terminal half-life (3.9 +/- 1.1 h), was not significantly increased.",Comparison of propranolol and sotalol pharmacokinetics in obese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1976782/),h,3.9,170978,DB00571,Propranolol
,2532460,terminal half-life,"In clinical pharmacology studies cilazapril, after its bioactivation to cilazaprilat, was characterized as a potent, reversible angiotensin-converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours consistent with saturable binding to ACE.",Clinical pharmacology of cilazapril. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2532460/),h,30 to 50,171142,DB00571,Propranolol
,7988100,terminal elimination half-life,"Following administration of single doses, fluvoxamine shows a biphasic elimination with a mean terminal elimination half-life of about 15 to 20 hours.",Clinical pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7988100/),h,15 to 20,171285,DB00571,Propranolol
,2894439,pulmonary clearance,"The difference in total body clearance after i.a. dosing from that after i.v. dosing indicated a significant contribution by pulmonary clearance, which ranged from about 20 to 30 mL min-1 kg-1, to the overall first-pass elimination after the i.v. administration.",High capacity for pulmonary first-pass elimination of propranolol in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894439/),[ml] / [kg·min],20 to 30,174015,DB00571,Propranolol
,2894439,pulmonary extraction ratio,The pulmonary extraction ratio was approximately 0.4 to 0.5 at the i.v. doses used.,High capacity for pulmonary first-pass elimination of propranolol in rats. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894439/),,0.4 to 0.5,174016,DB00571,Propranolol
,2894439,pulmonary transit time,Mean pulmonary transit time was estimated to be about 1 to 2 min.,High capacity for pulmonary first-pass elimination of propranolol in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2894439/),min,1 to 2,174017,DB00571,Propranolol
,29736244,oral clearance,"Typical oral clearance was estimated at 3.06 L hour-1 kg-1 (95% CI: 1.14-8.61 L hour-1 kg-1), close to adult clearance data.",Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Modeling and dosing regimen recommendations. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29736244/),[l] / [h·kg],3.06,174346,DB00571,Propranolol
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],40,175115,DB00571,Propranolol
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],37,175116,DB00571,Propranolol
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],22,175117,DB00571,Propranolol
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],55,175118,DB00571,Propranolol
,18043474,serum concentrations,"At 60, 90, and 120 mg/day, the mean +/- SD serum concentrations were 33+/-22.0, 43+/-22.2, and 48+/-17.0 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],33,175119,DB00571,Propranolol
,18043474,serum concentrations,"At 60, 90, and 120 mg/day, the mean +/- SD serum concentrations were 33+/-22.0, 43+/-22.2, and 48+/-17.0 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],43,175120,DB00571,Propranolol
,18043474,serum concentrations,"At 60, 90, and 120 mg/day, the mean +/- SD serum concentrations were 33+/-22.0, 43+/-22.2, and 48+/-17.0 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],48,175121,DB00571,Propranolol
,2879960,volume of distribution,"In control vs propranolol treatment conditions, there was no significant difference in desmethyldiazepam volume of distribution (1.27 vs 1.23 liters/kg) or in free fraction in serum (1.83 vs 1.80% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[l] / [kg],1.27,175186,DB00571,Propranolol
,2879960,volume of distribution,"In control vs propranolol treatment conditions, there was no significant difference in desmethyldiazepam volume of distribution (1.27 vs 1.23 liters/kg) or in free fraction in serum (1.83 vs 1.80% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[l] / [kg],1.23,175187,DB00571,Propranolol
,2879960,free fraction in serum,"In control vs propranolol treatment conditions, there was no significant difference in desmethyldiazepam volume of distribution (1.27 vs 1.23 liters/kg) or in free fraction in serum (1.83 vs 1.80% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),%·unbound,1.83,175188,DB00571,Propranolol
,2879960,free fraction in serum,"In control vs propranolol treatment conditions, there was no significant difference in desmethyldiazepam volume of distribution (1.27 vs 1.23 liters/kg) or in free fraction in serum (1.83 vs 1.80% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),%·unbound,1.80,175189,DB00571,Propranolol
,2879960,half-life,"There was a small although statistically significant prolongation of desmethyldiazepam half-life (55 vs 61 h, P less than 0.05) and reduction in clearance (0.281 vs 0.247 ml/min/kg, P less than 0.02) attributable to propranolol.",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),h,55,175190,DB00571,Propranolol
,2879960,half-life,"There was a small although statistically significant prolongation of desmethyldiazepam half-life (55 vs 61 h, P less than 0.05) and reduction in clearance (0.281 vs 0.247 ml/min/kg, P less than 0.02) attributable to propranolol.",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),h,61,175191,DB00571,Propranolol
,2879960,clearance,"There was a small although statistically significant prolongation of desmethyldiazepam half-life (55 vs 61 h, P less than 0.05) and reduction in clearance (0.281 vs 0.247 ml/min/kg, P less than 0.02) attributable to propranolol.",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[ml] / [kg·min],0.281,175192,DB00571,Propranolol
,2879960,clearance,"There was a small although statistically significant prolongation of desmethyldiazepam half-life (55 vs 61 h, P less than 0.05) and reduction in clearance (0.281 vs 0.247 ml/min/kg, P less than 0.02) attributable to propranolol.",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[ml] / [kg·min],0.247,175193,DB00571,Propranolol
,2879960,volume of distribution,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[l] / [kg],1.29,175194,DB00571,Propranolol
,2879960,volume of distribution,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[l] / [kg],1.34,175195,DB00571,Propranolol
,2879960,elimination half-life,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),h,55,175196,DB00571,Propranolol
,2879960,elimination half-life,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),h,59,175197,DB00571,Propranolol
,2879960,clearance,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[ml] / [kg·min],0.284,175198,DB00571,Propranolol
,2879960,clearance,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),[ml] / [kg·min],0.276,175199,DB00571,Propranolol
,2879960,free fraction in serum,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),%·unbound,1.96,175200,DB00571,Propranolol
,2879960,free fraction in serum,"There was no significant difference between controls and cigarette smokers in desmethyldiazepam volume of distribution (1.29 vs 1.34 liters/kg), elimination half-life (55 vs 59 h), clearance (0.284 vs 0.276 ml/min/kg), or free fraction in serum (1.96 vs 1.92% unbound).",Influence of propranolol coadministration or cigarette smoking on the kinetics of desmethyldiazepam following intravenous clorazepate. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2879960/),%·unbound,1.92,175201,DB00571,Propranolol
,2739756,HCl,HCl (28.7 +/- 22.5 ng/ml) was applied.,Stereoselective hemodynamic effects of (R)-and (S)-propranolol in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2739756/),[ng] / [ml],28.7,176538,DB00571,Propranolol
,15553104,retention times,"The retention times of ondansetron and internal standard (propranolol hydrochloride, CAS 318-98-9) were 9.38 and 13.40 min, respectively.","A rapid, sensitive and validated method for the determination of ondansetron in human plasma by reversed-phase high-pressure liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553104/),min,9.38,176969,DB00571,Propranolol
,15553104,retention times,"The retention times of ondansetron and internal standard (propranolol hydrochloride, CAS 318-98-9) were 9.38 and 13.40 min, respectively.","A rapid, sensitive and validated method for the determination of ondansetron in human plasma by reversed-phase high-pressure liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15553104/),min,13.40,176970,DB00571,Propranolol
,7757308,peak nimodipine plasma concentration,Mean peak nimodipine plasma concentration was decreased after combined administration of the two drugs (16.1 +/- 8.1 micrograms/l vs. 12.4 +/- 9.5 micrograms/l).,Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757308/),[μg] / [l],16.1,177821,DB00571,Propranolol
,7757308,peak nimodipine plasma concentration,Mean peak nimodipine plasma concentration was decreased after combined administration of the two drugs (16.1 +/- 8.1 micrograms/l vs. 12.4 +/- 9.5 micrograms/l).,Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757308/),[μg] / [l],12.4,177822,DB00571,Propranolol
,7757308,AUCss,"Nimodipine AUCss slightly decreased under propranolol co-medication from 44.9 +/- 15.1 micrograms x l/l to 38.8 +/- 22.5 micrograms x h/l, resulting in an AUC ratio of 88.8 +/- 44.5%.",Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757308/),[l·μg] / [l],44.9,177823,DB00571,Propranolol
,7757308,AUCss,"Nimodipine AUCss slightly decreased under propranolol co-medication from 44.9 +/- 15.1 micrograms x l/l to 38.8 +/- 22.5 micrograms x h/l, resulting in an AUC ratio of 88.8 +/- 44.5%.",Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757308/),[h·μg] / [l],38.8,177824,DB00571,Propranolol
,7757308,AUC ratio,"Nimodipine AUCss slightly decreased under propranolol co-medication from 44.9 +/- 15.1 micrograms x l/l to 38.8 +/- 22.5 micrograms x h/l, resulting in an AUC ratio of 88.8 +/- 44.5%.",Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757308/),%,88.8,177825,DB00571,Propranolol
,7757308,relative bioavailability,"The relative bioavailability of propranolol was 104.1 +/- 38.3% after the combined propranolol and nimodipine medication, all other pharmacokinetic parameters remained unchanged.",Chronic administration of nimodipine and propranolol in elderly normotensive subjects--an interaction study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7757308/),%,104.1,177826,DB00571,Propranolol
,7965671,steady-state reservoir,"Mean steady-state reservoir, i.e. hepatic inflow concentrations (Cin), were 4.97, 10.4, and 20.4 microM, respectively.",Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965671/),μM,4.97,178444,DB00571,Propranolol
,7965671,hepatic inflow concentrations (Cin),"Mean steady-state reservoir, i.e. hepatic inflow concentrations (Cin), were 4.97, 10.4, and 20.4 microM, respectively.",Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965671/),μM,4.97,178445,DB00571,Propranolol
,7965671,hepatic inflow concentrations (Cin),"Mean steady-state reservoir, i.e. hepatic inflow concentrations (Cin), were 4.97, 10.4, and 20.4 microM, respectively.",Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965671/),μM,10.4,178446,DB00571,Propranolol
,7965671,hepatic inflow concentrations (Cin),"Mean steady-state reservoir, i.e. hepatic inflow concentrations (Cin), were 4.97, 10.4, and 20.4 microM, respectively.",Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965671/),μM,20.4,178447,DB00571,Propranolol
,7965671,bioavailability,The bioavailability (hepatic outflow concentration/Cin) of propranolol increased with Cin from 0.012 to 0.150 to 0.288 in the recirculating IPRL.,Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965671/),,0.012,178448,DB00571,Propranolol
,7965671,bioavailability,The bioavailability (hepatic outflow concentration/Cin) of propranolol increased with Cin from 0.012 to 0.150 to 0.288 in the recirculating IPRL.,Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965671/),,0.150,178449,DB00571,Propranolol
,7965671,bioavailability,The bioavailability (hepatic outflow concentration/Cin) of propranolol increased with Cin from 0.012 to 0.150 to 0.288 in the recirculating IPRL.,Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965671/),,0.288,178450,DB00571,Propranolol
,7965671,Cin,NLA did not appear to be the inhibiting metabolite because in further single-pass experiments with propranolol Cin of 21.6 microM the presence of NLA (21.6 microM) in perfusate had no effect on propranolol bioavailability (n = 7) compared with control experiments (n = 5).,Product inhibition and dose-dependent bioavailability of propranolol in the isolated perfused rat liver preparation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7965671/),μM,21.6,178451,DB00571,Propranolol
,2612540,AUC,"However, partial propranolol AUC values between 0-0.33, 0-0.5, 0-1.0 and 0-1.5 h were significantly larger after single and multiple doses of nifedipine indicating higher propranolol concentrations during the absorption phase.",Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612540/),h,0-0.33,179947,DB00571,Propranolol
,2612540,AUC,"However, partial propranolol AUC values between 0-0.33, 0-0.5, 0-1.0 and 0-1.5 h were significantly larger after single and multiple doses of nifedipine indicating higher propranolol concentrations during the absorption phase.",Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612540/),h,0-0.5,179948,DB00571,Propranolol
,2612540,AUC,"However, partial propranolol AUC values between 0-0.33, 0-0.5, 0-1.0 and 0-1.5 h were significantly larger after single and multiple doses of nifedipine indicating higher propranolol concentrations during the absorption phase.",Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2612540/),h,0,179949,DB00571,Propranolol
,8008710,apparent steady-state conditions,"(+)-Propranolol was infused at two rates into the pyloric vein (a portal vein tributary) of 15 male Sprague Dawley rats until apparent steady-state conditions were established (i.e., 8 hr at each rate).","Accumulation kinetics of propranolol in the rat: comparison of Michaelis-Menten-mediated clearance and clearance changes consistent with the ""altered enzyme hypothesis"". ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008710/),h,8,180311,DB00571,Propranolol
,8008710,apparent steady-state concentrations,"When the low dose was given first, the apparent steady-state concentrations achieved during low- and high-rate infusion steps were 166 +/- 37 and 774 +/- 235 ng/mL, respectively.","Accumulation kinetics of propranolol in the rat: comparison of Michaelis-Menten-mediated clearance and clearance changes consistent with the ""altered enzyme hypothesis"". ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008710/),[ng] / [ml],166,180312,DB00571,Propranolol
,8008710,apparent steady-state concentrations,"When the low dose was given first, the apparent steady-state concentrations achieved during low- and high-rate infusion steps were 166 +/- 37 and 774 +/- 235 ng/mL, respectively.","Accumulation kinetics of propranolol in the rat: comparison of Michaelis-Menten-mediated clearance and clearance changes consistent with the ""altered enzyme hypothesis"". ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008710/),[ng] / [ml],774,180313,DB00571,Propranolol
,8008710,steady-state concentrations,"When the sequence of infusion rates was reversed, steady-state concentrations were 492 +/- 142 and 298 +/- 79 ng/mL for the high and low infusion rates, respectively.","Accumulation kinetics of propranolol in the rat: comparison of Michaelis-Menten-mediated clearance and clearance changes consistent with the ""altered enzyme hypothesis"". ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008710/),[ng] / [ml],492,180314,DB00571,Propranolol
,8008710,steady-state concentrations,"When the sequence of infusion rates was reversed, steady-state concentrations were 492 +/- 142 and 298 +/- 79 ng/mL for the high and low infusion rates, respectively.","Accumulation kinetics of propranolol in the rat: comparison of Michaelis-Menten-mediated clearance and clearance changes consistent with the ""altered enzyme hypothesis"". ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008710/),[ng] / [ml],298,180315,DB00571,Propranolol
,6160322,"t1/2, beta","The mean t1/2, beta was 3.6 hr for both drugs, but due to a larger volume of distribution, the total body clearance was significantly higher for metoprolol (1.20 liters/min) than for propranolol (0.81 liters/min).",Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160322/),h,3.6,181049,DB00571,Propranolol
,6160322,total body clearance,"The mean t1/2, beta was 3.6 hr for both drugs, but due to a larger volume of distribution, the total body clearance was significantly higher for metoprolol (1.20 liters/min) than for propranolol (0.81 liters/min).",Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160322/),[l] / [min],1.20,181050,DB00571,Propranolol
,6160322,total body clearance,"The mean t1/2, beta was 3.6 hr for both drugs, but due to a larger volume of distribution, the total body clearance was significantly higher for metoprolol (1.20 liters/min) than for propranolol (0.81 liters/min).",Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160322/),[l] / [min],0.81,181051,DB00571,Propranolol
,263396,half-life,Patients with cirrhosis had a significantly longer quinidine half-life (9 +/- 1 hr; p less than .01) when compared to control patients (6 +/- 0.5h).,Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),h,9,181398,DB00571,Propranolol
,263396,half-life,Patients with cirrhosis had a significantly longer quinidine half-life (9 +/- 1 hr; p less than .01) when compared to control patients (6 +/- 0.5h).,Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),h,6,181399,DB00571,Propranolol
,263396,volume of distribution,This was not related to a reduced quinidine clearance rate but rather to an increase in quinidine volume of distribution (4.1 +/- .4 L./Kg. in cirrhotic patients vs 2.6 +/- 1 L./Kg. in control patients; p less than .01).,Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),[l] / [kg],4.1,181400,DB00571,Propranolol
,263396,volume of distribution,This was not related to a reduced quinidine clearance rate but rather to an increase in quinidine volume of distribution (4.1 +/- .4 L./Kg. in cirrhotic patients vs 2.6 +/- 1 L./Kg. in control patients; p less than .01).,Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),[l] / [kg],2.6,181401,DB00571,Propranolol
greater,263396,unbound fraction,Abnormal quinidine binding (greater than 25 per cent unbound fraction) was noted in seven of the eight cirrhotic patients.,Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),%,25,181402,DB00571,Propranolol
,263396,half-life,"In contrast, patients receiving propranolol had a normal quinidine half-life of 6 +/- 0.5 hr.",Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),h,6,181403,DB00571,Propranolol
,263396,clearance,"However, these patients had a significantly reduced quinidine clearance (3.3 +/- .7 ml./min./Kg. vs. 5.3 +/- .5 ml./min./Kg. in controls; p less than .05) and higher peak concentrations (1.25 +/- .20 micrograms/ml. vs. .80 +/- .5 micrograms/ml. in controls; p less than .05).",Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),[ml] / [·kg·min],3.3,181404,DB00571,Propranolol
,263396,clearance,"However, these patients had a significantly reduced quinidine clearance (3.3 +/- .7 ml./min./Kg. vs. 5.3 +/- .5 ml./min./Kg. in controls; p less than .05) and higher peak concentrations (1.25 +/- .20 micrograms/ml. vs. .80 +/- .5 micrograms/ml. in controls; p less than .05).",Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),[ml] / [·kg·min],5.3,181405,DB00571,Propranolol
,263396,peak concentrations,"However, these patients had a significantly reduced quinidine clearance (3.3 +/- .7 ml./min./Kg. vs. 5.3 +/- .5 ml./min./Kg. in controls; p less than .05) and higher peak concentrations (1.25 +/- .20 micrograms/ml. vs. .80 +/- .5 micrograms/ml. in controls; p less than .05).",Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),[μg] / [ml],1.25,181406,DB00571,Propranolol
,263396,peak concentrations,"However, these patients had a significantly reduced quinidine clearance (3.3 +/- .7 ml./min./Kg. vs. 5.3 +/- .5 ml./min./Kg. in controls; p less than .05) and higher peak concentrations (1.25 +/- .20 micrograms/ml. vs. .80 +/- .5 micrograms/ml. in controls; p less than .05).",Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/263396/),[μg] / [ml],.80,181407,DB00571,Propranolol
,8251610,Vdss,Verapamil was distributed to the extravascular tissues very rapidly as indicated by the large Vdss (2.99 +/- 0.57 l kg-1) and Vd beta (5.08 +/- 0.54 l kg-1).,Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),[l] / [kg],2.99,182463,DB00571,Propranolol
,8251610,Vd beta,Verapamil was distributed to the extravascular tissues very rapidly as indicated by the large Vdss (2.99 +/- 0.57 l kg-1) and Vd beta (5.08 +/- 0.54 l kg-1).,Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),[l] / [kg],5.08,182464,DB00571,Propranolol
,8251610,apparent terminal plasma T1/2,"The apparent terminal plasma T1/2, MRTiv, and CLp were 1.59 +/- 0.46, 1.26 +/- 0.12 h, and 40.4 +/- 9.73 ml min-1 kg-1, respectively.",Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),h,1.59,182465,DB00571,Propranolol
,8251610,MRTiv,"The apparent terminal plasma T1/2, MRTiv, and CLp were 1.59 +/- 0.46, 1.26 +/- 0.12 h, and 40.4 +/- 9.73 ml min-1 kg-1, respectively.",Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),h,1.26,182466,DB00571,Propranolol
,8251610,CLp,"The apparent terminal plasma T1/2, MRTiv, and CLp were 1.59 +/- 0.46, 1.26 +/- 0.12 h, and 40.4 +/- 9.73 ml min-1 kg-1, respectively.",Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),[ml] / [kg·min],40.4,182467,DB00571,Propranolol
,8251610,blood to plasma,"The average blood to plasma and plasma to blood cell concentration ratios were 0.85 and 1.47, respectively.",Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),,0.85,182468,DB00571,Propranolol
,8251610,plasma to blood cell concentration ratios,"The average blood to plasma and plasma to blood cell concentration ratios were 0.85 and 1.47, respectively.",Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),,1.47,182469,DB00571,Propranolol
,8251610,hepatic extraction ratio,"In contrast to propranolol, blood data rather than plasma data should be used to predict the hepatic extraction ratio of verapamil (0.87).",Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),,0.87,182470,DB00571,Propranolol
,8251610,plasma protein binding,The plasma protein binding of verapamil in humans (90%) and rats (95%) were quite similar and constant over the wide concentration range studied.,Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),%,90,182471,DB00571,Propranolol
,8251610,plasma protein binding,The plasma protein binding of verapamil in humans (90%) and rats (95%) were quite similar and constant over the wide concentration range studied.,Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251610/),%,95,182472,DB00571,Propranolol
,1261164,T 1/2,These data were pooled and a plasma concentration/time curve was obtained which was consistent with an average T 1/2 of 3.5 hr in this population.,Disposition of propoxyphene and propranolol in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1261164/),h,3.5,183670,DB00571,Propranolol
,3360971,peak plasma triazolam concentration (Cmax),"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],5.4,183829,DB00571,Propranolol
,3360971,peak plasma triazolam concentration (Cmax),"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],3.9,183830,DB00571,Propranolol
,3360971,total area under the plasma concentration curve (AUC),"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [h·ml],21.3,183831,DB00571,Propranolol
,3360971,total area under the plasma concentration curve (AUC),"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [h·ml],16.1,183832,DB00571,Propranolol
,3360971,oral clearance,"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ml] / [min],485,183833,DB00571,Propranolol
,3360971,oral clearance,"Compared with control, peak plasma triazolam concentration (Cmax) was significantly increased by cimetidine (5.4 versus 3.9 ng/mL), total area under the plasma concentration curve (AUC) increased (21.3 versus 16.1 ng/mL X hr), and oral clearance decreased (485 versus 668 mL/min).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ml] / [min],668,183834,DB00571,Propranolol
,3360971,Cmax,"During propranolol alone, triazolam Cmax (4.1 ng/mL), AUC (14.3 ng/mL X hr), and clearance (759 mL/min) did not differ significantly from control, whereas kinetic variables for triazolam with cimetidine plus propranolol were similar to those with cimetidine alone.","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],4.1,183835,DB00571,Propranolol
,3360971,AUC,"During propranolol alone, triazolam Cmax (4.1 ng/mL), AUC (14.3 ng/mL X hr), and clearance (759 mL/min) did not differ significantly from control, whereas kinetic variables for triazolam with cimetidine plus propranolol were similar to those with cimetidine alone.","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [h·ml],14.3,183836,DB00571,Propranolol
,3360971,clearance,"During propranolol alone, triazolam Cmax (4.1 ng/mL), AUC (14.3 ng/mL X hr), and clearance (759 mL/min) did not differ significantly from control, whereas kinetic variables for triazolam with cimetidine plus propranolol were similar to those with cimetidine alone.","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ml] / [min],759,183837,DB00571,Propranolol
,3360971,Plasma free fraction,Plasma free fraction for triazolam (17 to 18% unbound) did not differ significantly among the four treatment conditions.,"Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),%·unbound,17 to 18,183838,DB00571,Propranolol
,3360971,steady-state plasma cimetidine concentrations,"Mean steady-state plasma cimetidine concentrations during trials 2 and 4 were similar (1.04 versus .98 micrograms/mL), whereas plasma propranolol was significantly higher during cimetidine plus propranolol than with propranolol alone (47 versus 29 ng/ml, P less than .001).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[μg] / [ml],1.04,183839,DB00571,Propranolol
,3360971,steady-state plasma cimetidine concentrations,"Mean steady-state plasma cimetidine concentrations during trials 2 and 4 were similar (1.04 versus .98 micrograms/mL), whereas plasma propranolol was significantly higher during cimetidine plus propranolol than with propranolol alone (47 versus 29 ng/ml, P less than .001).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[μg] / [ml],.98,183840,DB00571,Propranolol
,3360971,steady-state plasma cimetidine concentrations,"Mean steady-state plasma cimetidine concentrations during trials 2 and 4 were similar (1.04 versus .98 micrograms/mL), whereas plasma propranolol was significantly higher during cimetidine plus propranolol than with propranolol alone (47 versus 29 ng/ml, P less than .001).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],47,183841,DB00571,Propranolol
,3360971,steady-state plasma cimetidine concentrations,"Mean steady-state plasma cimetidine concentrations during trials 2 and 4 were similar (1.04 versus .98 micrograms/mL), whereas plasma propranolol was significantly higher during cimetidine plus propranolol than with propranolol alone (47 versus 29 ng/ml, P less than .001).","Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360971/),[ng] / [ml],29,183842,DB00571,Propranolol
,3608376,Clearance,"Clearance was 0.63 +/- 0.18 and 0.71 +/- 0.24 litre h-1 kg-1, and volume of distribution at steady state was 4.02 +/- 2.98 and 3.07 +/- 1.58 litres/kg during and after pregnancy respectively.",The influence of pregnancy on drug action: concentration-effect modelling with propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608376/),[l] / [h·kg],0.63,184409,DB00571,Propranolol
,3608376,Clearance,"Clearance was 0.63 +/- 0.18 and 0.71 +/- 0.24 litre h-1 kg-1, and volume of distribution at steady state was 4.02 +/- 2.98 and 3.07 +/- 1.58 litres/kg during and after pregnancy respectively.",The influence of pregnancy on drug action: concentration-effect modelling with propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608376/),[l] / [h·kg],0.71,184410,DB00571,Propranolol
,3608376,volume of distribution at steady state,"Clearance was 0.63 +/- 0.18 and 0.71 +/- 0.24 litre h-1 kg-1, and volume of distribution at steady state was 4.02 +/- 2.98 and 3.07 +/- 1.58 litres/kg during and after pregnancy respectively.",The influence of pregnancy on drug action: concentration-effect modelling with propranolol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608376/),[l] / [kg],4.02,184411,DB00571,Propranolol
,3608376,volume of distribution at steady state,"Clearance was 0.63 +/- 0.18 and 0.71 +/- 0.24 litre h-1 kg-1, and volume of distribution at steady state was 4.02 +/- 2.98 and 3.07 +/- 1.58 litres/kg during and after pregnancy respectively.",The influence of pregnancy on drug action: concentration-effect modelling with propranolol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608376/),[l] / [kg],3.07,184412,DB00571,Propranolol
,6101148,peak plasma levels,"Mean peak plasma levels of propranolol and 4-hydroxypropranolol in six patients receiving a single dose of a slow-release 160-mg formulation of propranolol were 28 and 6 ng/ml, respectively.",Combined high-performance liquid chromatographic procedure for measuring 4-hydroxypropranolol and propranolol in plasma: pharmacokinetic measurements following conventional and slow-release propranolol administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6101148/),[ng] / [ml],28,184522,DB00571,Propranolol
,6101148,peak plasma levels,"Mean peak plasma levels of propranolol and 4-hydroxypropranolol in six patients receiving a single dose of a slow-release 160-mg formulation of propranolol were 28 and 6 ng/ml, respectively.",Combined high-performance liquid chromatographic procedure for measuring 4-hydroxypropranolol and propranolol in plasma: pharmacokinetic measurements following conventional and slow-release propranolol administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6101148/),[ng] / [ml],6,184523,DB00571,Propranolol
,19448909,biological half-life,A prolongation of propranolol biological half-life from 5.41 +/- 0.75 to 11.46 +/- 1.66 h (P = 0.0028) and an increase in propranolol volume of distribution from 8.70 +/- 2.83 to 19.33 +/- 6.52 L/kg (P = 0.0032) were observed after CABG with CPB.,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),h,5.41,184673,DB00571,Propranolol
,19448909,biological half-life,A prolongation of propranolol biological half-life from 5.41 +/- 0.75 to 11.46 +/- 1.66 h (P = 0.0028) and an increase in propranolol volume of distribution from 8.70 +/- 2.83 to 19.33 +/- 6.52 L/kg (P = 0.0032) were observed after CABG with CPB.,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),h,11.46,184674,DB00571,Propranolol
,19448909,volume of distribution,A prolongation of propranolol biological half-life from 5.41 +/- 0.75 to 11.46 +/- 1.66 h (P = 0.0028) and an increase in propranolol volume of distribution from 8.70 +/- 2.83 to 19.33 +/- 6.52 L/kg (P = 0.0032) were observed after CABG with CPB.,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),[l] / [kg],8.70,184675,DB00571,Propranolol
,19448909,volume of distribution,A prolongation of propranolol biological half-life from 5.41 +/- 0.75 to 11.46 +/- 1.66 h (P = 0.0028) and an increase in propranolol volume of distribution from 8.70 +/- 2.83 to 19.33 +/- 6.52 L/kg (P = 0.0032) were observed after CABG with CPB.,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),[l] / [kg],19.33,184676,DB00571,Propranolol
,19448909,biological half-life,No significant changes were observed in either atenolol biological half-life (from 11.20 +/- 1.60 to 11.44 +/- 2.89 h) or atenolol volume of distribution (from 2.90 +/- 0.36 to 3.83 +/- 0.72 L/kg).,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),h,11.20,184677,DB00571,Propranolol
,19448909,biological half-life,No significant changes were observed in either atenolol biological half-life (from 11.20 +/- 1.60 to 11.44 +/- 2.89 h) or atenolol volume of distribution (from 2.90 +/- 0.36 to 3.83 +/- 0.72 L/kg).,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),h,11.44,184678,DB00571,Propranolol
,19448909,volume of distribution,No significant changes were observed in either atenolol biological half-life (from 11.20 +/- 1.60 to 11.44 +/- 2.89 h) or atenolol volume of distribution (from 2.90 +/- 0.36 to 3.83 +/- 0.72 L/kg).,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),[l] / [kg],2.90,184679,DB00571,Propranolol
,19448909,volume of distribution,No significant changes were observed in either atenolol biological half-life (from 11.20 +/- 1.60 to 11.44 +/- 2.89 h) or atenolol volume of distribution (from 2.90 +/- 0.36 to 3.83 +/- 0.72 L/kg).,Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19448909/),[l] / [kg],3.83,184680,DB00571,Propranolol
,2536896,clearance,"This group metabolized propranolol more rapidly than the white group, which resulted in a 76 percent higher clearance of an oral dose (3740 +/- 737 vs. 2125 +/- 214 ml per minute; P less than 0.05) because of increased metabolism through multiple metabolic pathways.",Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536896/),[ml] / [min],3740,185502,DB00571,Propranolol
,2536896,clearance,"This group metabolized propranolol more rapidly than the white group, which resulted in a 76 percent higher clearance of an oral dose (3740 +/- 737 vs. 2125 +/- 214 ml per minute; P less than 0.05) because of increased metabolism through multiple metabolic pathways.",Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2536896/),[ml] / [min],2125,185503,DB00571,Propranolol
,8009573,Oral clearances,"Oral clearances for L-propranolol for Phases A, B, and C were 198 +/- 70, 156 +/- 76, and 143 +/- 85 L/h, respectively.",Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009573/),[l] / [h],198,185922,DB00571,Propranolol
,8009573,Oral clearances,"Oral clearances for L-propranolol for Phases A, B, and C were 198 +/- 70, 156 +/- 76, and 143 +/- 85 L/h, respectively.",Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009573/),[l] / [h],156,185923,DB00571,Propranolol
,8009573,Oral clearances,"Oral clearances for L-propranolol for Phases A, B, and C were 198 +/- 70, 156 +/- 76, and 143 +/- 85 L/h, respectively.",Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009573/),[l] / [h],143,185924,DB00571,Propranolol
,8009573,Oral clearances,"Oral clearances for D-propranolol for Phases A, B, and C were 203 +/- 96, 172 +/- 96, and 152 +/- 102 L/h, respectively.",Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009573/),[l] / [h],203,185925,DB00571,Propranolol
,8009573,Oral clearances,"Oral clearances for D-propranolol for Phases A, B, and C were 203 +/- 96, 172 +/- 96, and 152 +/- 102 L/h, respectively.",Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009573/),[l] / [h],172,185926,DB00571,Propranolol
,8009573,Oral clearances,"Oral clearances for D-propranolol for Phases A, B, and C were 203 +/- 96, 172 +/- 96, and 152 +/- 102 L/h, respectively.",Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009573/),[l] / [h],152,185927,DB00571,Propranolol
less,2872328,duration of action,The duration of action and elimination half-life both averaged less than 15 min.,Pharmacodynamics and onset of action of esmolol in anesthetized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872328/),min,15,187614,DB00571,Propranolol
less,2872328,elimination half-life,The duration of action and elimination half-life both averaged less than 15 min.,Pharmacodynamics and onset of action of esmolol in anesthetized dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2872328/),min,15,187615,DB00571,Propranolol
,24869944,flow rate,"The mobile phase was a mixture of acetonitrile and 10mM ammonium acetate buffer (36:64, v/v), adjusted to pH 9.4 with 20% ammonium solution at a flow rate of 1.0mL/min.",Determination of domperidone in human plasma using high performance liquid chromatography with fluorescence detection for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24869944/),[ml] / [min],1.0,187970,DB00571,Propranolol
,24869944,Retention times,"Retention times for domperidone and internal standard (propranolol) were 8.3min and 11.2min, respectively.",Determination of domperidone in human plasma using high performance liquid chromatography with fluorescence detection for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24869944/),min,8.3,187971,DB00571,Propranolol
,24869944,Retention times,"Retention times for domperidone and internal standard (propranolol) were 8.3min and 11.2min, respectively.",Determination of domperidone in human plasma using high performance liquid chromatography with fluorescence detection for clinical application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24869944/),min,11.2,187972,DB00571,Propranolol
,7291727,maximum A/V ratios,"The maximum A/V ratios shortly after a rapid intravenous bolus dose were 277-, 15-, 34-, 33-, 5.4- and 3240-fold, respectively, for the above six drugs.",Arterial-venous plasma concentration differences of six drugs in the dog and rabbit after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291727/),,27,190508,DB00571,Propranolol
,7291727,maximum A/V ratios,"The maximum A/V ratios shortly after a rapid intravenous bolus dose were 277-, 15-, 34-, 33-, 5.4- and 3240-fold, respectively, for the above six drugs.",Arterial-venous plasma concentration differences of six drugs in the dog and rabbit after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291727/),,15,190509,DB00571,Propranolol
,1712266,half-life,"Using this method, we showed that single oral doses of cilazapril 4 mg, captopril 25 mg and enalapril 10mg shifted the angiotensin I dose-effect curve to the right and determined a pharmacological half-life of about 4 hours for cilazapril.",Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712266/),h,4,192097,DB00571,Propranolol
,1712266,apparent Ki-dose,"The dose representing 50% inhibition of ACE activity (apparent Ki-dose) was about 0.6mg, 3 hours after cilazapril administration.",Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712266/),mg,0.6,192098,DB00571,Propranolol
,14567646,Cmax,Cmax (185.1 +/- 56.8 ng/ml) was reached at hour 3.,Iontophoretic in vivo transdermal delivery of beta-blockers in hairless rats and reduced skin irritation by liposomal formulation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14567646/),[ng] / [ml],185.1,192387,DB00571,Propranolol
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,6.1,192732,DB00571,Propranolol
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,7.1,192733,DB00571,Propranolol
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,26.5,192734,DB00571,Propranolol
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,16.7,192735,DB00571,Propranolol
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,0.12,192736,DB00571,Propranolol
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,197,192737,DB00571,Propranolol
,3304770,terminal half-life,"Compared with conventionally formulated propranolol, long acting propranolol has a prolonged terminal half-life (8 to 11 hours), due to slower absorption from the gut.",Pharmacokinetics of long acting propranolol. Implications for therapeutic use. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304770/),h,8 to 11,195556,DB00571,Propranolol
less,3304770,Systemic bioavailability,Systemic bioavailability of long acting propranolol is 30 to 50% less than that of the conventional formulation.,Pharmacokinetics of long acting propranolol. Implications for therapeutic use. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304770/),%,30 to 50,195557,DB00571,Propranolol
,25558834,Chb,"Values for Cb s corresponded to the actual values for all tested drugs, and mean Chb and maximal Chb -to-maximal Cb ratio predicted for oral fluvoxamine administration (50 mg twice-a-day administration) were nearly 100 nM and 2.3, respectively, which would be useful for the predictions of the DDIs caused by fluvoxamine.",Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558834/),nM,100,195960,DB00571,Propranolol
,25558834,maximal Chb -to-maximal Cb ratio,"Values for Cb s corresponded to the actual values for all tested drugs, and mean Chb and maximal Chb -to-maximal Cb ratio predicted for oral fluvoxamine administration (50 mg twice-a-day administration) were nearly 100 nM and 2.3, respectively, which would be useful for the predictions of the DDIs caused by fluvoxamine.",Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558834/),,2.3,195961,DB00571,Propranolol
,25558834,liver uptake,"Fluvoxamine and tacrine are known to exhibit relatively large F values despite having CLtot similar to or larger than hepatic blood flow, which may be because of the high liver uptake (almost 0.6) upon intravenous administration.",Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558834/),,0.6,195962,DB00571,Propranolol
,14727847,Cmax,"The mean Cmax and AUC(inf) for the small batch of propranolol were 79.0 microg/L and 536 microg/L/hr, and for the large batch they were 83.5 microg/L and 575 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [l],79.0,196843,DB00571,Propranolol
,14727847,Cmax,"The mean Cmax and AUC(inf) for the small batch of propranolol were 79.0 microg/L and 536 microg/L/hr, and for the large batch they were 83.5 microg/L and 575 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [l],83.5,196844,DB00571,Propranolol
,14727847,AUC(inf),"The mean Cmax and AUC(inf) for the small batch of propranolol were 79.0 microg/L and 536 microg/L/hr, and for the large batch they were 83.5 microg/L and 575 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [h·l],536,196845,DB00571,Propranolol
,14727847,AUC(inf),"The mean Cmax and AUC(inf) for the small batch of propranolol were 79.0 microg/L and 536 microg/L/hr, and for the large batch they were 83.5 microg/L and 575 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [h·l],575,196846,DB00571,Propranolol
,14727847,Cmax,"Cmax and AUC(inf) for the small batch of metoprolol were found to be 95.5 microg/L and 507 microg/L/hr and for the large batch, 95.1 microg/L and 495 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [l],95.5,196847,DB00571,Propranolol
,14727847,Cmax,"Cmax and AUC(inf) for the small batch of metoprolol were found to be 95.5 microg/L and 507 microg/L/hr and for the large batch, 95.1 microg/L and 495 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [l],95.1,196848,DB00571,Propranolol
,14727847,AUC(inf),"Cmax and AUC(inf) for the small batch of metoprolol were found to be 95.5 microg/L and 507 microg/L/hr and for the large batch, 95.1 microg/L and 495 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [h·l],507,196849,DB00571,Propranolol
,14727847,AUC(inf),"Cmax and AUC(inf) for the small batch of metoprolol were found to be 95.5 microg/L and 507 microg/L/hr and for the large batch, 95.1 microg/L and 495 microg/L/hr.",Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14727847/),[μg] / [h·l],495,196850,DB00571,Propranolol
,3371839,Cmax,"An elevation of the mean Cmax was found, from 73.9 +/- 14.1 when nifedipine was taken alone, to 115.7 +/- 12.1 (SE) ng/ml (P less than 0.02) when the agent was combined with propranolol.",Pharmacokinetic interaction between nifedipine and propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371839/),[ng] / [ml],73.9,199403,DB00571,Propranolol
,3371839,Cmax,"An elevation of the mean Cmax was found, from 73.9 +/- 14.1 when nifedipine was taken alone, to 115.7 +/- 12.1 (SE) ng/ml (P less than 0.02) when the agent was combined with propranolol.",Pharmacokinetic interaction between nifedipine and propranolol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371839/),[ng] / [ml],115.7,199404,DB00571,Propranolol
,3371839,AUC0----infinity,"The AUC0----infinity increased as well, from 287.1 +/- 33.5 to 363.0 +/- 54.3 (SE) (micrograms.hr)/l (P less than 0.01), indicating an increase in bioavailability.",Pharmacokinetic interaction between nifedipine and propranolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371839/),[hr·μg] / [l],287.1,199405,DB00571,Propranolol
,3371839,AUC0----infinity,"The AUC0----infinity increased as well, from 287.1 +/- 33.5 to 363.0 +/- 54.3 (SE) (micrograms.hr)/l (P less than 0.01), indicating an increase in bioavailability.",Pharmacokinetic interaction between nifedipine and propranolol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3371839/),[hr·μg] / [l],363.0,199406,DB00571,Propranolol
,10800722,Specific activities,Specific activities ranged from 26.5-39.3 TBq (about 700-1000 Ci)/mmol and the radiochemical yield was 2.4-8.6% (corrected for decay).,"Synthesis and biodistribution of [11c]procaterol, a beta2-adrenoceptor agonist for positron emission tomography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10800722/),tbq,26.5-39.3,199523,DB00571,Propranolol
,10800722,t1/2,"The clearance of [11C]procaterol was biphasic, with a rapid distribution phase (t1/2 0.17 min) representing 90% of the injected dose followed by an elimination phase (t1/2 18.1 min).","Synthesis and biodistribution of [11c]procaterol, a beta2-adrenoceptor agonist for positron emission tomography. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10800722/),min,0.17,199524,DB00571,Propranolol
,10800722,t1/2,"The clearance of [11C]procaterol was biphasic, with a rapid distribution phase (t1/2 0.17 min) representing 90% of the injected dose followed by an elimination phase (t1/2 18.1 min).","Synthesis and biodistribution of [11c]procaterol, a beta2-adrenoceptor agonist for positron emission tomography. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10800722/),min,18.1,199525,DB00571,Propranolol
,10800722,total/non-specific binding ratios,"In a dynamic PET-study, the lungs of untreated control rats could barely be detected and total/non-specific binding ratios rose to only 1.2 at 20 min postinjection.","Synthesis and biodistribution of [11c]procaterol, a beta2-adrenoceptor agonist for positron emission tomography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10800722/),,1.2,199526,DB00571,Propranolol
,21233561,detection limit,"Under the optimal conditions, the linear range for PRO was from 0.003 to 2 µg/mL (r(2) = 0.9993), and the detection limit was 1.3 ng/mL (S/N = 3).",Pharmacokinetics of propranolol hydrochlorid in human urine by capillary electrophoresis coupled with electrochemiluminescence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233561/),[ng] / [ml],1.3,202977,DB00571,Propranolol
,21233561,S/N,"Under the optimal conditions, the linear range for PRO was from 0.003 to 2 µg/mL (r(2) = 0.9993), and the detection limit was 1.3 ng/mL (S/N = 3).",Pharmacokinetics of propranolol hydrochlorid in human urine by capillary electrophoresis coupled with electrochemiluminescence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233561/),,3,202978,DB00571,Propranolol
,21233561,recovery,The recovery was between 96.71 and 97.30%.,Pharmacokinetics of propranolol hydrochlorid in human urine by capillary electrophoresis coupled with electrochemiluminescence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233561/),%,96.71 and,202979,DB00571,Propranolol
,21233561,recovery,The recovery was between 96.71 and 97.30%.,Pharmacokinetics of propranolol hydrochlorid in human urine by capillary electrophoresis coupled with electrochemiluminescence. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233561/),%,97,202980,DB00571,Propranolol
,21233561,urinary excretion ratio,The peak excretion rate in urine was observed during the 0.5-1 h after oral administration of a 10-mg PRO tablet and the urinary excretion ratio of PRO was 13.6% within 12 h.,Pharmacokinetics of propranolol hydrochlorid in human urine by capillary electrophoresis coupled with electrochemiluminescence. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21233561/),%,13.6,202981,DB00571,Propranolol
,19188036,flow rate,"The chromatographic separation was achieved using an isocratic mobile phase consisting of a mixture of acetonitrile and 0.5% formic acid (90:10 (v/v), pH 3.5) flowing through C18 column at a flow rate of 0.2ml/min.",Chromatography-tandem mass spectrometry method for the simultaneous quantitation of metoprolol succinate and simvastatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188036/),[ml] / [min],0.2,203269,DB00571,Propranolol
,19188036,m,"Ions were monitored in positive mode and the mass transitions measured were m/z 268.1-->m/z 103.2, m/z 441.3-->m/z 325.1 and m/z 260.0-->m/z 129.5 for MET, SIM and WIS, respectively.",Chromatography-tandem mass spectrometry method for the simultaneous quantitation of metoprolol succinate and simvastatin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19188036/),,268.1,203270,DB00571,Propranolol
,25915108,apparent permeability,"3. In vitro permeability studies from apical-to-basal direction conducted in Caco-2 cells and MDCK-II cells showed that etamicastat apparent permeability was 1.2 × 10(-5) and 1.1 × 10(-6 )cm/s, respectively, 5- and 50-fold lower as compared to nepicastat.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),[cm] / [s],1.2 × 10(-5),203539,DB00571,Propranolol
,25915108,apparent permeability,"3. In vitro permeability studies from apical-to-basal direction conducted in Caco-2 cells and MDCK-II cells showed that etamicastat apparent permeability was 1.2 × 10(-5) and 1.1 × 10(-6 )cm/s, respectively, 5- and 50-fold lower as compared to nepicastat.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),[cm] / [s],1.1 × 10(-6 ),203540,DB00571,Propranolol
greater,25915108,efflux ratio,"The secretory efflux ratio in MDCK-II cells overexpressing human P-gp showed an efflux ratio greater than 2, for both compounds, which was significantly decreased by elacridar.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),,2,203541,DB00571,Propranolol
,25915108,plasma free fraction,"Despite its lower bioavailability and higher clearance, as compared to nepicastat, etamicastat showed preferential distribution to peripheral tissues and high plasma free fraction (15.5%), which may explain its effects upon peripheral DBH and catecholamine levels.",Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25915108/),%,15.5,203542,DB00571,Propranolol
,8846617,oral bioavailability,"Despite complete absorption, oral bioavailability in man is approximately 50% on account of first-pass hepatic metabolism.",Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,50,204181,DB00571,Propranolol
,8846617,terminal elimination half-life,Fluvoxamine shows a biphasic pattern of elimination with a mean terminal elimination half-life of 12 to 15 hours after a single oral dose; this is prolonged by 30 to 50% at steady-state.,Overview of the pharmacokinetics of fluvoxamine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),h,12 to 15,204182,DB00571,Propranolol
,8846617,Plasma protein binding,Plasma protein binding of fluvoxamine (77%) is low compared with that of other SSRIs.,Overview of the pharmacokinetics of fluvoxamine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8846617/),%,77,204183,DB00571,Propranolol
,758238,apparent volume of distribution,"Compared with the paired normothermic control studies, hypothermia markedly reduced the apparent volume of distribution (6.78 +/- 1.65 vs 2.08 +/- 0.58 L/kg; p less than 0.001) and the total body clearance of propranolol (64.4 +/- 11.0 vs 32.3 +/- 7.2 ml/kg/min; p less than 0.005).",Effects of hypothermia on propranolol kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758238/),[l] / [kg],6.78,205479,DB00571,Propranolol
,758238,apparent volume of distribution,"Compared with the paired normothermic control studies, hypothermia markedly reduced the apparent volume of distribution (6.78 +/- 1.65 vs 2.08 +/- 0.58 L/kg; p less than 0.001) and the total body clearance of propranolol (64.4 +/- 11.0 vs 32.3 +/- 7.2 ml/kg/min; p less than 0.005).",Effects of hypothermia on propranolol kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758238/),[l] / [kg],2.08,205480,DB00571,Propranolol
,758238,total body clearance,"Compared with the paired normothermic control studies, hypothermia markedly reduced the apparent volume of distribution (6.78 +/- 1.65 vs 2.08 +/- 0.58 L/kg; p less than 0.001) and the total body clearance of propranolol (64.4 +/- 11.0 vs 32.3 +/- 7.2 ml/kg/min; p less than 0.005).",Effects of hypothermia on propranolol kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758238/),[ml] / [kg·min],64.4,205481,DB00571,Propranolol
,758238,total body clearance,"Compared with the paired normothermic control studies, hypothermia markedly reduced the apparent volume of distribution (6.78 +/- 1.65 vs 2.08 +/- 0.58 L/kg; p less than 0.001) and the total body clearance of propranolol (64.4 +/- 11.0 vs 32.3 +/- 7.2 ml/kg/min; p less than 0.005).",Effects of hypothermia on propranolol kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/758238/),[ml] / [kg·min],32.3,205482,DB00571,Propranolol
,7448344,maximal intrinsic clearance,"Apparent intrinsic clearance values were shown to decrease with increase in dose, with a true maximal intrinsic clearance of 5.4 l kg-1 h-1.",Dose-dependent disposition of oral propranolol in normal subjects. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7448344/),[l] / [h·kg],5.4,205486,DB00571,Propranolol
,7408406,clearance,"Oral propranolol, 40 mg every 6 hr, induced a fall in theophylline clearance from 0.0464 +/- 0.0294 +/- 0.0129 l/kg/hr (p < 0.001).",Effects of metoprolol and propranolol on theophylline elimination. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7408406/),[l] / [h·kg],0.0464,207056,DB00571,Propranolol
,24295490,lag time,"The optimized formulation displayed complete drug delivery, zero-order release rate with 4-h lag time.",In vitro and in vivo evaluations of a novel pulsed and controlled osmotic pump capsule. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24295490/),h,4,208803,DB00571,Propranolol
,24295490,relative bioavailability,The results of in vivo pharmacokinetics in beagle dogs clearly suggested the controlled and sustained release of PNH from the system and that the relative bioavailability of this preparation was about 1.023 comparing the marketed preparation.,In vitro and in vivo evaluations of a novel pulsed and controlled osmotic pump capsule. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24295490/),,1.023,208804,DB00571,Propranolol
,3761140,Cmax,"By using III, the highest values of the mean Cmax (795 +/- 160 ng/ml) and of the mean AUC (459 +/- 21 h X ng/ml) were obtained.",Pharmaceutical evaluation of hollow type suppositories. Improvement of bioavailability of propranolol in rabbits after rectal administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761140/),[ng] / [ml],795,209728,DB00571,Propranolol
,3761140,AUC,"By using III, the highest values of the mean Cmax (795 +/- 160 ng/ml) and of the mean AUC (459 +/- 21 h X ng/ml) were obtained.",Pharmaceutical evaluation of hollow type suppositories. Improvement of bioavailability of propranolol in rabbits after rectal administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3761140/),[h·ng] / [ml],459,209729,DB00571,Propranolol
,2439812,elimination half-life,"In pharmacokinetic terms, however, these drugs show no pronounced difference in their elimination half-life (ranging between 4 and 8 h).",Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439812/),h,4 and 8,210689,DB00571,Propranolol
,12856830,elimination rate constant,"As for the lipophilic drug propranolol, a significant decrease in elimination rate constant was found (from 0.24 +/- 0.08 h(-1) to 0.16 +/- 0.04 h(-1), p < 0.03) in comparison to normolipemic subjects.",Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856830/),1/[h],0.24,210857,DB00571,Propranolol
,12856830,elimination rate constant,"As for the lipophilic drug propranolol, a significant decrease in elimination rate constant was found (from 0.24 +/- 0.08 h(-1) to 0.16 +/- 0.04 h(-1), p < 0.03) in comparison to normolipemic subjects.",Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856830/),1/[h],0.16,210858,DB00571,Propranolol
,12856830,area under the concentration-time curve,"In the case of the hydrophilic atenolol, the most marked alterations were also seen in subjects with mixed form of hyperlipidemia, especially significantly lower values of area under the concentration-time curve (8950.8 +/- 2060.5 ng/ml x h and 6715.4 +/- 1813.8 ng/ml x h, p < 0.05) as well as higher elimination rate constant (0.08 +/- 0.03 h(-1) and 0.13 +/- 0.05 h(-1), p < 0.05) in comparison with the controls, respectively.",Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856830/),[ng] / [h·ml],8950.8,210859,DB00571,Propranolol
,12856830,area under the concentration-time curve,"In the case of the hydrophilic atenolol, the most marked alterations were also seen in subjects with mixed form of hyperlipidemia, especially significantly lower values of area under the concentration-time curve (8950.8 +/- 2060.5 ng/ml x h and 6715.4 +/- 1813.8 ng/ml x h, p < 0.05) as well as higher elimination rate constant (0.08 +/- 0.03 h(-1) and 0.13 +/- 0.05 h(-1), p < 0.05) in comparison with the controls, respectively.",Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856830/),[ng] / [h·ml],6715.4,210860,DB00571,Propranolol
,12856830,elimination rate constant,"In the case of the hydrophilic atenolol, the most marked alterations were also seen in subjects with mixed form of hyperlipidemia, especially significantly lower values of area under the concentration-time curve (8950.8 +/- 2060.5 ng/ml x h and 6715.4 +/- 1813.8 ng/ml x h, p < 0.05) as well as higher elimination rate constant (0.08 +/- 0.03 h(-1) and 0.13 +/- 0.05 h(-1), p < 0.05) in comparison with the controls, respectively.",Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856830/),1/[h],0.08,210861,DB00571,Propranolol
,12856830,elimination rate constant,"In the case of the hydrophilic atenolol, the most marked alterations were also seen in subjects with mixed form of hyperlipidemia, especially significantly lower values of area under the concentration-time curve (8950.8 +/- 2060.5 ng/ml x h and 6715.4 +/- 1813.8 ng/ml x h, p < 0.05) as well as higher elimination rate constant (0.08 +/- 0.03 h(-1) and 0.13 +/- 0.05 h(-1), p < 0.05) in comparison with the controls, respectively.",Comparative pharmacokinetics of propranolol and atenolol in primary hyperlipidemia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856830/),1/[h],0.13,210862,DB00571,Propranolol
,9653960,flow-rate,"The mobile phase used for the resolution of propafenone enantiomers and the internal standard propranolol was 0.25 M sodium perchlorate (pH 4.0)-acetonitrile (60:40, v/v), at a flow-rate of 0.7 ml/min.",Enantioselective analysis of propafenone in plasma using a polysaccharide-based chiral stationary phase under reversed-phase conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653960/),[ml] / [min],0.7,211507,DB00571,Propranolol
,9653960,recovery,"The method showed a mean recovery of 99.9% for (S)-propafenone and 100.5% for (R)-propafenone, and the coefficients of variation obtained in the precision and accuracy study were below 10%.",Enantioselective analysis of propafenone in plasma using a polysaccharide-based chiral stationary phase under reversed-phase conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653960/),%,99.9,211508,DB00571,Propranolol
,9653960,recovery,"The method showed a mean recovery of 99.9% for (S)-propafenone and 100.5% for (R)-propafenone, and the coefficients of variation obtained in the precision and accuracy study were below 10%.",Enantioselective analysis of propafenone in plasma using a polysaccharide-based chiral stationary phase under reversed-phase conditions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653960/),%,100.5,211509,DB00571,Propranolol
,17376707,free fraction,"Ex vivo, an increase in AGP serum concentration from 55 to 675 microg/ml resulted in a profound decrease in the free fraction of S(-)-propranolol from 14+/-0.6 to 1.9+/-0.3%.",Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17376707/),%,14,211813,DB00571,Propranolol
,17376707,free fraction,"Ex vivo, an increase in AGP serum concentration from 55 to 675 microg/ml resulted in a profound decrease in the free fraction of S(-)-propranolol from 14+/-0.6 to 1.9+/-0.3%.",Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17376707/),%,1.9,211814,DB00571,Propranolol
,7291728,apparent/true biliary clearance ratio,"This was supported by an apparent/true biliary clearance ratio of approximately 20 in the adult, and only 2-3 in the fetus.",Fetal hepatic function: the disposition of propranolol in the pregnant sheep. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291728/),,20,213829,DB00571,Propranolol
,7291728,apparent/true biliary clearance ratio,"This was supported by an apparent/true biliary clearance ratio of approximately 20 in the adult, and only 2-3 in the fetus.",Fetal hepatic function: the disposition of propranolol in the pregnant sheep. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291728/),,2-3,213830,DB00571,Propranolol
,2427689,Total apparent volume of distribution,Total apparent volume of distribution was 0.4153 +/- 0.0301 liters/kg (mean +/- S.E.M.) for the 12-mg/kg group and 0.4946 +/- 0.0691 liters/kg for the 60-mg/kg group (P greater than .05).,Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427689/),[l] / [kg],0.4153,213989,DB00571,Propranolol
,2427689,Total apparent volume of distribution,Total apparent volume of distribution was 0.4153 +/- 0.0301 liters/kg (mean +/- S.E.M.) for the 12-mg/kg group and 0.4946 +/- 0.0691 liters/kg for the 60-mg/kg group (P greater than .05).,Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427689/),[l] / [kg],0.4946,213990,DB00571,Propranolol
,2427689,Elimination clearance,Elimination clearance was 0.0061 +/- 0.0006 liters/min/kg for the 12-mg/kg group and 0.0086 +/- 0.0013 liters/min/kg for the 60-mg/kg group (P greater than .05).,Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427689/),[l] / [kg·min],0.0061,213991,DB00571,Propranolol
,2427689,Elimination clearance,Elimination clearance was 0.0061 +/- 0.0006 liters/min/kg for the 12-mg/kg group and 0.0086 +/- 0.0013 liters/min/kg for the 60-mg/kg group (P greater than .05).,Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427689/),[l] / [kg·min],0.0086,213992,DB00571,Propranolol
,2427689,elimination phase half-life (T1/2 beta),"The elimination phase half-life (T1/2 beta) was 57.0 +/- 4.1 and 53.1 +/- 3.2 min for the 12- and 60-mg/kg groups, respectively (P greater than .05).",Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427689/),min,57.0,213993,DB00571,Propranolol
,2427689,elimination phase half-life (T1/2 beta),"The elimination phase half-life (T1/2 beta) was 57.0 +/- 4.1 and 53.1 +/- 3.2 min for the 12- and 60-mg/kg groups, respectively (P greater than .05).",Cardiovascular actions and pharmacokinetics of desethyl-N-acetylprocainamide in the dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2427689/),min,53.1,213994,DB00571,Propranolol
,3391006,initial maintenance dose,"Standard pharmacokinetic formulas predicted a loading dose (52.2 +/- 38.3 micrograms/kg), steady-state plasma concentration, and the initial maintenance dose (16.1 +/- 16.2 micrograms/kg/hr; range 6.1 to 56.0 micrograms/kg/hr) to control heart rate.",Supraventricular tachycardia treated with continuous infusions of propranolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391006/),[μg] / [h·kg],16.1,214113,DB00571,Propranolol
,3391006,Heart rate,Heart rate decreased from 146 +/- 22 to 98 +/- 16 beats/min (p less than 0.0001).,Supraventricular tachycardia treated with continuous infusions of propranolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391006/),[beats] / [min],146,214114,DB00571,Propranolol
,3391006,Heart rate,Heart rate decreased from 146 +/- 22 to 98 +/- 16 beats/min (p less than 0.0001).,Supraventricular tachycardia treated with continuous infusions of propranolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3391006/),[beats] / [min],98,214115,DB00571,Propranolol
,4067813,bioavailability,"Orally administered NIP underwent extensive first-pass metabolism leading to low bioavailability (11%), despite of complete gastrointestinal absorption.","Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent. Influence of the route of administration on bioavailability in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4067813/),%,11,214944,DB00571,Propranolol
,4067813,hepatic extraction ratio,"On the constant infusion for 30 min into the portal vein, hepatic extraction ratio was 0.71.","Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent. Influence of the route of administration on bioavailability in dogs. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4067813/),,0.71,214945,DB00571,Propranolol
,4067813,systemic availability,"On the other hand, the systemic availability and the hepatic extraction ratio of propranolol were 11% and 0.86, respectively, suggesting that the first-pass metabolism through the liver actually contributes to the reduced availability.","Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent. Influence of the route of administration on bioavailability in dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4067813/),%,11,214946,DB00571,Propranolol
,4067813,hepatic extraction ratio,"On the other hand, the systemic availability and the hepatic extraction ratio of propranolol were 11% and 0.86, respectively, suggesting that the first-pass metabolism through the liver actually contributes to the reduced availability.","Pharmacokinetics of nipradilol (K-351), a new antihypertensive agent. Influence of the route of administration on bioavailability in dogs. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4067813/),,0.86,214947,DB00571,Propranolol
,2863348,Total body clearance,Total body clearance of the drug was reduced extensively with age between weeks 5 and 11 (94 to 43 ml min-1 kg-1) and decreased gradually thereafter.,Effect of age on the hepatic clearance of propranolol in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863348/),[ml] / [kg·min],94 to 43,215790,DB00571,Propranolol
,2863348,plasma free fraction,"The plasma free fraction of propranolol also decreased with age, falling from more than 20% in 3 to 5 weeks-old rats to about 10% in rats of 52 to 104 weeks.",Effect of age on the hepatic clearance of propranolol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863348/),%,20,215791,DB00571,Propranolol
,2863348,plasma free fraction,"The plasma free fraction of propranolol also decreased with age, falling from more than 20% in 3 to 5 weeks-old rats to about 10% in rats of 52 to 104 weeks.",Effect of age on the hepatic clearance of propranolol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863348/),%,10,215792,DB00571,Propranolol
,8490110,AUCpo,Oral glucose treatment caused a statistically significant decrease (50.4 +/- 12.3 vs 36.6 +/- 15.2 min micrograms ml-1; p < 0.05) in the AUCpo of propranolol when this drug was given by oral intubation (10 mg kg-1).,"Pharmacokinetics of D-propranolol following oral, intra-arterial and intraportal administration: contrasting effects of oral glucose pretreatment. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490110/),[min·μg] / [ml],50.4,216836,DB00571,Propranolol
,8490110,AUCpo,Oral glucose treatment caused a statistically significant decrease (50.4 +/- 12.3 vs 36.6 +/- 15.2 min micrograms ml-1; p < 0.05) in the AUCpo of propranolol when this drug was given by oral intubation (10 mg kg-1).,"Pharmacokinetics of D-propranolol following oral, intra-arterial and intraportal administration: contrasting effects of oral glucose pretreatment. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490110/),[min·μg] / [ml],36.6,216837,DB00571,Propranolol
,8490110,apparent mean residence time,"This glucose treatment also caused the apparent mean residence time of propranolol after an oral dose to increase from 0.70 +/- 0.08 h to 1.79 +/- 0.29 h (p < 0.05), but did not change its rate of elimination (suggesting collectively a decreased apparent intrinsic clearance and prolonged drug absorption).","Pharmacokinetics of D-propranolol following oral, intra-arterial and intraportal administration: contrasting effects of oral glucose pretreatment. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490110/),h,0.70,216838,DB00571,Propranolol
,8490110,apparent mean residence time,"This glucose treatment also caused the apparent mean residence time of propranolol after an oral dose to increase from 0.70 +/- 0.08 h to 1.79 +/- 0.29 h (p < 0.05), but did not change its rate of elimination (suggesting collectively a decreased apparent intrinsic clearance and prolonged drug absorption).","Pharmacokinetics of D-propranolol following oral, intra-arterial and intraportal administration: contrasting effects of oral glucose pretreatment. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8490110/),h,1.79,216839,DB00571,Propranolol
,23434527,recoveries,The recoveries ranged from 94 to 100% and the matrix effect did not result in a severe signal suppression.,A rapid liquid chromatography tandem mass spectrometry-based method for measuring propranolol on dried blood spots. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23434527/),%,94 to 100,217943,DB00571,Propranolol
,24565899,lag time,In vitro optimized formulation showed nearly 4.5h lag time and 5.24 ± 1.74% drug releases in initial 4.5h following rapid release 97.11 ± 1.87% in 6h.,Chronotherapeutic delivery of hydroxypropylmethylcellulose based mini-tablets: an in vitro-in vivo correlation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24565899/),h,4.5,219160,DB00571,Propranolol
,7073151,systemic clearance,Cimetidine reduced the systemic clearance of lidocaine from 766 +/- 50 mL/min to 576 +/- 47 mL/min (p less than 0.05); the apparent volume of distribution at steady-state and the degree of plasma protein binding of lidocaine also were decreased.,Increased toxicity and reduced clearance of lidocaine by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7073151/),[ml] / [min],766,220871,DB00571,Propranolol
,7073151,systemic clearance,Cimetidine reduced the systemic clearance of lidocaine from 766 +/- 50 mL/min to 576 +/- 47 mL/min (p less than 0.05); the apparent volume of distribution at steady-state and the degree of plasma protein binding of lidocaine also were decreased.,Increased toxicity and reduced clearance of lidocaine by cimetidine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7073151/),[ml] / [min],576,220872,DB00571,Propranolol
,33212399,m/z,"Detection was performed by multiple reactions monitoring with precursor-to-product ion transitions with m/z 411.2 → 191.0 for RISP, m/z 427.2 → 207.0 for 9-OH-RISP and m/z 260.1 → 116.0 for IS.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),,411.2,221334,DB00571,Propranolol
,33212399,m/z,"Detection was performed by multiple reactions monitoring with precursor-to-product ion transitions with m/z 411.2 → 191.0 for RISP, m/z 427.2 → 207.0 for 9-OH-RISP and m/z 260.1 → 116.0 for IS.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),,191.0,221335,DB00571,Propranolol
,33212399,m/z,"Detection was performed by multiple reactions monitoring with precursor-to-product ion transitions with m/z 411.2 → 191.0 for RISP, m/z 427.2 → 207.0 for 9-OH-RISP and m/z 260.1 → 116.0 for IS.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),,427.2,221336,DB00571,Propranolol
,33212399,m/z,"Detection was performed by multiple reactions monitoring with precursor-to-product ion transitions with m/z 411.2 → 191.0 for RISP, m/z 427.2 → 207.0 for 9-OH-RISP and m/z 260.1 → 116.0 for IS.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),,207.0,221337,DB00571,Propranolol
,33212399,m/z,"Detection was performed by multiple reactions monitoring with precursor-to-product ion transitions with m/z 411.2 → 191.0 for RISP, m/z 427.2 → 207.0 for 9-OH-RISP and m/z 260.1 → 116.0 for IS.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),,260.1,221338,DB00571,Propranolol
,33212399,m/z,"Detection was performed by multiple reactions monitoring with precursor-to-product ion transitions with m/z 411.2 → 191.0 for RISP, m/z 427.2 → 207.0 for 9-OH-RISP and m/z 260.1 → 116.0 for IS.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),,116.0,221339,DB00571,Propranolol
,33212399,lag-time,"Pharmacokinetic evaluation of the analytes from long-acting microparticles in rat plasma showed two peaks indicating an initial burst effect within 24 h of administration followed by controlled drug release pattern upto 45 days, while marketed formulation (Risperdal Consta®) showed no plasma concentration during the lag-time of 21 days followed by maximal drug absorption between 28 and 40 days.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),d,21,221340,DB00571,Propranolol
,33212399,maximal drug absorption,"Pharmacokinetic evaluation of the analytes from long-acting microparticles in rat plasma showed two peaks indicating an initial burst effect within 24 h of administration followed by controlled drug release pattern upto 45 days, while marketed formulation (Risperdal Consta®) showed no plasma concentration during the lag-time of 21 days followed by maximal drug absorption between 28 and 40 days.",Systematic development of a bioanalytical UPLC-MS/MS method for estimation of risperidone and its active metabolite in long-acting microsphere formulation in rat plasma. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33212399/),d,28 and 40,221341,DB00571,Propranolol
,2878678,plasma elimination half-life,In six subjects the plasma elimination half-life of bufuralol was 2.61 +/- 0.18 h and in the other three subjects 4.85 +/- 0.35 h.,Pharmacodynamic and pharmacokinetic studies on bufuralol in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878678/),h,2.61,221444,DB00571,Propranolol
,2878678,plasma elimination half-life,In six subjects the plasma elimination half-life of bufuralol was 2.61 +/- 0.18 h and in the other three subjects 4.85 +/- 0.35 h.,Pharmacodynamic and pharmacokinetic studies on bufuralol in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2878678/),h,4.85,221445,DB00571,Propranolol
,4014773,intraportal-intrinsic clearance,"During halothane anesthesia, intraportal-intrinsic clearance was decreased by 62% (P less than 0.05) from 2,110 +/- 298 to 799 +/- 233 ml/min, while systemic clearance was decreased (P less than 0.05) from 470 +/- 33 ml/min preanesthesia to 280 +/- 38 ml/min during halothane anesthesia.",The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),[ml] / [min],"2,110",221976,DB00571,Propranolol
,4014773,intraportal-intrinsic clearance,"During halothane anesthesia, intraportal-intrinsic clearance was decreased by 62% (P less than 0.05) from 2,110 +/- 298 to 799 +/- 233 ml/min, while systemic clearance was decreased (P less than 0.05) from 470 +/- 33 ml/min preanesthesia to 280 +/- 38 ml/min during halothane anesthesia.",The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),[ml] / [min],799,221977,DB00571,Propranolol
,4014773,systemic clearance,"During halothane anesthesia, intraportal-intrinsic clearance was decreased by 62% (P less than 0.05) from 2,110 +/- 298 to 799 +/- 233 ml/min, while systemic clearance was decreased (P less than 0.05) from 470 +/- 33 ml/min preanesthesia to 280 +/- 38 ml/min during halothane anesthesia.",The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),[ml] / [min],470,221978,DB00571,Propranolol
,4014773,systemic clearance,"During halothane anesthesia, intraportal-intrinsic clearance was decreased by 62% (P less than 0.05) from 2,110 +/- 298 to 799 +/- 233 ml/min, while systemic clearance was decreased (P less than 0.05) from 470 +/- 33 ml/min preanesthesia to 280 +/- 38 ml/min during halothane anesthesia.",The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),[ml] / [min],280,221979,DB00571,Propranolol
,4014773,elimination half-life,The intravenous elimination half-life was increased (P less than 0.05) from 87 +/- 12 to 155 +/- 23 min during anesthesia.,The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),min,87,221980,DB00571,Propranolol
,4014773,elimination half-life,The intravenous elimination half-life was increased (P less than 0.05) from 87 +/- 12 to 155 +/- 23 min during anesthesia.,The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),min,155,221981,DB00571,Propranolol
,4014773,liver plasma flow,"Although halothane anesthesia tended to lower liver plasma flow from 642 +/- 80 to 473 +/- 47 ml/min, this change was not significant.",The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),[ml] / [min],642,221982,DB00571,Propranolol
,4014773,liver plasma flow,"Although halothane anesthesia tended to lower liver plasma flow from 642 +/- 80 to 473 +/- 47 ml/min, this change was not significant.",The effect of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014773/),[ml] / [min],473,221983,DB00571,Propranolol
,24906133,elimination half-life,"After intravenous propranolol, patients showed a 1.8-fold increase in the area under the plasma concentration-time curve (AUC0-∞), a 1.8-fold increase in volume of distribution and a 3-fold increase in the elimination half-life (mean ± SEM: 641±100 vs. 205±43 minutes) compared to controls.",A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24906133/),min,641,222068,DB00571,Propranolol
,24906133,elimination half-life,"After intravenous propranolol, patients showed a 1.8-fold increase in the area under the plasma concentration-time curve (AUC0-∞), a 1.8-fold increase in volume of distribution and a 3-fold increase in the elimination half-life (mean ± SEM: 641±100 vs. 205±43 minutes) compared to controls.",A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24906133/),min,205,222069,DB00571,Propranolol
,24906133,bioavailability,"After oral application, AUC0-∞ and elimination half-life of propranolol were increased 6- and 4-fold, respectively, and bioavailability 3-fold (83±8 vs. 27±9.2%).",A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24906133/),%,83,222070,DB00571,Propranolol
,24906133,bioavailability,"After oral application, AUC0-∞ and elimination half-life of propranolol were increased 6- and 4-fold, respectively, and bioavailability 3-fold (83±8 vs. 27±9.2%).",A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24906133/),%,27,222071,DB00571,Propranolol
,24906133,Total serum bile acid concentrations,Total serum bile acid concentrations were higher in patients than controls (42±11 vs. 2.7±0.3 µmol/L) and were linearly correlated with the serum chenodeoxycholic acid concentration.,A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24906133/),[μM] / [l],42,222072,DB00571,Propranolol
,24906133,Total serum bile acid concentrations,Total serum bile acid concentrations were higher in patients than controls (42±11 vs. 2.7±0.3 µmol/L) and were linearly correlated with the serum chenodeoxycholic acid concentration.,A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24906133/),[μM] / [l],2.7,222073,DB00571,Propranolol
,6434219,elimination t1/2,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,58,222575,DB00571,Propranolol
,6434219,elimination t1/2,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,49,222576,DB00571,Propranolol
,6434219,clearance,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],0.20,222577,DB00571,Propranolol
,6434219,clearance,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],0.24,222578,DB00571,Propranolol
,6434219,clearance,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),,168,222579,DB00571,Propranolol
,6434219,AUC,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),,168,222580,DB00571,Propranolol
,6434219,AUC,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[μg] / [h·ml],5.63,222581,DB00571,Propranolol
,6434219,AUC,"Propranolol prolonged diazepam elimination t1/2 (58 and 49 hr), reduced its clearance (0.20 and 0.24 ml/min/kg), and increased the 168-hr AUC for desmethyldiazepam, the major metabolite of diazepam (5.63 and 4.81 micrograms/ml . hr).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[μg] / [h·ml],4.81,222582,DB00571,Propranolol
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,13.2,222583,DB00571,Propranolol
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,12.7,222584,DB00571,Propranolol
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],1.33,222585,DB00571,Propranolol
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],1.36,222586,DB00571,Propranolol
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,15.9,222587,DB00571,Propranolol
,6434219,t1/2,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),h,18.5,222588,DB00571,Propranolol
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],1.1,222589,DB00571,Propranolol
,6434219,clearance,"Propranolol had no significant effect on lorazepam t1/2 (13.2 and 12.7 hr) or clearance (1.33 and 1.36 ml/min/kg), nor on alprazolam t1/2 (15.9 and 18.5 hr) or clearance (1.1 and 0.8 ml/min/kg).","Propranolol interactions with diazepam, lorazepam, and alprazolam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6434219/),[ml] / [kg·min],0.8,222590,DB00571,Propranolol
,2312765,steady state concentration (Css),The mean (SEM) of the steady state concentration (Css) per mg/kg daily dose was 21.8 (3.1) ng.,Steady state pharmacokinetics of propranolol in Saudi Arabian patients and comparison with data for different populations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312765/),ng,21.8,224960,DB00571,Propranolol
,2312765,TCLor,The frequency distribution of the apparent oral clearance (TCLor) of propranolol was bimodal with 88% of the patients showing TCLor of 18 to 372 l.hr-1 while the remainder had TCLor of 471 to 749 l.hr-1.,Steady state pharmacokinetics of propranolol in Saudi Arabian patients and comparison with data for different populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312765/),[l] / [h],18 to 372,224961,DB00571,Propranolol
,2312765,TCLor,The frequency distribution of the apparent oral clearance (TCLor) of propranolol was bimodal with 88% of the patients showing TCLor of 18 to 372 l.hr-1 while the remainder had TCLor of 471 to 749 l.hr-1.,Steady state pharmacokinetics of propranolol in Saudi Arabian patients and comparison with data for different populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312765/),[l] / [h],471 to 749,224962,DB00571,Propranolol
,2312765,TCL,The mean (SEM) of the TCLor per kg body weight for all 48 patients was 3.16 (0.38) l.hr-1.kg-1.,Steady state pharmacokinetics of propranolol in Saudi Arabian patients and comparison with data for different populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312765/),[l] / [h·kg],3.16,224963,DB00571,Propranolol
,2312765,or,The mean (SEM) of the TCLor per kg body weight for all 48 patients was 3.16 (0.38) l.hr-1.kg-1.,Steady state pharmacokinetics of propranolol in Saudi Arabian patients and comparison with data for different populations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2312765/),[l] / [h·kg],3.16,224964,DB00571,Propranolol
,2336841,oral clearance,"3. The oral clearance of MTP of 1.2-1.4 l/min for the 80, 160 and 320 mg doses was about one third of the value previously reported for propranolol.",Pharmacokinetics and metabolism of oral doses of a 4'-methylthio derivative of propranolol in man. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2336841/),[l] / [min],1.2-1.4,225293,DB00571,Propranolol
,2336841,half-life,"The half-life for MTP (3.3-4.1 h) was, however, similar to that of propranolol.",Pharmacokinetics and metabolism of oral doses of a 4'-methylthio derivative of propranolol in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2336841/),h,3.3-4.1,225294,DB00571,Propranolol
,2336841,unbound fraction,"6. This study also demonstrated higher plasma binding of MTP (unbound fraction 3.7%) than of propranolol (10.5%; P less than 0.01), a factor probably contributing to decreased tissue distribution of MTP.",Pharmacokinetics and metabolism of oral doses of a 4'-methylthio derivative of propranolol in man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2336841/),%,3.7,225295,DB00571,Propranolol
,2336841,unbound fraction,"6. This study also demonstrated higher plasma binding of MTP (unbound fraction 3.7%) than of propranolol (10.5%; P less than 0.01), a factor probably contributing to decreased tissue distribution of MTP.",Pharmacokinetics and metabolism of oral doses of a 4'-methylthio derivative of propranolol in man. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2336841/),%,10.5,225296,DB00571,Propranolol
,15762767,half-life,The compound has a half-life of approximately 3 hours.,"Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15762767/),h,3,226151,DB00571,Propranolol
,15762767,absolute bioavailability,Almotriptan is well absorbed after oral administration and the mean absolute bioavailability is 69.1%.,"Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15762767/),%,69.1,226152,DB00571,Propranolol
,2352138,ratio AUC(+):AUC,The ratio AUC(+):AUC(-) was 1.73 +/- 0.28.,Effects of truncal vagotomy and partial gastrectomy on the pharmacokinetics of propranolol enantiomers in dogs. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352138/),,1.73,226174,DB00571,Propranolol
,21640186,area under the plasma concentration-time curve (AUC),"After per oral phenytoin dosing, the mean area under the plasma concentration-time curve (AUC) was found to be 35.03±1.83hμg/ml which was increased significantly, i.e. 62.33±2.49hμg/ml (P<0.001) when verapamil was co-administered.",Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21640186/),[hμg] / [ml],35.03,227035,DB00571,Propranolol
,21640186,area under the plasma concentration-time curve (AUC),"After per oral phenytoin dosing, the mean area under the plasma concentration-time curve (AUC) was found to be 35.03±1.83hμg/ml which was increased significantly, i.e. 62.33±2.49hμg/ml (P<0.001) when verapamil was co-administered.",Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21640186/),[hμg] / [ml],62.33,227036,DB00571,Propranolol
,21640186,maximum plasma concentration,Similarly the mean maximum plasma concentration of phenytoin increased from 3.2±0.148μg/ml without verapamil to 6.983±0.272μg/ml (P<0.001) with verapamil.,Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21640186/),[μg] / [ml],3.2,227037,DB00571,Propranolol
,21640186,maximum plasma concentration,Similarly the mean maximum plasma concentration of phenytoin increased from 3.2±0.148μg/ml without verapamil to 6.983±0.272μg/ml (P<0.001) with verapamil.,Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21640186/),[μg] / [ml],6.983,227038,DB00571,Propranolol
,1777376,apparent liver blood flow,3. The addition of nisoldipine was also associated with significant changes in apparent liver blood flow (measured by indocyanine green clearance) from 1.4 to 2.4 l min-1 in the atenolol group and from 1.3 to 2.3 l min-1 in the propranolol group.,The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol and propranolol. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777376/),[l] / [min],1.4 to 2.4,227822,DB00571,Propranolol
,1777376,apparent liver blood flow,3. The addition of nisoldipine was also associated with significant changes in apparent liver blood flow (measured by indocyanine green clearance) from 1.4 to 2.4 l min-1 in the atenolol group and from 1.3 to 2.3 l min-1 in the propranolol group.,The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol and propranolol. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1777376/),[l] / [min],1.3 to 2.3,227823,DB00571,Propranolol
,22969313,Steady-state AUC,"Steady-state AUC was significantly increased following multiple dosing (961.31±7.47 vs 2954.19±1153.34 ng.hr/ml), however, the volume of distribution (V(d)) declined (543.89±292.91 vs 224.14±1003.12 L) significantly compared to that of a single dose.",The Pharmacokinetics of Single Dose vs Steady-State Doses of Propranolol in Cirrhotic Malay Patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22969313/),[h·ng] / [ml],961.31,228676,DB00571,Propranolol
,22969313,Steady-state AUC,"Steady-state AUC was significantly increased following multiple dosing (961.31±7.47 vs 2954.19±1153.34 ng.hr/ml), however, the volume of distribution (V(d)) declined (543.89±292.91 vs 224.14±1003.12 L) significantly compared to that of a single dose.",The Pharmacokinetics of Single Dose vs Steady-State Doses of Propranolol in Cirrhotic Malay Patients. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22969313/),[h·ng] / [ml],2954.19,228677,DB00571,Propranolol
,22969313,volume of distribution (V(d)),"Steady-state AUC was significantly increased following multiple dosing (961.31±7.47 vs 2954.19±1153.34 ng.hr/ml), however, the volume of distribution (V(d)) declined (543.89±292.91 vs 224.14±1003.12 L) significantly compared to that of a single dose.",The Pharmacokinetics of Single Dose vs Steady-State Doses of Propranolol in Cirrhotic Malay Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22969313/),l,543.89,228678,DB00571,Propranolol
,22969313,volume of distribution (V(d)),"Steady-state AUC was significantly increased following multiple dosing (961.31±7.47 vs 2954.19±1153.34 ng.hr/ml), however, the volume of distribution (V(d)) declined (543.89±292.91 vs 224.14±1003.12 L) significantly compared to that of a single dose.",The Pharmacokinetics of Single Dose vs Steady-State Doses of Propranolol in Cirrhotic Malay Patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22969313/),l,224.14,228679,DB00571,Propranolol
,22969313,apparent systemic clearance (CL),The apparent systemic clearance (CL) was significantly reduced at steady-state (436.04±209.4 vs 129.51±48.42 ml/min) in comparison to single dose therapy.,The Pharmacokinetics of Single Dose vs Steady-State Doses of Propranolol in Cirrhotic Malay Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22969313/),[ml] / [min],436.04,228680,DB00571,Propranolol
,22969313,apparent systemic clearance (CL),The apparent systemic clearance (CL) was significantly reduced at steady-state (436.04±209.4 vs 129.51±48.42 ml/min) in comparison to single dose therapy.,The Pharmacokinetics of Single Dose vs Steady-State Doses of Propranolol in Cirrhotic Malay Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22969313/),[ml] / [min],129.51,228681,DB00571,Propranolol
,22969313,peak plasma concentration (Cp(max)),The peak plasma concentration (Cp(max)) was greatly increased at steady-state (54.32±22.37 vs 136.10±38.63 ng/ml).,The Pharmacokinetics of Single Dose vs Steady-State Doses of Propranolol in Cirrhotic Malay Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22969313/),[ng] / [ml],54.32,228682,DB00571,Propranolol
,22969313,peak plasma concentration (Cp(max)),The peak plasma concentration (Cp(max)) was greatly increased at steady-state (54.32±22.37 vs 136.10±38.63 ng/ml).,The Pharmacokinetics of Single Dose vs Steady-State Doses of Propranolol in Cirrhotic Malay Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22969313/),[ng] / [ml],136.10,228683,DB00571,Propranolol
,8429118,Vd,"Mean kinetic variables for antipyrine in controls and primary biliary cirrhosis patients were: Vd, .54 versus .49 L/kg; half-life, 12.0 versus 15.1 hours (P < .07); clearance, .55 versus .41 mL/min/kg (P < .04).",Antipyrine kinetics in patients with primary biliary cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429118/),[l] / [kg],.54,230066,DB00571,Propranolol
,8429118,Vd,"Mean kinetic variables for antipyrine in controls and primary biliary cirrhosis patients were: Vd, .54 versus .49 L/kg; half-life, 12.0 versus 15.1 hours (P < .07); clearance, .55 versus .41 mL/min/kg (P < .04).",Antipyrine kinetics in patients with primary biliary cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429118/),[l] / [kg],.49,230067,DB00571,Propranolol
,8429118,half-life,"Mean kinetic variables for antipyrine in controls and primary biliary cirrhosis patients were: Vd, .54 versus .49 L/kg; half-life, 12.0 versus 15.1 hours (P < .07); clearance, .55 versus .41 mL/min/kg (P < .04).",Antipyrine kinetics in patients with primary biliary cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429118/),h,12.0,230068,DB00571,Propranolol
,8429118,half-life,"Mean kinetic variables for antipyrine in controls and primary biliary cirrhosis patients were: Vd, .54 versus .49 L/kg; half-life, 12.0 versus 15.1 hours (P < .07); clearance, .55 versus .41 mL/min/kg (P < .04).",Antipyrine kinetics in patients with primary biliary cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429118/),h,15.1,230069,DB00571,Propranolol
,8429118,clearance,"Mean kinetic variables for antipyrine in controls and primary biliary cirrhosis patients were: Vd, .54 versus .49 L/kg; half-life, 12.0 versus 15.1 hours (P < .07); clearance, .55 versus .41 mL/min/kg (P < .04).",Antipyrine kinetics in patients with primary biliary cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429118/),[ml] / [kg·min],.55,230070,DB00571,Propranolol
,8429118,clearance,"Mean kinetic variables for antipyrine in controls and primary biliary cirrhosis patients were: Vd, .54 versus .49 L/kg; half-life, 12.0 versus 15.1 hours (P < .07); clearance, .55 versus .41 mL/min/kg (P < .04).",Antipyrine kinetics in patients with primary biliary cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8429118/),[ml] / [kg·min],.41,230071,DB00571,Propranolol
,662597,half-life,"Observation of plama levels showed that the half-life propanolol in the case of overdose is prolonged: 8.6 hours in this case, with a maximum plasma level of 1536 ng/ml.",[Deliberate self-overdose with propranolol. Changes in serum levels (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/662597/),h,8.6,231302,DB00571,Propranolol
,662597,maximum plasma level,"Observation of plama levels showed that the half-life propanolol in the case of overdose is prolonged: 8.6 hours in this case, with a maximum plasma level of 1536 ng/ml.",[Deliberate self-overdose with propranolol. Changes in serum levels (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/662597/),[ng] / [ml],1536,231303,DB00571,Propranolol
,18572651,entrapment efficiency,"The mean diameter was 388 and 357 nm for coated and uncoated nanoparticles, respectively, and the entrapment efficiency ranged from 20 to 32%.",Increase in the vascular residence time of propranolol-loaded nanoparticles coated with heparin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18572651/),%,20 to 32,232195,DB00571,Propranolol
,8297546,plasma half-life,"Systemic exposure is limited because of extensive sequestration by the liver and/or first-pass metabolism, a plasma half-life of approximately 30 min, no circulating active metabolites, and no accumulation of drug during chronic dosing.",Pharmacokinetics of fluvastatin and specific drug interactions. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8297546/),min,30,232734,DB00571,Propranolol
,2802213,intrinsic clearance,"The study was repeated 24 h later during 2 MAC halothane anesthesia, when the intrinsic clearance of total propranolol was decreased by 67.5 +/- 5%, from 6.14 +/- 1.1 1/min to 1.84 +/- 0.4 1/min (P less than 0.05).",Halothane inhibition of propranolol metabolism is stereoselective. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802213/),[1] / [min],6.14,232774,DB00571,Propranolol
,2802213,intrinsic clearance,"The study was repeated 24 h later during 2 MAC halothane anesthesia, when the intrinsic clearance of total propranolol was decreased by 67.5 +/- 5%, from 6.14 +/- 1.1 1/min to 1.84 +/- 0.4 1/min (P less than 0.05).",Halothane inhibition of propranolol metabolism is stereoselective. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802213/),[1] / [min],1.84,232775,DB00571,Propranolol
,2802213,clearance,"The decrease in intrinsic clearance was stereoselective, (-)-propranolol being affected to a greater extent than (+)-propranolol; thus, the decrease in the clearance of (-)-propranolol, from 10.96 +/- 2.71/min to 2.6 +/- 0.71/min (73 +/- 5%) was significantly (P less than 0.05) greater than the decrease in the clearance of (+)-propranolol, (62 +/- 3%) from 4.3 +/- 0.8 1/min to 1.5 +/- 0.3 1/min.",Halothane inhibition of propranolol metabolism is stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802213/),1/[min],10.96,232776,DB00571,Propranolol
,2802213,clearance,"The decrease in intrinsic clearance was stereoselective, (-)-propranolol being affected to a greater extent than (+)-propranolol; thus, the decrease in the clearance of (-)-propranolol, from 10.96 +/- 2.71/min to 2.6 +/- 0.71/min (73 +/- 5%) was significantly (P less than 0.05) greater than the decrease in the clearance of (+)-propranolol, (62 +/- 3%) from 4.3 +/- 0.8 1/min to 1.5 +/- 0.3 1/min.",Halothane inhibition of propranolol metabolism is stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802213/),1/[min],2.6,232777,DB00571,Propranolol
,2802213,clearance,"The decrease in intrinsic clearance was stereoselective, (-)-propranolol being affected to a greater extent than (+)-propranolol; thus, the decrease in the clearance of (-)-propranolol, from 10.96 +/- 2.71/min to 2.6 +/- 0.71/min (73 +/- 5%) was significantly (P less than 0.05) greater than the decrease in the clearance of (+)-propranolol, (62 +/- 3%) from 4.3 +/- 0.8 1/min to 1.5 +/- 0.3 1/min.",Halothane inhibition of propranolol metabolism is stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802213/),[1] / [min],4.3,232778,DB00571,Propranolol
,2802213,clearance,"The decrease in intrinsic clearance was stereoselective, (-)-propranolol being affected to a greater extent than (+)-propranolol; thus, the decrease in the clearance of (-)-propranolol, from 10.96 +/- 2.71/min to 2.6 +/- 0.71/min (73 +/- 5%) was significantly (P less than 0.05) greater than the decrease in the clearance of (+)-propranolol, (62 +/- 3%) from 4.3 +/- 0.8 1/min to 1.5 +/- 0.3 1/min.",Halothane inhibition of propranolol metabolism is stereoselective. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2802213/),[1] / [min],1.5,232779,DB00571,Propranolol
,11881704,retention times,"The retention times for ethambutol, neostigmine bromide, and propranolol are 2.0, 1.4, and 1.1 min, respectively, with a total run time of 2.8 min.","A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881704/),min,2.0,232871,DB00571,Propranolol
,11881704,retention times,"The retention times for ethambutol, neostigmine bromide, and propranolol are 2.0, 1.4, and 1.1 min, respectively, with a total run time of 2.8 min.","A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881704/),min,1.4,232872,DB00571,Propranolol
,11881704,retention times,"The retention times for ethambutol, neostigmine bromide, and propranolol are 2.0, 1.4, and 1.1 min, respectively, with a total run time of 2.8 min.","A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881704/),min,1.1,232873,DB00571,Propranolol
,11881704,total run time,"The retention times for ethambutol, neostigmine bromide, and propranolol are 2.0, 1.4, and 1.1 min, respectively, with a total run time of 2.8 min.","A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881704/),min,2.8,232874,DB00571,Propranolol
,11881704,detection limits,The detection limits for ethambutol are 0.05 microg/mL for plasma and 0.005 microg/mL for the BAL supernatants and AC suspensions.,"A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881704/),[μg] / [ml],0.05,232875,DB00571,Propranolol
,11881704,detection limits,The detection limits for ethambutol are 0.05 microg/mL for plasma and 0.005 microg/mL for the BAL supernatants and AC suspensions.,"A high-pressure liquid chromatographic-tandem mass spectrometric method for the determination of ethambutol in human plasma, bronchoalveolar lavage fluid, and alveolar cells. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11881704/),[μg] / [ml],0.005,232876,DB00571,Propranolol
,8947979,clearance,"While receiving propranolol 40 mg, VPA clearance was reduced from 1.66 L/hr to 1.19 L/hr and dropped to 1.08 L/hr on propranolol 80 mg.",A pharmacokinetic study to determine the drug interaction between valproate and propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8947979/),[l] / [h],1.66,233386,DB00571,Propranolol
,8947979,clearance,"While receiving propranolol 40 mg, VPA clearance was reduced from 1.66 L/hr to 1.19 L/hr and dropped to 1.08 L/hr on propranolol 80 mg.",A pharmacokinetic study to determine the drug interaction between valproate and propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8947979/),[l] / [h],1.19,233387,DB00571,Propranolol
,8947979,clearance,"While receiving propranolol 40 mg, VPA clearance was reduced from 1.66 L/hr to 1.19 L/hr and dropped to 1.08 L/hr on propranolol 80 mg.",A pharmacokinetic study to determine the drug interaction between valproate and propranolol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8947979/),[l] / [h],1.08,233388,DB00571,Propranolol
,8947979,Plasma half-life,Plasma half-life of VPA ranged from 7.3-18 hours and did not change with coadministration of propranolol.,A pharmacokinetic study to determine the drug interaction between valproate and propranolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8947979/),h,7.3-18,233389,DB00571,Propranolol
,6121708,t 1/2,"Peak plasma concentrations were higher for the parent drug but due to a longer elimination half-life, the metabolite concentrations became higher after a few hours (bufuralol t 1/2 = 2.7 +/- 0.9 h, metabolite t 1/2 = 6.1 +/- 1.5h).",The genetic control of bufuralol metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121708/),h,2.7,234409,DB00571,Propranolol
,6121708,t 1/2,"Peak plasma concentrations were higher for the parent drug but due to a longer elimination half-life, the metabolite concentrations became higher after a few hours (bufuralol t 1/2 = 2.7 +/- 0.9 h, metabolite t 1/2 = 6.1 +/- 1.5h).",The genetic control of bufuralol metabolism in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121708/),h,6.1,234410,DB00571,Propranolol
,6121708,bioavailability,The bioavailability of the tablet tested was 46 +/- 15%.,The genetic control of bufuralol metabolism in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121708/),%,46,234411,DB00571,Propranolol
,1932613,elimination half-life,"When administered alone, DTZ concentration peaked at 161.4 ng ml-1 3 h following the final dose with an elimination half-life of 6.1 h.",Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),h,6.1,234477,DB00571,Propranolol
,1932613,oral clearance,DTZ oral clearance was 65.1 l h-1.,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),[l] / [h],65.1,234478,DB00571,Propranolol
,1932613,tmax,"However, DTZ tmax was extended from 2.9 h to 3.5 h (p less than 0.05) and Cmax was 144.7 ng ml-1.",Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),h,2.9,234479,DB00571,Propranolol
,1932613,tmax,"However, DTZ tmax was extended from 2.9 h to 3.5 h (p less than 0.05) and Cmax was 144.7 ng ml-1.",Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),h,3.5,234480,DB00571,Propranolol
,1932613,Cmax,"However, DTZ tmax was extended from 2.9 h to 3.5 h (p less than 0.05) and Cmax was 144.7 ng ml-1.",Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),[ng] / [ml],144.7,234481,DB00571,Propranolol
,1932613,Oral clearance,Oral clearance of PPL decreased from 80.4 l h-1 to 61.0 l h-1 while the half-life increased from 5.9 h to 8.0 h (p less than 0.05).,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),[l] / [h],80.4,234482,DB00571,Propranolol
,1932613,Oral clearance,Oral clearance of PPL decreased from 80.4 l h-1 to 61.0 l h-1 while the half-life increased from 5.9 h to 8.0 h (p less than 0.05).,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),[l] / [h],61.0,234483,DB00571,Propranolol
,1932613,half-life,Oral clearance of PPL decreased from 80.4 l h-1 to 61.0 l h-1 while the half-life increased from 5.9 h to 8.0 h (p less than 0.05).,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),h,5.9,234484,DB00571,Propranolol
,1932613,half-life,Oral clearance of PPL decreased from 80.4 l h-1 to 61.0 l h-1 while the half-life increased from 5.9 h to 8.0 h (p less than 0.05).,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),h,8.0,234485,DB00571,Propranolol
,1932613,Cmax,PPL Cmax increased from 155.1 ng ml-1 to 167.5 ng ml-1.,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),[ng] / [ml],155.1,234486,DB00571,Propranolol
,1932613,Cmax,PPL Cmax increased from 155.1 ng ml-1 to 167.5 ng ml-1.,Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1932613/),[ng] / [ml],167.5,234487,DB00571,Propranolol
>,14570767,IC50,"In the absence of preincubation, the racemate was found to be a weak inhibitor (IC50 > 100 microM) of phenacetin O-deethylation (POD) (CYP1A2), paclitaxel 6alpha-hydroxylation (CYP2C8), diclofenac 4'-hydroxylation (CYP2C9), (S)-mephenytoin 4'-hydroxylation (CYP2C19), bufuralol 1'-hydroxylation (CYP2D6), testosterone 6beta-hydroxylation (CYP3A4), chlorzoxazone 6-hydroxylation (CYP2E1), and bupropion hydroxylation (CYP2B6).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,100,238065,DB00571,Propranolol
,14570767,kinact,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238066,DB00571,Propranolol
,14570767,apparent KI,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.035,238067,DB00571,Propranolol
,14570767,kinact/KIratio,"The effect was NADPH-, time-, and concentration-dependent, and was characterized by a kinact (maximal rate of enzyme inactivation) and apparent KI(inhibitor concentration that supports half the maximal rate of inactivation) of 0.035 min(-1) and 117 microM, respectively (kinact/KIratio of 0.0003 min-1 microM(-1)).","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0003,238068,DB00571,Propranolol
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.037,238069,DB00571,Propranolol
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,98.2,238070,DB00571,Propranolol
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0004,238071,DB00571,Propranolol
,14570767,kinact,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.012,238072,DB00571,Propranolol
,14570767,KI,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),μM,66.6,238073,DB00571,Propranolol
,14570767,kinact/,"Preincubation-dependent inhibition of POD activity was also observed with the individual (S)-(-)- and (R)-(+)-enantiomers of zileuton [(S)-(-)-zileuton; kinact, 0.037 min(-1), KI, 98.2 microM, kinact/KIratio, 0.0004 min(-1) microM(-1); (R)-(+)-zileuton; kinact, 0.012 min(-1), KI, 66.6 microM, kinact/KIratio, 0.0002 min(-1) microM(-1)].","Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570767/),1/[min],0.0002,238074,DB00571,Propranolol
,3366165,elimination half-life,"The elimination half-life varied significantly with the time of day, being shortest at 08 h (3.3 h) and longest at 20 h (4.9 h).",Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3366165/),,08,239432,DB00571,Propranolol
,3366165,elimination half-life,"The elimination half-life varied significantly with the time of day, being shortest at 08 h (3.3 h) and longest at 20 h (4.9 h).",Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3366165/),h,3.3,239433,DB00571,Propranolol
,3366165,elimination half-life,"The elimination half-life varied significantly with the time of day, being shortest at 08 h (3.3 h) and longest at 20 h (4.9 h).",Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3366165/),h,4.9,239434,DB00571,Propranolol
,3366165,tmax,"No circadian variation was found in the maximum decrease in heart rate, but the time to peak effect was dependent on the time of drug intake; tmax was 2.3 h at 08 h and 7.0 h at 02 h.",Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3366165/),h,2.3,239435,DB00571,Propranolol
,3366165,tmax,"No circadian variation was found in the maximum decrease in heart rate, but the time to peak effect was dependent on the time of drug intake; tmax was 2.3 h at 08 h and 7.0 h at 02 h.",Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3366165/),h,7.0,239436,DB00571,Propranolol
,17589660,flow rate,"Peaks eluted at 8.4 (Propranolol) and 17.5 min (verapamil, internal standard) from a C18 column, with a mobile phase 0.1 M acetate buffer, pH 5.0, and acetonitrile (60:40, v/v) at flow rate 0.7 mL/min, detected at 290 nm (excitation) and 358 nm (emission).",Propranolol plasma monitoring in children submitted to surgery of tetralogy of Fallot by a micromethod using high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589660/),[ml] / [min],0.7,239474,DB00571,Propranolol
,17589660,sensitivity,"Confidence limits of the method showed high selectivity and recovery, sensitivity of 0.02ng/mL, good linearity (0.05-1000 ng/mL), precision of 8.6% and accuracy of 3.1%.",Propranolol plasma monitoring in children submitted to surgery of tetralogy of Fallot by a micromethod using high performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589660/),,0.02,239475,DB00571,Propranolol
,17589660,drug plasma concentration,"On the other hand a decrease on drug plasma concentration was obtained between periods, the beginning of surgery to the postoperative day 2 (7.09 ng/mL and 0.05 ng/mL, p<0.05 respectively) and from the end of CPB to the postoperative day 2 (2.79 ng/mL e 0.05 ng/mL, p<0.05).",Propranolol plasma monitoring in children submitted to surgery of tetralogy of Fallot by a micromethod using high performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589660/),[ng] / [ml],7.09,239476,DB00571,Propranolol
,17589660,drug plasma concentration,"On the other hand a decrease on drug plasma concentration was obtained between periods, the beginning of surgery to the postoperative day 2 (7.09 ng/mL and 0.05 ng/mL, p<0.05 respectively) and from the end of CPB to the postoperative day 2 (2.79 ng/mL e 0.05 ng/mL, p<0.05).",Propranolol plasma monitoring in children submitted to surgery of tetralogy of Fallot by a micromethod using high performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589660/),[ng] / [ml],0.05,239477,DB00571,Propranolol
,17589660,drug plasma concentration,"On the other hand a decrease on drug plasma concentration was obtained between periods, the beginning of surgery to the postoperative day 2 (7.09 ng/mL and 0.05 ng/mL, p<0.05 respectively) and from the end of CPB to the postoperative day 2 (2.79 ng/mL e 0.05 ng/mL, p<0.05).",Propranolol plasma monitoring in children submitted to surgery of tetralogy of Fallot by a micromethod using high performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17589660/),[ng] / [ml],2.79,239478,DB00571,Propranolol
,16510542,steady-state CNS/total plasma concentration ratios,"Average steady-state CNS/total plasma concentration ratios (i.e., [CNS]/[total plasma]) for steps 1 to 5 ranged from 0.4 to 0.5.",A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510542/),,0.4 to 0.5,240130,DB00571,Propranolol
,16510542,steady-state [CNS]/[free plasma] ratios,"However, average steady-state [CNS]/[free plasma] ratios ranged from 2 to 3, suggesting active transport of DPHM into the CNS.",A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510542/),,2 to 3,240131,DB00571,Propranolol
,16510542,Plasma protein binding,Plasma protein binding averaged 86.1 +/- 2.3% (mean +/- S.D.) and was not altered with increasing drug dose.,A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510542/),%,86.1,240132,DB00571,Propranolol
,16510542,terminal elimination half-lives (t1/2beta),"Plasma, CSF, and ECF demonstrated biexponential pharmacokinetics with terminal elimination half-lives (t1/2beta) of 10.8 +/- 5.4, 3.6 +/- 1.0, and 5.3 +/- 4.2 h, respectively.",A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510542/),h,10.8,240133,DB00571,Propranolol
,16510542,terminal elimination half-lives (t1/2beta),"Plasma, CSF, and ECF demonstrated biexponential pharmacokinetics with terminal elimination half-lives (t1/2beta) of 10.8 +/- 5.4, 3.6 +/- 1.0, and 5.3 +/- 4.2 h, respectively.",A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510542/),h,3.6,240134,DB00571,Propranolol
,16510542,terminal elimination half-lives (t1/2beta),"Plasma, CSF, and ECF demonstrated biexponential pharmacokinetics with terminal elimination half-lives (t1/2beta) of 10.8 +/- 5.4, 3.6 +/- 1.0, and 5.3 +/- 4.2 h, respectively.",A pharmacokinetic study of diphenhydramine transport across the blood-brain barrier in adult sheep: potential involvement of a carrier-mediated mechanism. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16510542/),h,5.3,240135,DB00571,Propranolol
,15758,Plasma half-life,"2. Plasma half-life is between 2 and 4 h, except for sotalol (10-12 h).",Pharmacokinetics of beta-receptor-blocking agents in relation to their anti-hypertensive effect. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15758/),h,2 and 4,241317,DB00571,Propranolol
,15758,Plasma half-life,"2. Plasma half-life is between 2 and 4 h, except for sotalol (10-12 h).",Pharmacokinetics of beta-receptor-blocking agents in relation to their anti-hypertensive effect. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15758/),h,10-12,241318,DB00571,Propranolol
,7273593,Oral bioavailability,Oral bioavailability of 1- and total propranolol averaged 40.7 +/- 8.5% and 42.4 +/- 12.9%.,No stereoselective first-pass hepatic extraction of propranolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273593/),%,40.7,241870,DB00571,Propranolol
,7273593,Oral bioavailability,Oral bioavailability of 1- and total propranolol averaged 40.7 +/- 8.5% and 42.4 +/- 12.9%.,No stereoselective first-pass hepatic extraction of propranolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273593/),%,42.4,241871,DB00571,Propranolol
,19716867,perfusion pressures,"Similar perfusion pressures (17.6+/-6.71 vs 17.7+/-8.87 cm H(2)O), lung wet/dry ratio (6.14+/-1.16 vs 5.16+/-0.87), physiological spaces, and permeability-surface area products were found for the two perfusates.",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),cm·h(2,17.6,242633,DB00571,Propranolol
,19716867,perfusion pressures,"Similar perfusion pressures (17.6+/-6.71 vs 17.7+/-8.87 cm H(2)O), lung wet/dry ratio (6.14+/-1.16 vs 5.16+/-0.87), physiological spaces, and permeability-surface area products were found for the two perfusates.",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),cm·h(2,17.7,242634,DB00571,Propranolol
,19716867,wet/dry ratio,"Similar perfusion pressures (17.6+/-6.71 vs 17.7+/-8.87 cm H(2)O), lung wet/dry ratio (6.14+/-1.16 vs 5.16+/-0.87), physiological spaces, and permeability-surface area products were found for the two perfusates.",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),,6.14,242635,DB00571,Propranolol
,19716867,wet/dry ratio,"Similar perfusion pressures (17.6+/-6.71 vs 17.7+/-8.87 cm H(2)O), lung wet/dry ratio (6.14+/-1.16 vs 5.16+/-0.87), physiological spaces, and permeability-surface area products were found for the two perfusates.",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),,5.16,242636,DB00571,Propranolol
,19716867,recovery,"However, the recovery of propranolol using perfusate A (49.3+/-10.1%) was significantly higher than that using perfusate B (38.9+/-9.91%).",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),%,49.3,242637,DB00571,Propranolol
,19716867,recovery,"However, the recovery of propranolol using perfusate A (49.3+/-10.1%) was significantly higher than that using perfusate B (38.9+/-9.91%).",Influence of perfusate composition on drug disposition in the in-situ perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19716867/),%,38.9,242638,DB00571,Propranolol
,24342894,clearance,"Therapeutic drug monitoring of carbamazepine was carried out, and a slow carbamazepine clearance of 1.45 L·h⁻¹ per 70 kg was observed.",Slow carbamazepine clearance in a nonadherent Malay woman with epilepsy and thyrotoxicosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342894/),[h⁻¹·l] / [70·kg],1.45,244420,DB00571,Propranolol
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,20,245762,DB00571,Propranolol
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,6,245763,DB00571,Propranolol
,13957,half-life,The half-life of morphine between 20 minutes and 6 hours is 2 to 3 hours and this value does not appear to be influenced by the age of the patient.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,2 to 3,245764,DB00571,Propranolol
,13957,half-life,The half-life of methadone averages 25 hours.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),h,25,245765,DB00571,Propranolol
,13957,half-life,Naloxone rapidly disappears from the serum in man and the initial distribution phase has a half-life of 4 minutes.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,4,245766,DB00571,Propranolol
,13957,half-life,The half-life of naloxone in serum following distribution is 64 minutes.,"The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/13957/),min,64,245767,DB00571,Propranolol
,6104973,half-life,"The peak blood level of betaxolol was reached 2 to 4 hr after its administration, the first-pass loss is likely to be low and the half-life is 12.3 h.",Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6104973/),h,12.3,245928,DB00571,Propranolol
,9044877,Radiochemical purity,Radiochemical purity of nebulized 123I-MIBG ranged between 97.18% and 98.70%.,Potential use of iodine-123 metaiodobenzylguanidine radioaerosol as a marker of pulmonary neuroadrenergic function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044877/),%,97.18,248455,DB00571,Propranolol
,9044877,Radiochemical purity,Radiochemical purity of nebulized 123I-MIBG ranged between 97.18% and 98.70%.,Potential use of iodine-123 metaiodobenzylguanidine radioaerosol as a marker of pulmonary neuroadrenergic function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044877/),%,98.70,248456,DB00571,Propranolol
,9044877,clearance rate,"The 123I-MIBG clearance rate was slower than that of 99mTc-DTPA under baseline conditions (135+/-32 min vs 69+/-27 min, P<0.01) and increased significantly after propranolol administrations, while the 99mTc-DTPA clearance did not change.",Potential use of iodine-123 metaiodobenzylguanidine radioaerosol as a marker of pulmonary neuroadrenergic function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044877/),min,135,248457,DB00571,Propranolol
,9044877,clearance rate,"The 123I-MIBG clearance rate was slower than that of 99mTc-DTPA under baseline conditions (135+/-32 min vs 69+/-27 min, P<0.01) and increased significantly after propranolol administrations, while the 99mTc-DTPA clearance did not change.",Potential use of iodine-123 metaiodobenzylguanidine radioaerosol as a marker of pulmonary neuroadrenergic function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9044877/),min,69,248458,DB00571,Propranolol
,7310641,volume of distribution,The volume of distribution was about 6 liters .,Pharmacokinetics of propranolol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7310641/),l,6,249146,DB00571,Propranolol
,7310641,bioavailability,"kg-1, bioavailability around 25%, with a mean terminal half-life of 6 hr.",Pharmacokinetics of propranolol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7310641/),%,25,249147,DB00571,Propranolol
,7310641,terminal half-life,"kg-1, bioavailability around 25%, with a mean terminal half-life of 6 hr.",Pharmacokinetics of propranolol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7310641/),h,6,249148,DB00571,Propranolol
,18557416,forces of detachment,"The forces of detachment for the mucoadhesive buccal tablets were 14.61 +/- 0.14, 13.21 +/- 0.13 and 11.71 +/- 0.12.",In vitro and in vivo evaluation of locust bean gum and chitosan combination as a carrier for buccal drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557416/),,14.61,249488,DB00571,Propranolol
,18557416,forces of detachment,"The forces of detachment for the mucoadhesive buccal tablets were 14.61 +/- 0.14, 13.21 +/- 0.13 and 11.71 +/- 0.12.",In vitro and in vivo evaluation of locust bean gum and chitosan combination as a carrier for buccal drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557416/),,13.21,249489,DB00571,Propranolol
,18557416,forces of detachment,"The forces of detachment for the mucoadhesive buccal tablets were 14.61 +/- 0.14, 13.21 +/- 0.13 and 11.71 +/- 0.12.",In vitro and in vivo evaluation of locust bean gum and chitosan combination as a carrier for buccal drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557416/),,11.71,249490,DB00571,Propranolol
,18557416,cumulative percentage release,"An in vitro study was carried out in pH 6.8 phosphate buffer and the cumulative percentage release of propranolol measured at 10 min intervals for 600 min was found to be 98.31 +/- 0.10, 92.24 +/- 0.41 and 90.18 +/- 0.76 respectively.",In vitro and in vivo evaluation of locust bean gum and chitosan combination as a carrier for buccal drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557416/),,98.31,249491,DB00571,Propranolol
,18557416,cumulative percentage release,"An in vitro study was carried out in pH 6.8 phosphate buffer and the cumulative percentage release of propranolol measured at 10 min intervals for 600 min was found to be 98.31 +/- 0.10, 92.24 +/- 0.41 and 90.18 +/- 0.76 respectively.",In vitro and in vivo evaluation of locust bean gum and chitosan combination as a carrier for buccal drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557416/),,92.24,249492,DB00571,Propranolol
,18557416,cumulative percentage release,"An in vitro study was carried out in pH 6.8 phosphate buffer and the cumulative percentage release of propranolol measured at 10 min intervals for 600 min was found to be 98.31 +/- 0.10, 92.24 +/- 0.41 and 90.18 +/- 0.76 respectively.",In vitro and in vivo evaluation of locust bean gum and chitosan combination as a carrier for buccal drug delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557416/),,90.18,249493,DB00571,Propranolol
,18557416,bioavailability (AUC(0-t*),"The bioavailability (AUC(0-t*) ng x h/ml) of the buccal propranolol hydrochloride tablets (F1, F2 and F3) and oral tablet (F4) was found to be 2244.18 +/- 210, 3580.69 +/- 460, 3889.19 +/- 290 and 1732 +/- 96 ng x hr/ml respectively.",In vitro and in vivo evaluation of locust bean gum and chitosan combination as a carrier for buccal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557416/),[h·ng] / [ml],2244.18,249494,DB00571,Propranolol
,18557416,bioavailability (AUC(0-t*),"The bioavailability (AUC(0-t*) ng x h/ml) of the buccal propranolol hydrochloride tablets (F1, F2 and F3) and oral tablet (F4) was found to be 2244.18 +/- 210, 3580.69 +/- 460, 3889.19 +/- 290 and 1732 +/- 96 ng x hr/ml respectively.",In vitro and in vivo evaluation of locust bean gum and chitosan combination as a carrier for buccal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557416/),[h·ng] / [ml],3580.69,249495,DB00571,Propranolol
,18557416,bioavailability (AUC(0-t*),"The bioavailability (AUC(0-t*) ng x h/ml) of the buccal propranolol hydrochloride tablets (F1, F2 and F3) and oral tablet (F4) was found to be 2244.18 +/- 210, 3580.69 +/- 460, 3889.19 +/- 290 and 1732 +/- 96 ng x hr/ml respectively.",In vitro and in vivo evaluation of locust bean gum and chitosan combination as a carrier for buccal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557416/),[h·ng] / [ml],3889.19,249496,DB00571,Propranolol
,18557416,bioavailability (AUC(0-t*),"The bioavailability (AUC(0-t*) ng x h/ml) of the buccal propranolol hydrochloride tablets (F1, F2 and F3) and oral tablet (F4) was found to be 2244.18 +/- 210, 3580.69 +/- 460, 3889.19 +/- 290 and 1732 +/- 96 ng x hr/ml respectively.",In vitro and in vivo evaluation of locust bean gum and chitosan combination as a carrier for buccal drug delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18557416/),[h·ng] / [ml],1732,249497,DB00571,Propranolol
,22282953,m,Detection was performed by a triple-quadrupole mass spectrometry with positive electrospray ionization (ESI) as source ionization in multiple-reaction monitoring (MRM) mode at m/z 361.0 --> 315.0 for NTD and m/z 260.2 --> 116.0 for IS.,Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of nitrendipine in dog plasma and its application to a pharmacokinetic study of a solid self-emulsifying pellet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282953/),,260.2,249764,DB00571,Propranolol
,22282953,extraction recoveries,"The mean extraction recoveries of NTD and IS were 90.2% and 82.4%, respectively.",Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of nitrendipine in dog plasma and its application to a pharmacokinetic study of a solid self-emulsifying pellet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282953/),%,90.2,249765,DB00571,Propranolol
,22282953,extraction recoveries,"The mean extraction recoveries of NTD and IS were 90.2% and 82.4%, respectively.",Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of nitrendipine in dog plasma and its application to a pharmacokinetic study of a solid self-emulsifying pellet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282953/),%,82.4,249766,DB00571,Propranolol
,30927010,extraction efficiency,The extraction efficiency ranged between 88.7 and 91.2%.,Sensitive Ultra-performance Liquid Chromatography Tandem Mass Spectrometry Method for Determination of Cycloserine in Plasma for a Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30927010/),%,88.7 and,250665,DB00571,Propranolol
,30927010,extraction efficiency,The extraction efficiency ranged between 88.7 and 91.2%.,Sensitive Ultra-performance Liquid Chromatography Tandem Mass Spectrometry Method for Determination of Cycloserine in Plasma for a Pharmacokinetics Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30927010/),%,91,250666,DB00571,Propranolol
,16823763,flow rate,"Chromatographic separation was obtained within 8.0 min using a reverse-phase Capcell-Pak C(18) column (150 x 4.6 mm i.d., 5 microm) and the mobile phase consisted of methanol-water containing 10 mM perchloric acid and 1.8 mM sodium heptane sulfonic acid (50:50, v/v) and was set at a flow rate of 1.5 mL/min.",High-performance liquid chromatographic determination of doxazosin in human plasma for bioequivalence study of controlled release doxazosin tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16823763/),[ml] / [min],1.5,251520,DB00571,Propranolol
,16823763,recoveries,"Average recoveries of doxazosin and the internal standard from human plasma matrix were 87.0 and 85.9%, respectively.",High-performance liquid chromatographic determination of doxazosin in human plasma for bioequivalence study of controlled release doxazosin tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16823763/),%,87.0,251521,DB00571,Propranolol
,16823763,recoveries,"Average recoveries of doxazosin and the internal standard from human plasma matrix were 87.0 and 85.9%, respectively.",High-performance liquid chromatographic determination of doxazosin in human plasma for bioequivalence study of controlled release doxazosin tablets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16823763/),%,85.9,251522,DB00571,Propranolol
,29746707,apparent clearance,"The estimated population mean apparent clearance and apparent central volume of distribution were 9.34 L/h and 146 L, respectively.",Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746707/),[l] / [h],9.34,252240,DB00571,Propranolol
,29746707,apparent central volume of distribution,"The estimated population mean apparent clearance and apparent central volume of distribution were 9.34 L/h and 146 L, respectively.",Population Pharmacokinetics and Pharmacodynamics of Oral Propranolol in Pediatric Patients With Infantile Hemangioma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746707/),l,146,252241,DB00571,Propranolol
,17466606,flow rate,"The HPLC separation of the analytes was performed on a Phenomenex C18 (250 mmx4.6 mm, 5 microm, USA) column, with a flow rate of 0.85 mL/min.",Determination of talinolol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17466606/),[ml] / [min],0.85,252819,DB00571,Propranolol
above,17466606,extraction recovery,The average extraction recovery was above 83%.,Determination of talinolol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17466606/),%,83,252820,DB00571,Propranolol
,17466606,recovery,The methodology recovery was between 101% and 102%.,Determination of talinolol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17466606/),%,101,252821,DB00571,Propranolol
,17466606,recovery,The methodology recovery was between 101% and 102%.,Determination of talinolol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17466606/),%,102,252822,DB00571,Propranolol
,17466606,limit of detection (LOD),The limit of detection (LOD) was 0.3 ng/mL for talinolol.,Determination of talinolol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17466606/),[ng] / [ml],0.3,252823,DB00571,Propranolol
,17466606,Cmax,"A single oral 50 mg dose of talinolol tablet was administered to 12 healthy Chinese volunteers, the main pharmacokinetic data are as follows: Cmax was 147.8+/-63.8 ng/mL; tmax was 2.0+/-0.7 h; t1/2 was 12.0+/-2.6 h.",Determination of talinolol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry: application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17466606/),[ng] / [ml],147.8,252824,DB00571,Propranolol
,17466606,tmax,"A single oral 50 mg dose of talinolol tablet was administered to 12 healthy Chinese volunteers, the main pharmacokinetic data are as follows: Cmax was 147.8+/-63.8 ng/mL; tmax was 2.0+/-0.7 h; t1/2 was 12.0+/-2.6 h.",Determination of talinolol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17466606/),h,2.0,252825,DB00571,Propranolol
,17466606,t1/2,"A single oral 50 mg dose of talinolol tablet was administered to 12 healthy Chinese volunteers, the main pharmacokinetic data are as follows: Cmax was 147.8+/-63.8 ng/mL; tmax was 2.0+/-0.7 h; t1/2 was 12.0+/-2.6 h.",Determination of talinolol in human plasma by high performance liquid chromatography-electrospray ionization mass spectrometry: application to pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17466606/),h,12.0,252826,DB00571,Propranolol
,2550167,t1/2,"In a single-blind randomized study, 10 healthy men took a placebo for 1 week and then took nadolol one time a day (t1/2, 18 to 24 hours) or propranolol three times a day (t1/2, 4 to 6 hours) in doses that were increased weekly for 4 weeks to reach 240 mg per day.",Beta-blockade disappearance rate predicts beta-adrenergic hypersensitivity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550167/),h,18 to 24,253025,DB00571,Propranolol
,2550167,t1/2,"In a single-blind randomized study, 10 healthy men took a placebo for 1 week and then took nadolol one time a day (t1/2, 18 to 24 hours) or propranolol three times a day (t1/2, 4 to 6 hours) in doses that were increased weekly for 4 weeks to reach 240 mg per day.",Beta-blockade disappearance rate predicts beta-adrenergic hypersensitivity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550167/),h,4 to 6,253026,DB00571,Propranolol
,6743489,Dose-corrected AUC0-24,"Dose-corrected AUC0-24 values were greater after Elanol than after Inderal LA (651 +/- 147 vs 402 +/- 159 ng ml-1 h, means +/- s.e. mean, P greater than 0.05).",Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743489/),[h·ng] / [ml],651,253743,DB00571,Propranolol
,6743489,Dose-corrected AUC0-24,"Dose-corrected AUC0-24 values were greater after Elanol than after Inderal LA (651 +/- 147 vs 402 +/- 159 ng ml-1 h, means +/- s.e. mean, P greater than 0.05).",Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743489/),[h·ng] / [ml],402,253744,DB00571,Propranolol
,6743489,Dose-corrected AUC0-24,"Dose-corrected AUC0-24 values were 797 +/- 148 ng ml-1 h after Inderal, 908 +/- 113 ng ml-1 h after Elanol and 602 +/- 122 ng ml-1 after Inderal LA.",Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743489/),[h·ng] / [ml],797,253745,DB00571,Propranolol
,6743489,Dose-corrected AUC0-24,"Dose-corrected AUC0-24 values were 797 +/- 148 ng ml-1 h after Inderal, 908 +/- 113 ng ml-1 h after Elanol and 602 +/- 122 ng ml-1 after Inderal LA.",Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743489/),[h·ng] / [ml],908,253746,DB00571,Propranolol
,6743489,Dose-corrected AUC0-24,"Dose-corrected AUC0-24 values were 797 +/- 148 ng ml-1 h after Inderal, 908 +/- 113 ng ml-1 h after Elanol and 602 +/- 122 ng ml-1 after Inderal LA.",Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6743489/),[ng] / [ml],602,253747,DB00571,Propranolol
,7835231,apparent steady-state oral availabilities,These reductions resulted in an increase in their respective apparent steady-state oral availabilities of 129 and 106%.,Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7835231/),%,129,254041,DB00571,Propranolol
,7835231,apparent steady-state oral availabilities,These reductions resulted in an increase in their respective apparent steady-state oral availabilities of 129 and 106%.,Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7835231/),%,106,254042,DB00571,Propranolol
,768905,late biological half-life,"It was shown, by calculation from the renal clearance, that the late biological half-life for the decline of 14C-acebutolol in plasma was 9.4 h and 13.2 h, respectively, in two of these patients treated with a single oral dose (200 mg) of 14C-acebutolol hydrochloride.",[Pharmacokinetics of acebutolol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),h,9.4,257759,DB00571,Propranolol
,768905,late biological half-life,"It was shown, by calculation from the renal clearance, that the late biological half-life for the decline of 14C-acebutolol in plasma was 9.4 h and 13.2 h, respectively, in two of these patients treated with a single oral dose (200 mg) of 14C-acebutolol hydrochloride.",[Pharmacokinetics of acebutolol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),h,13.2,257760,DB00571,Propranolol
,768905,late biological half-life plasma,"In one of the patients treated by intravenous infusion (20 mg/10 mn), the late biological half-life plasma was calculated to be 7.5 h.",[Pharmacokinetics of acebutolol]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),h,7.5,257761,DB00571,Propranolol
,768905,Renal clearance,Renal clearance of acebutolol was shown to be close to a mean of 83 ml plasma/mn for each of three patients (two oral and one intravenous) in spite of the fact that one of the orally treated patients had an elevated level of urea in his plasma (47 mg/100 ml) indicative of some impairment of kidney function.,[Pharmacokinetics of acebutolol]. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),[ml·plasma] / [mn],83,257762,DB00571,Propranolol
,768905,recovery of 14C,The recovery of 14C-radioactivity in the urine (29 p. cent) and faeces (64 p. cent) was 93 p.cent of the dose of labelled acebutolol in one of the orally treated patients.,[Pharmacokinetics of acebutolol]. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),cent·p,29,257763,DB00571,Propranolol
,768905,recovery of 14C,The recovery of 14C-radioactivity in the urine (29 p. cent) and faeces (64 p. cent) was 93 p.cent of the dose of labelled acebutolol in one of the orally treated patients.,[Pharmacokinetics of acebutolol]. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),cent·p,64,257764,DB00571,Propranolol
,768905,recovery of 14C,The recovery of 14C-radioactivity in the urine (29 p. cent) and faeces (64 p. cent) was 93 p.cent of the dose of labelled acebutolol in one of the orally treated patients.,[Pharmacokinetics of acebutolol]. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/768905/),cent·p,93,257765,DB00571,Propranolol
,8729584,plasma half-life,"Systemic exposure is limited, as fluvastatin is subject to first-pass metabolism, and the plasma half-life of the drug is approximately 30 minutes.",Development and pharmacology of fluvastatin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),min,30,257876,DB00571,Propranolol
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,40,257877,DB00571,Propranolol
,8729584,rate of bioavailability,"Studies of the effect of food on the pharmacokinetics of fluvastatin have demonstrated marked reductions in the rate of bioavailability--from 40% to 60%; however, a comparison of fluvastatin administration with the evening meal or at bedtime has revealed no significant differences in the extent of bioavailability (area under the curve) of these two regimens.",Development and pharmacology of fluvastatin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8729584/),%,60,257878,DB00571,Propranolol
,31384829,m/z,"Detection was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring (MRM), with the transitions of m/z 130.2 → 60.1, m/z 462.3 → 191.0, m/z 260.2 → 183.0 and m/z 390.2 → 268.2 for MET, CFZ, PPL and TDF, respectively, in the positive ion mode.",Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),,260.2,258990,DB00571,Propranolol
,31384829,m/z,"Detection was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring (MRM), with the transitions of m/z 130.2 → 60.1, m/z 462.3 → 191.0, m/z 260.2 → 183.0 and m/z 390.2 → 268.2 for MET, CFZ, PPL and TDF, respectively, in the positive ion mode.",Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),,183.0,258991,DB00571,Propranolol
,31384829,m/z,"Detection was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring (MRM), with the transitions of m/z 130.2 → 60.1, m/z 462.3 → 191.0, m/z 260.2 → 183.0 and m/z 390.2 → 268.2 for MET, CFZ, PPL and TDF, respectively, in the positive ion mode.",Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),,390.2,258992,DB00571,Propranolol
,31384829,m/z,"Detection was performed on a triple quadrupole mass spectrometer employing electrospray ionization technique, operating in multiple reaction monitoring (MRM), with the transitions of m/z 130.2 → 60.1, m/z 462.3 → 191.0, m/z 260.2 → 183.0 and m/z 390.2 → 268.2 for MET, CFZ, PPL and TDF, respectively, in the positive ion mode.",Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),,268.2,258993,DB00571,Propranolol
higher,31384829,recoveries,All obtained recoveries were higher than 90.0% while the accuracy was in the range of 88.14-113.05% and the relative standard deviation was below 10.0% for all investigated drugs by the proposed method.,Novel LC-MS/MS method for analysis of metformin and canagliflozin in human plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31384829/),%,90.0,258994,DB00571,Propranolol
,1659437,Cmax,"The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),[ng] / [ml],120,260754,DB00571,Propranolol
,1659437,Cmax,"The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),[ng] / [ml],126,260755,DB00571,Propranolol
,1659437,tmax,"The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),h,4.5,260756,DB00571,Propranolol
,1659437,tmax,"The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),h,3.0,260757,DB00571,Propranolol
,1659437,AUC,"The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),[h·ng] / [ml],580,260758,DB00571,Propranolol
,1659437,AUC,"The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),[h·ng] / [ml],566,260759,DB00571,Propranolol
,1659437,"t 1/2,z","The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),h,1.9,260760,DB00571,Propranolol
,1659437,"t 1/2,z","The appropriate average parameter values in the presence of propranolol were, respectively: Cmax (120 ng ml-1 vs 126 ng ml-1), tmax (4.5 h vs 3.0 h), AUC (580 ng ml-1 h vs 566 ng ml-1 h), t 1/2,z (1.9 h vs 1.8 h).",Lack of an interaction between propranolol and sumatriptan. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1659437/),h,1.8,260761,DB00571,Propranolol
,6860527,area under the,"The plasma propranolol concentration time curve after LA propranolol showed slowed absorption, and the area under the curve was significantly lower than after conventional propranolol (acute dosing; LA propranolol 160 mg 560 mg ml-1 h, conventional propranolol 80 mg twice daily 1135 mg ml-1 h, conventional propranolol 160 mg daily 1414 mg ml-1 h).",The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6860527/),[h·mg] / [ml],1135,262062,DB00571,Propranolol
,6860527,area under the,"The plasma propranolol concentration time curve after LA propranolol showed slowed absorption, and the area under the curve was significantly lower than after conventional propranolol (acute dosing; LA propranolol 160 mg 560 mg ml-1 h, conventional propranolol 80 mg twice daily 1135 mg ml-1 h, conventional propranolol 160 mg daily 1414 mg ml-1 h).",The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6860527/),mg,141,262063,DB00571,Propranolol
,7898090,half-life,"We showed that single oral doses of cilazapril 4 mg, captopril 25 mg, or enalapril 10 mg shifted the angiotensin I dose-effect curve to the right and determined a pharmacologic half-life of about 4 h for cilazapril.",Review of studies on the clinical pharmacodynamics of cilazapril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7898090/),h,4,262739,DB00571,Propranolol
,7898090,apparent Ki dose,The dose representing 50% inhibition of ACE activity (apparent Ki dose) was about 0.6 mg 3 h after cilazapril administration.,Review of studies on the clinical pharmacodynamics of cilazapril. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7898090/),mg,0.6,262740,DB00571,Propranolol
,2693499,half-life,"It has a half-life of 15-18 hours, and is demonstrated to be effective as an antihypertensive agent for 24-30 hours.",Dilevalol: a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2693499/),h,15-18,265055,DB00571,Propranolol
,33190084,flow rate,"The chromatographic separation was performed on an Eclipse Plus C18 column (2.1 × 50 mm, 3.5 μm) at a flow rate of 0.3 mL/min with a gradient mobile phase of methanol/water containing 0.5 % formic acid (v/v).",Simultaneous determination of YZG-331 and its metabolites in monkey blood by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33190084/),[ml] / [min],0.3,265072,DB00571,Propranolol
,33190084,recoveries,There was no obvious matrix effect and the recoveries of the analytes were 90.6 %-118.2 %.,Simultaneous determination of YZG-331 and its metabolites in monkey blood by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33190084/),%,90.6,265073,DB00571,Propranolol
,33190084,recoveries,There was no obvious matrix effect and the recoveries of the analytes were 90.6 %-118.2 %.,Simultaneous determination of YZG-331 and its metabolites in monkey blood by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33190084/),%,118.2,265074,DB00571,Propranolol
,33190084,oral bioavailability,The oral bioavailability of YZG-331 in monkeys is 74.1 %.,Simultaneous determination of YZG-331 and its metabolites in monkey blood by liquid chromatography-tandem mass spectrometry. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33190084/),%,74.1,265075,DB00571,Propranolol
,16055224,relative bioavailability,The matrix-in-cylinder system had a relative bioavailability of 156% (fasted conditions) and 222% (fed conditions) compared to the marketed reference product.,Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire core. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16055224/),%,156,265576,DB00571,Propranolol
,16055224,relative bioavailability,The matrix-in-cylinder system had a relative bioavailability of 156% (fasted conditions) and 222% (fed conditions) compared to the marketed reference product.,Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire core. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16055224/),%,222,265577,DB00571,Propranolol
,2708546,Clearance of pinacidil (Clp,Clearance of pinacidil (Clp = Dose/AUC) was 31 L/hr in patients younger than 45 years and 27 L/hr in those older than 60.,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],31,267136,DB00571,Propranolol
,2708546,Clearance of pinacidil (Clp,Clearance of pinacidil (Clp = Dose/AUC) was 31 L/hr in patients younger than 45 years and 27 L/hr in those older than 60.,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],27,267137,DB00571,Propranolol
,2708546,Clp,Clp was significantly smaller in white patients compared with other races (Clp = 28 vs. 34 L/hr).,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],28,267138,DB00571,Propranolol
,2708546,Clp,Clp was significantly smaller in white patients compared with other races (Clp = 28 vs. 34 L/hr).,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],34,267139,DB00571,Propranolol
,2708546,Clp,Clp was significantly less in patients taking hydrochlorothiazide (27 vs. 31 L/hr) and greater in smokers (33 vs. 29 L/hr).,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],27,267140,DB00571,Propranolol
,2708546,Clp,Clp was significantly less in patients taking hydrochlorothiazide (27 vs. 31 L/hr) and greater in smokers (33 vs. 29 L/hr).,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],31,267141,DB00571,Propranolol
,2708546,Clp,Clp was significantly less in patients taking hydrochlorothiazide (27 vs. 31 L/hr) and greater in smokers (33 vs. 29 L/hr).,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],33,267142,DB00571,Propranolol
,2708546,Clp,Clp was significantly less in patients taking hydrochlorothiazide (27 vs. 31 L/hr) and greater in smokers (33 vs. 29 L/hr).,"Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2708546/),[l] / [h],29,267143,DB00571,Propranolol
,3575876,extraction ratios,"The drugs, antipyrine, phenytoin, indocyanine green, and d-propranolol, have extraction ratios from 0.01 to 0.99 in the rat.",Effect of Fluosol-DA hemodilution on the kinetics of hepatically eliminated drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3575876/),,0,268182,DB00571,Propranolol
,29329091,flow rate,"Separation was performed with a gradient mobile phase of methanol/water with 0.5% formic acid (v/v) on Eclipse Plus C18 column (2.1×50mm, 3.5μm) at a flow rate of 0.3mL/min.",Determination of IMM-H004 and its active glucuronide metabolite in rat plasma and Ringer's solution by ultra-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29329091/),[ml] / [min],0.3,268305,DB00571,Propranolol
higher,29329091,recoveries,There was no obvious matrix effect and the recoveries of the analytes were higher than 94.2%.,Determination of IMM-H004 and its active glucuronide metabolite in rat plasma and Ringer's solution by ultra-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29329091/),%,94.2,268306,DB00571,Propranolol
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,13.00,270253,DB00571,Propranolol
,30096386,Ki,"Among the CV drugs screened, simvastatin and lovastatin were shown to inhibit the liver metabolism of sinomenine with Ki values of 13.00 and 25.83 μM, respectively.",Co-administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450-mediated pathways. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30096386/),μM,25.83,270254,DB00571,Propranolol
,28213295,flow rate,Separation was carried out in Zorbax SB-C18 column at a flow rate of 0.3mL/min utilizing acetonitrile/water as mobile phases which contain 0.5% formic acid (v/v).,"Determination of IMM-H004, a novel neuroprotective agent, in rat plasma and brain tissue by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28213295/),[ml] / [min],0.3,270960,DB00571,Propranolol
,28213295,mass transition ion,The mass transition ion-pairs were 305→248 for IMM-H004 and 260→183 for IS in positive ion mode.,"Determination of IMM-H004, a novel neuroprotective agent, in rat plasma and brain tissue by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28213295/),,305,270961,DB00571,Propranolol
,28213295,mass transition ion,The mass transition ion-pairs were 305→248 for IMM-H004 and 260→183 for IS in positive ion mode.,"Determination of IMM-H004, a novel neuroprotective agent, in rat plasma and brain tissue by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28213295/),,24,270962,DB00571,Propranolol
,28213295,mass transition ion,The mass transition ion-pairs were 305→248 for IMM-H004 and 260→183 for IS in positive ion mode.,"Determination of IMM-H004, a novel neuroprotective agent, in rat plasma and brain tissue by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28213295/),,260,270963,DB00571,Propranolol
,28213295,mass transition ion,The mass transition ion-pairs were 305→248 for IMM-H004 and 260→183 for IS in positive ion mode.,"Determination of IMM-H004, a novel neuroprotective agent, in rat plasma and brain tissue by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28213295/),,183,270964,DB00571,Propranolol
higher,28213295,recovery,The recovery of the analyte was higher than 85.3%.,"Determination of IMM-H004, a novel neuroprotective agent, in rat plasma and brain tissue by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28213295/),%,85.3,270965,DB00571,Propranolol
,2439797,t1/2,"Monophasic elimination characteristics with t1/2 of 4.8 +/- 0.42 (prop), 6.87 +/- 0.46 (aten), and 9.19 +/- 0.38 h (biso) become apparent.","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),h,4.8,274170,DB00571,Propranolol
,2439797,t1/2,"Monophasic elimination characteristics with t1/2 of 4.8 +/- 0.42 (prop), 6.87 +/- 0.46 (aten), and 9.19 +/- 0.38 h (biso) become apparent.","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),h,6.87,274171,DB00571,Propranolol
,2439797,t1/2,"Monophasic elimination characteristics with t1/2 of 4.8 +/- 0.42 (prop), 6.87 +/- 0.46 (aten), and 9.19 +/- 0.38 h (biso) become apparent.","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),h,9.19,274172,DB00571,Propranolol
,2439797,maximum concentrations,"The maximum concentrations observed after administration of the doses mentioned previously were 220 +/- 71 (prop), 904 +/- 104 (aten), and 445 +/- 32 (biso) (ng/ml plasma).","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),[ng] / [ml],220,274173,DB00571,Propranolol
,2439797,maximum concentrations,"The maximum concentrations observed after administration of the doses mentioned previously were 220 +/- 71 (prop), 904 +/- 104 (aten), and 445 +/- 32 (biso) (ng/ml plasma).","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),[ng] / [ml],904,274174,DB00571,Propranolol
,2439797,maximum concentrations,"The maximum concentrations observed after administration of the doses mentioned previously were 220 +/- 71 (prop), 904 +/- 104 (aten), and 445 +/- 32 (biso) (ng/ml plasma).","Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2439797/),[ng] / [ml],445,274175,DB00571,Propranolol
